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Background and rationale: Weaning foods fed to infants in rural Gambia are often
contaminated, resulting in infections which contribute to initiating a persistent inflammation
of the gut. This enteropathy, which causes intestinal damage and malabsorption, is strongly
associated with the high degree of growth faltering seen in Gambian infants. There is evidence
that supplementary omega-3 long-chain polyunsaturated fatty acids (n-3 LCPs) might
ameliorate this damage by reducing gastro-intestinal inflammation. Additionally, n-3 LCPshave
been shown to benefit mental development and problem-solving ability in infants, but this has
not yet been tested in an African population.
Methods: A randomised, double-blind, controlled trial (500mg combined n-3 LCPsper day
for six months) was conducted in a population of rural African infants aged 3 months - 9
months. The primary outcomes were infant anthropometric indicators and gut integrity
(measured by urinary lactulose-mannitol ratios). Plasma fatty acid status (plasma fatty acid
profiles), cognitive development (Willatts Test and an attention assessment at 12 months of
age), intestinal mucosal inflammation (faecal calprotectin), and daily morbidities were the
secondary outcome measures.
Results: One-hundred and seventy-two Gambian infants completed the trial. Except for an
increase in mid-upper-arm circumference z-scores in the intervention group (95% Cl: 0.06,0.56;
p=0.017), no significant differences between treatment groups were detected for growth and
lactulose-mannitol ratios at 9 months. At 12 months mid-upper-arm circumference remained
greater in the intervention group, and significant increases in skinfold thicknesses were
detected (pSO.022 for ali). Supplementation resulted in a significant increase in plasma n-3 LCP
levels (p<O.001) and decrease in n-6 LCP:n-3 LCPratios (p<O.OOl). Plasma n-6 fatty acid levels
were not affected. No difference was detected for the other secondary outcomes.
Conclusion: Fish oil supplementation proved safe and successfully increased plasma n-3
fatty acid status, but the results of this trial do not support the use of supplementary n-3 LCPs
in young, breast-fed, rural Gambian infants for improving overall growth performance,
intestinal integrity, and cognitive development, or reducing intestinal and systemic
inflammation.
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CHAPTER 1: BACKGROUND AND INTRODUCTION
1.1 Growth faltering and intestinal inflammation in rural
Gambian infants
1.1.1 Background
1.1.1.1 The Gambia
The Republic of The Gambia is a long, narrow country in West Africa with an area of
10 380km2. It is bordered in the North, East and South by Senegal and on the West by the
Atlantic Ocean. Its long narrow shape, seen in Figure 1, corresponds to the meandering of the
River Gambia, around which the country is formed. River flood plains, flanked by low hills,
form the predominant terrain. The climate is tropical with two main seasons: a hot rainy
season (June to October) and a cooler, dry season (November to May).
The nation achieved independence from the United Kingdom in 1962, and became a
republic within the Commonwealth five years later. According to a United Nations 2007
estimate, the country has 1.7 million inhabitants, most of who belong to the ethnic tribes of
Mandinka (42%), Fula (18%), Wolof (16%), Jola (10%),and Sarahule (9%).
Sixty-three percent of inhabitants live in rural areas, where 23% of people have no access
to safe drinking water. life expectancy at birth is 57 years, and the infant mortality rate is
97/1000 live births (2005 est. (1)). Seventy percent of the labour force is employed by the
agricultural sector, which contributes around 30% to the (nominal) gross domestic profit of
$808 million. Groundnut production, followed by other crops, livestock farming, fishing and
forestry, make up the Agricultural Sector (1).
Further country details are provided in Box 1.
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Figure 1: Map of The Gambia, showing the West Kiang area and the River Gambia
Box 1: country profile
Government: Democratic
Capital: Banjul
10380; 11.5% of which water
153.5/km2
90% Muslim
Area:
Population density:
Religion:
GDP (nominal) per capita: $495
GDP (purchasing power parity): $1 389
Population growth rate: 2.4%
Life expectancy at birth: 57 years
Total fertility rate: 4.76 children born/woman
Birth rate: 34.9 births/l/OOO population
Death rate: 11.3 deaths/l/OOO population
Net migration rate: 2.97 migrant(s)/l/OOO population
Percent living below the international poverty line: roughly 30%
Adult literacy rate: 37.8%.
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1.1.2 The study area and field station
West Kiang (indicated on the map in Figure 1), the area where fieldwork and data
collection for this thesis was done, is one of the districts of the Lower River administrative
division. It consists of 36 registered villages, lies approximately 145km inland from the capital,
and spans an area of 80 km2. Roughly 16000 individuals of the registered West Kiang villages
are surveyed regularly by means of the Kiang West Demographic Surveillance System. Keneba
is the largest village in this rural area where subsistence farming (primarily rice and groundnut)
predominates.
Along the lower river region of the River Gambia, marine fish may be caught. Most
abundant are bonga (an oily fish), catfish, threadfins, barracuda, tongue-sole and shrimps.
Most of the shrimp and sole, as well as large fish such as barracuda, are taken further down to
the coast where they are purchased by industrial fishing companies. The smaller fish are sold
in the villages, often dried and salted. These are frequently added as an ingredient to sauces,
or sometimes served fried in small amounts.
The staple food is rice. It is eaten with sauces made of groundnut, leaves, and small
quantities of vegetables (when available), meats and fish.
The Medical Research Council (MRC) has been involved with work in the area since the
1950s. The Nutrition Group of the MRC Laboratories is based in Keneba. The MRC clinic
provides medical care focussing on maternal and child health. It also provides emergency,
midwifery and nursing care in collaboration with the local Government Divisional Health
services. Supported by its reputation for improving community health and providing
employment, the MRC enjoys an excellent relationship with the locals living in the area. The
station houses its own entire infrastructure in this isolated area, consisting of laboratories,
clinic, vehicles, electricity and water, in order to adequately support the body of research
projects it runs. Some photos ofthe station can be viewed in Figure 2.
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Figure 2: Photographs of the MRC Keneba field station showing, clockwise, from top
right: the motorbike fleet; gate clinic; consultation room, bleeding laboratory and data
office; laboratory; library, records office, research room and administrative office;
some of the station vehicles.
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1.1.3 Growth faltering
Growth faltering and under-nutrition are important underliers of infant morbidity and
mortality in sub-Saharan Africa, as in many other developing countries (2-4). Malnutrition
increases the risk of disease and early death, and, according to the latest lancet Maternal and
Child Undernutrition Series (2008), plays a major role in over a third of under-five deaths each
year (2).
It is well-known that malnutrition delays growth. Acute starvation, provided it is not too
severe or enduring, may leave almost no imprint on a child's eventual attainment in growth
(5). Chronic malnutrition, in contrast, has lasting effects. As explained by Tanner (1989), in
some populations most members grow to be smaller adults than they should because of
chronic undernourishment during most or all of their childhood (5). Such chronic malnutrition
is a feature of many countries in the developing world (6).
The growth velocity (an important indicator of nutritional status (5)) of Gambian infants
falls severely from around 3-4 months (mo) onwards compared with reference standards (7-9).
Before this age, infants are only slightly below their expected weight-far-age, with evidence of
catch-up growth taking place quite successfully from a moderately low birth-weight. This
catch-up growth, and the deterioration in mean Z-scores for weight- and length-far-age, head
circumference (HC) and body mass index around weaning age, is demonstrated in Figure 3 by a
sample of infants measured against Western reference norms (10, 11) recently (12). Although
annual increments in growth between 1 and 7 years of age are similar to those in Europe,
Gambian children remain shorter and lighter than their UK counterparts, never fully regaining
the losses incurred in early infancy (7).
Many suitably-targeted macro- and micronutrient intervention trials have been
undertaken in The Gambia and other developing countries in an attempt to reduce
malnutrition and hence its consequences for the children involved. Effects on long-term
growth faltering, however, have been small or nil (13-17). Even when a considerably large
amount of high-quality food was supplemented, growth remained poor and stunting ensued
(18). Growth faltering could thus not, to any significant degree, be attributed simply to
micronutrient or energy inadequacies.
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Figure 3: Growth performance of Gambian infants as measured against UK
standards, expressed as weight, length, He and body mass index Z-scores, from
birth to 52 weeks
A search for other factors involved in the growth-failure sequelae led to investigations
around the role of possible nutrition-disease relationships (19). Infections are well known
important contributors of poor growth (20-22). Due to the unhygienic and unsanitary
environments surrounding them, infants in developing countries are often chronically exposed
to infections. Gastrointestinal infection, in particular, is strongly associated with wasting (22,
23). However, although acute episodes of illness often result in short-term weight-loss, efforts
to relate long-term growth, especially in height, to overt clinical diseases have produced little
or no association (24, 25). Furthermore, since there was no improvement in growth despite a
decline in diarrhoea prevalence over a 15 year period (26), investigations in The Gambia were
shifted towards other factors, such as sub-clinical disease states, which were likely retarding
growth.
The repeated immunostimulation experienced by infants of developing countries, even in
the absence of overt clinical disease symptoms, has been discussed as a significant contributor
to growth faltering (27-29). The role of the gastrointestinal tract and, notably, the small
intestinal mucosa, has received particular interest because it represents an extensive area of
23
Chapter 1: Background and Introduction
interface between the body and the environment, and thus it not only functions as a barrier to
pathogens and environmental toxins, but also as an absorptive surface for nutrients (19, 3D,
31). Both these functions are imperative for satisfactory growth performance, as shall be
discussed in the following section.
1.1.4 Chronic environmental enteropathy
Persistent enteropathy, as characterised histologically by small-intestine mucosal villous
shortening and broadening, crypt hvperplasla, increased crypt depth, and lymphocyte
infiltration into the lamina propria and epithelium, is a feature of many Gambian children. (The
basic anatomy of the intestinal mucosa can be viewed in Figure 4, and the pathologies
mentioned above, studied by small bowel biopsies, in Figure 5). First described in 1962 (32),
persistent enteropathy was found to affect individuals throughout the tropics in Africa, Asia,
South America and the Caribbean (33). For this reason it acquired the name "tropical
enteropthy". The condition was only observed in those living in less developed or more
contaminated environments of the tropics. It was later found that people living in temperate
areas may also develop similar histological and functional changes if living in environments
with similarly high levels of microbiological pathogens (34, 35). For these reasons the
expression "chronic environmental enteropathy" is now accepted as a more accurate
description ofthe condition than "tropical enteropathy".
Associated functional changes include subclinical malabsorption of fat and an increased
mucosal permeability (36). The latter is demonstrated by markedly and consistently raised
lactulose-mannitol ratios (LMRs) in the dual-sugar permeability test (30). Raised LMRs have
also been described in children In several other parts ofthe developing world (37, 38).
The dual-sugar permeability test assesses both gut integrity and absorptive capacity. By
measuring absorption of the indigestible disaccharide, lactulose (MW 342), through
paracellular tight junctions, gut leakiness may be evaluated. Absorptive capacity, on the other
hand, is measured by the passive absorption of the monosaccharide mannitol (MW 182)
through the transcellular route. Higher LMR ratios are therefore indicative of poorer gut
integrity (39, 40). This concept and test will be further explained in the Methods section.
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Muscularis Mucosae
Submucosa-_
Figure 4: Intestinal mucosa showing the crypt and lamina propria
Reprited from Schenk (1972) (41) and Kelly (2004) (42)
Figure 5: Histological intestinal mucosal villi changes found in tropical enteropathy. A & B:
Normal; C: Initial signs of cell infiltrate, crypt hyperplasia & villous shortening. D, E& F:
Advanced signs of villous broadening & shortening with increased crypt depth, crypt
hyperplasia, & cell infiltrate
25
Chapter 1: Background and Introduction
1.1.4.1 Causes and consequences of environmental enteropathy
The adverse and unhygienic environmental conditions to which infants in developing
countries are exposed are thought to be a major cause of enteropathy. It is thought that the
passage of bacteria, viruses, and parasites along the gastrointestinal tract with contaminated
weaning foods and water leads to infections causing gut injury which, for various reasons (43),
is never fully repaired. However, no specific organism or mechanism has yet been recognised
as a major cause of enteropathy, and bacteria probably do not require enteropathogenic
capabilities to induce these effects (8). Instead, chronic exposure to a wide variety of
pathogenic organisms and/or food allergens, causing repeated episodes of often
asymptomatic enteropathy, is its generally accepted aetiology (8, 44). The degree of allergic
responses contributing to gut inflammation in this disorder is likely to be small, however, as
the children susceptible to environmental enteropathy are rarely atopic (45).
Mucosal injuries resulting from inflammatory responses appear to be slow or resistant to
healing and repair, and once injured, the gut is vulnerable to still further damage. Even if
further injury is not triggered, intestinal mucosal damage - by setting off bacterial overgrowth,
absorption of foreign proteins and toxins, or malabsorption of nutrients - may delay healing
(43). Two general enteropathic mechanisms are described by lunn (8), as summarised in
Figure 6.
Firstly, a loss of mucosal enzyme function, resulting from partial villous atrophy, causes
maldigestion and malabsorption of food. This is especially pertinent in the case of lactase.
Essential for the digestion of lactose, a major carbohydrate and source of energy in
breast-milk, lactase activity is particularly affected by villous damage. Second, mucosal
damage, resulting in increased gut permeability, allows the translocation of antigenic
macromolecules which then stimulate and perpetuate local and systemic immune and
inflammatory responses. Both of these enteropathic responses, and this inflammatory
condition overall, are strongly associated with growth failure (9, 30).
In a study Investigating the relationship between enteropathy and growth performance,
lunn et 01. (30) showed that abnormalities of the mucosa of the small intestine, i.e. increased
lMRs, accounted for up to 43% of growth faltering in a group of rural Gambian children. It is
currently accepted that most of this growth faltering (55-60%) is related to increased lactulose
uptake, and 40 - 45 % to reduced mannitol updake ((8).
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Small intestinal
mucosal damage
Villous atrophy Compromised
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Loss of mucosal
enzymes
Mucosal inflammatory
and immune reaction
Maldigestion &
malabsorption
Systemic
immune reaction
Growth faltering
Taken from Lunn (2000) (8)
Figure 6: Diagrammatic representation of the mechanisms leading to poor
growth in Gambian children
Growth-depressing intestinal permeability values appear to occur in approximately 75% of
rural Gambian children between the ages of 3 and 15 mo (30, 39, 46). As already mentioned,
contaminated weaning foods fed to infants are likely to be a major initiator of this persistent
inflammation of the gut (8).
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Although tropical enteropathy may occur in apparently healthy individuals, it could
potentially result in subclinical malabsorption due to the disturbances of digestive and
absorptive function causing considerable losses of nutrients (36, 47). Infants affected by
enteropathy might maintain satisfactory nutritional status when healthy, but in states of
disease or food shortage, they have a greater predisposition towards malnutrition than those
without enteropathy (35, 36).
1.1.4.2 Other enteropathies explored: Crohn's Disease and ulcerative colitis
The literature focussing on other inflammatory enteropathic disease states, particularly in
regard to intervention studies, is far richer than the literature focussing on environmental
enteropathy. In order to make informed inferences about the results of these studies, a brief
description will be provided of the inflammatory bowel diseases (IBDs).
Although the consequence of different aetiologies and pathogenic mechanisms (e.g.
gene-environmental interactions strongly underlie the pathogenesis of inflammatory IBD (48)),
and a feature of both children and adults in the developed but not developing world, these
diseases share some similarities with environmental enteropathy in so far as they are
characterised by a persistent inflammation of the gastrointestinal tract with an underlying
immunologic mechanism. Additionally, the LMRs seen in malnourished Gambian children are
similar to those In children with IBD and coellc disease in the UK.
Crohn's disease and ulcerative colitis are the best known forms of IBD and can involve
either or both the small and large bowel (48). "Active" IBD is characterised by acute
inflammation. "Chronic" IBD Is characterised by architectural changes such as crypt distortion
and scarring. Crypt abscesses, consisting of neutrophils in crypt lumens, may occur in many
forms of IBD (49).
Ulcerative colitis involves the colon, producing a continuous mucosal inflammation always
Involvins the rectum. Its aetlolosy is unknown. Crohn's disease, on the other hand, can involve
any part of the gastrointestinal tract, but most frequently involves the distal small bowel and
colon. Inflammation is typically transmural and patchy, and can range from small ulcers to
chronic Inflammation (48). The aetlolosy Is unknown, although infectious and immunologic
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mechanisms are thought to play a part (49, 50). Both conditions are more common in
Caucasians and in women.
The distinguishing features of IBO are summarised in a table produced by Fiochhi (1998)
(50), where ulcerative colitis is contrasted against Crohn's disease. This summary is given in
Table 1.
1.2 Long-chain polyunsaturated fatty acids
The essential polyunsaturated fatty acids (PUFAs), linoleic acid (C18:2 omega-6) and
a-linolenic acid (C18:3 omega-3), are vital structural components of cell membrane
phospholipids. Unlike cellular proteins which are genetically determined, the fatty acid (FA)
composition of cell membranes is largely dependent on dietary intake (51). Linoleic and
a-linolenic acid can be converted to their long-chain (~20 carbon chain length) derivatives via a
series of elongation and desaturation reactions. The most important omega-6 (n-6) long-chain
polyunsaturated fatty acid (LCP) is arachidonic acid (AA; C20:4n-6), for which linoleic acid
serves as parent FA. a-Linolenic acid may be converted to the n-3 LCPseicosapentaenolc acid
(EPA; C20:5n-3) and further to docosahexaenoic acid (OHA; C22:6n-3); these are the major n-3
LCPs(Figure 7). However, these conversions, illustrated in Figure 8, take place inefficiently and
in a constricted manner (52-54). Particularly in infants, conversions are slow and studies
suggest that pre-formed LCPs are needed to sufficiently meet infants' accretion needs,
especially of OHA (55-57).
The essential n-3 and n-6 PUFAs can be synthesised de novo only in plants. The four main
vegetable oils (palm, soybean, rapeseed and sunflower) are rich in linoleic acid. Various other
oils, as well as poultry and certain grains and cereals are further dietary sources of n-6 PUFAs.
Fish, flax seeds, some nuts, and milk from grass-fed cows are sources of a-linolenic acid. The
n-6 LCP, AA, can be obtained from milk, meat and eggs, while n-3 LCPs are less widely
distributed in the food chain and are obtained almost exclusively from marine foods. Organ
meats and some egg yolks are its only other dietary sources.
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Figure 7: Structure of the n-3 LCPsDHA (left) and EPA (right)
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Figure 8: Metabolism of fatty acids to form LCPs
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By observing -that symptoms such as growth retardation, dermatitis and reproductive
failure (resorption of foetuses or perinatal death) that occurred in mice fed fat-free diets for
several months could be reversed by supplementation with vegetable oils, Burr and Burr
proposed linoleic and a-linolenic acids as essential for growth and development as early as
1930 (59, 60). Later, Interest in the health benefits of n-3 FAs was generated when, in the
1970s, Dyerberg and Bang (61-63) discovered that the Inuit of Greenland had low rates of
coronary heart disease and cancer although surviving on remarkably high-fat diets. Due to its
antithrombotic and serum cholesterol lowering effects, EPA received particular interest for its
potential use in the prevention of heart attacks (64, 65). Subsequently, and up to the present
day, n-3 LCPs have, by virtue of their potential benefits in health and disease, remained a
subject of rigorous investigation.
As part of their functions in cell phospholipids, chiefly in the central nervous system where
they serve as structural components of neuronal phospholipids, PUFAs are important
determinants of lipid-protein interactions in membrane domains which affect receptor, ion
channel, enzyme, and cellular uptake and excretion activities. LCPs, specifically, influence
membrane stability, membrane fluidity, cell mobility, the formation of receptors, and binding
of ligands to their receptors. Besides these, they influence the activation of intracellular
signalling pathways either directly or through the formation of eicosanoids, gene expression
and cell differentiation (51).
Parent PUFAsand their derivatives may serve as substrate for energy generation, but LCPs
are relatively protected from ~-oxidatlon. When in free form, LCPs serve as mediators for
thromboregulation and varied Inflammatory and pathogenic responses, primarily by acting as
the precursor for bloactive elcosanolds (66, 67). These signalling molecules include
prostaglandins and thromboxanes - both of which are cyclo-oxygenase products, and
leukotrienes, a IIpoxygenase product.
Elcosanolds from AA are Involved in vasoconstriction and platelet aggregation,
Inflammation, and leukocyte chemotaxis and adhesion (68, 69). In contrast, the less-potent
elcosanolds from EPA are Involved in attenuation of platelet aggregation and vasoconstriction
(70). Apart from their effects on eicosanoid production, n-3 LCPs have further potent
Inflammation lowering effects via Influences on the modulation of inflammation and immunity
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by affecting, amongst others, intracellular signalling pathways, transcription factor activity and
gene expression (71). Metabolites of n-3 FAs are thus significantly less inflammatory than
those of n-6 FAs, and assist in inflammation attenuation.
The two families of n-3 and n-6 PUFAs compete for the same metabolic enzymes,
influencing subsequent physiological effects and conversion to eicosanoids, making the n-6 to
n-3 FA ratio an important feature in PUFAstatus (72, 73). It is believed that the ratio which the
evolutionary (hunter-gatherer) human diet most likely provided - an n-6:n-3 ratio of 1:1 to 4:1
- is more beneficial to human health than the ratios provided by the typical modern day
Western diet of between 10:1 and 30:1 (74-76). The conversion of C18 precursors to LCPs, it
has recently been argued, is, however, less influenced by the n-6:n-3 ratio than the absolute
amount of n-3 FAconsumed (77).
Roughly 2.2 g of PUFAsare deposited in maternal and foetal tissues daily during pregnancy
(78). LCPs are required in high concentration by developing organs of the foetus and are
therefore vital for growth. Marked increases in AA and DHA concentrations in the brain and
retina arise, accompanying central nervous system maturation (79-81). LCPplasma and tissue
pools also accumulate (82), predetermining the infant's FA status at birth. The foetus relies
heavily upon its mother's diet for its own LCP supply, making maternal LCP status during
gestation a major determinant of the FAstatus ofthe infant at birth (83, 84).
1.2.1 Dietary n-3 LCPs in rural Gambian infants
. In many rural areas of the developing world diets are low in n-3 LCPs (85-88). Breastfed
babies are probably relatively protected from deficiency as human milk provides preformed
LCPs which are well absorbed and readily used. Most local weaning diets, however,
(Introduced at 3 to 4 mo of age), have very low n-3 LCP content (88). Thus the period of
transition from being fully breastfed, to partial breastfeeding and then weaning is important
for the n-3 LCPstatus of Infants.
Gambian infants' n-3 FAs Intakes per kilogram of body weight drop to profound
Inadequacy shortly after weaning, when compared to the Food and Agriculture Organisation
(1994) recommended Intakes (78), as demonstrated In Figure 9. The earliest breast-milk
supplements are paps made of rice or sometimes other grains. At around 8 or 9 mo infants are
fed by the mother with small quantities of her own portion during meals. Breast-feeding stops
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by roughly 20 mo, by which time the infant receives much the same dietary composition as the
adult (7).
Growth and stresses such as those brought by pregnancy, and excessive loss and
replacement of tissue, increase the requirement for PUFAs and, if the requirement is not met
by the diet, deficiency occurs (89). The growth of new tissue during pregnancy, as mentioned
above, raises the requirement for essential FAs, and also for DHA. A Dutch research group
found that amounts of DHA in the plasma phospholipids in women who were pregnant for the
first time were significantly higher than in women who had been pregnant at least once
before, and that a significant negative correlation existed between gravida number and the
DHA content in maternal plasma samples (90). Furthermore, measures of DHA status gave
significantly better values in the umbilical cord plasma and vessel walls of infants born to
women after their first pregnancy than to those after their second or higher pregnancy, and
significant associations were observed between birth order and the relative amounts of DHA in
cord tissues. Although DHA levels probably have time to normalise between pregnancies (91"
the high fertility rate of Gambian women (4.8 births/woman) could make them susceptible to a
reduction and eventual depletion of DHA stores after consecutive pregnancies, which could
then be reflected in a lower neonatal DHA status.
Aside from the low n-3 LCP Intake through weaning foods and possible Increased
deficiency risks in those born to multigravidae, the gut damage that Gambian infants
commonly present with places them at further risk of n-3 LCP deficiencies. Chronic
environmental enteropathy, especially when accompanied by diarrhoea, leads to fat
malabsorption and fat losses (92). All these factors combined, therefore, likely leave Gambian
infants at an increased n-3 LCPrequirement.
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Figure 9: Intakes of the n-3 fatty acids (I-linolenic acid (18:3; left) and DHA (22:6; right) in
Gambian children from birth to 36 months
Studies at MRC, Keneba, have identified a range of health problems that might be caused
partly by an n-3 LCP-deficient diet, and yet these have not been investigated in any detail to
date (88). This has primarily been due to the difficulty of assaying the minor components of
the FA spectrum in order to examine possible associations. Measuring the relative proportions
of individual FAs requires a significant amount of time and requires particularly careful sample
preparation and handling to reduce measurement error (93). These errors are not easy to
avoid and are also influenced by the amount of individual fat in the sample (94). Accounting
for only a fraction of the total fat in animal cells, this makes LCPsespecially challenging to
measure. Nonetheless, developments in gas chromatography (GC) methods have now greatly
improved their analytical sensitivity and permit accurate analysis in small sample volumes.
Detrimental health outcomes that might be caused, in part, by poor n-3 LCPstatus include
growth failure and persistent inflammation of the gastrointestinal tract. There is evidence that
supplementary n-3 LCPs might ameliorate this enteropathy by reducing intestinal
inflammation. A reduction in intestinal inflammation and associated gut damage could, in turn,
reduce the degree of associated growth faltering. Additionally, n-3 LCPshave been found to
have beneficial effects on mental development and problem-solving ability in infants.
In the light of these potential benefits, the next section will concentrate on n-3 LCPs in
regard to health and development, especially of infants.
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1.3 n-3 LCPsin relation to infant health and development
1.3.1 Growth
As mentioned in the previous section, n-3 FAs remained the subject of intensive
investigation after interest in their roles in human health were sparked in the 1970s. The
conference on Health Effects of PUFAs in Seafoods held in Washington, DC (95) in 1985, was
the first major international meeting to establish the importance of n-3 LCPsin immune and
membrane functioning (51). The participants recommended, amongst others, the support of
research into the role of n-3 FAs in growth and development.
Consequently, various groups in the scientific community began researching on the
essentiality of n-3 LCPsthroughout the life cycle (51), using both animal and human models.
Studies in rats and rhesus monkeys ascertained that n-3 deficient diets during pregnancy and
lactation result in impaired development in the offspring (96, 97). Crawford et al. (1973) (98)
found that human milk, unlike cow's milk, contained EPA and DHA, and recommended their
inclusion in infant formula. It was also confirmed that EPA and DHA concentrations in the
erythrocytes of breast-fed infants are higher than in those of bottle-fed infants (99).
LCPsupplementation has been extensively investigated in several randomised trials with
growth as the endpoint. Two systematic reviews addressing LCPsupplementation in infants
have been published for the Cochrane Library. The first one, examining effects in term infants
(lOO), Included twelve studies which measured growth as outcome (55, 101-115) and
concluded that there is no effect of LCPson term infant growth, based on meta-analysis results
and null effects found in all included studies.
The second review, examining effects of LCPs in preterm infants (116), included thirteen
studies assessing growth at different postnatal ages. Largely due to differences in formulations
and doses, results of the effects of LCPson growth were mixed: four studies reported positive
effects (117-120), two studies reported negative effects using a formula containing only n-3
FAs and no AA (121, 122), one study reported mild negative effects using a formula
supplemented with both n-3 LCPsand AA (123), and six studies found no effect (79, 124-128).
Meta-analysis of five studies (which were in suitable format) (79, 117, 118, 122, 125) showed
benefits on weight and length gain at 2 mo post-term. Meta-analysis at 12 mo (n=271) and 18
mo (n=396) post-term, however, showed no significant effects on weight, length, or HC as a
result of LCPsupplementation. Overall results led to the conclusion that "no clear long-term
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benefits were demonstrated for infants receiving formula supplemented with LCPs.There was
no evidence that supplementation of formula with n-3 and n-6 LCP impaired the growth of
preterm infants."
A meta-analysis published in 2005 (101), including fourteen studies investigating the
effects of LCPsupplementation on the weight, length and HC of term infants in North America
(55, 104), Europe (107, 111-114, 129-131) and Australia (81, 103), found no evidence to
support the hypothesis that LCPsupplementation, with or without added AA, influences the
growth of term infants at any assessment age, in either a positive or negative way.
It is important to note, however, that these trials have been focused on generally
well-nourished infants in affluent societies, who were already growing near optimum rate. It is
likely to be expected that the impact of LCPsupplementation on growth would be insignificant
in these conditions. Infants living In less advantaged areas of the developing world, in addition
to already displaying poor overall growth, might have intakes of these fats that fall below
recommendations. Such children may, In contrast, respond differently to LCPsupplementation.
Yet, apart from scattered observational data, this question is not featured in the literature.
Furthermore, because n-3 lCPs may improve infant intestinal mucosal integrity (by their
immunomodulatory effects, discussed further in the next section), the rationale exists that
they may have their effect via this pathway in a population such as infants in rural Gambia
suffering from high rates of enteropathy.
As summarised above, two trials found that preterm infants who received (exclusively)
formula milk supplemented with n-3 lCPs but no AA suffered a negatively affected growth
(121, 122). This was most likely brought about by reduced circulating AA levels in these infants
who were consuming no AA and were thus dependent entirely on metabolic conversions from
precursors In order to meet their AA supply (130). However, in breast-fed infants, this risk of
AA inadequacy is minimised and several trials have found no danger of DHA
supplementation-Induced AA deficiency, considering that a rich source of preformed AA is
ensured via the breast-milk.
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1.3.2 Immune function, inflammation, and gut integrity
Figure 10 demonstrates how EPAaffects eicosanoid production by serving as precursor to
non-inflammatory eicosanoids and reducing the production of the proinflammatory series-2
eicosanoids.
Apart from their roles in modulating eicosanoid generation from AA and acting as
precursor to alternative eicosanoids, n-3 LCPshave more recently been found to give rise to a
novel group of mediators termed 0 and E-series resolvins, derived from DHA and EPA,
respectively. These compounds, formed bycyclooxygenase-2 and lipoxygenase, appear to
assist in anti-inflammatory and inflammation resolving actions (132-136). It is thought that
resolvins reduce inflammation by inhibiting not only the production of inflammatory products,
but also their transport (133).
Furthermore, EPA, together with DHA, may inhibit inflammatory cytokine production
(137), and so influence immune function by diminishing the production of chronic
inflammatory factors such as interleukins 1~, 2 and 6, and tumour necrosis factor (138) from
AA. EPA and DHA may also act as modulators of gene expression, and reduce
pro-inflammatory signal transduction in pathways such as nuclear factor kappa Band
peroxisome proliferator-activ~ted receptor gamma (PPAR-Y) expression (139). By modulating
the activation of nuclear factor kappa B, e.g. the transcription of genes regulating the
Inflammatory response (cytokines, chemokines, cell adhesion molecules and acute phase
proteins) is in turn influenced (140).
Numerous diseases and conditions in humans, such as rheumatoid arthritis, type-1
diabetes, cystic fibrosis, psoriasis, systemic inflammatory response to surgery, and lBO, are
characterised by the excessive or inappropriate production of inflammatory mediators. The
anti-Inflammatory effects of n-3 lCPs led to the hypothesis that deficiencies of these FAs may
result In Increased inflammation, and that n-3 lCP supplementation in those with
inflammatory diseases may bring about therapeutic benefits. The mechanisms by which n-3
lCPs might work to reduce intestinal inflammation, as summarised by Teitelbaum (2001) (141),
are shown diagrammatically in Figure 11. Accordingly, many n-3 lCP supplementation trials
have been conducted to test this hypothesis.
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Figure 10: Synthesis of eicosanoids from arachidonic acid and eicosapentaenoic acid, and sites
of inhibition by eicosapentaenoic acid. PG: prostaglandin; PGI: prostacyclin; TXA: thromboxane;
COX: cyclooxygenase; LOX: lipoxygenase
Most cases have demonstrated anti-inflammatory effects although, except in rheumatoid
arthritis, evidence for clinical benefits is still lacking. Several reviews have been published on
the topics of n-3 LCPs/fish oil and rheumatoid arthritis (142-145), cystic fibrosis (146), psoriasis
(147), patients critically ill or undergoing surgery (148), and IBD (149, 150). In a general review
on PUFAsand inflammation, Calder (2006, citing the aforementioned reviews) concluded that
the anti-inflammatory actions of n-3 LCP-induced effects may be of therapeutic use in
conditions with an acute or chronic inflammatory component (151).
The several clinical trials conducted to test the effects of n-3 PUFAsupplements on clinical
outcomes in lBO, which have been included in published systematic reviews (152-155), have
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been summarised in Table 1. Overall, the studies have reported mixed findings. The results of a
comprehensive systematic review on IBD suggested that the available data were insufficient to
draw conclusions about the effects of n-3 FAs on clinical, endoscopic, or histologic scores or
induced remission or relapse rates, and that future studies are required to assessthe effects of
n-3 FAson clinical outcomes in IBD (152).
Since 2007 (i.e. after the start of the trial described in this thesis) two Cochrane reviews on
omega-3 FAs in relation to remission in ulcerative colitis and Crohn's Disease have been
published (153, 155). A similar Cochrane review addressing fish oil in relation to induction of
remission in ulcerative colitis was published in 2007 (154). Only three studies were included on
the subject of remission in ulcerative colitis. A pooled meta-analysis showed no benefit of n-3
FAs. However, it was stated that further studies using enteric coated capsules (which release
their contents in the small bowel) may be justified. Similarly, no benefit was found for
maintenance of remission in Crohn's Disease, and the data did not support routine
maintenance treatment with n-3 FAs.
The data on trials using fish oil for the induction of remission in ulcerative colitis were
limited and so provided insufficient information for determining whether fish oil treatment is
effective. All three analyses found fish oil/n-3 FA treatment to be safe.
Thus, despite several favourable studies as shown in Table 2 - particularly that of Belluzzi
(1996) which, in a well-designed trial with a substantial sample size (n=78), found n-3 LCPs
effective in significantly improving remission in Crohn's Disease - the most recent view is that
n-3 LPShave either no clinical benefits in 18Ds,or that the data are inconclusive.
Despite the bulk of investigations surrounding the role and therapeutic potential of n-3
LCPs In IBD and other "inflammatory conditions, studies investigating the physiological
functions of early dietary n-3 LCPs In relation to environmental enteropathy and its related
growth faltering in infants are lacking, leaving it a largely under-researched area.
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Figure 11: Mechanism by which n-3 lCPs might exert immunomodulatory and anti-inflammatory
effects
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Chapter 1: Background and introduction
1.3.3 Cognitive development
DHA and AA accrue rapidly in the human brain during the third trimester and the early
postnatal period, when the rate of brain growth is maximal and therefore vulnerable to the
effects of nutritional deficiencies. Epidemiological evidence reports associations between
infant DHA status and neurodevelopmental outcomes as shown in several studies (170-174).
During the perinatal period, n-3 FAsare required by the membranes of photoreceptor cells
for membrane biogenesis, and by synapses for synaptogenesis. They are also required during
response to injury to the nervous system and retinal stimulation, both of which trigger the
release of DHA from membrane phospholipids (51, 175). After 30 weeks gestation a
preferential desaturation of n-3 PUFAsoccurs in the brain, DHA increases quadratically, and AA
decreases linearly in phosphatidylethanolamine (176). In the retina and forebrain, the
proportion of n-3 FAs Increases while n-6 FAs decrease throughout development, as
demonstrated by a sharp Increase in the ratio DHA:AA (51).
Evidence around the importance of essential FAs in early cognitive development first
emerged when infants receiving breast-milk displayed cognitive advantages over those
receiving formula milk (177-180). Although the mechanisms underlying neurodevelopment
related to DHA Intake In humans remain to be elucidated, it has been suggested that the
effects on central nervous system development are likely mediated by the role of essential FAs
on gene expression, membrane structures, and electrophysiologic responses (181). Since
breast-milk and the standard formula sold at the time differed in respect to their LCPcontents
- with formula milk containing no preformed LCPs- trials testing the effect of LCP-enriched
formulas on Infant visual and neurodevelopment were undertaken to test for any benefits
derived.
Visual development, or acuity, is typically tested using electrophysiological measures such
as visual evoked potential, or forced choice preferential looking. Cognitive development may
be measured using either generalised or more specific developmental tests. Commonly used
standard generalised tests are the Bayley, Griffith, Catell and Gesell scales of infant
development, or the Brunet-Lezine test of psychomotor development, which predominantly
measure perceptual and motor abilities. More specific, non-standardised evaluations, testing
for example problem solving (e.g. the Willatts Test), information processing, language
development, or more abstract cognitive abilities each measuring different components of
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brain development, are also used. The Willatts Test is based on the original thoughts and
theories of the prominent Swiss philosopher-scientist Jean Piaget, which were developed in
the early-mid zo" century. The procedure and scoring were later designed and developed by
Willatts (182, 183). It was found that the ability of young children to solve simple problems
develops rapidly during a limited period after 6 mo of age. At 9-12 mo this problem-solving
ability enables the child to solve more complex problems, such as combined pulling and
searching to retrieve a toy.
At least nine formula milk supplementation trials conducted in preterm (79, 80, 121, 122,
124, 127, 184-187) and thirteen trials in term infants (55, 81, 102, 105, 108, 113, 188-197)
have been described and summarised in a thorough review on PUFAs in brain and visual
development by Uauy in 2001 (181). The review concluded that evidence for a beneficial
effect of AA and DHA supplementation on central nervous system functioning is strong, and
that the preliminary information on cognitive development is insufficient to fully establish a
claim for an LCPeffect on mental development.
A Cochrane review, also published in 2001 (198), included seven studies assessing
LCP-supplemented formula milk in relation to the intellectual development of term infants.
Three studies, using the Bayley Scales of infant development, showed no effect of
supplementation on development (81, 113, 190, 199, 200), while one study reported a positive
effect of LCP supplementation at 18 mo (108). Using the Brunet-Lezine developmental
quotient, one study reported a positive effect of supplementation at 4 mo (192) but not at
follow up at 1 and 2 years (191). Another study (201) found beneficial effects of LCPs on
novelty preference measured by the Fagan Infant Test at 9 mo, and Willatts et al. (1998)
reported better problem solving at 10 mo with supplementation (195). The reviewer
concluded that "At present there is little evidence from randomised trials of LCP
supplementation to support the hypothesis that LCP supplementation confers a benefit for
visual or general development of term Infants ...A beneficial effect on information processing is
possible but larger studies over longer periods are required to conclude that LCPUFA
supplementation provides a benefit when compared with standard formula."
Since 2001 this Cochrane review has been updated and re-published in 2008 (lOO) (review
also cited under Section 1.3.1) to include four further studies, all of which measured infant
development using the Bayley Scales and found no effect of the LCP-supplemented formula
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(104-106,110, 11S). A Cochrane review investigating the subject of LCP-supplemented formula
in preterm infants found similar results.
Considering that investigators used different developmental tests, measuring different
components of brain development, conflicting results are not surprising. Studies examining the
role of LCPs in infant development using standard generalised tests have rarely shown any
benefit. Studies using more specific components such as look duration, attention, or
problem-solving abilities (Willatts Test), however, mostly found benefits of LCP
supplementation. Indeed, DHA is important to cognitive processes supported by the frontal
regions of the brain (202-207), where functions which integrate and control attention and
response components with long-term and working memory take place. A number of studies on
look duration in human as well as primate infants have found associations between n-3 or DHA
levels/intakes and accelerated development in attention maturity (122, 131, 208, 209). DHA
has also been shown to lead to improvements in synaptic efficiency (210) and transmission
speed (2U), theoretically aiding in the efficiency with which information is processed. For this
reason, tests which measure frontal region processes, such as attention and problem solving,
may be more valuable and appropriate when examining n-3 LCP in relation to cognitive
development. Furthermore, it has been suggested that problem-solving measures are more
indicative of infant cognition than are the more standardised tests (196, 212).
Overall, no real benefit of LCPsupplementation in formula fed to generally healthy infants
In developed country settings Is suggested by the literature. However, research investigating
n-3 LCP supplementation in a developing country setting such as rural Gambia is lacking.
Developmental advantages such as those reported by groups using frontal cortex related
measures, e.g the Willatts Test and attention assessments, might be detected in children with
less adequate nourishment. Furthermore, most of the formula milk LCPdoses were designed
so as to match concentrations in breast-milk. If a larger dose would be administered, aiming
not to just to meet a requirement, but to act as therapeutic agent, effects may become more
noticeable. If, then, a DHA-derived cognitive benefit was to be observed in Gambian infants,
intervention programmes designed to improve n-3 LCP status in infancy could lead to
Improvement in cognitive function of children in this and other lower-income communities.
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1.4 Introduction to the present study
The effects of supplementing 3 to 9 mo old Gambian infants with fish oil, providing SOOmg
combined DHA+EPA per day, are described in this thesis. The knowledge base regarding the
role of n-3 LCPs in growth, chronic environmental enteropathy, and cognitive outcomes in
infants living in rural areas of the developing world is weak. Some evidence of an effect of n-3
LCPsas found in fish oil on reducing chronic inflammation by immune-modulating effects is
found in the literature.
Growth and stress increase the requirement for PUFA, and unless intake is equal to
increased need, deficiency occurs. Lactation is a time of special mobilisation of PUFA for the
synthesis of infant tissue, of which the brain, rich in n-3 LCPs, places an important demand.
The requirement for PUFAs during lactation has been estimated at 5-7% of calories (89). In
Gambian infants, fat loss due to high rates of chronic environmental enteropathy and diarrhea
is likely, and intakes through weaning foods are low. The present study aimed to ensure a rich
enough supply of n-3 LCPsto infants in the intervention group to not only fulfil a requirement,
and account for any fat losses and malabsorption, but also to have a therapeutic effect.
Gut inflammation and damage first sets in at around 3-4 mo, with the introduction of
weaning foods, and appears especially resistant to repair. The aim of the study, therefore, was
to start supplementing infants (with fish oil containing a high concentration of n-3 LCPs)at 3
mo, in order to prime the Intestinal mucosa and delay or prevent gut damage in the first place.
Fish oil was hypothesised not only to reduce intestinal damage caused by chronic
enteropathy (as measured by absorptive surface area and intestinal "leakiness" in the
dual-sugar permeability test), but to improve growth also - whether as a consequence of an
Improved intestinal mucosal integrity or directly. The trial further allowed investigations into
the effect of fish oil supplementation on developmental outcomes. Although the mechanism is
not fully understood, evidence suggests that cognitive function in children is affected by
nutritional status particularly during the rapid growth phase in first two years of life (213, 214),
and stunting during infancy has been related to poor cognitive function in late childhood (215,
216). It would not be unlikely, therefore, for Gambian infants to suffer developmental insults
in early life, considering the high rates of stunting and malnutrition they endure. A trial
providing nutritional intervention which includes a developmental outcome was thought to be
of benefit In this area where the knowledge gap in regard to rural Gambians is wide.
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Further areas of investigation identified were non-specific markers of inflammation, acute
phase proteins, and general morbidities.
Studies have concluded that environmental enteropathy is characterised by cell-mediated
inflammation in the lamina propria (217). Calprotectin is a sensitive but non-specific marker of
intestinal inflammation and disease activity, which can also be used to monitor the response to
treatment (218). Different diseases, including bacterial infections, lead to the activation of
neutrophils, consequently increasing the concentration of calprotectin in human biological
materials.
Calprotectin in faeces correlates with the number of polymorphonuclear granulocytes
entering the gut lumen. Studies show that the marker correlates well with endoscopic and
histological grading of disease activity in ulcerative colitis and faecal excretion of
indium-111-labelled neutrophils (219, 220). Whereas the dual-sugar permeability test reflects
the Integrity of only the ileum and jejunum (sugars are broken down by bacteria in the large
Intestine (221)), faecal calprotectin could potentially arise from cell-mediated inflammation in
any part of the gastrointestinal tract.
Acute phase proteins were further used to investigate the effect of the Investigational
product on systemic markers of Inflammation and acute phase responses. General morbidities
experienced by Infants (diarrhoea, vomiting, fever etc.) were measured for safety/side effects
monitoring purposes, and to examine any treatment effects in terms of real clinical wellness.
The well-establlshed demographic surveillance system serving the population where the
study was set provides a unique opportunity to follow-up this population for long term
observations and for the asking of further questions.
48
Chapter 1: Background and introduction
1.4.1 Study rationale
1.4.1.1 justification
The research question was considered important because, amongst others, -
a) It had the potential to provide causal beneficial impact of supplementation on a
vulnerable group of the population;
b) It was the first study that looked for an impact of n-3 LCP supplementation on
chronic environmental enteropathy and growth faltering in a developing country
setting;
c) It would provide further insight into the physiological mechanisms of n-3 LCPsand
add further scientific knowledge to the body of literature on the topic;
d) It would provide ground work for future developmental studies in this population.
The study was justified before its start as follows:
Chronic inflammation of the gastrointestinal tract is common in rural Gambian infants and
strongly associated with growth faltering. There is undoubtedly a pressing need for
interventions to successfully redress or prevent this chronic environmental enteropathy and
growth faltering prevalent in rural Gambia and other developing countries.
Improving n-3 LCP status may be associated with outcomes which reduce chronic
inflammation and gut damage. N-3 LCPsupplementation may also positively influence brain
growth, which, as seen In Figure 3 (by inference from the head circumferences), is far below
USNational Centre for Health Statistics (NCHS)standards. Outcomes will thus contribute to the
understanding of the functions of early dietary FAs and their relationship with infant growth
and health In developing countries, and any positive results observed be of scientific and
public health importance.
Studies Investigating the physiological functions of early dietary FAs in relation to
environmental enteropathy In infants are lacking. This is, therefore, an under-researched area
necessitating contributions towards understanding the physiologic role of PUFAs, and
particularly n-3 lCPs, in relation to infant gut integrity, inflammation, and growth faltering, in a
developing country setting.
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1.4.1.2 Potential costs
Poor environment causes chronic immunostimulation by environmental antigens that
keeps the acute phase response working overtime. Increased gut permeability may be an
adaptive response - a modulator of immune functioning/absorption appropriate to the
environment. Short stature, for example, sacrifices height for the sake of surviving on less
nutrition. Similarly, alterations in intestinal morphology and absorption capacity may serve
some benefit to the infant. In lBO, for example, mucosal healing is often not associated with
clinical well-being (222). Inflammation is, overall, a protective mechanism against pathogens,
toxins and allergens. One question therefore was whether a modulated immune response
could result in a weakened communication of a harmful luminal Signal, and whether the
ensuing reduced inflammation and intestinal permeability would be detrimental to host
defence, causing, perhaps, a lack of response for controlling pathogens.
Chronic inflammation, however, is detrimental to tissues by perpetuating damage and,
unlike acute responses, may stem from immune-dysregulation or an exaggerated response to
non-dangerous signals. n-3 LCPsmay therefore restore or improve this regulation, overall, and
prevent or delay tissue damage in the first place, and seal "permeability leaks" that allow
access to antigens. Animal studies, for example, provide support for the role of n-3 lCPs in
providing mucoprotection and maintaining intestinal integrity (223), and have shown that n-3
LCPsreduce mucosal damage associated with ulcerative colitis, promote histological recovery,
and lower mucosal inflammatory eicosanoid levels (224).
Therefore, it was believed that, although no emphasis should be removed from the
importance of Improved sanitation and hygiene in infant health and growth, the randomised
controlled trial described below was an important attempt to ameliorate the widespread
enteropathy seen in Gambian infants, and hence to improve their health, growth and
development.
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CHAPTER 2: HYPOTHESES, AIMS AND OBJECTIVES
2.1 Research hypotheses
2.1.1 Primary hypotheses
1. Dietary n-3 LCP supplementation will improve rural African infants' growth
performance.
2. Dietary n-3 LCP supplementation will protect infant mucosal epithelial integrity.
2.1.2 Secondary hypotheses
1. Dietary n-3 LCP supplementation improves infant plasma n-3 FA status.
2. Dietary n-3 LCP supplementation will enhance the cognitive development of rural
African infants.
3. Dietary n-3 lCP supplementation will reduce the degree of intestinal inflammation
of rural African infants.
4. Dietary n-3 LCP supplementation will reduce infant systemic inflammation.
5. Dietary n-3 lCP supplementation will reduce the incidence of morbidities in rural
African infants.
6. n-3 LCP status will predict gut Integrity and function of rural African infants.
2.2 Aims
2.2.1 Primary aims
To Investigate whether supplementing infants with n-3 LCP s will
1. Improve the growth of rural African children;
2. Reduce, delay, or repair gut damage caused by chronic environmental
enteropathy.
2.2.2 Secondary aims
To assessthe influence of n-3 LCP supplementation on plasma fatty acid profiles, intestinal
and systemic inflammation, and morbidity patterns of rural African infants, and enhance infant
problem solving and attention behaviour.
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2.3 Objectives
2.3.1 Primary objectives
1. To assessthe influence of increasing n-3 LCPstatus on infant growth performance.
2. To test whether n-3 LCP status predicts, and supplementation improves, gut
integrity and function as assessed by the LMR in the dual-sugar permeability test.
2.3.2 Secondary objectives
1. To monitor the influence of supplementation with n-3 LCPson plasma fatty acid
concentrations.
2. To test whether n-3 LCPsupplementation enhances infant cognitive development
as measured by an infant planning test and attention assessment.
3. To test whether n-3 LCP supplementation is associated with the acute phase
response protein expression and systemic inflammation, as assessed by plasma
C-reactive protein (CRP),at-ectd glycoprotein (AGP) and albumin concentrations.
4. To test whether n-3 LCPstatus influences the degree of gut mucosal inflammation
by measuring markers of intestinal inflammation.
5. To test whether n-3 LCP supplementation is associated with infant morbidity
patterns as assessed by morbidity questionnaires and nurse and doctor visits.
6. To investigate cross-sectional associations of outcome variables with n-3 LCP
status.
7. To investigate whether n-3 LCP status at birth predicts later cognitive
development.
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CHAPTER 3: METHODS
3.1 Trial design
The study was a parallel-group, randomised, double-blind, placebo controlled two-arm
trial designed to evaluate the influence of early n-3 lCP supplementation on infant health and
development.
The primary endpoint measures were:
a) Growth
b) Gut integrity
The secondary endpoint measures were:
a) Plasma fatty acid status
b) Infant cognitive development
c) Systemic Inflammatory and acute phase markers
d) Intestinal Inflammation
e) Infant morbidities
3.2 Study population
The study population comprised infants aged 3-9 mo living in the sixteen larger villages of
the West Kiang region of rural Gambia. Initially, all infants were recruited from the database of
an ongoing Peri-conceptual Micronutrient Supplementation Trial in West Kiang. This was
because the data were available, up-to-date, and relatively reliable, and included most West
Klang mothers likely to give birth starting from a few months before the start of the n-3 lCP
supplementation trial onwards.
However, It became apparent that many more births were occurring outside of the
perlconceptual micronutrient trial than expected. This was because some women who were
not likely to give birth and were therefore excluded from the trial (e.g. breast-feeding/not
knowing date of last menstrual period/contraceptive use etc.) nevertheless went on to give
birth. Additionally, nearly a third of the recruited women did not turn up for an obligatory
sonar scan, subsequently not being included in the trial, but possibly giving birth.
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Because recruitment was therefore taking longer than expected, potential subjects were
later drawn from the West Kiang Demographic Surveillance System rather than the original
cohort so as to speed up recruitment. Approximately 135 subjects were already recruited
before moving to recruitment from the Demographic Surveillance System database.
3.2.1 Eligibility criteria
All infants born from the Peri-conceptual Micronutrient Supplementation Trial (later this
changed to "AII infants born" whether from this trial or not) in 16 specified villages of the West
Kiang region of The Gambia, not enrolled in any other study, were eligible to take part in the
study. Subjects with severe congenital abnormalities that could affect growth and
development, those from multiple births, and those with known HIV infection were excluded,
as these conditions might have influenced growth in unpredictable ways.
3.2.2 Selection, enrolment, randomisation and allocation
The village selections were made to permit for adequate recruitment numbers, based on
projections of village birth rates drawn from 2005 West Kiang Surveillance data. Potential
subjects were identified from a central database. They were recruited at 2 to 2.5 mo of age.
A computer-generated permuted block randomisation (block size = 16), ensuring a uniform
distribution of treatments across the seasons of birth, was implemented by the trial
statistician. After subjects were recruited and their parents had provided written consent, they
were enrolled into the study and assigned randomly, using the block-randomisation described
above, on an individual basis and according to date of recruitment, to one of four treatment
codes. Two of these codes corresponded to the active group, and two to a control group, so
that infants were allocated to either the n-3 lCP or control groups in a 1:1 ratio. Infants that
remained in the study stayed on the same allocations throughout the duration of treatment.
3.2.3 Sample size
For the purpose of power calculations, "growth" was assumed to be the difference
between weight or length at 3 and 9 mo of age and that intervention differences were tested
using a t-test. Power and significance levels were set at 90% and 5% respectively.
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Below is given the mean and standard deviation (SO) of the difference between
measurements at 3 and 9 mo of age (i.e. "growth" rate) for 1621 children born in Keneba since
1989:
Variable Mean growth
weight (kg) 1.94
iength (mm) 100
SOgrowth
0.65
25
These figures were applied to the usual formula for Hest sample size:
n =
where:
n = Sample required;' 61.62 = Standard deviations; u=1.96,
v = 1.28; ~1-~2 = Difference between the means
Using this formula values for the minimum detectable differences in growth between
intervention groups were obtained. These were expressed both as absolute units (kg and mm)
and as percentage of the mean growth. It was concluded that a sample size of 75 per group
(see equations below and Table 3) would allow the detection of differences in growth rates of
17.7% and 13.2% for weight and length gain, respectively, between intervention groups.
For growth in weight:
1'1 - ~ = J(1.28 + 1.196)]2 x (2 x 0.165)]2 / 752
= O.343kg (17.7%)
For growth in length:
1'1 - ~ = Jr-Cl-.2-8-+-1-.-r9-6-)]-:z-X-C-2-X-2-5-)2 /752
= 13.233mm (13.2%)
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Table 3. Minimum detectable differences in growth between intervention groups in different
sample sizes
Difference in length gain Difference in weight gain
n per group mm %of mean Kg %ofmean
25 22.921 22.9% 0.594 30.6%
50 16.208 16.2% 0.420 21.7%
75 13.233 13.2% 0.343 17.7%
100 11.460 11.5% 0.297 15.3%
125 10.251 10.3% 0.266 13.7%
A target of n=90 per group was thus set, allowing for a 20% loss to follow-up.
3.2.3.1 Power calculations for gut integrity
No adequately reliable estimates of the variance of LMRs in this population were available
before the study. Instead, after approximately 25% of the collected urine samples were
analysed, power calculations were made in order to test whether, given the reliability of the
test, and the degree of intra and inter-individual variation, it was meaningful to continue with
the rest of the sample analysis.
A one-way analysis of variance of LMR on individual study number (using STATA's
"Ioneway" command), gave an intra-class correlation of 0.42 (95% Cl: 0.24,0.61). The
estimated reliability for the mean of three samples was 66%. Applying the chosen power and
significance level, a sample size of n=90 per group would then thus enable the detection of a
minimum difference of 0.48 SOs.Adjusting for the reliability estimate of the test then gave a
final detectable difference of 0.60 50s. This adjustment expressed the detectable effect size in
terms of between-individual variation, indicating the variance due to genuine differences in
individual gut integrity, independent of measurement methods or errors.
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3.2.3.2 Sample size and cognitive development
Previous (unpublished) data obtained from Peter Willatts for both the Willatts test and the
Attention Assessment were used to calculate how small a difference in cognitive test scores
could be detected given our sample size (which had reached n=90). Using ~=0.9, a=O.05, a
sample size of 90 per group, and SOs of 4.35 and 12.6 for the Willatts Test and mean look
duration (Attention Assessment) respectively, the ability to pick up a difference of 2.1 points in
the Willatts Test and 6.1 in mean look duration was calculated. These differences are 10% and
16% smaller than the differences detected in the studies reported by Peter Willatts.
3.3 Allocation concealment and blinding
Each of the four treatment codes mentioned in section 3.2.2 was represented by a simple
picture (shown in Appendix 1). Infants in the treatment group were therefore allocated to one
of two possible pictures, and infants in the placebo group to one of the other two pictures.
Four different codes as opposed to two were used to assist in blinding. The wife of a colleague,
who was not involved In the study, allocated each picture to a treatment type. This allocation
was sent to the company who provided the oils, who labelled the bottled oils accordingly. The
trial statistician and another colleague (independent of the trial) then kept the
picture-treatment allocation in a sealed envelope until analyses were complete.
The Principal Investigator (PI) remained blinded as to which two codes corresponded to
each other as well as to which picture-group each infant-mother pair had been allocated to for
the duration of data collection. With the exception of the trial statistician - who required the
information for safety monitoring analyses - and the database manager who had access to the
Information, all researchers remained blinded as to which two treatment codes/images
pictures corresponded to each other until all data collection was complete. The PI remained
blinded to treatment allocation until analyses were complete.
After mothers had given their consent, and their infants had been recruited, a fieldworker
issued them with a card printed with the appropriate picture. The cards were prepared and
produced by the data-office staff. One side of the card was printed with the code picture, the
other contained the subject details such as 008, name, sex, and mother's name (Appendix 2).
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Mothers were asked to bring their picture-coded cards when their infants were brought to
be administered the supplement. This enabled field workers to correctly identify which oil to
administer to each infant. Fieldworkers were also given a treatment booklet. It contained
details of infants and their corresponding treatment images from which to read off allocations
in the event of a mother failing to present her card before supplementation, and from which
to cross-check for any card-swapping.
Placebo and treatment oils both contained 1.25% lemon oil with the intention of
flavouring the oils similarly and masking the fish-smell/taste of the active oil for blinding
purposes, and 0.5% rosemary extract as a natural antioxidant. Field workers who were
unaware of which picture codes represented treatment or placebo administered the
supplement.
3.4 The study intervention
3.4.1 Description of treatments
The active group received 2ml highly purified fish oil donated by Nordic Naturals Inc,
Watsonville, CA. This oil, produced from deep-sea anchovies and sardines, was constituently
similar to their commercially available "0mega-3 liquid" (label from commercial product
shown in Appendix 3). However, vitamin E (d-alpha-tocopherol) - added to protect against
oxidation - was requested to be lowered from a concentration of 301U/5ml to 51U/5ml which
Is more appropriate for infants and was advised by the Independent Trial Monitor. The fish oil
contained 10% olive oil to dilute the dose slightly so as to supply 200mg DHA and 300mg EPA
per 2ml. The supplement was administered daily for 24-25 weeks. The dosage of 500mg
combined DHA+EPA per day was designed to achieve a substantial increase in plasma n-3
PUFA to both eliminate any existing deficiencies and to elicit a therapeutic response.
The placebo group were given the same volume of organic food-grade extra virgin olive oil,
also received from Nordic Naturals. This oil predominantly contained oleic acid (67%, a
monounsaturated FA), with small amounts of palmitic (14.4%), linoleic (13.2%), and linolenic
(0.6%) acids. Both fish and placebo oils were bottled in 237m I blue glass bottles with black,
cone-lined caps, and were stored at 4°C.
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3.4.2 Administration of treatments
Fieldworkers administering treatments were stationed in each of four study areas. They
were assigned the duty to visit the villages that were allocated to them each morning, where
they would meet the mothers and subjects at a central meeting point. Mothers were asked to
bring their infants to this meeting point every day.
Village assistants appointed in each village were given the task of preparing tea and bread
to serve to the mothers when they brought their infants, and of tracing and calling those
mothers who were absent. Sterile, graded, 3ml pastettes were used to squeeze the oil into the
side of the mouth of each infant (Figure 12). In order to ensure that it had been swallowed,
and to enhance absorption, mothers were asked to breast-feed their infants immediately after
the oil had been given (Figure 12).
Fieldworkers working in the field were provided with gas-fridges, ice packs and cool boxes
for storage and transportation of oils. The supplement was kept cool at all times to prevent
heat-induced oxidation and so minimise deterioration and rancidificaiton of oils.
In four cases, the mothers of subjects were required to travel outside of the study area for
periods of roughly two to four weeks. In three of these cases, they had access to a fridge.
These three mothers were provided with supplement, ice packs and pastettes, and shown how
to supplement their infants themselves. While they were away, they were contacted daily by
telephone to ask whether they had supplemented their infants, and to ask about the infant's
well-being. In the fourth case, the mother was staying In the village of an MRC fieldworker who
was on leave for a month. Despite being on leave, this fieldworker visited the mother daily to
supplement her infant and complete the morbidity questionnaire.
Towards the end of the study, when it was the dry season and mothers started travelling
to the coast more regularly, a fieldworker was stationed at the coast full-time for a month and
a half. He went around lodgings supplementing the infants for the duration of their stay at the
coast.
The fleldworker administering the dose, using a pre-printed weekly compliance record
sheet prepared separately for each Infant, recorded daily compliance.
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Figure 12: Infant receiving dose, left, and mother breast-feeding immediately afterwards,
right
3.5 Measurements and data collection
Primary endpoints and stool measurements were taken in triplicate at baseline and
endpoint visits. This was done with the intention of minimising some of the intra-individual
variance, and so the standard error, associated with these outcomes and their measurements.
By using the median of the three growth measurements, for example, the more inaccurate
readings were most likely lost, and by using the median of three urinary-sugar determinations,
some of the standard error introduced by day-to-day biological variation was minimised.
Mothers and their infants were brought to MRC Keneba three times at baseline (3 mo of
age) and three times at 9 mo of age (alternate days for both), for a five-hour clinic visit. During
each of the visits anthropometric measures, urine, and stool samples were collected. Blood
was drawn from infants, and breast-milk from the mothers, once at baseline and once at
endpoint.
Mothers expressed approximately Sml breast-milk from both breasts before their infants
received their first feed at the clinic, and again immediately after they had fed their infants.
The breast-milk samples were pooled by mixing together 1ml of each of the four collected
samples, and a 2ml aliquot of this pooled sample stored at -80°C until analysis.
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Human breast-milk lipid concentration increases several fold between the beginning and
end of a feed (225-228). In order, therefore, to gain a more accurate indication of the amount
of fatty acids consumed by infants during an average feed, it was important to not only sample
the fat-rich hind milk, but also the more dilute foremilk. However, this timing could have been
a possible source of error in estimating the true average fatty acid concentrations of the
breast-milk. Many studies on the topic have used a full breast expression or only a hind-milk
sample from women, and the fatty acid concentration of the breast-milk investigated in this
way. Sample timing therefore needs to be considered when making comparisons with other
literature. Nevertheless, it is known that although the lipid concentration of breast-milk
changes across a feed, the fatty acid composition of the lipid stays constant (226, 229, 230).
When making comparisons with other studies, the relative fatty acid concentrations of the
Gambian mothers' milk were consldered, rather than the absolute concentrations of fatty
acids, and in this way the errors introduced by sample timing avoided.
A malaria slide was prepared at each blood draw for timely detection of any parasite
infection. It also served to protect the Investigators, as, were an infant to fall seriously ill
shortly after their blood was drawn, the community might have ascribed the cause to the
drawing of blood.
Infants were brought for their final follow-up visit involving a cognitive test at 12 mo of
age.
Each month a basic weaning foods questionnaire was completed by the mother and
fleldworker Intending to, for descriptive purposes, gain some indication of the age at which the
Infants were weaned, and onto which foods.
For safety monitoring purposes only, length, weight, He and knee-heel length was
measured In the field at 5 and 7 mo of age, by trained fieldworkers. These data were used at
interim safety monitoring assessments to check for any treatment-group differences in
growth.
The various samples and data collected during the clinic visits, and at other time-points,
are summarised in Table 4.
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3.6 Primary endpoint measurements
3.6.1 Growth
Infant length was measured with a Harpenden Infantometer Measuring Table to within 0.1
cm precision. Weight was measured to within 0.01 kg precision using a Seca (Model 336)
electronic baby scale. Knee-heel length, measured with a hand-held Chasmors Knee to Heel
Measure sliding calliper (0.1 cm precision), was used as a sensitive measure of lower-leg
growth.
Skinfold thickness, measured with a sklnfold calliper (Holtain!Tanner/Whitehouse Model)
to 2 mm precision at specific sites, always using the left side of the body, was assessed as an
indicator of subcutaneous fat accumulation. Mid-upper-arm circumference (MUAC), indicative
of muscle mass and subcutaneous fat, was measured on the left arm, using a paper measuring
tape specially designed for this purpose, to a precision of O.lcm. HCwas determined as a proxy
for brain size. Because it changes rapidly during infancy, HC can also be used to monitor
growth. It was measured with a stretch-proof measuring tape (Model CTM08) around the
maximum circumference of the head (forehead to occiput) to the nearest O.lcm.
All equipment was purchased from Chasmors Ltd., London, UK. The PI, assisted by a
trained field worker, took anthropometric measurements using regularly calibrated standard
equipment.
Growth data were expressed in absolute units at baseline and endpoint, and growth rate
between these two polnts. Infant weight-for-height, as well as
welght/height/head-clrcumference/MUAC/subscapular and triceps skinfolds-for-age were
expressed as z-scores based on the 2006 WHO Growth Reference Data (231, 232). By
calculating the z-scores the data were automatically corrected for age and sex.
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Table 4: Data collection and measurements by time-point
Time-point Samples/data
Day 1 of 3 mo and 9 mo visits
Infants
2ml venous blood
Weaning foods questionnaire
Malaria slides
Day 1, 2 and 3 of 3 mo and 9 mo visits Urine (LMR)
Stool samples (calprotectin)
Anthropometry (3 measures)
Throughout for 6 mo Daily morbidities, nurse/clinic visits
4 mo
Compliance monitoring
Weaning foods questionnaire
Anthropometry in field for safety monitoring
Weaning foods questionnaire
Anthropometry in field for safety monitoring
Weaning foods questionnaire
Weaning foods questionnaire
Cognitive test
Mothers
4ml breast-milk
5 mo
7 mo
8 mo
12 mo
Day 1 of 3 mo and 9 mo infant visits
12 mo infant visit Education questionnaire
Other data available
Buffy coats collected for DNA extraction
Cord blood serum, maternal serum
9 mo
Birth (from PMMST)
3.6.2 Gut integrity
Intestinal surface area and permeability were measured by way of the dual-sugar
permeability test. For this, infants were given a 2ml/kg body weight dose of sugar solution,
containing 400mg lactulose (Lactulose Solution BP, Sandoz Ltd.) and lOOmg mannitol
(Sigma-Aldrich Co.) per 2 ml water.
An indication of passive intestinal absorption, the recovery of the monosaccharide,
mannitol, is reduced in the presence of villous atrophy. Uptake of the disaccharide, lactulose,
is measured as a marker of intestinal leakiness. Whereas lactulose passage across the intestinal
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barrier is prevented by healthy enterocytes, in the damaged gut it is more readily absorbed,
probably paracellularly. This comparison is illustrated in Figure 13. Intestinal permeability,
therefore, is measured as urinary lactulose concentration divided by urinary mannitol
concentration. By measuring total urine volume passed, percentage recoveries of the two
probes could be calculated as a reflection of the amounts taken up by the passive and the
paracellular intestinal routes.
The value of this test is well expressed by lunn et al. (1991) (30): "Because of its
non-invasive nature and simplicity, and because no complicated equipment is required,
mucosal status can now be assessed frequently on large numbers of individuals, even under
field conditions. It provides a quick and objective way of determining the pathological impact
on the gut, and ultimately on growth performance, of the wide range of potentially adverse
environmental conditions to which infants in developing countries are constantly exposed."
On the morning that Infants were brought Into the clinic, they were given the sugar
solution by means of a graded syringe approximately 30 minutes after their last feed.
Breast-milk was then withheld for a further hour. Total urine volume passed over the next 5
hours was collected using paediatric urine bags (Hollister U-bag, Abbot labs, Queensborough,
Kent, U.K.,). Figure 14 and Figure 15 show photos of the urine collection visits and urine bags.
Urine was drained into collecting bottles (Figure 15) containing 2-3 drops
chlorhexldlnegluconate (5% weight/volume) as a bacteriostatic agent. After urine volumes
were measured, 2 x 2ml aliquots were collected and stored at -80·C for later sugar analysis.
Urinary lactulose and mannitol concentrations were measured in Keneba using a 96-well
microplate enzymatic assay. The method was developed by Dr Peter lunn in Cambridge as an
adaptation of a previously described technique for use on the Cobas-Bio centrifugal analyzer
(233-236). All samples were measured In duplicate.
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Figure 13: To the left a healthy gut with normal absorptive capacity and healthy tight
junctions. To the right intestinal mucosa displaying poor integrity with less absorptive
capacity and leaky tight junctions.
Figure 14: Mothers and infants during urine-collection time
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Figure 15: Urine bottles used to drain urine into, and Hollister U-bag used for urine collection
3.6.2.1 Labora tory work in Keneba
Lactulose assay
The assay measures urinary lactulose concentration by measuring the amount of fructose -
one of its component monosaccharides - released when enzymatically hydrolysing lactulose
with ~-galactosidase. Fructose is then phosphorylated by ATP using hexokinase, forming
fructose-6-phosphate which is converted to glucose-6-phosphate by phosphoglucose
isomerase. Glucose-6-phosphate is further oxidised by glucose-6-phosphate dehydrogenase to
form gluconate-6-phosphate, in the presence of NAD. An equimolar amount of NAD becomes
reduced to NADH, which absorbs at 340nm. The resulting increase in absorbance is directly
proportional to the fructose concentration, and so therefore also the lactulose concentration.
This reaction is illustrated in Figure 16.
In order to account for any free fructose which may be present in the urine and augment
the lactulose concentration artificially, the concentration of free fructose is also measured (in a
similar reaction but without the addition of ~-galactosidase) and subtracted from the
determined lactulose concentration.
The assay simultaneously allows the measurement of lactose in the sample. Previous data
show that in breastfed Gambian infants, poor gut integrity is associated with lactose
maldigestion (46). Lactase concentrations are low in a damaged intestine because of the
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vulnerable position of lactase bearing cells in the brush border, which become damaged by
enteropathy (46). Urinary lactose concentrations were therefore also assessed as an additional
observation.
Lactulose
8-galactosidase (31'C)
Fructose Galactose
CH2~ OH 1
~H~H·
OH
Fructose-6-Phosphate
Hexokinase +A TP___ ..J
Glucose-6-phosphate
ATP ADP
I
Glucose-6-P dehygrog. _j
I ---
, +ADP
- PGIr
1 OH_ ....
NADP
NADPH
Gluconate-6-Phosphate
OH OH OH
HO 0 , ; l
'p".-~~o
HO/' \\ :'
o OH OH
Figure 16: Enzymatic reactions involved in the lactulose assay. PGI - phoglucoseisomerase
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When the urine is treated with ~-galactosidase, as explained above, lactose is hydrolysed
into glucose + galactose. In the reactions that follow, using the same enzymes as for fructose
determination, glucose is phosphorylated to glucose-6-phosphate and then oxidised to
gluconate-6-phospate in the presence of NAD. During this oxidation, an equimolar amount of
NAD is reduced to NADH. The consequent increase in absorbance at 340nm is directly
proportional to glucose (and therefore lactose) concentration. Similar to what is done for the
lactulose determination, free glucose is also measured without the addition of ~-galactosidase
and subtracted from the lactose concentration to give the final urinary lactose value.
Mannitol Assay
For the quantitative, enzymatic determination of mannitol in urine, NAD is added to it in
the presence of mannitol dehydrogenase. Mannitol is converted to fructose, while NAD
becomes reduced to NADH (Figure 17). The consequent increase in absorbance at 340nm (due
to NADH) is directly proportional to mannitol concentration.
Mannitol
Manntitoldehygrogenase + NAD
Fructose
C~HlOH OH
o
CH70H
OH
Figure 17: Mannitol assay reaction
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All enzymes were purchased from Sigma-Aldrich Co., apart from mannitol dehydrogenase
that was bought from Biocatalysts ltd. Plates were read using an Appliskan plate reader with
automated injection feed (Thermo Scientific, part of Thermo Fischer Scientific, Waltham, MA,
USA).
Assay workup
Reagents and standards were tested by running a series of standard curve repeats, and
later urine-sample repeats.
The mannitol assay responded well during preparatory runs, and the protocol could be
followed without the need for any adjustments. The standard curve test produced a good
linear fit (R2>O.99), with good reproducibility between parallel curves (percent coefficient of
variation < 2%). The same held true when testing urine sample replicates.
A great number of challenges were faced with the lactulose assay, however. The first few
standard curve series repeats produced intermittent highly erroneous results in inconsistent
patterns, with poor reproducibility. After making certain adjustment (e.g. adding small reagent
volumes by hand rather than via the automatic injection feed) it appeared as though, on a
half-plate containing six sets of standards, the reaction was not going through to completion in
all six of the cases. These results are presented in Figure 18. Some curves demonstrated a good
linear fit, while others clearly did not. However, when omitting the B-galactosidase step (for
plates Intended for measuring glucose and fructose concentrations), the standard curves
produced high degrees of reproducibility and goodness of fit. Because the errors were far
more prominent in the lactose/lactulose part of the assay, where B-galactosidase was added, it
appeared that the B-galactosidase enzyme may be at fault, or that the temperature/pH
conditions were not optimal for the hydrolysis of lactulose and lactose. Additionally, after
further Inspection, it became apparent that the hexokinase reaction had not plateaued before
the phosphoglucoselsomerase was added, so a longer incubation time for this reaction was
also tested.
After all reagents were prepared freshly and their pH checked, two standard curve series
were treated with a four-hour-Iong B-galactosidase incubation period (in contrast to the
standard two hours), two series with a longer hexokinase reaction incubation, and two series
with the standard protocol.
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The results of these incubations (Figure 19) were that, as before, the glucose/fructose
assay (requiring no B-galactosidase addition) responded well. For lactose/lactulose assays,
wells that were allowed to incubate according the standard protocol produced the best curve
fits, and wells exposed to a longer hexokinase step incubation were failures. One of the series
allowed to incubate for four hours during the B-galactosidase step produced a curve with good
fit, whereas the matching second series did not. Hence, it appeared that neither the
incubation time nor the enzyme was at fault, but that some other cause was affecting different
well columns differently.
1.2 Lactose 001 1
Lactose 002 0.9
1 1-'- Lactose 003 0.8_ Lactose OD4
0.8 _ Lactose ODS 0.7
_._ Lactose 006 0.6
0.6 0.5 Lactulose 001
0.4 ........ tactulose 002
0.4 0.3 _._ Lactulose 003
0.2 --i- l.actulose OD40.2 -+- Lactulose ODS0.1 /
_._ Lactulose OD6
0 ,- -- -r---._--, 0 ----,-----,
0 50 100 150 0 50 100 150
Figure 18: Lactulose assay standard curve test results. "OO"S are "change in optical density."
To the left: reaction measuring lactose concentration, and to the right: lactulose
concentration.
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Figure 19: Results of standard curves treated with varying incubation times
Various plate layouts were designed and tested, and so each possible cause for faulty
reactions was investigated and ruled out. A big influence appeared to be interferences caused
by the plate reader. After seeking advice from Peter Lunn the injection feed jets were cleaned
and the machine serviced. This effected a big improvement on assay results. Yet, still at times
the optical density readings increased abruptly and unexpectedly half-way through a plate
reading and the assay had to be repeated; but this, it was realised, occurred only when a
number of plates were read in succession, so the machine was in future turned off and allowed
to cool down between runs if many were done in sequence. Although % coefficient of
variations [Cvs] between replicates were occasionally inexplicably high, overall they were on
average acceptable «10%) and standard curve R2 always greater than 0.98.
71
120
120
Chapter 3: Methods
Calculations
Differences between optical densities were calculated to generate values for free glucose,
free fructose, lactose+glucose and lactulose+fructose urinary readings. Concentrations for
these optical density changes were determined against relevant individual standard curves,
and adjustments made for any concentrated urine samples that were required to be diluted in
order to fall within the standard curve. Average concentrations between replicates were
determined, and final lactulose and lactose concentrations calculated by subtracting free
fructose and glucose values from lactulose+fructose and lactose+glucose values, respectively,
at baseline and endpoint.
Optical density change was similarly calculated for mannitol. Concentrations were
determined against the standard curves, and a mean baseline and endpoint mannitol
concentration computed for each individual.
The ratios of lactulose-to-mannitol, as well as lactose-to-Iactulose, were calculated for
each sample (unaveraged), and the individual median LMRs and lactose:lactulose ratios
determined for baseline and endpoint.
Finally, percent recoveries for lactulose and mannitoi were calculated by computing the
total amount of sugar passed in the urine (concentration of sugar measured by the assay x
total urine volume collected) as a percentage of the original dose given.
3.7 Secondary endpoint measurements
3.7.1 Plasma fatty acids
An experienced nurse drew approximately 2ml venous blood from infants at baseline and
endpoint. Blood was kept on Ice until centrifugation 5 - 20 minutes after collection, and then
spun at 3000rpm for 20 minutes at 4°C. The plasma supernatants were transferred to
mlcrotubes and the headspaces flushed with nitrogen to minimise the oxidation of volatile
PUFAs, before storing them in 81-space mlcrotube boxes at -80°C.
At baseline blood was drawn Into IIthium-heparin-coated tubes. As part of a potential
collaborative study, buffy coats were collected for DNA extraction purposes at 9 mo. Because
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heparin may inhibit PCR reactions, EDTA was used as anticoagulant at 9 rno, after verifying that
the change in anticoagulant would not interfere with FA and clinical chemistry assays.
Once filled, boxes were sent to the MRC Collaborative Centre for Human Nutrition
Research in Cambridge, UK, by air, on dry ice, for extraction, derivatisation and analysis of FAs
by GC with flame ionisation detection. Plasma was sent in four different batches. Once
received in Cambridge they were once again stored at -80 QC. In order to avoid batch
differences, laboratory analysis commenced only once all samples had been received.
Apart from measuring only the FAs of interest, additional markers were also used to assess
PUFA status. Because plasma content of essential fats does not necessarily indicate proper use
of these FAs by cells and tissues, additional status markers are useful for determining
functional PUFA status. The essential FA status index, for example, was assessed. It measures
the ratio of all essential-ta-nonessential unsaturated FAs and increases in value as PUFA status
improves.
Docosapentaenoic acid (22:5 n-6) is synthesised in conditions of DHA functional shortage.
DHA:docosapentaenoic ratio was therefore similarly used as a functional DHA status marker.
The ratio n-6:n-3 FAs was another measure of interest. This ratio has been found to have
significant correlations with outcome measures, with lower ratios related to outcomes that are
more beneficial.
The FAs and FA relationships of interest are given in Table 5.
Table 5: Fatty acids and fatty acid relationships assessed
Monounsaturated n-6 PUFAs n-3 PUFAs Fatty acid relationships
Sum of all n-6 DPA
AA/EPA+DHA
DHA/DPA
(n-3 + n-6)/(n-7+ n-9)
Oleic acid C18:2 (linoleic) C18:3 (a-linolenic)
AA EPA
DHA Sum of n-6 ~ C20/ Sum of n-3 ~ C20
Sum of all n-3
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3.7.1.1 Laboratory work at Human Nutrition Research Centre, Cambridge
Preparation of total lipid extract
Total lipid extracts were prepared from 200 I,d of thawed plasma, to which 25 III of internal
standard was added to compensate for any losses during extraction and derivatisation, using
an adaptation of the method of Folch (237). Plasma was homogenised with chloroform and
methanol, and washed with 1M NaCI solution. After vortexing briefly, the mixture was
centrifuged at low speed (2000rpm) for ten minutes to separate the phases. The lower phase
was then collected and evaporated to near dryness.
Preparation offatty acid methyl ester (FAME)
FAME's were prepared by acid-catalyzed esterification. Boron triflouride (14%) was added
to the reconstituted lipid residue, and the mixture heated for 45 minutes at 75 DC.After
cooling, hexane and water were added, and the mixture centrifuged at low speed for ten
minutes. The upper hexane layer was then transferred to a glass tube and placed under a
vacuum drier. Once dry, the residue was reconstituted with hexane, and this mixture
transferred to a GCauto sampler vial, ready for GCanalysis.
Analysis of samples by GC
A BPX70 column (70% cyanopropylpolysilphenylene-siloxane, supplied by SGE), with
polarity designed specifically for FAME analvsls, was used for fractionation. This column can
withstand temperatures up to 250 DC and its nominal dimensions are 30m long, 250111
diameter and 0.25 III film thickness. The carrier gas was helium. The front inlet temperature
was set to 240°C and pressure to 13 psi.
Elution profiles for each sample were obtained, consisting of 38 peaks representing
relative proportions of the different FAs. Each of the FA components was quantified against a
calibration range of external standards of known concentration (ngllll), using linear regression.
Absolute as well as relative percentage values of the different FAswere therefore available.
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3.7.2 Cognitive Development
Following the advice of the PI's upgrading panel, this endpoint was included in the trial as
an added outcome. The tests were therefore only piloted at a later stage, and once training
and piloting was complete, ethical approval was sought and gained later than the approval
granted for the main study. For this reason parents were visited a second time to seek
informed consent for participating in this component of the study. The information and
consent forms used are presented in Appendix 4.
At 12 mo of age (±7 days) infants were brought in for their final follow-up visit to test their
cognitive development by means of a 2-step means-end problem-solving test (Willatts Test)
and an attention assessment.
The aim of the Willatts Test is to present a challenge to an infant, and then observe
whether they are capable of planning and executing a solution in order to solve the challenge.
The challenge is to retrieve a toy, which is either concealed or out of reach. The infant needs to
manipulate an intermediary object (cloth or cover) in order to retrieve the goal and the
intentionality which the child uses to retrieve this goal (toy) is then assessed.
Infant habituation, a decrease in attention to a repeatedly presented stimulus, is
considered a basic tool for assessing cognition or processing speed in infancy. As already
mentioned in the Introduction, evidence from n-3 and DHA supplementation (and depletion)
studies suggest that attention in infancy may be associated with DHA intake.
The Toddler Attention Assessment involves a single-object free-play task, where toddlers'
attention to a complex toy Is assessed. The toddler is seated at a table, the toy presented for 5
minutes, and the toddler allowed to explore and manipulate it freely. The time from the start
to end of each look to the toy, and each look away from the toy, is recorded. A mean duration
for looks to the toy and the number of episodes of inattention is then calculated. Procedures
for the assessment are described below, and in Colombo et al. 2004.
Both the PI and a British graduate student attended a two-day training session with Peter
Willatts In Dundee, UK, before the start of the cognitive development pilot study. They
received training for conducting both the Willatts Test and the Toddler Attention Assessment,
as Peter Wlllatts had previously worked closely with the developer of the attention test.
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The graduate student performed all test scoring. A 30% sample of Willatts problem-solving
tests were scored by the PI for test validation purposes. Because this test is open to a high
degree of subjective interpretation and inter-observer variability it was important to validate it
for quality control purposes.
Due to cultural constraints and distress or curiosity displayed by some of the infants when
in contact with white adults, a trained Gambian fieldworker carried out all tests. They were
filmed and saved for later viewing and scoring.
To control for any potential stimulatory influences infants may have received in the home
were their mother educated as opposed to illiterate, the mother, with the help of the
fleldworker, filled out a basic education questionnaire in order to gain an indication of the
highest level of education, if any, she had received. This form is shown in Appendix 5.
3.7.2.1 Test procedures
On the morning of the test, mothers were asked to ensure that their infant had been
recently fed prior to testing to avoid them being hungry, and therefore distracted, during the
15 minute test.
The mother was asked to sit on a chair with her infant on her lap facing a table placed in
front of her. The Infant's arms were required to be free to play with the objects in front of
them on the table. The mother was asked to make sure her child is secure on her lap, but to
not restrict movement by holding him/her. She was also asked not to help, encourage, or
prompt her child by either words or actions and not to encourage the infant's eye contact
when he/she looks up at her.
For standardisation, the Willatts Test was performed first, followed by the Toddler
Attention Assessment. If an Infant did not respond during the Willatts Test, the Attention
Assessment was completed first, and a second attempt at the Willatts test made thereafter.
After completion of both tests, anthropometry measurements of the child were also taken.
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3.7.2.2 Willatts Test
The steps of this two step means-end-problem solving test are listed below:
Part 1-Cover Pretest (carried out twice)
A small toy was handed to the infant so that they showed interest and picked it up. If the
infant showed no interest, the toy was replaced with another.
A small towel cloth (20cmx20cm, called the "cover") was presented to the child. He/she
was allowed to handle it and become familiar with it.
The toy was placed on a sliding tray (25x30cm), with the cover over it so that it became
hidden. It was ensured that the child was watching while this was done.
The tray was pushed towards the child so that the cover with the toy underneath it became
within reach.
Thirty seconds were allowed for the child to solve the problem and retrieve the toy by
removing the cover (Figure 20, left).
Part 2 - Cloth Pretest (carried out twice)
A towel cloth (20cmx30cm, different colour to cover) was handed to the child so that they
could handle it and become familiar with it.
The cloth was placed on the tray and the toy placed on top of it, at the far end of the cloth
from the infant. It was ensured that the child was watching while this was done.
The tray was pushed towards the child so that end of the cloth became within reach of the
infant, but not the toy (forcing the infant to pull the edge of the cloth towards them
bringing the toy with it; Figure 20, middle).
Thirty seconds were allowed for the child to solve the problem and pick up the toy by
pulling the cloth close enough to reach the toy.
Part 3 - Barrier Pretest (carried out twice)
A foam barrier (Figure 20, right) was presented to the child to handle for a short while.
The barrier was then placed on the tray and the toy placed directly behind it. The tray was
pushed towards the child so that the barrier was within easy reach.
Thirty seconds were allowed for the child to solve the problem and pick up the toy by
picking up and removing the barrier in order to reach the toy.
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Part 4 - Two Step Problem (repeated 5 times)
With the infant watching, the towel was placed on the tray with the toy on the cloth at the
far end of the table, so that the infant could not reach the toy. The cover was then placed
over the toy as shown in Figure 2l.
The tray was pushed towards the infant so that the near edge of the cloth became within
reach.
The child was allowed thirty seconds in which to solve the two step problem and retrieve
the toy by pulling the cloth close enough to reach the cover (Figure 21) and then remove
the cover to pick up the toy.
Figure 20: From left to right the cover pretest, cloth pretest, and barrier pretest steps
Figure 21: Two-step problem test setup and challenge
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Scoring
For the 2-step trials, each of three behaviours while solving the problem - 1) behaviour
with the cloth/cover, 2) fixation on the toy, 3) and behaviour with the toy - was scored on a
scale of 0 to 2. "0" was given for no evidence of intention, "1" for possible intention, and "2"
for clear evidence of intention for retrieving the goal.
A brief description the behaviour scores are given In Box 2.
The two outcome measurements were as follows:
a) Trial behaviour scores were averaged to give a mean "total intention score".
b) Each trial in which there was a score of "1" or more for all three behaviours was
considered to be an intentional solution. The number of trials in which the child
showed some sign of Intention became the "total intentional solution score".
However, the results from the pilot study indicated that the scores obtained on the pretest
trials were useful as they contained a large amount of information which appeared to have
good discriminatory power for distinguishing between infants of differing degrees of problem
solving abilities. Thus the average that Infants obtained across all pretest trials attempted was
used as a third outcome called "pretest average".
Full scoring Instructions and the scoring sheets are provided in Appendix 6.
79
Chapter 3: Methods
Box 2: Infant behaviour scores
Cover/Cloth behaviour:
Score=O: Child failed to -
a) contact the cover/cloth,
b) bring the toy within reach/reveal the toy by lifting the cover, or
c) engage in playing or examining the cloth at any time.
Score=l:
a) Infant pulled the cloth/lifted the cover without any play or examination and
brought the toy within reach/revealed the toy, but began an activity which may
have been playing with or examining the cover/cloth, but did not carry it through
to completion, and
b) did no let go of the cloth/cover for more than 1 sec before the toy was within
reach.
Score=2:
The infant pulled the cloth/lifted the cover without any play or examination and
brought the toy within reach/revealed the toy.
Fixation behaviour:
1. Score=O: The infant looked away from the toy for more than 2 seconds.
2. Score=l: The infant briefly looked away from the toy, but looked back within 2
seconds.
3. Score=2: The infant was continuously looking at the toy.
Toy Behaviour:
1. Score=O: Infant failed to contact the toy or touched the toy but made no attempt
at grasping it.
2. Score=l: Infant attempted to grasp the toy but did not pick it up.
3. Score=2: Infant successfully grasped the toy and picked it up.
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3.7.2.3 Toddler Attention Assessment
A "V-Tech" Nursery Rhyme" toy, as in Figure 22 below, was presented to the infant for free
play. The Nursery Rhyme is a complex electronic toy with various interesting features such as
colourful buttons, songs and sounds, which stands in front of the infant on the table. After the
toy was presented to the child they were encouraged to play with it. The tester would
demonstrate by pressing some of the buttons. The infant was then allowed five minutes to
explore and manipulate the toy freely. Precautions were taken to prevent any distractions
during this time of play. At the end of five minutes the filming was discontinued and the test
procedure complete.
Figure 22: Infant playing with V-tech ® toy during an attention assessment
Scoring
The video recording was played back using "Virtual Dub mpeg2" software which allowed
frame-by frame playback viewing, so that each frame corresponded to a given time-interval.
When the video playback was stopped at an event (start of trial, start of look, end of look) the
frame number was noted and copied into a Microsoft Excel spreadsheet set up for the scoring
purpose (see example in Appendix 7). (Looks/looks away shorter than 1 second were not
noted). The duration of each look at the toy was then automatically calculated by Excel.
The two outcome measurements were:
a) Mean Length of Looks at the toy (or "mean look duration"): total looking time divided
by the number of looks at the toy.
b) Inattention Rate: number of looks away from the toy per minute.
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3.7.2.4 Rationale for using the mentioned tests
A variety of different cognitive tests has been used in infants at this age, some composite,
others specific. Global measures of development and intelligence, (e.g. Griffith, Bayley and,
Gesell scales) are popular tests, which have been thoroughly validated and frequently used,
and are so useful for making population comparisons. However, they generally give aggregate
measures of different psychological processes, including motor and perceptual skills,
consequently making It difficult to infer from the results which specific cognitive,
psychological, or behavioural processes may have been affected by the exposures in question.
Furthermore, the literature suggests that even during infancy cognitive functions develop
independently (238), and particular kinds of interventions affect certain specific cognitive
functions differentially.
Considering the above, and after receiving advice from an expert in early child
development and nutrition (Prof Sally McGregor) it was decided that a non-global measure,
allowing a more specific understanding of the physiological functions of n-3 LCPs in infant
cognition, was appropriate. The Willatts Test was then chosen as most suitable because of the
following advantages:
1. It has been used in several studies to assesscognitive behaviour in young i~fants.
2. It has proven sensitive to past nutritional interventions in Infants (131, 195) and has
been successfully used in developing countries (239), where it was able to detect
differences between groups of infants aged 7 mo after a two-month intervention.
3. Unlike most of the composite measure assessments, it is relatively easy and quick to
perform, therefore not requiring intensive training regimes for testers.
4. It may be scored from videotapes, facilitating In standardisation and quality control.
By conductlng this test at 12 mo, it was possible to combine it with the Infant attention
assessment, which was a recommendation made by Peter Willatts. Given the simplicity of the
test, and the suggested important role of DHA in attention in childhood, it was considered
warranted to include the Toddler Attention Assessment to our outcome measures.
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3.7.3 Acute-phase proteins
Plasma samples shipped to the MRC Human Nutrition Centre in Cambridge were also
analysed for their inflammatory markers, once FAmeasurements were complete.
One of the consequences of increased gut permeability is the translocation of antigenic
macromolecules, which stimulate and perpetuate local and systemic inflammatory responses
(8). In order to test whether n-3 lCP supplementation is associated with reduced infant
systemic inflammation (either via immune-modulation, or by reducing gut leakiness), the
concentrations of the acute-phase proteins plasma CRP,AGP and albumin were assessed.
3.7.3.1 C-reactive protein
CRP levels rise dramatically (up to 50 000 fold in acute inflammation) during general,
non-spedfic inflammatory responses to infectious and non-infectious insults, and is so
classified as a positive acute-phase reactant. This increment, rising above normal within six
hours and peaking at 48 hours, is due to an increase in the plasma concentration of
interleukin-6, produced predominantly by macrophages (240). CRP levels are largely
determined by the rate of production, which is determined by the severity of insult, and so are
useful in detecting and monitoring inflammatory processes.
The protein is thought to play an important role in innate immunity, in assisting in
complement binding to foreign and damaged cells, and in enhancing phagocytosis by
macrophages (240).
CRP was measured using a commercial colorimetric immunoassay (Dimension-
CardloPhase· high sensitivity C-reactive protein method, Siemens Healthcare Diagnostics ltd,
Camberley, UK).
Using this method, the sample was incubated with chromium dioxide particles and a
JJ-galactosldase conjugate, which were each coated with a monoclonal antibody specific for
CRP. CRP therefore became conjugated to both the chrome particle and conjugate during
Incubation. Unbound conjugate was removed by magnetic separation and washing, and then
bound conjugate combined with a chromogenic substance
(o-nltrophenyl-beta-D-galactopyranoside). p-galactosldase was then allowed to catalyze the
hydrolysis of the chromogenic substance, resulting In a colour change read at 405/510nm. The
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subsequent change in absorbance was finally taken to be directly proportional to the CRP
concentration ofthe sample.
3.7.3.2 a-t-Acid glycoprotein
Similar to CRP,AGP is a positive acute-phase protein, rising in response to systemic tissue
injury, inflammation or infection. Its biological function is not clear, but data support an
anti-inflammatory and immunomodulating role. Glucocorticoids and a cytokine group of
mainly interleukin-1 beta, tumour necrosis factor-alpha, and interleukin-6 and its related
cytokines regulate AGP gene expression (241).
The determination of AGP is based on an immuno-turbidimetric specific reaction, using a
commercial kit sold by Sentinel Diagnostics (Sentinel CH. SpA, Milan, Italy), which contains
specific anti-ACP polyclonal antiserum. Antiserum and its corresponding antigen react in
optimal pH conditions and In the presence of polyethylene glycolepolymer. The turbidity of the
resulting immuno-complex is proportional to the concentration of AGP in the plasma sample.
3.7.3.3 Albumin
Serum albumin Is produced in the liver and is the most abundant blood plasma protein. Its
levels decrease In the blood during the acute-phase response. Hypoalbuminaemia may be
caused by protein-losing enteropathy, malnutrition, and genetic variations.
Plasma concentration was measured using the Flex· reagent cartridge (Siemens
Healthcare Diagnostics Ltd, Camberley, UK), employing an adaptation of the bromocresol
purple dye-binding method (242, 243). In the presence of a solubilising agent, the die binds to
albumin at pH 4.9, and the amount of albumin-dye complex (read at 600nm) is proportional to
the albumin concentration.
3.7.4 Intestinal inflammation
The calcium-binding, anti-microbial protein, calprotectin, is found primarily in neutrophils,
but lower concentrations are found in monocytes and macrophages. It competes for zinc to
Inhibit zinc dependent enzymes and so kill microorganisms. Bowel content is rich in bacteria
and other microorganisms releasing substances which may be toxic, and so stimulate
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leukocytes, in particular polymorphonuclear granulocytes, to migrate to the gut lumen where
they release their contents, including substances like calprotectin.
Mothers were asked to collect a sample of their infants' stool into a stool pot provided the
evening before they were due to come to Keneba for the clinic visit, and to continue the
collection during the clinic visit if no stool was passed the previous evening. Calprotectin is
extremely stable and stool samples can be stored for six days at room temperature.
Samples were homogenised by vigorous stirring for five minutes to remove any possible
clusterings of protein pockets. Homogenised stool (roughly s-7ml) was transferred to a
pre-weighed 30ml tube. They were then weighed again, covered with parafilm with three
holes punctured into the top, covered lightly with the lid, and frozen at -80°C. The regular
weighing was done in order to calculate the moisture loss and so determine the water content
of stools.
Frozen stools were freeze-dried overnight, or until all sample matter had dried through.
Although not specified in the kit protocol, drying of stools was intended to correct for differing
stool water concentrations so as to be left with similar dilutions of inflammatory products
across otherwise variably dilute stools. A high inter- and intra-variation in moisture content of
stools in this population is common, which becomes amplified by regular diarrhoea episodes.
An example of two such different stools is shown in Figure 23. Once dried, the stools were
each weighed again and transferred to a mortar and pestle where they were homogenised into
a fine powder, transferred to 2ml tubes, and stored at _20DC for later analysis.
Figure 23: Example of two stools of different dilution moisture content
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Calprotectin concentration was measured using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (Phical, CALPROAS, Oslo, Norway). The kit is used primarily
for determining disease activity and monitoring response to treatment in adult IBD patients,
and those with colorectal cancers.
For this assay, extracted re-suspended stool samples were incubated in 96-well plates
coated with polyclonal antibodies against calprotectin. After washing, the epitope bound
calprotectin was allowed to react with immunoaffinity purified enzyme labelled
anti-calprotectin. The amount of enzyme left bound after incubation and washing is roughly
proportional to the amount of calprotectin in the sample or standard. A substrate for the
enzyme was then added and allowed to react, resulting in a colour change proportional to the
enzyme (and so calprotectin) concentration in wells. A concentration of greater than 50mg/kg
wet stool is regarded as a positive test in adults (median is 25kg/mg). In active IBD conditions,
the concentration can reach up to 200 - 20 OOOmg/kg(220, 244-246).
3.7.4.1 Laboratory work in Keneba
Before the start of the sample analysis, preparations were made to test methods, and
adapt the protocol where needed. It was known that paediatric calprotectin levels are higher
than those of adults, but the only Information available on the normal calprotectln
concentrations in the study population being the highly variable and questionable results from
the pilot study - achieved using un-optimised techniques - these had to be measured in order
to choose appropriate dilutions. Adaptations to the protocol to accommodate freeze-drying of
stools, suitable homogenisation methods and Incubation times etc were assessed, and also
determinations of the average water content of stools. Adjustments to fit the available
equipment (e.g. shaker/centrifuge/agitator pins) and relatively warm laboratory temperature
were made and optimised to write a modified protocol.
Ten stool samples were collected on the same morning from 10 different study infants for
assay workup purposes. A 5g aliquot of each sample was transferred to a clean stool pot and
mixed thoroughly with a wooden spatula. The mixed stool was separated into 4 separate,
pre-weighed 30ml tubes, weighed again, and frozen at -80°C overnight, before freeze-drying.
Weighed, freeze-dried stools were then homogenised and the fine powder transferred into
four separate 2ml tubes and used for all assay workup purposes.
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Firstly, extraction conditions were tested. This was done by applying different extraction
buffer volumes with or without added (improvised) agitator pins, and different vortexing and
shaking times and conditions, to samples grouped into different batches. Variability was
greatest amongst batches using lower buffer volumes, no agitator pins, and shorter vortexing
and shaking speeds, suggesting an incomplete extraction. A shaking time of 45 minutes (as
opposed to the 25 minutes recommended), a doubling of the recommended vortexing time,
and a slightly higher extraction buffer-to-sample-ratio than protocol specifications gave the
least variable results.
Secondly, dilution extent and incubation times were optimised. When matching degrees of
dilution and incubation times to those stated in the protocol, adjusting for a roughly 80%
average moisture loss during freeze-drying, calprotectin concentrations fell on the very high
end of the standard curve, and the highest standard's reading exceeded an optical density of
"2". In order to determine which dilution would bring the average down towards the middle of
the curve, and ensure that the highest standard reading was brought down, batches of serial
dilutions were prepared and resulting concentrations determined. From the readings, the
optimal dilution was (accounting for extraction as well as sample dilution buffers) more than
three times more than the recommended. The accompanying ideal final incubation time was
found to be 30% shorter than the kit protocol instructions, which was most likely due to the
warm laboratory temperature which accelerated the reaction.
Once conditions had been optimised, intra-assay variability was assessed: one of the mixed
stool samples was divided into four, and one of these parts further divided into four samples,
as Illustrated in Figure 24. Samples were extracted, and for one sample, the extraction
supernatant was separated into four and further processed. For samples "ii" and "iii" a serial
dilution series was prepared to assess whether the readings correspond well to the different
dilutions. The samples, controls, blanks and standards were plated out as illustrated below (in
Figure 24).
The standard curve R2correlation coefficient value was 0.99, demonstrating a good fit, as
shown in Figure 25. Optical densities, with corresponding concentrations read from the
standard curve are shown in Figure 26.
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Interpretation
"Control" concentrations (218ng/ml- 232ng/ml) were well within the range required, and
the average of 223ng/ml was close to the target of 222ng/ml. Blanks read well below an
optical density of 0.2, as was desired.
Percentage CVs between replicates were high, but inconsistently so, varying between less
than 1% and greater than 30%. The higher CVswere contributed mostly by replicates repeated
across eight wells, and by the most dilute standard. Because of the time it took to plate out
across eight wells from left to right, CVswere likely influenced by resulting differing incubation
times. To avoid this in future work, half-plates rather than full plates were run. In addition,
intervals between pipetting of sample or standard into wells, and filling with conjugate or
substrate solutions were timed carefully. Careful attention was paid to pipetting the most
dilute standard for future analyses, but despite this, high CVs between replicate of this
standard were hard to avoid some of the times. Because of the very small quantity of
calprotectin it contained its susceptibility to even minor pipetting differences was high.
Unexpected was that samples which had been weighed out separately ("i"-"iv") displayed
lower variation than those that had not ("a"-"d"). Samples that had been taken from the same
extraction homogenant and centrifuged separately were exposed to some source of variation
which was most likely due to sampling from different parts of the 14ml of homogenate. For
future work, allquots were always taken from the same part of the extraction homogenate
solution. One of the samples ("i") failed to result in a reading as the calprotectin concentration
lay below the detectable range. Because all four replicates were affected, but not samples "ii"
- "iv", the problem most likely occurred during the final sample dilution. It could be that too
little sample was unwittingly added to the sample diluent, or that the dilution step for "I" was
completely missed.
The most concentrated dilutions of the two dilution series were too high for the standard
curve. The most dilute sample (1:200) replicate average was roughly half (120) of the doubly
concentrated sample (1:100; 260), as was hoped.
After studying the results and adjusting the protocol by means of further assay piloting,
the following method was followed:
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Adapted protocol
• To minimise costs, a combined stool sample for each infant at each time-point was
measured, rather than the individual samples each at baseline and endpoint. The dried
stool powders of each infant per time-point (a maximum of 3 at baseline and 3 at
endpoint) were weighed in a 1:1:1 (w/w/w) ratio into a clean eppendorf tube and
vortexed thoroughly to mix.
• 15mg of the mixed dried stools (as opposed to the usual 100mg wet stool) were
weighed out from the eppendorfs into 14ml falcon tubes, two agitator pins added, and
49S5~1 of extraction buffer pipetted into each falcon tube, before vortexing to mix,
and transferring to a shaker to agitate for 45 minutes at maximum speed.
• 1.4ml of extraction homogenate was centrifuged at 10 OOOgfor 20 minutes, and 500~1
of the resulting supernatant transferred to an eppendorf and kept for ELISAanalysis.
• Controls, samples and standards were determined in duplicate, following the
principles already described. Plates were read at a wavelength of 405nm using an
Appllskan plate reader (Thermo Scientific, part of Thermo Fischer Scientific, Waltham,
MA, USA).
• Optical density readings were given in duplicate, and read from the standard curve to
give a calprotectln concentration expressed in ng/ml.
• The values of the diluted samples were adjusted for the dilutions and converted to
ms/kg dry stool by multiplying by the total dilution factor (S300) and then multlplvlng
by the 0.001 conversion factor, so that, for example, a reading of 100ns/ml became
S30ms/kg.
• For group comparisons, this expression in dry weight was adequate, but to enable the
comparison with reference values, stools were also expressed per kg of wet stool. This
was done by calculating the moisture content of stool by subtracting their dry weights
from their wet weights, and converting dry stool weights into their equivalent wet
weights. For example, for a stool with 80% moisture, 830ms/kg dry weight =
830mg/Sq wet weight = 166ms/kg wet weight.
89
Chapter 3: Methods
Mixed-stool sample
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Figure 24: Illustration of intra-assay variability test procedure. "s"- standard, "c"-
control, "b" - blank
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Figure 25: Standard Curve from assay work-up
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Neopterin
A breakdown product of cyclic guanosine monophosphate released from activated
phagocytic cells, neoopterin is an early biochemical marker of cellular immunity (247). This
marker's main determinant is stimulation of cells by interieron-y (IFN- y) and has been used in
monitoring the course of inflammation associated with increased cellular immune activity.
Neopterin was therefore chosen as a marker of intestinal cell-mediated inflammation.
A commercial ELISA kit (IBl, Hamburg, DE) designed for measuring neopterin
concentrations in serum and urine was adapted for faecal measurements during the pilot
study. The pilot study stool analyses took place in the UK. During the main study in Keneba,
however, numerous difficulties were experienced in setting up the assay and in achieving
satisfactory standard curves and assay CVs although the same protocol was followed as in the
UK. The difficulties were probably due to the kit components being vulnerable to damage
during transit between the UK and Keneba and so not responding optimally during analysis, or
because of some other effect in the laboratory in Keneba influencing the assay.
When considering these problems in the light of the number of other outcomes already
incorporated in the study, Including an alternative marker of intestinal inflammation, and the
costliness of the neopterin kits, It was decided to remove faecal neopterin as a marker of
Intestinal Inflammation and rather focus on the other endpoint and laboratory assessments.
Work on the assay was therefore discontinued before the cause of the problem could be
found.
3.7.5 Morbidity assessments
A general health questionnaire (designed with input from the trial statistician and
database developer; Appendix 8) was administered by trained fieldworkers every day after
infants were supplemented so as to assess their general health. The mother was the usual
respondent, but when she was not available the nursemaid or other member of the compound
caring for the infant stood In. Mothers/caretakers were asked whether the infant had
experienced any form of un-wellness during the past 24 hours, and about the occurrences of
diarrhoea, vomiting, cough, fever, and abnormal bleeding. This monitoring was done both to
assess any observed effect of treatment on morbidity patterns in infants, and to ensure a high
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standard of safety monitoring. Morbidity data was sent to the trial statistician at two to three
monthly intervals. A morbidity report, showing group differences, was then prepared and sent
to the safety monitor for evaluation.
If a mother felt that her infant was in need of medical attention she was free to take her
infant to the clinic in Keneba to be seen by a doctor, or request a visit by a nurse. If the infant
was seen by a nurse or doctor, the diagnosis and treatment details were recorded on a
"morbidity/adverse event form" (Appendix 9).
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3.8 Other measurements and observations
3.8.1 Cognitive development in relation to umbilical cord and maternal
serum DHAand AAconcentrations
Previous data have found that in an Inuit population in Arctic Quebec, cord DHA
concentration was related to later infant development whereas breast-milk DHA was not
(248). This suggests that DHA exposure during pregnancy may be more strongly related to later
developmental outcomes than exposure postnatal, and indeed a recent review on DHA
supplementation in pregnancy and lactation also confirms evidence to suggest this (249).
Maternal and cord serum samples were collected at the delivery of infants born to
mothers taking part in the previously mentioned peri-conceptual micronutrient
supplementation trial. The PI of this study granted a request for using a number of these blood
serum residuals In order to investigate their FA content. A sample of 104 maternal and cord
serum residuals that overlapped with infants taking part in the n-3 LCPstudy were identified
and sent to the MRC Human Nutrition Research Centre in Cambridge for FA analyses.
The maternal and cord samples were analyzed for their relative proportions of DHA and AA
(also an important constituent of the brain) concentrations, and these values were correlated
with the developmental scores that infants achieved on the Willatts and Attention Tests.
Relative maternal and cord FA concentrations were further compared to assess how strongly
maternal levels predicted infant ones.
It was hypothesised that because the cord serum would reflect maternal diet during late
gestation, the difference between the cord and the 9 mo blood LCP levels would give a
measure n-3 LCP exposure from breast-milk and diet post-natal. By using this measure, a
similar analysis was performed, testing the relationship of post-natal n-3 LCP exposures on
cognitive development.
3.8.2 Growth outcomes at 12 mo
During the 12 mo developmental outcomes testing clinic visit, infants were also measured
to assess their growth. The same methods and equipment were used as described for
anthropometric measurements at 3 and 9 mo of age. The measurements were taken only
once, however, and by a trained fieldworker rather than the PI.
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The availability of 12 mo anthropometric data meant that any effects of treatment which
may have been detected between groups at 9 mo of age could be evaluated at 12 mo to
investigate whether the differences where maintained, or indeed manifest only then.
3.8.3 Overall growth compared with WHO references at 3, 9 & 12 rna of age
Growth measurements were assessed against WHO reference curves in order to examine
and contrast the patterns of growth at 3, 9 and 12 mo of age, evaluate them according to WHO
recommendations, and compare the data with previous findings in West Kiang.
3.8.4 Weaning foods
A very basic questionnaire (Appendix 10) was administered to mothers in their own
language every month, asking whether their infants had been fed anything other than
breast-milk, and if so, what. From this a brief descriptive summary was compiled, indicating
how many of the infants in the study had been weaned at each monthly interval, and what the
majority had been weaned onto.
3.8.5 Relationship between calprotection levels and LMRs
Stool calprotectin concentration measures intestinal and colonic inflammation whereas
urinary LMRs reflect the permeability and surface area of the small intestinal mucosa. The
relationship between the Integrity of the intestinal mucosa and intestinal inflammation was
Investigated by correlating urinary lMRs with stool calprotectin levels. This analysis also gave
some suuestlons as to whether calprotectin and lMR measures were Interrelated or instead
entirely Independent Indicators (whether due to the mechanisms which Influence them, the
differential timings of their physical expression, or the areas of the intestine they were
reflecting), and whether one could be used to predict the other to any degree.
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3.9 Statistical methods
The main analysis was intention-ta-treat. Multiple, linear and log-linear regression, and
negative binomial regression analyses, where appropriate, were used to test effect of
treatment on all primary and secondary endpoints.
In order to look at the possibility of dose effects, a further analysis fitting the number of
doses of treatment, controlled for compliance, in the regression models above were done for
all primary and secondary endpoints. By adjusting for compliance and number of doses, the
effect of treatment as it was received in each individual case was measured on the various
outcomes.
Frequency distribution and normality of dependent variables were checked by plotting the
data and by drawing histograms. Where the data were skewed, log transformations were used
to both normalise the distribution, and stabilise the variance of the skewed variables.
3.9.1 Data cleaning
Growth, weaning foods and morbidity data were cleaned during the running of the trial, as
the data were entered and accessible. The rest of the data were cleaned at the end of the
study, or once laboratory analyses were complete. Owing to real-time checks facilitated by the
double entry system, specific entry forms and automatic range checks, the number of errors
that had to be dealt with during the later stages of data cleaning were limited.
Queries generated In Microsoft Access' were used to test for any entries which were
incompatible (e.g. "fever" and "child well over past 24 hours" on same record), erroneous (e.g.
if a growth measurement at 9 mo was mistakenly entered at 3 mo, consequently showing 4
baseline and 2 endpoint entries), out of range (where normal data ranges were available), or
mistakenly entered a second time. ID number discrepancies were also checked with the aid of
check letters which were added on to the end of ID numbers at the start of the study. The ID
numbers in each dataset (especially data arising from laboratory analyses) were checked
against a set of correct ID numbers, and digit or letter discrepancies investigated and
corrected. Data were then plotted in order to check for outliers and any noticeable errors.
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Errors and outliers were cross-checked against hard copies of data records where available
(Le. not for laboratory results). Illegible hand-writing, incorrect dates, or misinterpretation of
the coding system used on the forms were common sources of error. Mistakes which could not
be rectified, and clear outliers, were dropped from the dataset.
3.9.2 Primary outcomes
Multiple regression analysis was conducted to test the effect of treatment on change in
growth and anthropometric z-scores.
As urinary LMR, lactulose:lactose ratio, and lactose percentage recovery data were
skewed, they were log transformed. Regression analysis was performed to test for treatment
effects on intestinal integrity.
As explained in Section 3.6.2.1, free fructose and glucose urinary sugar concentrations
were subtracted from the urinary lactulose and lactose concentrations. Because the urinary
sugar concentrations are so small and their determinations therefore very susceptible to small
technical errors, It occasionally happened that when free fructose/glucose values were
subtracted from lactulose/lactose values, a negative end result was found. In order to
compensate for such negatives, "+10" was added to the data before log-transformation, to
solve the problem of negatives so that data was not lost in a possibly biased way.
Instead of using the calculated LMR for regression analysis, lactulose (logged) was
regressed on mannitol (logged), so that mannitol concentration was controlled for. This was
considered more efficient than calculating and comparing the ratio, as it did not assume a
proportional relationship which may not be true, especlallv If there was error in the
measurements.
For all analyses baseline values were fitted as covariates in order to correct for any
modification of treatment effect they may have caused and to minimise variance introduced
by different Initial nutritional and Intestinal statuses.
91
Chapter 3: Methods
In a subsequent analysis, the following variables were added as extra covariates to the
regression models above:
1. Breastmilk DHA and EPA
2. Sex
3. Season of birth
4. Age of commencement of treatment
These variables were identified as potential variance inflators or/and effect modifiers, and
by adding them to the regression model the data could be corrected for such influences by
these variables.
When a significant difference between groups was detected for any of the primary
outcomes, the analysis was repeated, but fitting plasma DHA and EPAconcentration (at 9 rno,
controlling for 3 mo) as covariate. It was thus possible to show (if it disappeared) whether the
observed treatment effect was indeed working via an increase in plasma DHA or EPA levels.
Seasonal effects were Investigated on 3 mo growth measurements, using a Fourier series.
Growth outcomes were plotted by month, and the seasonal effect tested using a Wald Test.
Breast-milk DHA and EPA, and season of birth, were examined for any interactions with
treatment on outcomes by adding these terms to the regression models and inspecting for an
interaction. For fitting season of birth a simple sine wave model (first two Fourier variables of
the Fourier series) was used.
3..9.3 Secondary outcomes
Plasma latty acids
n-3 LCPconcentrations were skewed, the data consequently being log transformed.
As mentioned in section 3.7.1.1, absolute FA values were obtained, and from these the
relative percentage FA values could be calculated by dividing the absolute FA values by the
total FAs. It was not known to what extent absolute versus relative values would be related to
treatment and other variables, and so the following analysis strategy was chosen: in order to
optimise the balance between using absolute FA values and % FA values in the analyses when
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plasma FA was treated as the outcome, "(Iog)absolute FA" was used as the dependent
variable, controlling for "(Iog)total FA". For the main LCPs,however, percentage and absolute
value differences were analysed and presented separately.
When plasma FA was fitted as a covariate, both percentage and absolute values were
fitted. This choice was made based on the relatively independent relationship of these two
variables.
Cognitive development
As summarised in Section 3.7.2.2 and 3.7.2.3, three outcome measures were obtained for
the Willatts Test and two for the Attention Assessment. Group comparisons were made
between these scores using regression analysis. The analyses were repeated fitting the
mother's highest degree of education as covariate.
The relationships between the various outcome measures were examined by first plotting
them against each other and then correlating, also comparing the relationship between
achievements on the two different tests.
Systemic and intestinal inflammatory markers
(alprotectln, AGP and (RP were log transformed due to skewed distributions. Group
means were compared using regression analysis, and the population above the normal was
also compared by group. Baseline measures were controlled for.
Morbidities
Binomial regression was used to test group differences in the number of visits at which
one or more symptom was recorded, and in the number of visits at which infants were
reported to have specific complaints e.g. vomiting, fever, cough etc. Interaction of season of
measurement with treatment was tested.
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3.9.4 Overall growth compared with WHO reference standards at 3,9 and
12 mo of age
Baseline, 9 mo, and 12 mo anthropometric z-scores were plotted against WHO growth
standards to assess the study population's growth and nutritional status in comparison to
reference data. Anthropometric indices at 12 mo were tested for treatment effects using
multiple regression, controlling for baseline values.
3.9.5 Plasma and breast-milk fatty acids
3.9.5.1 Comparison of breast-milk fatty acid levels in this population with those of
other populations
A summary of the average FA concentrations in this population was prepared and
compared with data from other populations.
3.9.5.2 Correlations between pre- and post-treatment plasma fatty acid
concentrations and between breast-milk and plasma fatty aicds
Indicative of the extent to which treatment altered FA profiles, over and above the
influence of normal diet or biological determinants, the above-mentioned correlations were
done with the aim of investigating how strongly pre-treatment and breast-milk DHA, EPA and
AA fatty acid profiles predicted endpoint plasma ones.
3.9.5.3 How much variation in plasma fatty acid levels is explained by breast-milk
versus treatment?
As a follow-up to the tests mentioned above, the partial R21S in an analysis of variance test
were compared with the purpose of comparing how much variation in plasma DHA and EPA
fatty acid levels was explained by the breast-milk intake of these fats and how much was
explained by treatment.
3.9.5.4 Do plasma or breast-milk fatty acids predict any of the other outcomes?
Different plasma and breast-milk PUFAswere tested to examine their relationship with the
anthropometric z-scores, gut integrity, cognitive development, and markers of inflammation
using simple linear regression on endpoint data, and a random effects regression on pooled 3
mo and endpoint data.
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3.10 Ethical, safety, and other considerations
3.10.1 Ethical considerations
The trial complied with MRC GCP (good clinical practice) guidelines, the then current
version of the Declaration of Helsinki and applicable local ethical and legal requirements.
Ethical approval was obtained from both the LSHTM and the joint Gambian Government/MRC
ethics boards (Appendix 11).
As part of community sensitisation, elders were visited in their respective villages
before the start of the trial to explain the purpose of the study to them. They then gave their
verbal approval for research to be conducted in their villages.
A standardised information sheet (Appendix 12) was read to the mother or caretaker, and
father, if reachable, in their own language by a trained field-worker. After a clear explanation
of the detail of the study, written parental consent (see Appendix 13 for consent form) for the
child to take part In the study was sought from both parents. It was stressed that recruitment
is voluntary and that a decision not to join would not jeopardise the provision of normal
healthcare. Participants were made to understand that they were free to leave the study at
any time, should they so wish.
Subject confidentiality and anonymity was protected as far as possible by following the
above-mentioned standards. Samples taken were coded with an ID number. Personally
Identifiable Information was never released to third parties.
Were there any cases of harm as a direct result of participating in the trial, medical care
and treatment would be provided free.
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3.10.2 Safety considerations
3.10.2.1 Potential adverse side effects
Safety concerns were considered as minimal as supplementation was with a naturally
occurring food ingredient.
Combined DHA+EPAformulations have been safely used in infants, without adverse effects
on growth, mental development, bleeding time, and lipid peroxidation, and several
randomised controlled trials support their safety (57, 250). The supplement used in this trial
was of high pharmaceutical grade. Its quality exceeded the stringent Norwegian Medicinal
Standards and the European Pharmacopoeia Standards.
The dosage chosen was high in relation to recommended daily intakes; however, it was
designed not to meet a requirement, but to attempt to account for potential fat losses and to
induce a therapeutic effect. The dosage, nonetheless, fell within the high range of
recommendations for daily omega-3 intakes of the US Institute of Medicine (251) of 500mg
omega-3/day for infants aged 1 - 18 mo. Additionally, one of the word's most distinguished
scientists in the area of FAs and infant nutrition (Prof Ricardo Uauy), was consulted, and the
dose was found acceptable as long as safety was monitored, and any abnormal/nose bleeds or
any other evidence of side effects were recorded.
Membranes enriched with PUFAsare more susceptible to oxidative damage and unless in
the presence of appropriate antioxidants, high doses of n-3 FAs may possibly cause tissue
oxidative damage. Another concern is that of increased erythrocyte haemolysis, unless
accompanied by appropriate antioxidant supplementation. 8y including the antioxidant
d-alpha-tocopherol in the oils, however, both these potential harmful effects were avoided.
There is some evidence that high doses of n-3 LCPsmay increase bleeding time by most
likely altering platelet-vascular interactions, but that the prolongation is modest and of no
clinical significance (252). Nevertheless, Including a bleeding time evaluation as an added
safety measure was considered.
The only methods available for use, which would test platelet function related bleeding
time, were a bleeding time evaluation or an ex vivo test using the PFA-100® system (Platelet
Function Analyzer). 80th these measurements, however, are invasive and present risks for
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infection: The bleeding time evaluation requires that a measured incision be made in the skin
on the forearm, and that the time to stop bleeding be measured. The PFA-100® system
requires that a minimum of 800111blood be drawn.
It was therefore decided, jointly with the trial safety monitor, that the only way to test
bleeding time would be too invasive to warrant the risk involved for monitoring the unlikely
case of increased bleeding time, and that instead the morbidity questionnaire will ask about
nose bleeds, blood in the stools, or any other abnormal bleeding occurrences.
Infants in West Kiang do not routinely receive vitamin K at delivery. Being mostly fully
breastfed, they are therefore, due to lack of vitamin K, at potential risk of haemorrhagic
disease of the newborn (HDN) caused by abnormal clotting function. Such effects are likely to
be extremely rare but potentially very serious for the individual concerned. Early HDN tends to
present in the first week of life. late HDN does occur but is rare, particularly after 8 weeks of
age, although it has been described to occur up to 12 weeks of age mainly in breast-fed
populations.
If, due to any bleeding prolongation caused by n-3 lCP supplementation, there were to be
a potential for Interaction, it was advised that the risk could easily be mitigated by offering oral
vitamin K (lmg) supplementation to all infants at entry. This route was discussed with the
safety and trial monitors, but was finally considered unjustified, given that late-onset HDN is so
rare, particularly after 8 weeks. Because infants would be entering the n-3 lCP
supplementation trial at 3 mo of age, the magnitude of risk was thought to be extremely small.
3.10.2.2 Other safety considerations
The risks of drawing blood from infants include temporary discomfort, potential bruising,
bleeding, and, extremely rarely, infection. Venipuncture was conducted under hygienic
standards by a qualified phlebotomist, and all attempts to minimise discomfort was made.
Participating children were visited daily byfieldworkers for health checks and in the event
of illness were entitled to receive immediate medical attention. Mothers were given priority
access to transport and the clinic, and clinical examinations took place on request.
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3.11 Trial administration
The trial was registered with the ISRCTN1Register (ISRCTN66645725). It was conducted
according to MRC GCPstandards, as agreed and discussed with the MRC Clinical Trials Support
Manager in The Gambia.
In the original trial registration with the ISRCTN Register a couple of errors were not
noticed until later: gut integrity was listed as a primary hypothesis but a secondary outcome,
and the stated dose was incorrect. When these errors were noticed later a letter was sent to
amend these details and to update changes/additions made to the study (such as the cognitive
development outcome add-on). The letter sent to the ISRCTNRegister administrator in order
to update the register is given in Appendix 14.
3.11.1 Quality assurance
A field supervisor carried out regular quality control visits to oversee the process of
recruitment, the administration and handling of investigational product, morbidity and
compliance monitoring, field anthropometry measurements, and equipment
handling/calibration etc. The PI conducted similar visits on a monthly basis. At these visits the
field supervisor filled out a quality control form (Appendix 15) for the fieldworker being
reviewed, noting any concerns or areas needing improvement. These areas were then
addressed with the fieldworkers.
Weekly team meetings were held where data forms were handed to the PI and looked
over before submitting to the data office. Any error, queries or discrepancies were dealt with
during the meetings. Queries generated by the data office because of incompatible
Information or measurements failing out of range were reviewed at the same meetings.
In Instances where the PI was unable to conduct anthropometry measurements, due to
travel or Illness, Infants were measured by a second observer. In order to measure the
inter-observer variability, and to adjust for it later on if required, a 30% sub sample of infants
was measured by both the PI and second observer.
1 International StandardRandomisedControlled Trial Number
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A second observer, for quality control purposes, repeated a total of 305 compliance and
morbidity questionnaires on a sample of 40% of the infants.
Oxidation values for the supplement oils were provided to the PI before the oils were sent
to The Gambia. In order to comply with Norwegian Medicinal Standards and European
Pharmacopoeia Standards, the peroxide value of fish oil has to be lower than 10 meq/kg. The
peroxide value gives an indication of total current oxidation state of oils. The oils supplied by
Nordic Naturals typically have a peroxide value of under 5meq/kg.
Anasidine value, which measures the aldehyde production during oxidation of fats, is used
as an indication of past oxidation, reflecting how the oil has been handled and stored.
(However, once vitamin E has been added to oils the anasidine value becomes affected, so can
only be measured in oils before vitamin E is added). An adjusted combination score for the
anasidine and peroxide values is called the "total oxidation value" and describes the total
oxidation to which oils have been exposed. According to the Council for Responsible Nutrition,
oil has to have a combined oxidation value of 26 or lower. Nordic Naturals provided a value of
7 for their oils (tested before the addition of vitamin E).
After eight months of storage, supplement oils were sent to Cambridge, on ice, to be
tested for their vitamin E and oxidation values. The Peroxide Value was tested using the
Wheeler Method (253), and vitamin Econcentration was tested using High Performance liquid
Chromatography.
3.11.2 Safety monitoring
An Independent Trial Safety Monitor (TSM) was appointed at the start of the trial,
according to the MRC GCPguidelines, in order to provide real-time safety oversight.
The TSM was responsible for reviewing SAEs immediately after they occurred. It was his
task to follow these until the events resolved or stabilised, or until a non-study-related-cause
was assigned, and to offer guidance on how to proceed. Any SAE found to be related to
treatment would warrant suspension of the trial until a safety review was done.
The TSM also moderated the growth and morbidity results at regular intervals and was
qualified to break blinding codes or stop the trial if considered necessary.
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3.1.1.2.1 Interim safety monitoring reports
Safety monitoring reports were sent to the TSM at interims of 3 months. The report
provided summary data on length, weight, knee-heel length, daily morbidities and nurse/clinic
visits. The trial statistician, who was unblinded to which infants were in the same groups, but
not to which group corresponded with active treatment, provided summary statistics by group
(calling them group "A" and "B"), noting any significant differences. A typical example of such a
report is given in Appendix 16.
3.11.2.2 Serious Adverse Events
The collection, recording, and reporting of serious adverse events (SAE) were under the
direct responsibility of the PI.
In the case of an SAEthe following steps were followed:
PI contacted by the fieldworker assigned to the infant as soon as
the fieldworker became aware of the event. Treatment suspended.
SAE initial report form was filled out by the PI and sent
immediately to the TSM, together with any available relevant
documentation and information.
Once the patient had been treated, a follow-up 5AE report was
prepared by the PI and sent to the T5M, together with any relevant
documentation e.g. doctors reports, test results etc.
The T5M assessed the 5AE, requested further information if
required, made an assessment of causality, and advised when
treatment was allowed to resume. 5AE filed in the subject's case
record form.
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The SAE initial and follow-up report forms are presented in Appendix 17. The definition of
an SAE, as used for purposes of the trial, is described in Box 3, and the guidelines for
assessment of causal relationship of SAEto administration of investigational product followed
in Box 4.
Box 3: Definition of an SAE
(Abridged from Clinical Trial Protocol Template, MRC Laboratories, The Gambia)
Any untoward medical occurrence that at any dose:
• Results in death;
• Is life-threatening;
• Requires inpatient hospitalisation or prolongation of existing hospitalisation;
• Results in persistent or significant disability or incapacity;
• Is a congenital anomaly or birth defect.
Important medical events that may not result in death, be life threatening, or
require hospitalisation may be considered an SAE when, based upon appropriate
medical judgment, they may jeopardise the patient or subject and may require medical
or surgical intervention to prevent one of the outcomes listed above.
An untoward medical occurrence that results in death from any cause at any time is
considered as an SAE.
An event is considered as life-threatening if a subject was, in the view of the
investigator, at immediate risk of death from the event that occurred.
Any requirement of hospitalisation is considered an SAE. However, hospitalisation
for either elective procedure related to a pre-existing condition which did not increase
in severity or frequency following initiation of the trial, or for routine clinical procedures
are not considered as SAEs, but must be recorded in the case record form (CRF).The
relationship to the investigational product will be checked "No".
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The written report to the TSM included a follow-up SAE Form, photocopies of pertinent
test results and medical notes, trial records, hospital report (if relevant and as soon as
available), and a summary of the outcome of the event plus the PI's opinion of relationship of
the investigational product to the event. The TSM would then review and make a final
assessment of causality. Guidelines for such an assessment are given in Box 4.
Box 4: Guidelines for assessment of causal relationship of SAEto administration of
investigational product
(Abridged from Clinical Trial Protocol Template, MRC Laboratories, The Gambia)
This interpretation will be based on the type of event, the relationship of
the event to the time of trial intervention, and the natura I history of the
underlying diseases, concomitant therapy, etc, as follows:
Not related
No temporal relationship to investigational product; and
Event could be explained by alternate aetiology
Possibly Related
Reasonable temporal relationship to investigational product; but
Event could also be explained by alternate aetiology
Probably Related
Reasonable temporal relationship to investigational product; and
Event could not be explained by alternate aetiology
Definitely Related
Reasonable temporal relationship to investigational product; and
Event could not be explained by alternate aetiology; or
Event could be confirmed with a positive re-challenge test.
108
Chapter 3: Methods
3.11.3 Data handling and record keeping
A central database with specific access entry forms and automatic range checks (for
morbidity) was created for the trial. Trained data-entry staff at MRC Keneba double entered all
data collected, and real-time checks were performed. The MRC Gambia database developer
and the PI oversaw this work.
Where inconsistencies between double entered data were found, the original form was
consulted and the incorrect entry amended. When data fell out of range, the PI advised
whether the extreme measurement was real or due to error. As the PI was taking all
anthropometric measurements it was not hard to distinguish between errors and
measurement which were real.
3.11.4 Trial Monitoring
In accordance with MRC GCPrequirements, and following advice given by the MRC Clinical
Trials Support Manager in The Gambia, an independent Trial Monitor was appointed to
monitor and supervise the progress ofthe trial, and ensure it abided by MRC GCPstandards.
The Trial Monitor was involved with finalising and approving the clinical protocol before it
was sent to the MRC prior to the start of the trial. Once the trial started, the Trial Monitor was
required to monitor the progress ofthe trial, adherence to the protocol and patient safety, and
to take consideration of new information relevant to the study. The PI sought consent from
the Trial Monitor before making any updates and changes to the trial protocol. All protocol
deviations were reported to the Trial Monitor.
A site visit was conducted half-way through the trial. The trial monitor was then given the
opportunity to observe procedures on the ground. These involved outcome measurements,
sample collection, processing and storage, and procedures in the field. It also involved an audit
of documentation procedures, data handling and the paper trail. Trial progress was noted, and
any problems and queries discussed at a meeting with the PI and her supervisor. Progress was
also recorded on a monitoring report submitted to the MRC.
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3.11.5 Fieldworker training
Field-workers had had some degree of field experience before joining the study. They had
all previously worked for the MRC and as part of on-the-job training had completed
fieldworker courses.
Details of additional training provided before the start of the trial are given below. With
the exception of anthropometry and motorbike usage, the PI provided all training.
Fieldworkers were also provided with a field manual specific to the study, containing reference
material, answers to questions, and a trouble-shooting guide. The matters listed below were
re-addressed, in turn, during the weekly team meetings for the duration of the trial.
Anthropometry
To teach fieldworkers how to most accurately collect anthropometric data in the field, for
purposes of safety monitoring measurements, training was provided by an experienced
Scientific Officer for measuring height, weight, and knee-heel length. A refresher course was
provided mid-way through the trial.
Supplement administration and care
Fieldworkers were trained in administration technique and dosing the correct volume.
They were also trained in safe and hygienic supplement storage practices, and instructed on
supplement handling in the field and during transportation.
Morbidity assessments
Rigorous training was provided to ensure that fleldworkers understood how to correctly fill
out the daily morbidity questionnaires. Great measures were also taken to make sure that
proper and standardised wording were used while conducting these interviews.
Recruitment and consenting
Emphasis was given to making sure the information sheet was translated properly, and the
fleldworkers were able to explain It clearly and accurately. They were also trained in answering
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specific potential, foreseeable questions, and in acceptable standards for collecting informed
consent.
Motorbike usage and transport
As stipulated by the MRC and station rules. Arrangements and procedures for the
transportation of subjects and their mothers for study and clinic purposes were discussed.
Village assistants responsibilities
Fieldworkers were explained the tasks and responsibilities of village assistants.
3.11.6 Standard operating procedures
Standard operating procedures were accessible for the following trial-related activities:
• Recruitment
• Supplement administration
• Call days
• Blood processing
• Anthropometry measurements
• Stool collection and processing
• Calprotectin determination
• Lactulose-mannitol solution preparation
• Urine collection
• Breast-milk collection and processing
• Sample storage and shipping
3.11. 7 Staff and scientists involved in trial
A graphic outline of staff and scientists who worked with or supervised the PI is given
below in Box 5. Although not exclusively, the local supervisor as well as clinic, laboratory,
data, field and driving teams were actively Involved in the study during the running phase,
while the advisory committee, trial statistician, trial monitors, and overall supervisor provided
support during study design and trial setup phases.
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3.12 Pilot studies
A pilot study (May - Sept 06) was carried out on ten 9 mo old infants and ten 3 mo old
infants randomly recruited from Keneba and its surrounding villages in order to establish the
discrimination ratios of the proposed outcome measures. Gut permeability and intestinal
inflammation were measured three times in each infant, with an interval of one week between
each. Plasma FA profiles and acute-phase markers were measured twice, three weeks apart.
The study also tested acceptability, ease of administration, and potential side effects of
the fish oil supplement. Fish oil, or olive oil placebo, were given to infants every day for a
week, after which a questionnaire was completed by mothers for the reporting of any side
effects.
Box 5: Outline of staff and scientists involved in the trial
Head MRC International Nutrition Group (PhD Supervisor)
Overall supervisor
Head MRC Keneba field station
Local supervisor
Tria I Statisticia n
Advisory Committee consisting of four LSHTMscientists
Database developer/manager Trial/safety monitors
Various ground staff:
Data office, drivers, administrative
support, laboratory, clinic etc.
1 Field Supervisor
6 Fieldworkers
16 Village assistants
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Lastly, all mothers expressed a pooled sample of breast-milk (three times, one week apart)
in order to evaluate its PUFAcontent.
The faecal and urinary assays showed very high variability within and between individuals.
In order to use urinary LMRs and faecal calprotectin (and neopterin) as markers in our study
the assays therefore required further work to investigate whether most of the variability was
explained biologically or due to collection/processing/laboratory methods and whether their
discrimination ratios could be improved.
The supplement was very well received by all infants. No side effects were reported.
The results ofthe sample assays follow in Table 6.
Table 6: Results of pilot study laboratory assays on urine, stool and plasma samples
CIJ
u
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CIJ~ > >.f u uCIJ ~ ~~
> ni ni > >I: .r: u u
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:;:, :;:, ~ ~"C "C:c ra ·s :~ > >CIJCIJ s: :.c ra "'E "C III IIIni' I: I: III III- ra raI: CIJ E ~ " " I I"' til) ~ "' ~ "'CIJ C ~ ::::I CIJ ~ CIJ ~0 "' o - .... .... .... ....s VI " Z ~ I: C I: eLMR 0.23 1.41 0-8.2 <0.2 190 91 8 NM
CALPROTECTIN 167 340 164-1473 25 107 57 10 6.0
(mg/kg wet
sample)
NEOPTERIN 9.2 2.9 6-15 32 23 10 2.9
(mg/kg dry
sample)
Plasma AGP (gIl) 1.5 0.3 0.8-2.4 <1.2 18 20 NM NM
Plasma albumin 39 2.7 36.8-44.3 34-54 7 6.5 NM NM
(gIl)
NM: Not measured
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Because of a hiatus caused by the resignation of the chief analyst at the Human Nutrition
Research Centre at Cambridge, where the plasma and breast-milk samples were sent to be
analysed, GCwork was delayed until after the ethical approval of the study was granted. The
samples were finally sent to King's College London but breast-milk and FA results were
unfortunately only available after the start of the main study.
A later pilot study, led by the same graduate student who scored the cognitive tests and
supervised by the PI, was conducted in September- December 2007. As both the Willatts Test
and Infant Attention Assessment had not been used in The Gambia before, both were piloted
in order to conduct the tests most effectively, particularly in terms of selecting the most
appropriate age to test the children.
Seventy-five infants aged 10 - 12 mo (twenty-five children in each age-group) were tested
with the following aims:
• Determine the most appropriate two-week age-interval (between 10, 11 and 12 mo of
age) in which to test the children;
• Detect any problems with administering the test;
• Assess the sUitability of chosen test equipment and toys to the Gambian context.
Results:
The infants responded better to Western than to Gambian home-made toys, provided
these were presented by a Gambian fieldworker. They responded well to the complex
V-TechGDtoy, despite its novelty and loud sounds, as long as the tester made the child feel
comfortable by encouraging them to play with and touch the toy.
In making a choice for deciding which age of testing was most appropriate, the following
were considered:
• The frequency distribution scores at different age groups;
• The number of children unable to achieve any scores (attaining "0");
• The correlations between scores achieved on different components of the Willatts
Test and the Attention Test at different age-groups.
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Infants, on average, did not achieve even half of the maximum possible intention score. At
12 mo the best scores (43% of the maximum, on average) were achieved, compared to the
lower 36% and 22% at the other ages. Similarly for the intentional solutions, average scores
were low, but at 12 mo they were the highest at 30% of maximum score.
Similarly on the Attention Test, 12 mo old infants performed better than younger infants.
The correlation between the two measures "look duration" and "inattention rate" was highest
for tests performed at 12 mo (r = -0.91), and correlations between the Attention Test and
Willatts Test, as well as the individual Willatts outcome measures, were also highest at 12 mo.
Because 1): the relationship between outcome measure were strongest at 12 mo; 2): the
Willatts Test proved too difficult for many of the younger infants (with some achieving a total
score of "0"); and 3): the higher response rate at 12 mo provided more information with which
to discriminate between more and less intelligent infants, it was decided that, between the
three ages assessed, 12 mo would be the most sensitive age-of-testing in this rural Gambian
population for conducting the tests of choice.
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CHAPTER 4: RESULTS AND SPECIFIC OlSCUS,)IONS
4.1 Trial profile
Assessed for eligibility (n=220)
Excluded (n=37)
Moved out of study area or travelling (n=21)
Not meeting inclusion criteria (n=7)
Died (n=6)
Refused to participate (n=3)
Randomised (n=183)
1
Allocated to receive Fish oil (n=92)
Received allocated treatment (n=90)
Did not receive allocated treatment (n=2)
Severely malnourished (n=l)
Not meeting inclusion criteria (n=l)
Allocated to receive Placebo (n=91)
Received allocated treatment (n=90)
Did not receive allocated treatment (=1)
Did not come for baseline
measurements (n=l)
Lost to follow up (n=5)
Moved/travelled (n=3)
Died (n=l)
Mistakenly enrolled - did not meet
inclusion criteria (n=l)
Lost to follow up (n=3)
Moved/travelled (n=l)
Died (n=l)
Did not come for endpoint
measurements (n=l)
Analysed (n=87) Analysed (n=85)
Figure 27: CONSORT flow chart
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Of the 220 assessed infants, 186 were eligible to take part in the trial. Three of these
infants were not included because of parental refusal, either because the husband did not
want his wife to spend time away from her house-hold duties, or because of distrust towards
the MRC. This refusal rate of 3/186, or 1%, however, was very low. The high acceptance rate
. was probably a reflection of the good relationship between the MRC and local communities,
the value the parents place on the medical treatment that they and their children receive from
the MRC, well-trained fieldworkers with good community rapport, and the desire of individuals
to contribute to the body of medical and nutritional research.
Figure 27 summarises the trial flow by means of a CONSORT2diagram. Of the 183 infants
randomised, three did not receive any treatment. Reasons for this are given in the diagram. Of
the remaining 180 subjects, data sets were available for 172 infants from which growth and
other outcomes could be determined. Eight infants were lost to follow-up: three in the fish oil
group and five In the control group. This drop-out rate was reasonably balanced between trial
arms and was therefore unlikely to lead to bias in the final sample size.
One infant with congenital abnormalities was recruited by a fieldworker unsure of whether
they were eligible to take part. When the infant was brought in to the clinic on his first due
visit, before commencement of treatment, it was clear upon examination that the
abnormalities were severe enough to influence growth and hence warrant the infant's
exclusion from the study. Another infant was mistakenly recruited a month too early and went
on to receive treatment. When the error was later discovered, the child was withdrawn from
the study, as will be explained in Section 4.9. Given that he did not meet the inclusion criteria
and because It was considered unethical to supplement an infant of 2 mo of age with a dose
which was approved for infants of 3 mo of age, the trial and safety monitors agreed with his
withdrawal from the study.
4.2 Dates of recruitment and follow-up
Age-eligible infants were recruited from May 2007 to January 2008. To allow for a 20% loss
to follow-up, a final sample size of 180 was targeted. Eventually, 183 infants were recruited
(when, towards the end of the study, the last list of potentially eligible infants was drawn up,
2 ConsolidatedStandardsof ReportingTrials
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and, from it, three more mothers than predicted were traced by different fieldworkers, and
recruited).
To facilitate the most efficient use of transport, subjects were brought in for baseline and
endpoint measurements in such a way that vehicle use between this and other studies, and
between the various study areas, were co-ordinated. Thus, some infants were brought in up to
±7 days before or after turning 3 mo of age. All subjects were consequently supplemented for
the duration of 24 to 25 weeks, starting one week after their first baseline measurement and
receiving the last dose of treatment during their 9 mo endpoint clinic visit. The last supplement
was administered in July 2008, and the final 12 mo cognitive and anthropometric
measurements conducted three months later, in October.
4.3 Baseline characteristics of study participants
Table 7: Baseline characteristics of study participants
Characteristic Fish oil group Placebo group Differences----
X;SD X;SD
Male 49 50
Female 38 35
Age (davs}' 92.3; 4.25 93.2; 4.22
Anthropometric indices (n=87) (n=85)
Weight (kg) 5.86; 0.84 5.75; 0.83 0.11
Length (cm) 60.1; 2.20 60.0; 25.6 0.10
HC (cm) 40.1; 1.24 40.0; 1.29 0.10
MUAC(em) 13.2; 1.15 13.0; 1.12 0.22
Knee-heel length 16.1; 0.75 16.0; 0.90 0.10
Biceps skinfold 6.84; 1.24 6.72; 1.38 0.12
Triceps skinfold 8.84; 1.62 8.60; 1.71 0.24
Subscapular skinfold 8.24; 1.50 8.21; 1.79 0.03
Anthropometric a-scores'
Weight-far-age -0.55; 1.13 -0.75; 1.25
Weight-far-length -0.29; 1.19 -0.43; 1.07
Length-far-age -0041; 0.95 -0.52; 1.26
HC-for-age -0.11; 0.85 -0.26; 0.99
MUAC-for-age -0.16; 1.07 -DAD; 1.11
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Body-mass-index-for-age
Triceps skinfold-for-age
Subscapular skinfold-for-age
Plasma FAs (ng/i..d)
OHA
EPA3
(% total FAs)
OHA
EPA3
Acute phase proteins
Plasma albumin (mg/L)
a-Acid glycoprotein(g/L)
C-reactive protein (mg/L)
Gut integrity
Urinary LMR
Lactose:lactulose ratio
Lactulose % recovery
Mannitol % recover/
Intestinal inflammation
Calprotectin dry wt (mg/kg)
Calprotectin wet wt (mg/kg)
AA
-0.44; 1.19 -0.63;1.15
-0.69; 1.09 -0.83; 1.11
0.27; 0.95 0.22; 1.15
(n=83) (n=85)
70.2; 23.8 76.4; 23.2
23.0 (14.5, 35.5) 24.3 (16.1,40.4)
125; 42.5 133; 39.9
3.75; 0.89 4.00; 0.95
1.15 (0.81, 1.66) 1.31 (0.82, 2.03)
6.66; 1.41 6.90; 1.51
(n=80) (n=78)
33.0; 3.01 33.0; 2.61
Median Median
(25,75 pctile) (25, 75 pctile)
0.95 (0.77, 0.11) 0.88 (0.69, 0.12)
3.02 (2.23, 5.31) 2.91 (2.22, 4.67)
(n=85) (n=82)
0.15 (0.10, 0.22) 0.15 (0.12, 0.20)
1.29 (0.88, 1.84) 1.35 (0.97, 1.87)
0.26 (0.19, 0.45) 0.24 (0.16, 0.34)
7.02 (3.46) 6.21 (2.94)
(n=82) (n=83)
124 (75.5, 192) 128 (73.5, 198)
1029 (627, 1534) 1058 (610, 1639)
6.2
1.3
8.0
0.25
0.16
0.24
0.00
0.77
0.11
0.00
0.06
0.02
0.81
3.5
29
AA
-1Age on the first day of supplementation
2Measured against WHO reference standards
30ata were skewed so for this FA the median and zs" & zs" percentiles instead of the mean & SO
are presented
4As these data were normal, the mean and SOare presented for mannitol recovery
Table 7 describes the age and sex characteristics of participants. Baseline measurements,
separated by treatment group, are also given.
As expected, there were no important differences between treatment group means at
baseline, demonstrating a successful randomisation procedure leading to good group
comparability. Furthermore, as mentioned in the previous chapter, in most cases, baseline
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values were fitted as covariates during analyses of endpoint variables, and so any modification
of treatment effect or variance inflation they may have caused would have been corrected for.
The balance between male and female infants (99:73) in the overall sample size was
uneven. This ratio (1.4:1) does not reflect the West Kiang demographic balance between male
and female infants, nor of male-to-female refusal rates for inclusion into the study, and was
most likely due to chance. The difference, however, lay only on the border of statistical
significance, and, importantly, the male-to-female ratios were similar between treatment
groups. The sex ratio, therefore, did not lead to bias when making group comparisons.
EPA, AGP, CRP, lactulose-mannitol, attention assessment and calprotectin data were
skewed and so for these the median and 25% and 75% percentiles, rather than the mean and
50s, are given as an indicator of spread and of central distribution.
4.3.1 Discussion
Although significance tests are often used to identify differences between baseline
characteristics, CONSORT and others (254-257) advise against this practice due to its
inappropriateness. If randomisation has been performed correctly, the only explanation for
group differences would be chance, in which case significance tests become redundant.
Additionally, when presenting twenty or more baseline characteristics, as is the case below, a
strong probability exists that at least one characteristic will be significantly Imbalanced due to
chance alone. Differences between group means were, therefore, presented and inspected for
any clinically significant differences, but not compared by statistical testing.
On average, infants were three months old when commencing with supplementation. The
youngest age was 2.8 mo (12 wks), and the oldest was 3.3 mo (14 wks).
All growth index z-score averages were negative, except subscapular skinfold. Thus even at
3 mo, some growth faltering could be detected in these infants. The growth faltering was,
however, not severe and no z-score average was smaller than -O.S.
Plasma FA levels are given both in absolute values and as relative percentage FAs. It is
difficult to make comparisons with other populations because of the limited data which exist
on infant plasma lipid n-3 LCPlevels.
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A third and nearly half of infants had higher than normal CRPand AGP levels, respectively,
and 15% had lower than normal albumin levels.' These acute phase protein levels were
comparable to those previously reported in Gambian infants (9, 258, 259).
Lactulose percent recoveries were similarly comparable to those previously measured in
Gambian infants of approximately this age, while LMRs were somewhat lower on average (9,
30, 258-260). The improved LMRs were due to higher mannitol % recoveries which were nearly
twice the amount of those previously reported, suggesting an improved villous surface area in
this population, but a similar degree of leakiness compared to previously studied Gambian
populations. The ratio was still, however, significantly higher than the ratio of <0.07 reported
in healthy European children (261, 262).
Finally, calprotectln levels could not be compared to previous Gambian data as none are
available. However, the median of 1033mg/kg in the Gambian infants is significantly higher
than the normal healthy reference of 263mg/kg (wet stool) in 3 mo old European infants (263),
and only nine infants had calprotectin levels falling below this cut-off.
4.4 Number of participants
The primary analysis was intention-ta-treat and involved all subjects who were recruited
and for whom 9 mo outcome measurements were available. Of the 183 subjects originally
recruited, three were withdrawn before they started receiving treatment. Of the remaining
180 infants, eight were withdrawn or lost to follow-up during the 6 mo intervention period. A
total of 172 subjects completed the study and were evaluated for the planned study outcomes
at 9 mo, where Information was available. The study dropout rate was therefore 8/180, or
4.4%.
This dropout was far below the expected 20% dropout rate. The following four factors
presumably contributed to the successful participant retention in the study:
1. Mothers were asked for a high degree of commitment at time of recruitment, and
were encouraged to decline from participating in the study if they foresaw the need to
travel for more than two or three weeks In the ensuing six months.
J Usingstandard adult cut-off rangesfrom healthy individuals: CRP:S5mg/L;AGP:Slg/L;albumin:S30mg/L.
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2. The daily cups of tea and bread provided for mothers when they brought their infants
for supplementation, as well as the high standard of medical care offered served as
incentives which led to greater cooperation in mothers' attendances of
supplementations and a high proportion of mothers remaining in the study throughout
their infant's treatment period.
3. Because resources allowed for a fieldworker to be stationed at the coast full-time
towards the end of the study, the mothers who travelled there during the dry season
could remain in the study even though they were away from the ordinary study area
for more than two or three weeks. Had this not been the case, the infants of these
mothers would have been lost to follow-up.
4. Field-workers were experienced and skilled in maintaining good relations with study
participants. Although participants understood that they were free to withdraw from
the study should they wish, when cases of discontent arose, every attempt was made
to understand what was causing the dissatisfaction, and to find a solution, so that they
could continue taking part without complaints. Also the PI met with participants who
expressed valid concern or complaints, and these were then addressed. One such
grievance, for example, was dissatisfaction with nurses who, the mothers felt, were
not giving their infants timely or acceptable standards of care. As mothers were
promised a high standard of medical care for their infants if they took part in the
study, this complaint was taken very seriously, and the nurse concerned consulted
together with the head nurse and mothers so that a solution could be found.
A total of 143 Infants came for their outcome measurements at 12 mo of age, viz. cognitive
development and anthropometry. Dropout at this 9 mo follow-up was, therefore, 20%,
calculated from the original 180 participating Infants, and was again reasonably balanced
between treatment groups. Thirteen infants from the fish oil group and sixteen from the
placebo group were lost to follow-up, primarily due to mothers travelling, or not turning up on
the day that their infants' testing was due.
This higher drop-out rate could be expected because parents were not involved in the
study In any way during the three months before cognitive testing, and so would more easily
leave to travel or fulfil family or other commitments.
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Anecdotal information from field-workers also indicated that some mothers did not
understand the value of the cognitive test, and so undermined its significance. They felt that a
few minutes' watching their infants playing with a toy could not be worth a great deal, and so
did not feel compelled to bring their infants in when requested.
4.5 Compliance
Compliance was measured as the percentage of doses taken versus doses offered during
each infant's supplementation period, as is summarised in Table 8. The distribution of
compliance is presented in Figure 28, showing a high density of compliance between ~97% and
100%, and a long tail extending at lower compliances of ~80 - 95%.
Any infants who were supplemented less than 90% of the time were classified as
non-compliant. Twenty-three infants fell into this category. Compliance and non-compliance
were individually regressed on treatment group to test for differences. There were no
significant differences in compliance and non-compliance rates between intervention groups
(Table 8).
The majority of instances (74%) of non-compliance were due to infants temporarily
travelling with their mothers out of the study area. Other missed doses were mainly due to
serious illness, where the protocol was suspended on advice of the T5M, and infants not being
traced in their villages when the fieldworker arrived for supplementation.
Table 8: Compliance with treatment, by treatment group
Compliance by treatment group1
Mean (SO, std error)
Non-compliant
Fish oil group
95.8 (5.00, 0.54)
13/87
Placebo group
96.1 (4.37, 0.48)
10/85
95% Cl (p-value)
-1.76 - 1.082 (0.639)
-0.07 - 0.133 (0.543)
lMeasured asproportion of dosestaken vs. dosesoffered
2et for difference in compliance rate (% of dosestaken) between treatment groups
3C1 for difference in percentageof non-compliant infants between treatment groups
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Figure 28: Distribution of compliance
As judged from compliance records, reports from fieldworkers, and observations by the PI,
the oils were generally well accepted by the infants, and the supplementation regimens by the
mothers. Thirteen cases of an infant vomiting the oil out after administration were reported in
total, and in only one instance did a mother object to having her infant dosed. This objection
arose because her infant had been experiencing diarrhoea and the mother was concerned that
the supplement was causing it. After three days, however, the diarrhoea cleared up and the
mother gave her approval for the supplementation to be continued.
Quality control of compliance estimates were conducted by a second observer who
returned to compounds and asked mothers/caregivers whether their infants had been
supplemented. This was done a few hours to a day after the relevant fieldworker had
supplemented the infants assigned to him. A total of 305 compliance report sheets were
repeated in this way. Four percent of infants were reported to have had no supplement given
when recorded by the routine fieldworker. In contrast, 7% of infants were reported to have
had no supplement given when recorded by the second observer. The calculated overall
discordance between observers was 3%.
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Compliance was correlated with the infant's village, sex, and date of recruitment by fitting
the variables in a regression model, to test whether any of these covariates influenced the
degree of doses taken. No associations between compliance and the named covariates were
observed.
4.5.1 Discussion
A similar compliance rate between intervention groups shows that group comparison
assessments were not affected by compliance bias. With an average compliance rate of over
95% and only one infant complying less than 80% of the time, poor compliance was not a
cause for concern in this population. It also suggests that the supplements did not cause
noticeable discomfort to the infants, as mothers (apart from the one passing occasion) did not
object to the daily dosing of their infants.
The daily village visits made by fieldworkers to administer and record dosages to each
participant, together with strict weekly monitoring of each infant's compliance, served to
maximise the overall supplementation adherence. Any doses missed were noted and discussed
at the weekly team meetings and special attention paid to ensure doses were not missed
unnecessarily. If a mother travelled with her infant outside of the study area, she was
contacted daily by telephone if she or her hosts owned one, in order to ask about the
wellbeing of her child and to verify her return travel plans.
The first two factors which most likely contributed to the low study participant drop-out
rate (the high degree of commitment asked from mothers, and daily cups of tea provided,
listed under Section 4.4) also likely added to the successful compliance rate.
From quaiity control reports It appeared that compliance may have been over-reported.
However, when the second observer returned to compounds for quality control visits, he
occasionally did not find the mother at home, and someone who was perhaps not present
when the infant was supplemented a day or a few hours earlier may have assumed that the
child received no supplement simply because they were unaware of the routine fieldworker's
earlier visit. Regardless of whether this was the case, even accounting for a 3% over-reporting
by fleldworkers, compliance was still high.
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4.6 Primary outcomes
4.6.1 Growth
There were no statistically significant differences in the growth indices of weight, length,
HC, biceps- and triceps-skinfold thickness and knee-heel length using intention-ta-treat
analysis (Table 9). A significantly larger MUAC z-score (95% Cl: 0.06,0.56; p=0.017) and a
borderline significant increase in MUAC growth rate (95% Cl: 0.00,0.51; p=0.049) was,
however, detected in the intervention group at the usual 5% significance level. (The more
pronounced treatment group difference in the MUAC z-score than absolute growth in MUAC
could be explained by the removal of variation due to sex differences and age, and by a
normalisation of the distribution by the z-score calculations).
A small significant difference for triceps skinfold-for-age was also detected, but the lower
limit of the 95% Cl was very close to zero (0.00 - 0.55), and the p-value was only borderline
significant (0.048).
Principal components analysis was used to predict the combined fatness scores of the
three skinfold measures: triceps, biceps and subscapular. When tested, there were no
differences In this combined fatness score between treatment groups (95% Cl: -0.05,0.79; p=
0.086).
The analysis was repeated, controlling for breast-milk DHA or EPA,sex, season of birth, and
age of commencement of treatment. Because z-score growth indicators were already
corrected for age and sex, the analysis was only repeated on absolute measures of growth. The
results were similar with respect to the significance of treatment effects (Table 12). However,
the (borderline) significant treatment effect seen on MUAC was changed to borderline
non-significant (95% Cl: -0.02,0.48; p=0.074) when controlling for the listed covariates and
breast-milk DHA. The diminishing effect was smaller but similar when controlling for
breast-milk EPA rather than DHA.
When testing them individually, breast-milk DHA and EPAwere the covariates which had
the greatest Influence on diminishing treatment effect. When investigating the distribution of
breast-milk DHA and EPA between treatment groups, a significantly different n-3 LCP
concentration was, Indeed, detected In the mothers of Infants In the control group versus
mothers of infants in the fish oil group (EPA: 95% Cl 0.61-0.93, p=0.008; DHA: 95% Cl 0.72-0.96,
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p=O.013). Mothers with infants in the control group had higher breast-milk concentrations of
both EPAand DHA than mothers with infants in the fish oil group.
The adjusted analysis results are summarised in Table 13, showing the effects of treatment
controlled for compliance, compared to the unadjusted analyses. The table also shows the
results of additionally fitting "doses of treatment taken" to the regression model, which gives
an indication of the dose effect over and above what is explained by the treatment groups.
In contrast to the intention-ta-treat analysis, which answered the question of whether the
intervention had an impact (in this case on growth), the secondary analysis answered the
question of whether receiving the intervention had an impact, and whether compliance
modified this impact. Not surprisingly, owing to the high compliance rate and narrow
distribution of compliance, the secondary analysis produced similar results to the primary
analysis, and there were no interactions found between compliance and treatment on growth.
When controlling for plasma n-3 LCPs (Table 12), the treatment effect seen on MUAC
z-scores was removed by plasma EPA (95 % Cl: -0.09,0.49, p=0.168), indicating that the effect
was working via this FA. It was to be expected that the effect would be working via n-3 LCPs,
but interesting that most of this effect was explained by EPA rather than DHA or their
combination.
Controlling for AA did not diminish the treatment effect.
Breast-milk DHA and EPA, and season of birth, were examined for any interactions with
treatment on outcomes by adding these terms to the regression models and inspecting for an
interaction. Season was weakly significant with length (p=0.0445) and knee-heel length
(p=0.0494). This provides weak evidence that infants who received treatment had a different
pattern of seasonal growth compared to infants who received placebo.
Because knee-heel length had not been used as a marker of growth in this population
before, and is not a commonly used indicator in paediatrics but has been reported to be a
sensitive and precise marker of short-term linear growth in infants (264), its relationship with
length was investigated. The two measures indeed displayed a strong linear relationship
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(r=O.95), more so than any of the other growth variables. A scatter plot of length versus
knee-heel length is shown in Figure 29.
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Figure 29: Graph showing length plotted against knee-heel
length (baseline and endpoint measures combined)
Table 9: Effect of n-3 LCP supplementation on primary endpoints, by treatment group
Endpoint Fish oil group Placebo group
x. so x; so
(n=87) (n=85)
Anth ropometric indices
Weight (kg) 7.79; 0.99 7.56; 1.08
Length (cm) 69.1; 2.45 68.6; 3.03
HC(cm) 43.8; 1.21 43.6; 1.48
MUAC(cm) 14.1; 1.02 13.7; 1.25
Knee-heel length 18.8; 0.88 18.7; 1.12
Biceps skinfold 6.71; 0.98 6.46; 1.12
Triceps skinfold 8.64; 1.42 8.22; 1.73
Subscapular skinfold 7.53; 1.77 7.39; 1.63
Effect size
(95% Cl)
p-value
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Anthropometric z-scores '
Weight-far-age -0.90; 1.09 -1.20; 1.28 0.15 (-0.08, 0.38) 0.208
Weight-far-length -0.57; 0.99 -0.76; 1.10 0.12 (-0.14,0.38) 0.377
Length-far-age -0.79; 1.02 -1.07; 1.30 0.79 (-0.27, 0.90) 0.084
HC-for-age -0.52; 0.84 -0.64; 1.06 -0.01 (-0.18,0.17) 0.954
MUAC-for-age -0.27; 0.92 -0.66; 1.18 0.31 (0.06,0.56) 0.017*
Body-mass-index-for-age -0.60; 0.99 -0.79; 1.12 0.08 (-0.16, 0.33) 0.503
Triceps skinfold-for-age -0.01; 0.85 -0.30; 1.09 0.27 (0.00, 0.55) 0.048*
Subscapular skinf-for-age 0.41; 1.12 0.27; 1.29 0.16 (-0.16, 0.48) 0.326
Change in growth
Weight (g) 1935; 669 1805;635 135 (-62, 332) 0.179
Length (cm) 9.04; 1.67 8.56; 2.00 0.49 (-0.50, 1.04) 0.076
Head eirc (cm) 3.68; 0,87 3.69; 0.68 0.00 (-0.23, 0.23) 0.991
MUAC (cm) 0.87; 0.90 0.68; 0.94 0.26 (0.00, 0.51) 0.049*
Knee-heel length (cm) 2.76; 0.61 2.63; 0.61 0.12 (-0.06,0.31) 0.190
Biceps skinfold (mm) -0.13; 1.10 -0.26; 1.33 0.20 (-0.08, 0.48) 0.152
Triceps skinfold (mm) -0.20; 1.60 -0.38; 1.60 0.30 (-0.11, 0.71) 0.149
Subscapular skinf (mm) -0.71; 1.65 -0.82; 1.51 0.12 (-0.31,0.55) 0.580
Gut integrity (n=86) (n=81)
Mannitol % recovery 4.22; 2.48 4.51; 2.04 -0.34 (-1.04; 0.35) 0.332
Median Median
(25, 75 petile) (25,75 petile)
LMR3.4,S 0.22(0.14,0.37) 0.22 (0.15,0.29) 0.96 (0.87,1.07) 0.507
Lactose: lactulose ratio3,s,6 1.80 (0.99, 2.69) 1.49 (1.02, 2.35) 1.00 (0.87, 1.14) 0.946
Lactulose % recover/'s 0.21 (0.11, 0.38) 0.23 (0.15,0.32) 0.91 (0.72,1.15) 0.434
General least squares regression analysis, entering the dependent variable and treatment. Median
growth measurements of each individual were used, controlling for baseline.
2Using WHO reference curves
3Data were log transformed
4Regression analysis, fitting (log) mannitol on (log) lactulose, controlling for baseline values
sFor skewed data, effect size and confidence intervals are expressed as the anti-log of calculated Cis
and regression coefficients.
6Regression analysis, fitting (log) lactose on (log) lactulose, controlling for baseline values
*p<0.05
The effects of fish oil on growth will be further addressed in Section 4.8.2, where growth
outcomes at 12 mo will also be discussed.
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4.6.1.1 Measurement reliability
The variation between similar anthropometric measurements taken on the same individual
on alternative days was calculated using data before it was corrected for outliers and other
obvious errors. This variation, also termed "measurement error" (265), was quantified by
calculating intra-class correlation coefficients and intra-subject 50s, as recommended by Bland
and Altman (266), using a one-way analysis of variance.
The intra-class correlation coefficient, calculated as the ratio of the within-subject to total
sample variance, estimates the combined variance due to measurement error (e.g. variability
in measuring technique and equipment) and small short-term random fluctuations (e.g. level
of tissue hydration, slight growth between days one and five of baseline and outcome
measures), and is calculated from the equation:
Correlation coefficient = (m*SSB - SST)/ ((m-l) * SST)
Where m = number of measurements per subject; SSB= sum of squares between subjects;
SST= total sum of squares.
Measures with the highest correlations discriminate best between subjects i.e. carry the
most information (267).
Seen in Table 10, aJI measurements apart from triceps- and biceps-skinfolds, had an
intra-class correlation coefficient of at least 0.90, averaged across baseline and endpoint
measures. Weight and head-circumference had the highest coefficients. The table also
presents intra-class SOs, used to determine the size of the measurement error in
straightforward clinical terms.
Although only the PI took most of the anthropometric measurements (>75%), a (trained)
second observer was required to stand in in cases where the PI was ill or travelling. A 30% sub
sample of measurements taken by both the PI and second observer were compared for
correlation and bias using Pearson product-moment correlations and two-tailed t-tests, the
results of which are presented in Table 11.
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Table 10: Anthropometric intra-class correlations and 50s, calculated from three
independent measurements, using a one-way ANOVA
Baseline Endpoint Combined
Weight (g)
Length (cm)
MUAC(em)
HC (cm)
TSF1(mm)
BSFz (mm)
SSF3(mm)
Knee-heel length
(cm)
ITriceps skinfold thickness
2Siceps skinfold thickness
3Subscapular skinfold thickness
Intra-class correlation Intra-class correlation
coefficient (95% Cl)
Intra-class
SO
147g
0.86cm
O.30cm
0.33cm
0.83mm
0.48mm
0.53mm
0.25cm
coefficient (95% Cl)
0.96 (0.95-0.97)
0.87 (0.83-0.90)
0.94 (0.92-0.95)
0.95 (0.94-0.97)
0.78 (0.73-0.86)
0.85 (0.81-0.88)
0.91 (0.88-0.92)
0.98 (0.98-0.99)
0.93 (0.91-0.94)
0.92 (0.91-0.95)
0.93 (0.91-0.94)
0.76 (0.70-0.81)
0.84 (0.80-0.87)
0.90 (0.87-0.92)
Table 11: Comparison of anthropometric measurements taken by the PI and second observer
0.92 (0.90-0.94) 0.94 (0.92-0.95)
Correlation between Difference between observers'
observer 1 & 2 measurements'
r1 Xl- Xz 95%CI p-value
Weight (g) 1.00 0.58 -3.64 - 4.80 0.785
Length (cm) 0.99 0.16 -0.03 - 0.35 0.106
MUAC(em) 0.96 0.06 -0.03 - 0.15 0.200
HC (cm) 0.98 0.16 0.05 - 0.26 0.005**
TSF(mm) 0.79~ -0.09 -0.37 - 0.19 0.513
BSF(mm) 0.88~ 0.02 -0.12 - 0.16 0.789
SSF(mm) 0.87~ -0.24 -0.46 - 0.02 0.031 *
Knee-heel length (cm) 0.98 0.25 0.17 - 0.32 0.000***
lpearson correlation coefficient
ZFrom paired t-test: comparison between observer measurements
~r<0.95
*p<0.05; **p<O.Ol ***p<O.OOl
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4.6.1.2 Seasonality
Baseline growth measurements were plotted by month and fitted, using a Fourier series
(Figure 30). A statistically significant seasonal effect on growth was detected on all growth
indices.
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Figure 30: Clockwise from top-left: Weight, length, triceps-skinfold, knee-heel length, subscapular
skinfold, and MUAC measurements, fitted by calendar month. Significance of seasonal effect on
growth for all outcomes above was p<O.OOl, tested using the Wald Test. (Month "4" corresponds to
May, "5" to June etc.)
132
Chapter 4: Results and specific discussions
4.6.1.3 Discussion
Although the fish oil group averages were consistently higher than the olive oil group
averages, group differences were not significant and the lower limit of the 95% Cis stretched to
below zero in most cases. At baseline the fish oil group average was higher for all
anthropometric indices except length, which explains part of the reason why no growth
benefits were found in the supplemented group although their anthropometric measures
averaged higher.
Since breast-milk n-3 LCPscorrelated with both the dependent variable (MUAC) and the
independent variable (treatment group), without lying on the causal pathway, they were
possibly confounding the relationship between treatment and MUAC. The observed borderline
treatment effect might not have been attributable to the intervention, but to breast-milk FAs.
The relationship between MUAC measurements and treatment could therefore have been a
spurious one, although the relationship between MUAC and n-s LCPswas not. However, the
unadjusted model only shows weak evidence of a treatment effect, so only minimal inferences
can be made from the relatively small change in treatment effect differences the adjusted
analysis showed.
The secondary analysis was performed by fitting "number of doses received", and
compliance, in the regression model. The main potential weakness of this analysis could be
that it assumes that compliance is similar and reflects the same things about individuals in the
two treatment groups. In the current study compliance was, however, similar between
treatment groups and so this risk did not apply. In another scenario, e.g. testing the effects of a
cancer drug which may have severe side effects, a similar compliance may not have been the
case.
Another possibility for the secondary analysis would have been a per-protocol analysis, in
which only infants who complied with the treatment at least 90% of the time, or who took at
least 90% of the doses that were offered to them, would be analysed. However, this method
was not chosen as it is cruder and can be biased: infants who complied less than 90% of the
time may be different in some unknown way to infants who did not.
Adding dose-effects to the regression model as covariate was Instead chosen as it was a
more efficient way of testing the effect of treatment whilst controlling for compliance, and in
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so doing not only testing whether treatment had an effect when administered per-protocol,
but testing whether compliance did indeed modify the effect of the treatment offered.
Essentially, by fitting the number of doses of treatment received to the model, the interaction
between treatment group and compliance was assessed.
Measurement reliability
The importance of anthropometry in nutritional assessment as an indicator of health
status has been well described in the literature (268, 269). Its advantages as a measurement of
nutritional status include the relative speed, simplicity, and inexpensiveness with which it can
be measured (270). Anthropometry is, however, prone to measurement error and
inter-observer bias, which may limit its interpretability.
In the present study, although accuracy (the extent to which measurements reflect "true"
values) was important for comparison of data with other populations, it was not as critical to
the ability to detect group differences as measurement precision (measurement error variance
(271) ) due to intra- and inter-observer variability (270) was. The precision indicated by the
intra-class correlation coefficients of three repeat measures was generally high, although for
triceps- and biceps-skinfold measures It was only moderately high.
By using the median of three measurements the most flawed and outlying readings were
in all likelihood avoided, deflating some of the variance introduced by measurement errors and
hence Increasing the precision.
Some of the lengths and the weight of the intra-subject SOsmay appear quite large, but in
comparison to the overall inter-individual variance in the sample they are not significant
contributors to the overall variance.
It is interesting to note the comparison between knee-heel length and length. Knee-heel
length measurements were biased between observers whereas length measurements were
not, and the correlation between observers was no better for knee-heel length (r=0.98) than
for length (r=0.99). Moreover, the intra-class SO expressed as percentage of the mean for
knee-heel length was larger (9.77%) in comparison to that for length (9.26%). Intra-class
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correlation was the only area where knee-heel length out-performed length in measurement
reliability estimates. These results therefore contradict suggestions that the precision of
knee-heel length measurements may be superior to those of length.
The repeatability was, nevertheless, higher for knee-heel length than length (0.93 vs 0.90).
Given its high repeatability, strong correlation with length measurements, and simple and
cheap method of measurement, knee-heel length may serve as a useful alternative to
heel-crown length as an indicator of linear growth in infants in settings when it is impractical or
otherwise difficult to measure length.
As is to be expected, given their susceptibility to inter- (and intra) observer variation,
skinfold measures had the weakest strength of association (0.79 - 0.88) when comparing
measurements between observers. All other measurements had strong correlations of r>0.95
between observers. As for bias, head-circumference and knee-heel length measurements were
taken consistently significantly higher by the first observer (p=O.OOS,p<O.OOl, respectively),
while subscapular-skinfold measurements were taken consistently higher by the second
observer (p=0.031). Because there was no sta~istically significant difference in the number of
measurements taken by the observers between groups, this bias would have been only a very
minor variance inflator and so there was little justification for fitting "observer" as covariate
when testing for the effect of treatment on growth. However, for analyses where
randomisation was not considered (observational analyses), adjustments for observer were
made where appropriate.
Seasonality
In The Gambia, as In many other developing countries, growth rate has repeatedly been
shown to differ between the rainy and dry seasons due to the differences in parasite load,
infections, food availability, and child care standards which the seasons bring (272). The rainy
season starts in June, and during this time crops are first planted. As the rainy season begins,
food supplies start to run low as reserves from the previous season's harvest become limited.
Simultaneously, the burden of infection, particularly of diarrhoea, peaks, resulting in weight
loss and growth restriction (273).
Many families in West Kiang can now afford to buy enough food when supplies run low,
due to, amongst others, remittances from family members living abroad or in the city.
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Additionally, the MRC station in Keneba continues to provide medical care to an increasing
number of families. Nevertheless, the influence of season is still prominent: Figure 30 shows
clearly that those infants who were born between June and August (Le. in height of the rainy
season), had achieved the lowest gains in growth by 3 mo of age compared to those born
before or after this time.
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Chapter 4: Results and specific discussions
4.6.2 Gut integrity
No group differences between LMRs (95% Cl: 0.87,1.07; p=0.507) or percentage recoveries
of lactulose (95% Cl: 0.72,1.15; p=0.434) and mannitol (95% Cl: -1.04,0.35; p=0.332) were
evident. (Because data for the LMRs and lactulose percentage recoveries were
log-transformed, Cis are given as the anti-log of calculated Cis, indicating the ratio of the
geometric means of fish oil to placebo groups (274, 275). The effect size similarly shows the
untransformed regression coefficient, indicating the same ratio). The lactose:lactulose ratio
was also investigated and again, there was no evidence of an effect of treatment on gut
integrity. These results are given in Table 9.
Fitting the same covariates as were fitted in the growth regression models, the results
were similar (Table 12). There was no statistically significant interaction between season,
breast-milk DHA, or breast-milk EPA and treatment on LMR or lactulose and mannitol
recoveries (p>0.09 for ali).
A significant interaction between compliance and treatment (p=0.012) was found for LMR.
The Cl, however, included "1" and the effect size was trivial (1.01, Table 13). There were no
compliance-treatment interactions for lactulose or mannitol recovery.
When urinary lactulose and mannitol concentrations were compared, a significantly higher
mannitol concentration was detected in the urine of the control group than in that of the
intervention group (95% Cl: 0.62,0.95; p=0.017; Table 14).
Table 14: Urinary lactulose and mannitol concentrations
-
Endpoint Fishoil group Placebo
(n=85) (0=83)
Median Median Effect size p-value
(25,75 pctile) (25, 75 pctile)
(95%Cl)
Urinary lactulose (mg/100ml) 14.9 (10,24) 18.2 (12,26) 0.88 (0.70,1.07) 0.184
Urinary mannitol (mg/100ml) 68.2 (48,109) 90.8 (59,136) 0.79 (0.62,0.95) 0.017
---
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4.6.2.1 Measurement reliability
The average intra-assay % CV, calculated across all replicates run during sample analysis,
was 3.01% (urine samples) and 3.97% (standards) for the lactulose assay, and 1.89% (samples)
and 2.36% (standards) for the mannitol assay. These can be seen plotted in Figure 31
(Iactulose) and Figure 32 (mannitol).
The calibration curve comprised seven individual standards. The concentration of the
fourth standard" (which lay midway on the calibration curve), as measured, was compared
across all plates and the overall % CV calculated. This standard was chosen as it fell in the
middle of the standard curve. For the lactulose assay it was 6.26% (plates without
B-galactosidase) and 10% (plates with B-galactosidase), and for the mannitol assay it was
4.46%.
"'N "'N..~..,,_.
.~
I'
.5 1 1.5
Rephcal. 2 (OD)
.5 1 1.5
Repllcale 2 (OD)
2.5
Figure 31: Correlation of ODs measured between two replicates. Left: lactulose assay
standards; right: lactulose assay urine samples.
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Figure 32: Correlation of ODs measured between two replicates: Left: mannitol assay
standards; right: mannitol assay urine samples
4 Because standards kept well and did not need frequent replacing, only four batches of sets of
standards were required to be made up in total, at sample analysis during the end of the study.
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The estimation of the repeatability of lMR within individual subjects at each time-point
was repeated on the complete set of samples. in the same manner as for the power calculation
described in the Methods section, using a one-way analysis of variance. The intra-class
correlation coefficient was 0.26 and the estimated reliability of an individual mean was 0.49. A
high amount of error was therefore introduced during measurement.
Upon inspecting the intra-class correlation coefficients separately for lactulose and
mannitol, it was evident that most of this error was brought in by the lactulose part of the
assay.
4.6.3 Discussion
Instead of comparing (log)lMR by fitting lMR into the regression model, (log)lactulose was
regressed on (Iog)mannitol. This regression model was used as an alternative way of examining
for differences in lactulose-mannitol relationships between groups, but. unlike the ratio, it a)
reduced some- of the between-individual variance, and b) relaxed the tight restriction of
proportionality that the ratio imposes.
The repeatability between three repeat measures on infants was not very high, due partly
to measurement error during the assaying stage, errors during urine collection, and day-ta-day
biological variation.
The lactulose part of the assay introduced a high degree of error, which is not surprising,
given the small amounts of sugar being measured ("'150~g/ml, which is roughly 5x smaller
than the average concentrations of mannitol being assayed). The assay is also comprised of a
number of steps and calculations, each allowing entry for additional variation.
The repeatability of the dual-sugar permeability test, also in regards to lactulose detection,
has been Investigated and found to be excellent when using gas chromatography (276).
High-performance liquid chromatography is also a sensitive method for examining small
amounts of lactose and other sugars in urine and blood serum (277, 278). Nevertheless, the
low cost and relative speed of using the enzymatic method for sugar determination makes it
attractive In comparison to these other methods, particularly where, as in the present study,
large numbers of samples are required to be analysed.
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Certain difficulties with urine collection present challenges for obtaining valid data: urine
can become contaminated with faeces; some infants do not pass urine, even for the duration
of five hours; water can filter into the urine bags when mothers wash their children after they
have passed stool. Most problematic, though, and certainly a factor introducing errors, is the
spillage, or missed collections of entire passages of urine, due to urine bags which become
detached, urine leaking out at the mouth of the bag - particularly in girls, or infants passing
further urine immediately after a bag is removed and just before the next one is attached.
Due to differences in absorption and excretion rates of the two sugars (due to e.g. varying
gastric emptying rates and intestinal transit times) (39), the final ratio can become distorted if
part but not all of the entire volume of urine passed over five hours is collected. Indeed this
was a common and seemingly unavoidable difficulty of the test, which would not be overcome
with the most sensitive or precise of assays.
These problems with the test are not unknown, and the study design allowing for three urine
collections at each time-point was constructed to minimise some of the errors and increase
the test's reliability. Nonetheless, the measurement error, combined with other components
of variance Inflation, remained large. Inspection of the group LMR means and 95% Cl,
however, reveals that it is unlikely that a real difference remained undetected, i.e. that a type
II error occurred. The limits of the 95% Cl show the ratio between the geometric means of LMR
In the fish 011to placebo groups to be 0.87 - 1.07, and even the lower limit precludes a real
clinically significant treatment effect.
An interesting finding was the significant difference in urinary mannitol concentrations.
Some allowance needs to be made for the possibility that the effect could be attributed to
chance - an· artefact of multiple testing, particularly when this comparison of mannitol
concentrations assessed Independent of the LMR was not stated as a primary outcome.
Furthermore, if the effect was real, one would expect to see the same difference in urinary
lactulose concentration.
However, it could be that such a difference in lactulose concentrations was not detected
due to the very' low concentrations of lactulose being assessed, and the high amount of error
introduced during its assaying. At any rate, the difference would not be expected for LMRs,
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because urine concentration would affect both lactulose and mannitol equally and hence
would be cancelled out. (Or, alternatively, dividing lactulose concentration by mannitol
concentration may Introduce so much error that the effect is lost).
What is clear, though, is that this difference has more to do with urine concentration than
an effect on mannitol uptake, and so has little to do with gut integrity. Even so, the possibility
of an effect of fish oil supplementation on urine dilution might be an important finding and
could raise interesting questions regarding its other, yet unknown, physiological effects.
4.7 Secondary outcomes
4.7.1 Plasma fatty acids
Fish oil supplementation resulted in a significant increase in the percentage of DHA (95%
Cl: 0.31,0.58; p<0.001) and EPA (95% Cl: 1.5,1.95; p<0.001) in the plasma total lipids,
confirming that tissue uptake ofn-3 LCPsin the fish oil supplemented infants had taken place.
Expressed in absolute amounts, the plasma EPA concentration was similarly statistically
significantly elevated, while the DHA concentration difference lay only on the cusp of
significance (95% Cl: -0.03,11.2; p=0.051). Results are tabulated in Table 15.
Figure 33 shows the graphs of plasma concentrations of DHA and EPA at 9 mo against 3
mo, scattered by treatment group. The elevated n-3 LCPsat 9 mo in the fish oil compared to
olive oil group can clearly be observed. There is also some indication that the control group
OHA levels at 3 mo have an association with those at 9 mo (r=O.44). This is, unsurprisingly, less
clear in the fish oil group (r=0.17). The relationship between DHA at 3 mo and 9 mo will be
assessed later, in Section 4.8.6 (Plasma and breast-milk fatty acids: further considerations).
Blood AA levels remained unchanged by the intervention. Similarly, total n-6 FA levels did
not differ between olive and fish oil groups. When expressed as a ratio, however, a marked
difference in n-6 to n-3 LCPs (95% Cl: -0.35,-0.18; p<0.001) and AA/(EPA+OHA) (95% Cl:
-0.32,-0.16; p<0.OO1)were detected, with lower ratios found in the fish oil group.
5 Ratiogeometric mean intervention group:placebogroup
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Table 15: Fatty acid endpoints, by treatment groups
Endpoint Fish oil Placebo
(n=86) (n=83)
x; SO X;SO Effect size (95% Cl) p-value
(% plasma total FA)
DHA 4.87; 1.01 4.44; 0.81 0.53 (0.28, 0.79 <0.001**
EPA1 2.13 1.34 1.652(1.45, 1.88)3 <0.001 **
(1.66,2.95 ) (0.94,1.72)
AA 7.28; 1.52 7.25; 1.35 0.09 (-0.33, 0.51) 0.680
(ng/IJ.I)
DHA 70.0; 20.6 65.4; 16.3 5.54 (-0.03, 11.2) 0.051
EPA1 31.1 19.3 1.61 (1.38, 1.84) <0.001 **
22.8,43.7 14.3; 25.0
AA 104; 29.0 107; 27.6 -2.38 (-10.8, 6.05) 0.578
Other FA indicators (ng/IJ.I)
Essential:nonessential PUFAs4 1.88; 0.39 1.75; 0.34 0.14 (0.02,0.25) 0.018*
DHA:22_Sn-6 28.4; 7.34 21.5; 7.31 6.85 (4.64, 9.05) <0.001 **
Total n3 FAs (ng/~l) 123; 41.2 104; 27.7 19.7 (9.08, 3004) <0.001 **
Total n6 FAs (ng/lll) 440; 118 452; 119 -9.77( -46.0, 26.5) 0.595
AA/(EPA+DHA) 1.05; 0.26 1.28; 0.31 -0.24(-0.32, -0.16) <0.001 **
Total n-6 ~ C201 Total n-3 ~C20 1.10; 0.26 1.34; 0.32 -0.25 (-0.35, -0.18) <0.001 **
roue t;"a skewed distribution for this FA, the median (25 percentile, 75 percentile) is presented
2Effect size (untransformed regression coefficient) indicating the ratio "fish oil group geometric
mean:control group geometric mean"
3CI limits (untransformed calculated 95% Cis) for the ratio "fish oil group geometric mean:control group
geometric mean"
4Ratio of (n-6 + n-3) I( n-9) unsaturated PUFAs. n-7 PUFAs should ordinarily be included in the ratio as
non-essential FAs but data for these were unavailable
*p<0.05; **p<O.OOl
The ratio DHA:C22_5n-6 is lower in conditions of DHA functional shortage. The increase in
this ratio in the fish oil group (95% Cl: 4.64,0.05, p<O.OOl) shows that DHA was not merely
absorbed into the bloodstream, but also used efficiently by cells and tissues.
Overall PUFA status was measured by the ratio essential:nonessential PUFAs, which
increases as essential FA status increases. There was a statistically significant higher essential
FA status in the intervention group (95% Cl: 0.02,0.25; p=0.018), although this difference may
only have been as small as 0.02, the lower limit of the 95% Cl.
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Figure 33: Plasma DHA (above) and EPA scattered at 9 mo vs. 3 mo, by treatment group
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Table 16: Other fatty acid profiles
FA Fish oil Placebo Effect size (95% Cl) p-value
(ng/lll) (n=87) (n=85)
x; 50 X;50
Saturated (C8:0 - C18:0)1 516 (150) 541 (137) -27.0 (-70.8, 16.7) 0.224
Saturated (C20:0 - C24:0)2 11.6 (2.79) 11.8 (3.60) -0.17 (-1.17, 0.83) 0.739
Monousaturated'' 350 (99.7) 373 (106) -23.4 (-54.4, 7.67) 0.139
Oleic acic {C18:1n9c} 307 {90.8} 325 (99.8) -19.0 {-47.8, 9.81} 0.195
n-3 PUFAs
C18:3n3 4.86 (2.87) 4.76 {2.16} 0.05 (-0.73, 0.84) 0.893
C20:3n3 0.73 {0.81} 0.74 (0.87) 0.02 (-0.24, 0.28) 0.878
C22:sn3 13.2 {4.64} 11.9 {3.82} 12.8 {8.42, 17.2} <0.001 **
n-6 PUFAs
C18:2n6c 317 (93.8) 322 {91.9} -4.40 {-33.0, 24.2} 0.761
C18:3n6 3.01 (2AO) 3.62 (4.77) -0.76 (-1.89, 0.37) 0.184
C20:3n6 17.1 (s.BO) 19.1 (6A9) -1.93 (-3.67, -0.10) 0.039*
C22:sn6 2.59 (1.00) 3.32 {1.24} -0.76 (-1.07, -0.44) <0.001 **
11ncludes 18:0; 17:0; 16:0; 15:0; 14:0; 13:0; 12:0; 11:0; 10:0; 8:0
21ncludes 24:0; 23:0; 22:0; 21:0; 20:0
31ncludes 14:1; 15:1; 16:1; 17:1; 18:1n9c; 20:1; 22:1n9; 24:1
*p<O.Os; * *p<O.OOl
Table 16 presents a more complete overview of FA profiles, by group. The only other
differences between groups were detected for (22:3n-3, (22:5n-6, and (20:3n-6.
There were no differences in saturated or monounsaturated FAs between groups,
including the monounsaturated oleic acid, the principle component of the olive oil placebo.
The adjusted analysis gave similar results to the unadjusted analysis (Table 1n and some
evidence for an interaction between compliance and treatment on DHA and EPA levels
(p=O.029 and p=0.026, respectively).
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4.7.1 . .1 Discussion
At least eight different biomarkers for measuring n-3 lCP status have been used in the
literature (279). Thls makes comparisons of dose effects on plasma FA status, and of FA
profiles of this sample of Gambian infants with those of other populations of infants difficult
(as the distribution of FAs among different biological compartments can vary substantially
(280) ), especially since the literature on infant plasma FA profiles is limited to start with. In
addition, as with any biomarker, measurement errors and variability introduced by sampling,
transport, sample handling, the use of different laboratories, and total analyte present in the
sample (93), present drawbacks to repeatability and comparability of results.
Plasma FA n-3 lCP status was a secondary endpoint, and no allowance was made for
multiple testing. Where p<0.001, the likelihood of a chance significant finding is very small,
however. But in making inferences about the difference in essential FA status (p=0.018), the
above should be kept in mind.
That the DHA% elevation was highly significant, while the absolute concentration of DHA
was not, suggests that DHA partly displaced other FAs in the blood tissues and hence formed a
larger proportion of the overall lipids, without increasing significantly in absolute
concentration. For example, the activity around the n-3 lCPs EPA,C22:5 and DHA metabolism
is catalysed by the same enzyme as the n-6 LCP metabolism of AA, C22:4, and n-6
docosapentaenoic acid (C22:5).
Figure 34, which was already presented in Chapter 1, is repeated here for reference. It is
known that in conditions where DHA is in limited supply, n-6 docosapentaenoic acid synthesis
is increased. It follows that in ample DHA supply, docoasopentaenoic acid levels will decrease.
Indeed, this n-6 LCP was significantly lowered in the fish oil group (Table 16), perhaps
explaining a component of the relative increase in DHA.
Additionally, DHA Is sometimes retro-converted back to EPA In humans. Studies have
found increases in both DHA and EPA in blood and cell lipids, for example, when
supplementing with DHA only (281). Considering that more EPA relative to DHA was
administered dally, it would seem unlikely that this retro-conversion occurred to any
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significant degree in these Gambian infants. Nevertheless, if it had, this could further explain
the lack of substantial increase in relative DHA levels in the plasma .
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Reprinted from reference (58)
Figure 34: Metabolism of fatty acids to form LCPs
The strong relationship between DHA at 3 mo and 9 mo in the control group (r=O.44)
Implies some stability of DHA In the blood. Whether this was mostly because of steady
breast-milk DHA concentrations rather than blood lipid profiles is uncertain, but will be further
addressed In Section 4.8.6. It Is remarkable that some infants had roughly five times the DHA
concentration and nearly ten times the plasma EPAconcentration in their plasma than others.
Figure 33 demonstrates this very wide Inter-Individual range of LCP concentrations. It Is
surprising that even a 6 mo-long daily FA supplementation regimen eVidently had no impact on
reducing the extent ofthls inter-individual variation.
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LCP incorporation into plasma phospholipids and other cell membranes is strongly
dependent on the diet (75). Yet, even when the overall intakes of these fats in infants were
matched, most likely fairly narrowly, to considerably high doses, some infants still had very low
n-3 LCPplasma concentrations while others had considerably high ones.
Possible explanations for these large inter-individual differences could be differences in a
child's ability to absorb, process and retain the administered LCPs. There is evidence for a
reduced fat absorption in children with acute infections (282), diarrhoea (283, 284), intestinal
infections and tropical enteropathy (92, 285), and helminth infections (284,286). A large part
of this malabsorption in situations of persisitent intestinal infection is explained by
morphological alterations in the mucosal villous, which affect digestive-absorptive functions
(92). Additionally, small-intestinal bacterial infections associated with environmental
enteropathy can lead to a deconjugation of the bile salts required for the formation of micelles
necessary for fat digestion. This deconjucation action in turn leads to maldigestion of fats (92).
Differing severities of these conditions leading to varying degrees of reduced nutrient
absorptions or steatorrhea in different children, most likely play a significant role in
determining overall lipid status.
The high variability in plasma LCP concentrations may also be a reflection of the great
variability known to exist In breast-milk LCPconcentrations (287, 288). However, DHA is the
most variable breast-milk FA and yet EPAwas far more variable than DHA concentration in the
plasma of these Infants. Furthermore, one would expect to see a minimisation of this
variability in the plasma of the treatment group if the variability was explained to such a large
extent by the diet or breast-milk intakes.
Certainly genetic and metabolic factors would be considered potential determinants of
PUFA status. Although the genetic effects of LCPs on molecular activities have been and
continue to be examined extensively, the genetic determinants of LCPstatus remains largely
under-explored. Recently, however, several polymorphisms and haplotypes of the genes
encoding desaturases - delta-S and delta-G - involved in catalysing the conversion of C18 PUFAs
to their longer chain derivatives have been identified. FADSl and FADS2 encode delta-5 and
delta-S, respectively (289). Evidence that polymorph isms of the FADSl and FADS2 gene
clusters are associated with serum phospholipid PUFA concentration has been found (290,
291). For example, high AA concentrations were associated with various FADS alleles.
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However, although these polymorph isms can predict a large extent (roughly 28%) of the
variation in AA plasma phospholipid levels in adults, they predict only about 2% of the DHA
variation (291, 292), and so probably do not explain any major extent of the variation in
Gambian infant DHA concentrations. Nevertheless, these findings show at least some genetic
contribution to physiological plasma concentrations of FAs.
The effects which the n-6 and n-3 series PUFAsexert on each other during metabolism and
synthesis provides an example of one of the metabolic influences PUFAs experience in
determining their eventual cellular concentrations. Other metabolic determinants may, no
doubt, exert similar suppression or enhancing effects on LCPs, their synthesis and effects.
Various studies have demonstrated that supplementation with n-3 PUFAs or n-3 PUFA
containing foods resulted in increased n-3 concentrations of plasma lipids and phospholipids,
and erythrocyte membrane FAs (293-295), and some have reported a simultaneous decrease
in n-6 plasma fractions (173, 296-298). Figure 34 shows how the different n-3 and n-6 FAs
undergo desaturation, elongation, and retroconversion. Delta-6 and delta-4 desaturases are
competed for between the two omega-chains (297), explaining some of the decrease in n-6
FAs reported as a consequence of n-3 supplementation.
Although some studies of n-3 supplementation have resulted in a concomitant decrease in
AA levels, this did not occur in the present study. A lowered n-6:n-3 ratio has indeed been
associated with improved. health outcomes, although AA remains a potent FA with biologically
important functions in infant health and development. An adequate AA status is imperative if
an infant is to thrive (83, 292, 299).
Both AA and DHA can be formed by endogenous conversion of their precursor essential
FAs. However, AA is synthesised via a short enzyme-catalysed pathway of only three
desaturation and elongation steps, whereas the synthesis of DHA is long, complex and indirect
(84, 292), with the result that DHA endogenous synthesis is far less effective than that of AA.
Indeed, as already mentioned, polymorphisms of the desaturase enzymes predict far more
variation in AA plasma phospholipid levels than DHA levels.
The plasma of all infants, regardless of treatment, remained rich in linoleic acid (C18:2n-6;
-320ng/",lj Table 16), the precursor to AA. It is likely that a substantial degree of endogenous
synthesis of AA took place, particularly if preformed AA from the breast-milk was in any way
151
Chapter 4: Results and specific discussions
insufficient. At any rate, there is no evidence to suggest that there was a physiological lack of
AA, and even a large dose of n-3 LCPs given daily did not have the undesirable effect of
reducing AA tissue levels.
4.7.2 Cognitive development
The secondary outcomes - cognitive development, acute phase proteins, and intestinal
inflammation - are summarised by treatment group, showing significance test results, in Table
18.
On both the Willatts and Attention tests, infants who did not receive fish oil performed
equally well as those who did (Table 18). There were no significant differences detected
between intention scores (95% Cl: -1.10,1.56; p=0.759), pretest scores (95% Cl: -1.26,2.14;
p=0.609), inattention rates (95% Cl: -0.64,0.24; p=0.365), or the mean look times (95%CI: 0.86,
1.20; p=0.884).
In an attempt to retrieve the toy, infants pulled the cloth off the table an equal number of
times in the placebo and fish oil groups (p=0.918), indicating that n-3 LCPsupplementation had
no impact on motor control (195).
The Attention Test data were skewed, and were thus log-transformed. The data for the
Willatts Test were not distributed normally either. Unlike the Attention Test data, however,
they appeared to be mixture distributions: uniform distributions with point density at zero.
The truncation of the scoring range at zero, while the range theoretically reaches further
below (for example, some infants succeeded in pulling the cloth or lifting the cover, but looked
away for more than two seconds and so achieved a zero on the relevant score, whereas other
Infants made no attempt to pull the cloth whatsoever yet also achieve a zero) might have
caused this. No simple transformation was available to efficiently normalise such data. Options
were the Inefficient approach of reducing to a binary variable, or the complex method of, e.g.,
likelihood approach modelling. However, as group means were being compared, with more or
less the same number of infants in each group, the distribution of the mean should have
followed the normal very closely and thus regression analysis was performed on the
untransformed data.
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Table 18: Secondary endpoints, by treatment group
Endpoint Fishoil Placebo
X;SO X;SO Effect size (95% Cl) p-value
Cognitive development
Willatts test (n=73) (n=65)
Average total Intention Score 4.63 (3.77) 4.45 (3.71) 0.201 (-1.10, 1.46) 0.759
Average intentional solutions 0.44 (0.52) 0.43 (0.54) 0.011 (-0.17, 0.19) 0.871
Pretests average score 8.61 (5.02) 8.16 (5.23) 0.44 (-1.26, 2.14) 0.609
Attention Test Median Median
(25, 75 pctile) (25, 75 pctile)
(n=74) (n=69)
Inattention rate 2.38 2.37 0.98 (0.82, 1.81) 0.868
(1.70,2.91) (1.70, 2.91)
Mean look duration 23.8 23.2 1.01 (0.86, 1.20) 0.884
(19.5,33.9) (17.2,35,5)
Acute phase proteins Mean; SO Mean;SO
(n=86) (n=83)
Plasma albumin (mg/L) 35.3;3.1 35.3;2.8 0.07 (-0.83, 0.96) 0.880
Median Median
(25,75 pctile) (25,75 pctile)
AGP (g/I) 1.01 1.03 0.97 (0.88, 1.08) 0.596
(0.85, 1.34) (0.82, 1.36)
CRP(mg/I) 4.7(3.1,8.2} 4.7(3.2,7.9} 0.98 (0.81, 1.19) 0.838
Intestinal inflammation (n=76) (n=69)
Calprotectin dry weight (mg/kg) 78.0 (43,120) 66.5 (46, 138) 0.90 (0.86, 1.42) 0.427
Calprotectin wet weight 647 (357,996) 552(382,1145)
Proportion abnormal Proportion abnormal
( 95% Cl: % abnormal) (95% Cl: % abnormal)
Plasma albumin (mg/L}2 5/86 (0.77,10.9) 3/83 (-0.49,7.71) 0.9333
AGP (g/L}2 44/86 (40.4, 61.9) 43/83 (40.8, 62.8) 0.5013
CRP(mg/L}2 39/86 (34.6,56.1) 36/83 (32.5,54.3) 0.7963
Calprotectin (rng/kg]" 70/79 (81.4, 95.8) 62/74 (75.2, 92.4) 0.3863
lControlling for number of trials
3Using standard adult cut-off ranges from healthy individuals: CRP:S5mg/L;AGP:S1g/L; albumin:S30mg/L
2Group differences analysed by Pearson's chi squared test
4 Using European healthy reference value (calprotectin:S;263mg/kg)
153
Chapter 4: Results and specific discussions
15
~
8 10
V)
c
.Q
C.,
:s
~5
I-
0
0
x
x •• xa<x·.x
• x ~ ••• x. x • x '"
•
• x ~
x
x x x
x
Xx: • ,.
x
•
x ••• x
• • x8x~· ~ ,x
• x ~ •
• x •• ~ x x x .~.x:.:xx.xx •. :<-
x e ""x.x .&)Ox x,.
• x
x
x
•
2 4 6
inattention rate
8
I • Controi x Fish oil I
Figure 35: Intention score versus inattention rate, by treatment group
Judging from scatter plots and Pearson product-moment correlation coefficients, the
Willatts and Attention tests had no relationship with each other. The correlations of
inattention rates and mean look duration with total intention scores, intentional solutions, and
pretest average scores, were r<±O.l in all instances. The poor association, with inattention
rate compared to total intention scores chosen as example, is graphically illustrated in Figure
35.
Sex differences between scores were tested using regression analysis. In the Willatts Test,
the average total intentional solutions score was significantly higher in boys than in girls
(p=O.0123), and for the intentional solutions and pretest scores the difference approached, but
did not reach, statistical significance (p=O.0672, p=O.0835, respectively, Table 19). There were
no sex differences in the Attention Test.
The mothers' highest level of education was determined by the highest grade or class she
had completed in Arabic or English school, or both. Schooling is offered in either medium in
West Kiang for a maximum of twelve years' Arabic tuition or/and nine years English tuition.
(The final three years' English tuition may be taken at the coast or regions further inland, but
none of the mothers had followed this route).
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Table 19: Cognitive development scores, by sex
Girls Boys Effect size (95%
n=56 n=82 Cl)
Willatts test X (SO; SE) X (SO; SE) P
Average total Intention 3.59 (3.74; 0.50) 5.20 (3.60; 0.40) 1.61 (0.35, 3.86) 0.012*
Score
Average intentional 0.33 (0.52; 0.07) 0.50 (0.53; 0.06) 0.17 (-0.01, 0.35) 0.067
solutions
Pretests average score 7.51 (5.45; 0.71) 9.02 (4.79; 0.53) 1.51 (-0.20, 3.21) 0.084
Attention Test Median Median
(25th;75thpercentile) (25th;75thpercentile)
Inattention rate 2.38 (1.70; 2.91) 2.37 (1.57; 3.39) 0.97 (0.80, 1.02) 0.739
Mean look duration 23.2 (17.2; 35.5) 23.8 (19.5; 33.9) 1.05 (0.88, 1.24) 0.595
*p<O.OS
Data were available for 94% of mothers whose infants completed the cognitive testing.
Twenty-five mothers received no form of formal schooling at all. The data are summarised in
Table 20. There were no differences in education level between the two groups (p=0.782 and
p=0.190 for Arabic and English school, respectively, using a Pearson's chi-squared test).
Table 20: Maternal years of education, by treatment group
Highest year completed Fish oil (n=68) Control (n=68)
-- ---
Arabic School
0-2 26 19
3-6 28 26
7-11 4 4
English School
1-4 4 9
5-9 6 10
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No association between the mothers' education levels and the performance of their
infants on any of the tests was found.
The analysis was repeated, fitting mother's highest level of education (highest grade
passed in Arabic school or English school) into the same regression models. The results were
unchanged in regard to group significant differences (Table 21).
Table 21: Cognitive development regression analysis (repeated), controlling for mother's
highest level of education
Adjusting for mother's
education
Endpoint Effect size (95% Cl) p-value
Total intentional solutions 0.53 (-0.75, 1.81) 0.414
Total solutions 0.06 (-0.12, 0.25) 0.482
Average pretest score 0.57 (-1.19, 2.36) 0.522
Inattention rate -1.77% (0.81,1.19) 0.854
Mean look duration 1.64% (0.86, 1.21) 0.850
The adjusted analysis, summarised in Table 22, again showed similar results to the
unadjusted analysis. This held true for all adjusted analysis results summarised in the table.
4.7.2.1 Inter-observer reliability
The scores of 39 infants marked by both the primary scorer and secondary observer were
scattered, with the line Y=Xsuperimposed (Figure 36). Correlations were examined by Pearson
product-moment correlation coefficients. Ninety-five percent Cis for the correlation
coefficients were estimated using the bootstrap approach. Bias between markers was tested
with a paired Hest, to test whether, even though a strong linea r relationship exists, one
marker was consistently marking higher or lower than the other.
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Inter-observer reliability was highest on the pretest (r=O.99) and total intention scores
(r=O.97), Table 23. There was also no statistically significant evidence of bias between markers
(p=O.121, p=O.2827, respectively). Total Intentional solutions were correlated at r=O.92, with
evidence of bias narrowly falling short of statistical significance (p=O.097).
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Figure 36: Scatter graphs showing scores of observer 1 plotted versus observer 2. Top to
bottom: average total intention score; average total intentional solutions; average pretest
scores.
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Table 23: Inter-observer reliability, Willatts Test
Correlation scoresbetween Difference between
observer 1 and 2 observers' mean scores3
""'r1;---S-ia-s--c-o-rr-e-c-te-d-C-,....2 -"X'l-- x""2-'95% C' P
0.97 0.936 - 0.989 0.21 (-0.06 - 0.49) 0.1210
0.92 0.821 - 0.961 -0.06 (-0.14 - 0.01) 0.0973
0.33 (0.33 - 1.00) 0.28270.981 - 0.993
Score
r total intention score
r total Intentional solutions
r total pretests score 0.99
lPearsoncorrelation coefficient
2Calculatedusingthe bootstrap approach
3From paired t-test: comparison between meansof scores
4.7.2.2 Discussion
Look duration decreases between roughly 2 mo and 9 mo of age (208). During this first
year of life, shorter look duration (as measured during infant habituation studies when a
stimulus is repeatedly presented) is believed to reflect more efficient information processing
and a greater ability to disengage (131, 300). Accordingly, shorter look durations have been
associated with childhood IQ, with infants who habituated faster (i.e. displayed shorter looking
times) scoring higher IQ scores (208,301,302).
In contrast, beyond 9 mo of age and into the second year of life, looking and examining, as
measured during free-play, is reflective of attention span or attention control, and an ability to
stay focussed on a task, rather than processing speed (208). An increase in looking times
measured during free-play is associated with more mature cognition, and positive
developmental outcomes as this age and into early childhood (208,303).
One would therefore expect longer look durations to reflect better attention to a task, and
an enhanced cognitive maturity. However, not even a weak correlation was detected between
scores attained on the Willatts and the Attention tests, as stated above. This could be because
the Attention Test is not measuring what it aims to i.e. has a low degree of validity, particularly
in the present population. Indeed, this particular single-object test has not been validated in
further population groups, and its use has been reported very rarely since its first description
in 2004.
Alternatively, there may be no real relationship between infant attention development
and problem-solving behaviours in this population at this age. As described above, there is a
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decline in looking time during the first year of life. This look time plateaus at around 9 mo of
age, but then gradually starts to increase. By 12 and 18 mo, longer look times are believed to
indicate enhanced attention. Given the poor performance the Gambian infants displayed on
the problem-solving test in comparison to other infant groups studied (discussed below), it
may be that they lag behind in their information processing and attention control domains so
that the "look-time" plateau is reached at a later stage than typically seen in infants reported
in the literature. Were the Gambian infants to reach this plateau at around 12 mo rather than
9 mo, some infants may still fall into the category of faster information processing linked to
shorter look times. Some infants, on the other hand, may be at a point in their development
which displays more mature attention behaviour, and where longer look times therefore
indicate enhanced cognitive behaviour. Still others might be hovering between the two
degrees, with their look times accordingly indicating very little.
In order to gain clarity on both the validity of the test and what it measures in this
population, as well as the appropriate age that it should be employed, further research testing
infants of different ages across the first years will be required.
The consistently higher average on all Willatts Test measures in boys compared to girls
suggests that boys in the population were cognitively further developed than girls in the area
of planning and problem solving behaviour. If this were true (and not merely due to chance) it
could reflect a biological difference in rates of cognitive maturation in boys compared to girls,
although this finding has not been made In the other studies testing problem solving behaviour
In Infants, and the consensus view is that there are no sex differences in intelligence (304). The
finding may, on the other hand, be rather related to different standards of care, or different
modes of interactions which caregivers display towards girls compared to boys. It is well
known that parents tend to interact differently with their male children than their female
children (305, 306). In rural Gambia, gender differences appear to be particularly pronounced
and marked differences in gender roles are the norm. Certain behaviours might be encouraged
and expected in boys but not in girls, or boys might receive preference treatment or attention
from other family members compared to girls.
Whatever the case may be this gender difference in cognitive development first needs to
be verified before inferences about its causes and consequences can be made.
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Sixteen percent of infants were unable to demonstrate any form of intention for retrieving
the toy whatsoever (obtaining an overall score of "0"), and only two percent were able to
obtain the maximum intention score. In comparison to infants from other populations the
scores compared poorly.
Infants who were investigated as part of a well-designed n-3 LCP supplementation study in
Denmark (n=73) obtained a similar intention score as the Gambian infants of 4.5, and a higher
number of Intentional solutions - 37% - compared to the 29% achieved in the Gambian sample
(307). However, these infants were 3 mo younger than infants in the present cohort,
completing their assessments at 9 mo of age. A group of 29 American infants obtained an
average score of 7.4 for Intention, and made intentional solutions on 52% of trials (308). These
infants, too, were 9 mo of age. In a similar study lead by the developer of the test in the UK, 9
mo old Infants (n=40) achieved an average intention score of 7.4, and intentional solutions on
38% of trials (131).
In non-developed countries the literature is scarce. One study in Kingston, Jamaica,
Investigating 135 low birth weight and 87 normal birth weight infant, similar procedures as
the "pretest" scoring procedure described were used, providing scores comparable to
"pretests average score" above. The Gambian infants achieved a mean of 1.9 on the support
step, and 2.4 on the cover. In the Jamaican sample the scores were 2.5 and 2.9, respectively,
even though these Infants were on average 7 mo old and mostly born at low birth weight
(239). In a large population-based study in Bangladesh, nearly 2116 seven month old infants
achieved a roughly 2.8 mean on the support step and 3.2 on the cover step (309, 310).
The comparatively poor performance of the Gambian infants is difficult to elucidate.
Because all scorers used the same scoring protocol, and all tests were validated by a second
.observer, It would seem unlikely that markers varied greatly in their strictness. Infants In
developed countries may be more accustomed to toys of the nature used, and environments
such as the settings where the test was conducted, compared to the rural African infants,
explaining some of the difference In results between these Infants. However, even 7 mo old
Infants from Bangladesh and Jamaica performed better on these tests than did the Gambian
Infants. No doubt the reason, simple or complex as It may be, may be understood through
further research on the topic, but the scope of this thesis does not permit it here.
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4.7.3 Acute phase proteins
The results of plasma acute phase proteins (Table 18) provide evidence that there is no
impact on a reduction in systemic inflammation by fish oil in the infants studied.
A recent study involving infants living in the same area (258) found mean AGP and CRP
concentration, at 9 mo of age of 1.25mg/1 and 7.78mg/I, respectively. This is not comparable
to the median concentrations presented in Table 18, but compared to the calculated mean
concentrations of 1.13g/1 and 7.4mg/1 for AGP and CRP, the findings are similar. Using
identical cut-offs, the same recent study surprisingly found somewhat different proportion of
abnormally high levels of acute phase proteins: 68.5% for AGP and 33% for CRP,compared to
the 52% and 45% in the present study.
4.7.4 Intestinal inflammation
There were no differences in average calprotectin levels between infants in the different
treatment groups (95% Cl: 0.86,1.426; p=0.427; Table 18), and elevated calprotectin levels
were equally distributed between groups (p=0.386)
Only 21 out of 153 Infants had calprotectin levels lower than a European reference of
263mg/kg for infants at 3 mo of age (263), and none were lower than the 79mg/kg for infants
of 6 mo of age, or 67mg/kg for infants of 12 mo. These calprotectin concentrations are
Indicative of the high degree of gastrointestinal tract inflammation characteristic of Gambian
Infants.
The median calprotectln concentration was 614mg/kg. This is significantly less than the
median of 1033mg/kg found at baseline, but younger Infants are known to have higher
physiological levels of calprotectln. The variation between infants is immense, as the 25th and
75th percentiles in Table 18 show. The minimum and maximum calprotectin wet weight
concentrations were 125 and 5200 mg/kg, respectively.
There were no sex differences for this inflammatory protein.
6 Ratioof geometric means(treatment group/placebo group)
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4.7.4.1 Measurement reliability
A control used on eighteen individual plate runs was used to calculate an inter-assay % CV
of 7.43%.
Additionally, a set of 21 samples was assayed twice, and from the concentrations
calculated in Run 1 versus Run 2, an overall mean inter-assay % CV of 9.79% and Pearson
correlation coefficient of >0.99 calculated. However, the CV distribution was skewed to the
right, so the median was calculated and found to be 6.1%.
All OD data on replicates of stool samples run on each plate were used to calculate an
overall mean intra-assay CVof 3.5%, and median CVof 2.6%, between replicates.
The concentrations of the 21 samples obtained in Run 1 versus Run 2 are plotted in Figure
37. Replicate ODs for all samples and standards are shown plotted in Figure 38 .
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Figure 37: Calculated concentrations of 21 samples read on two independent plate runs,
showing average concentrations from Run 1 on the Y-axis, and average concentrations from
Run 2 on the X-axis
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Figure 38: ODs for replicates 1 & 2 plotted against each other for samples (above) and
standards (below)
4.7.5 Infant morbidities
Using the number of visits an infant was reported ill with any symptom as a negative
binomial variable, group comparisons showed evidence of no treatment effect. Similar
negative binomial regression analyses indicated no statistically significant impact of the
intervention on rates of fever, respiratory complaints, vomiting, or nurse visits/doctor
visits/referrals amongst infants. Although the difference was not statistically significant,
diarrhoea rates were far higher (roughly 25%) in the control than the fish oil group. These
results are presented below, in Table 24.
Because the number of times a particular complaint was reported increased with the
number of times the infant was visited - but possibly not in a straightforward multiplicative
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way, since the risk may change with age - log(number of visits) was controlled for in each of
the analyses.
Nose/abnormal bleeding and miscellaneous complaints were not observed frequently
enough to analyse meaningfully, so for this only the total number of observations in each
treatment group is given in Table 24. There was no evidence of increased bleeding in the
fish-oil supplemented group.
The most common complaints were cough and respiratory conditions, followed by fever.
The analysis was repeated, adjusting for compliance and fitting compliance and treatment
doses taken, and is summarised in Table 25. The results when adjusting for compliance were
similar, and no significant interactions between compliance and treatment group on morbidity
outcomes were observed.
In a similar analysis, season of visit was controlled for by adding the first two pairs of the
Fourier series as extra covariates. Some evidence, but just statistically significant (p=O.0489), of
an interaction of treatment with season was seen for fever, and there was no interaction
observed on any of the other morbidity outcomes.
Table 24: Morbidity endpoints, by treatment group
Morbidity rates
Fish oil Control
Total Total Effect size p-value
recorded recorded
(95% Cl)
(n=87) (n=85)
3603 3088 0.13 (-0.08, 0.34)2 0.238
474 605 -0.27 (-0.61, 0.06) 0.110
1479 1297 0.11 (-0.12, 0.34) 0.338
1645 1503 0.06 (-0.2,0.32) 0.670
186 161 0.13 (-0.10, 0.36) 0.268
251 268 -0.12 (-0.56, 0.03) 0.570
12 17
Unwell, any complaint"
Diarrhoea"
Fever3
Respiratory complaints'
Nurse/doctor vlslts"
Vomiting3
Abnormal bleeds/other complatnts'"
'Number ~vT;its at which one or more symptom was recorded
2The number of times a condition was recorded for each individual was analysed as a negative binomial
variable
3Number of visits at which any infant was reported to have this complaint
4Too few observations to make meaningful statistical comparisons
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Table 25: Morbidity outcomes, adjusted analysis
Adjusting for compliance
Interaction between compliance &
treatment (fitting compliance &
dosesof treatment received)
Morbidity rates Effect size p-value
(95% Cl)
Unwell, any complaint 0.12 (-0.09, 0.33) 0.275
Diarrhoea -0.28 (-0.62, 0.05) 0.096
Fever 0.10 (-0.13, 0.33) 0,402
Respiratory complaints 0.05 (-0.22, 0.32) 0.725
Nurse/doctor visits 0.13 (-0.09, 0.37) 0.242
Vomiting -0.13 (-0.56,0.30) 0.563
Effect size p-value
(95% Cl)
0.02 (-0.01,0.04) 0.223
0.03 (-0.01,0.07) 0.114
0.00 (-0.02, 0.03) 0.754
0.02 (-0.01,0.05) 0.144
-0.00 (-0.03, 0.23) 0.772
0.21 (-0.03, 0.08) 0,438
The markedly higher diarrhoea incidence in the control group compared to the fish oil
group may have been an explanation for why this group of infants also had lower MUAC and
skinfold thickness measurements than infants supplemented with fish oil. A reduction in
diarrhoea incidence over the 6-month period might have had an influence on body fat
accumulation, so that fat gain increased, or fat loss decreased, during this time. To investigate
the hypothesised mechanism, an analysis was performed to investigate group differences in
MUAC and skinfold measurements and z-scores, while controlling for diarrhoea incidence.
These adjusted analyses are presented alongside the unadjusted analyses in Table 26. The
results observed when adjusting for diarrhoea incidence did not differ to any large extent to
those observed when adjustment was not made.
Table 26: MUAC and skinfold thicknesses at 9mo of age, adjusted for the incidence of
diarrhoea between baseline and endpoint
Unadjustedanalysis Adjusted analysis,controlling
for diarrhoea incidence---p-value Effect size p-value
(95% Cl)
0.017* 0.28 (0.03, 0.53) 0.031
0.048* 0.26 (-0.02, 0.53) 0.065
Anthropometric endpoint Effect size
(95% Cl)
MUAe-for-age 0.31 (0.06, 0.56)
Triceps skinfold-for-age 0.27 (0.00,0.55)
Subscapularskint-tor-age 0.16 (-0.16,0,48)
MUAe (cm) 0.26 (0.00,0.51)
Bicepsskinfold (mm) 0.20 (-0.08, 0.48)
Triceps skinfold (mm) 0.30 (-0.11, 0.71)
Subscapularskint (mm) 0.12 (-0.31,0.55)
0.326 0.13 (-0.20,0.45) 0.434
0.049* 0.22 (-0.03,0.48) 0.085
0.152 0.17 (-0.12, 0.45) 0.231
0.149 0.28 (-0.13, 0.70) 0.177
0.580 0.07 (-0.36,0.50) 0.748
---- --------
"P<O.Os
IGeneralleast squaresregression,entering the dependent variable and treatment
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4.7.5.1 Measurement reliability
Morbidity questionnaires were repeated by a second observer on a sample of 40% of
infants and discrepancies between observers examined. The second observer filled out a total
of 305 questionnaires.
For each pair of visits, the reports of whether an infant was ill with a particular complaint
(e.g. fever) were compared between observers. Either a "yes" or a "no" was recorded by each
observer. When a "yes / no" or lino / yes" combination between the quality control and
routine reports occurred, it was counted as a discordant result. Such discordances between
observers were totalled, and compared for each complaint.
The results of discordances are given in Table 27. This table also gives the percentage of
times a complaint was recorded as "no", by observer.
Table 27: Compliance and morbidity questionnaire quality control (QC)results
%~scorda~t % reported "no" - QC % reported "no" - routine
Diarrhoea 6 93 96
Vomiting 3 96 95
Cough/rapid breathing 20 73 84
Fever 17 75 83
Unwell, any co_:_;m.:.!p:..:.la:..:.i_:_;n.;_t__ _;;.25:__ 6_1 7_4 _
4.7.5.2 Discussion
The fish oil supplement had little impact on the prevalence and patterns of common
morbidities, proving it to be neither harmful nor beneficial in this aspect in the population of
infants studied, also in regard to bleeds. There was, however, some possible effect of fish oil
on reducing diarrhoea incidence, as seen by the large difference in average incidence between
the study groups. This is an interesting observation, and difficult to explain, especially since
diarrhoea is a known potential side-effect of fish oil supplementation in adults. In order to
verify whether this was a chance finding, and to investigate the biological mechanism for the
reduction if real, further research is needed. Nevertheless, regardless of whether a significant
reduction in diarrhoea may be affected by n-3 LCPs,it has been shown that even a large daily
dose of fish oil did not cause any diarrhoea hazard in the studied infants.
168
Chapter 4: Results and specific discussions
When an analysis was done in which MUAC and skinfold thickness measurements were
adjusted for diarrhoea incidences, the borderline significant difference between groups
observed for triceps z-score and MUAC were lost. For MUAC z-score, the p-value for the group
difference remained significant but increased (0.017 to 0.031). The p-values for the other
measurements all increased. These results suggest that diarrhoea incidence did explain some
of the effect of treatment seen in MUAC and skinfold thicknesses. However, since the
occurrence of diarrhoea was weakly correlated with treatment, and treatment had only a
weak effect on these anthropometric measures in the first place, the resulting small change in
significance might have been expected when diarrhoea was added to the regression model.
The results therefore do not prove a causal relationship between diarrhoea and
MUAC/sklnfold thickness, since diarrhoea incidence could have acted as a crude surrogate
measure for treatment. The results do, nevertheless, provide some evidence for the
hypothesised mechanism to be true.
Discordances flagged up by comparing quality control and routine morbidity data
(particularly for respiratory complaints, fever, and unspecific complaints) is a reminder of how
difficult It Is to make reliable estimates of morbidity events through the use of morbidity
questionnaires. Extensive reviews on the subject have highlighted the methodological issues,
Inherent problems, and lack of standardisation and validation In relation to morbidity
measurements (311). Kroeger (1983) (312) noted that morbidity interviews rely on "people's
memory, their willingness to communicate with the interviewers and - at least for children -
on proxy reporting." Furthermore, interviews are susceptible to differences in perception and
reporting which are Influenced by social and cultural factors (312, 313).
In the present study the daily interviews, apart from facilitating estimates of illness
durations and more straightforward data analyses, also placed little demand on mothers'
memory, unlike interviews which ask about events which have taken place far further back. A
mother had simply to recall the previous 24 hours, and also knew to expect an interview each
day. Recall bias would therefore not be an important cause of inaccuracies. When the quality
control interview was conducted, It sometimes fell on the second day, though, and a mother
may have become confused by the time, or vague as to what symptoms her child had
dlsptayed two days earlier.
169
Chapter 4: Results and specific discussions
A mother or caregivers willingness to communicate with the interviewer may have
differed between mothers, between fieldworkers, and between the beginning of her 6 mo
participation and the end. An unwilling mother, or one in haste, may have said that there is
nothing the matter with her infant because she felt the interviewer was disturbing her with
what she experienced as annoying and time-consuming daily probing, and she may not have
been as cooperative after a certain period of daily appearances by the fieldworker as in the
beginning. On the other hand, when the second observer visited her, she may have been more
willing to cooperate, seeing the visit as special and serving a more important function than the
routine visit. When comparing the results in Table 27, it is clear that a greater number of
complaints were reported during the quality control visit than the routine one.
The daily visits were therefore useful for minimising recall bias, but mothers may have
found the Interviewing burden high and so answered as briefly as possible, consequently
leading to a greater number of false negative reports.
Over-willing mothers, on the other hand, may have felt that they are showing the
field-worker some Interest and answering more favourably if they list at least some complaint
during visits. She may have felt that by repeatedly reporting no incidences whatsoever, the
fleldworker might interpret this as lying, forgetfulness, or unwillingness to cooperate. Yet
other mothers may have felt embarrassed to report a symptom of illness in their children
because of fear that it might reflect badly on her capability as parent. A child that is repeatedly
reported to be ill might, the mother could fear, lead to some or other negative consequence to
herself or to her family. In contrast to this, it was found during the trial that some mothers
report symptoms when none are present in order to be given some medicine. She may report
nightly fevers, for example, and after some time request a nurse's visit in the hope that he will
give her child medication. This kind of bias leads to false positive reports.
Bias and false reporting lead to a degree of clouding of the results of morbidity surveys
and paint an inaccurate picture of a child or community's burden of morbidity, making
especially observation data vulnerable to errors. When performing simple treatment group
comparisons however, the implications of these errors become less serious because they are
likely to occur with the same frequency in each group. It is unlikely that over and
under-reportlng will influence results to the extent that significant group differences are found
In error, or that significant group differences that in truth exist are not detected.
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4.8 Other observations
4.8.1 Cognitive development in relation to umbilical cord and maternal
serum DHA and AA concentrations
Cord and maternal sample laboratory analyses gave 104 sets of results, providing relative
percentages of serum FAs. Combining these prenatal data and the available cognitive
development results, 83 complete sets of overlapping data were obtained.
Maternal and cord percent FAs are summarised in Table 28. DHA and AA, and the ratio
AA:DHA, were consistently higher in cord than in maternal serum. All LCPswere correlated
between mothers and infants, as expected. Plasma DHA and the ratio AA:DHA were most
strongly correlated.
Table 28: Maternal and cord serum OHA and AA concentrations
----
Maternal Serum (n=104) Cord Serum (n=104) Correlation
%FA
Mean; SO Mean; SO coefficient (p)
OHA 3.76; 0.91 5.93; 1.85 0.366 (0.0001)
AA 6.20; 1.15 11.0; 2.83 0.260 (0.0076)
AA/OHA 1.74; 0.53 1.97; 0.63 0.594 «0.0001)
DHA and AA, which are important constituents of the brain's grey matter, and believed to
be important for adequate cognitive development, was correlated against each of the
cognitive test results. No clear pattern of association was detected for any of the
combinations.
Via regression analyses, partial correlation coefficients were assessed for DHA, AA, and
AA:DHA, fitting Willatts and Attention Test outcome measures as the dependent variable in
separate models. Maternal education level was added to all models, and when testing total
intention and total intentional solutions, the trial count was also fitted (Table 30).
As a measure of post-natal n-3 LCP exposure, cord serum FA concentrations were
subtracted from 9 mo plasma FA concentrations, and this variable used in further analyses.
They are summarised in Table 29, together with breast-milk LCP concentrations and the
Pearson correlation coefficient for their linear relationship. Breast-milk LCP measurements,
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due to the limited samples drawn from each mother and the typically large day-to-day
variation characteristic of breast-milk, would most likely be subject to a high degree of
variability. This blood based measure of post-natal LCP exposure, in contrast, provided the
advantage of integrating the breast-milk changes to show how the combination of dietary
intake of LCPsand their metabolism altered FAstatus since birth.
Table 29: Plasma-based indicator of post-natal LCPexposure and breast-milk LCP
concentrations at 3 mo, and the correlation between them
Plasma Breast-milk
Correlation coefficient (p)
Mean; SO Mean; SO
OHA 4.15; 2.09 0.77; 0.39 -0.03 (0.769)
AA 3.79; 3.03 0.49; 0.11 -0.10 (0.328)
AA/DHA 0.96; 1.07 0.77; 0.35 0.15 (0.127)
EPA 0.68; 1.25 0.36; 0.29 0.01 (0.957)
DHA/EPA 7.36; 58.2 2.69; 1.08 0.19 (0.059)
In a similar fashion to above, this change in FA status, both for DHA and AA, was plotted
against the developmental outcome scores, and regression analysis performed.
Of the FAstested, there were no significant associations with cognitive development, apart
from an inverse relationship between cord DHA and total intention score (partial r= -0.2528,
p=0.031). This relationship was plotted. There was only a very small degree of noticeable
association, as seen in Figure 39. The figure also shows some of the distortion of the
distribution caused by the truncation of the intention score data at zero (referred to earlier).
4.8.1.1 Discussion
The correlation between cord and maternal serum DHA and AA, also found in other
populations, points to the dependence of the foetus on its mother for DHA, and, less so, AA
supply. In a study involving 210 infant mother pairs from five different countries, for example,
highly significant positive correlations (p<O.OOl)were found between the relative values of the
n-6 (r=0.35) and n-3 (r=0.39) FAs (after correction of gestational age at birth and the effect of
countries) (314). The higher DHA and AA concentrations in cord vs. maternal serum give
indication of a preferential placental uptake of the LCPsfrom the mother (315).
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No group in the literature has related maternal and cord LCPconcentrations with either
infant planning tests or the Attention assessment at 12 mo. Associations between prenatal
DHA concentrations and other infant cognitive measures have been measured, however.
Positive relationships have been found in some studies but not in others. The study by
Jacobson et al. (2008) (248L finding positive associations between cord plasma DHA and infant
cognitive performance has already been discussed in the previous chapter. In the USA, it was
found in 17 mother-infant pairs, that infants born to mothers with higher DHA status displayed
a greater central nervous system maturity, as measured by sleep-state patterning (correlations
between maternal DHA and wakefulness: r=0.42, not significant) (316), and that motor indices
in 44 infants at 12 mo correlated positively with plasma phospholipid DHA content at 4 mo of
age (p~=0.02) (317). In Canada, a prospective study of 83 infants exclusively breast-fed for at
least 3 rno, found the measured infant DHA status to be significantly related to visual acuity at
12 mo of age (r=0.30, p=O.03), and although the extent to which the results could be attributed
to other confounding factors is not certain, the data suggest that maternal DHA breast-milk
levels may influence the development of visual acuity and neural pathways in breast-fed
infants (174).
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Figure 39: Scatter plot for average intention scores vs. cord DHA %
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However, Ghys, Bakker and colleagues in the Netherlands, found no association between
umbilical cord LCPlevels and later cognitive performance at 4 and 7 years of age (318,319). In
128 infants, the association of cognitive development at 4 years with DHA at birth measured
close to zero (r<0.05) in bivariate and multiple regression analyses, controlling for relevant
confounders. Similarly at 7 years, no associations with DHA were found for various cognitive
scores, after correcting for confounders (p>0.2 for ali).
The current study has found evidence of a negative correlation between cord DHA and
later cognitive development. This result is not strongly significant (p=0.031), and is not
supported by additional associations between either cord, maternal, or postnatal DHA statuses
on the same outcome. Furthermore, none of the other outcomes were influenced by infant or
maternal DHA levels. In the current section, more than 40 statistical tests were done to
investigate the relationship between LCPsand cognitive development. One would expect to
find, therefore, at least one or two significant relationships due to chance only.
This given, In addition to a lack of similar evidence from the literature, it is very unlikely
that a true association between cord DHA and infant cognitive development exist as measured
by the tests chosen. Furthermore, when removing the 22 observations for which the total
intention score was "ON, in an attempt at normalising the data, the association between DHA
and this score was lost (p=0.882).
4.8.2 Growth outcomes at 12 months
The results of the anthropometric measurements taken during the cognitive testing visits
are presented in Table 31.
Treatment effects seen on MUAC z-scores at 9 mo were maintained at 12 mo (increasing
from 95% C:I-O.06-O.56, p=0.017). Those effects seen on triceps skinfold z-scores at 9 mo were
amplified at 12 mo (increasing from 0.00-0.55, p=O.048), and a new group difference was
observed for subscapular sklnfold thickness z-score at 12 mo, not previously seen at 9 mo.
These effects were echoed when investigated as length in centimetres, with significant
group effects detected not only for MUAC, triceps and subscapular skinfolds, but also for
biceps skinfold thicknesses.
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Principal components analysis was performed, as before, combining triceps, subscapular,
and biceps-skinfold thicknesses. The result was regressed and a significant treatment effect
observed (95% Cl: 0.09,0.98; p=0.019).
Table 31: Anthropometric indices at 12 mo of age, by treatment group, controlled for
baseline measures
Fish oil group Placebo group
(n=79) (n=76)
Endpoint x; SO x; so Effect size p-value
(95% Cl)
Anthropometric indices
Weight (g) 8323; 1120 8041; 1093 109 (-112, 329) 0.332
Length (cm) 71.8; 7.54 71.9; 3.21 -0.50 (-2.22, 1.21) 0.564
HC(em) 44.8; 1.30 44.6; 1.49 -0.04 (-0.31, 0.22) 0.751
MUAC (cm) 14.3; 1.08 13.8; 1.06 0.29 (0.04, 0.55) 0.023*
Knee-heel length (cm) 20.0; 1.09 19.8; 1.15 0.12 (-0.12, 0.36) 0.307
Biceps skinfold (mm) 6.70; 1.19 6.24; 1.10 0.41 (0.09, 0.74) 0.014*
Triceps skinfold (mm) 8.48; 1.35 7.90; 1.29 0.45 (0.07,0.84) 0.022*
Subscapular skinfold (mm) 6.93; 1.39 6.47; 1.17 0.44 (0.08, 0.80) 0.018*
Anth ropometric z-scores
Weight-far-age -1.09; 1.13 -1.41; 1.21 0.11 (-0.13, 0.35) 0.357
Weight-far-length -0.79; 1.10 -1.03; 0.97 0.17(-0.09,0.43) 0.207
Length-far-age -.1.00; 1.11 -1.30;1.32 0.08 (-0.15,0.32) 0.489
HC-for-age -0.61; 0.87 -0.72; 1.02 -0.04 (-0.24, 0.16) 0.713
M UAC-for-age -0.20; 0.94 -0.64; 0.98 0.33 (0.09, 0.57) 0.008*
Body-mass-index-for-age -0.69; 1.12 -0.90; 0.94 0.09 (-0.15, 0.34) 0.459
Triceps skinfold-for-age 0.19; 0.79 -0.15; 0.82 0.31 (0.06, 0.55) 0.014*
Subscapular sf-far-age 0.23; 1.05 -0.14; 1.02 0.36 (0.06, 0.67) 0.019*
- --
*p<O.OS
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4.8.2.1 Discussion
That the treatment effects at 12 mo were maintained - and amplified - provides further
evidence for an effect of fish oil supplementation on increasing MUAC and skinfold
thicknesses.
Whilst an increase in muscle-mass would be reflective of an improved nutritional status,
increased subcutaneous fat accumulation would not necessarily be so.
n-3 lCP supplementation studies have found either no change or a decrease in skinfold
measurements in infants, as summarised in a review by lapillonne (320). Only one other study,
in 72 Danish infants (321), found an increase in body-mass-index (BMI) and subscapular
skinfold in infants whose mothers were supplemented with 4.5g of fish oil during 4 mo of
lactation. This difference was detected two years after completion of the intervention, but not
during the intervention or at the 9 mo follow-up. The authors suggest that the late onset of the
effect could indicate some kind of programming effect, and others have also suggested that
n-3 lCPs regulate growth by Influencing gene transcription activity (320). In the light of a
potential late-onset (inflated) treatment effect, interesting results may be found if the infants
in the present study were to be re-visited and assessed at a follow-up two or three years from
the date that intervention was ended.
Although the skinfolds were increased, BMI scores were not significantly elevated by
treatment, which one would perhaps suspect. However, when investigating the number of
infants in the treatment group with BMI z-score>O.5, there were three times more in the fish
oil group than the control group (12 and 4, respectively), and a chi-squared test gave some
evidence for a relationship between BMI z-score>O.5 and treatment (p=0.4).
The fish oil group MUAC average was moved towards the WHO reference mean, improving
this growth indicator with regard to the reference norms. Even so, MUAC in the treatment
group was still relatively low on average, at -0.20 z-scores. The skinfolds, in contrast, were
pushed from a negative average in the control group to a positive average in the intervention
group. It is difficult to know whether these observed increases would potentially have harmful
or beneficial effects.
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According to the WHO reference curves, skinfold thicknesses and BMI are declining at 12
mo of age. An alternative explanation to an increased fatness is that the fish oil was delaying
this decline, and could potentially delay the later adiposity rebound, lowering the risk of adult
obesity (322, 323). This possibility has been mentioned by the Danish research group
mentioned above. Alternatively, the increased fatness could be maintained into later life, with
associated disease risks.
4.8.3 Overall growth compared with WHO references at 3,9 & 12 months of
age
Growth indicators of weight, length and He compared well with WHO references at 3 mo
of age (Figure 40). By 9 mo, however, growth faltering had become noticeable, with z-score
distributions shifting towards the negative side of the x-axis (Figure 41). This shift moved
further left at 12 mo of age (Figure 42).
Using WHO recommendations for stunting (Iength-for-age z-score <-2) and wasting
(weight-far-length z-score <-2), the stunting rates (13% at 9 mo, 21% at 12 mol were more
pronounced than wasting (9% at 9 mo, 17% at 12 mol. He measurements dropped severely
from baseline to 12 mo, with a mean z-score at baseline of -0.2 falling to -0.7 at 12 mo of age.
By 12 mo 9% of infants had a He z-score of <-2.
MUAe scores were slightly higher than weight, length and He scores. The triceps skinfold
z-score mean improved from being close to -1 at baseline (-0.8 z-scores) to close to zero (-0.2
z-scores) at the other time points. Average subscapular skinfold measurements were slightly
higher than WHO means at baseline (0.2 z-scores) and 9 mo (0.3 z-scores), but moved towards
the norm at 12 mo (0.04 z-scores).
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Figure 40: Baseline growth measurements plotted (red) against WHO standards (green).
Z-scores are given along the x-axis.
lweight-for-Iength, 2Iength-for-age, 3weight-for-age, 4HC-for-age, sMUAC-for-age, 6triceps
skinfold-for-age, 7subscapular skinfold-for-age
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Figure 41: Growth measurements at 9 mo of age, plotted (red) against WHO standards
(green). Z-scores are given along the x-axls.
lweight-for-Iength, 2Iength-for-age, 3weight-for-age, 4HC-for-age, 5MUAC-for-age, 6triceps
skinfold-for-age, 7subscapular skinfold-for-age
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Figure 42: Growth measurements at 12 mo of age, plotted (red) against WHO standards
(green). Z-scores are given along the x-axis.
lweight-for-Iength, 2Iength-for-age, 3weight-for-age, 4HC-for-age, sMUAC-for-age, 6triceps
skinfold-for-age, 7subscapular skinfold-for-age
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4.8.3.1 Discussion
It is not surprising to see this pattern of growth faltering, with relatively good growth
present at 3 mo and dropping to average z-scores of lower than -1 for weight and length
indices at 12 mo. As mentioned in the introduction, this pattern has typically been observed in
the West Kiang population, with growth faltering setting in at time of weaning, at around 3 or
4 mo of age.
Interestingly, the smallest z-score observed was for triceps skinfold thickness-for-age
(-0.76 z-scores), whereas the subscapular skinfold distribution was the largest. These two
measures, seemingly indicating conflicting information on the subcutaneous fat accumulation
of these infants, could be due to a systematic error in measurement of one (or both) of the
skinfolds. However, when compared to a small sample of previous data in this population, the
subscapular:triceps ratios were not dissimilar.
Assuming the measurements were not systematically erroneous, the trunk and extremity
fat deposition in this population differs at 3 mo from the norm in the WHO standards. Ethnic
differences in skin folds have been documented by various groups (324-328) who found that
racial differences in subscapular:trlceps ratios exist. Certain African and Caribbean
populations, for example, have a higher subscapular:triceps skinfold ratio than American and
British children and adolescents. Although a global database is used in the new WHO growth
standards, the high subscapular:trlceps skinfold ratio in the West Kiang population at 3 mo is
still prominent when compared with the other, essentially well-nourished populations, and
probably an adaptive attribute of young Gambian infants.
Evidence to support this phenomenon as an adaptive attribute is given by Yajnik et al.
(2003) (328). In a study comparing the body size measurements of 631 term babies born in
rural India with those of 338 term babies born in Southampton, UK, Indian babies had
markedly reduced visceral sizes and MUAC measurements, but similar subscapular skinfold
thicknesses compared with British-born infants. Thus, although these babies were much
smaller or, apparently, "thinner" than the Southamptlon babies, they were simultaneously
relatively adipose, as judged by their central fat adiposity. The evolutionary benefit of this
described "thin-fat" baby syndrome was explained by the advantage which fat stores provide
for neonatal survival, providing energy reserves, insulation, and a depository of precursors for
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brain development. The authors went on to propose that this phenotype results from
persistence of central fat laid down in utero.
4.8.4 Weaning foods
Exclusive breastfeeding was reported by 52.7% of mothers when their infants were 3 rna
of age (intervention group: 54.2%; placebo group: 49.4%). Of the infants who were not being
exclusively breastfed at 3 mo, ,28.6% had been consuming water as the only weaning
substance.
Cessation of full breast-feeding occurred by the time their infants had reached 4 rna of age
in 71.9% of mothers, and 5 mo of age in 83.9% of mothers. Only 2.68% reported exclusively
breastfeeding their infants by the time they had reached 6 mo. No infants were still being
exclusively breast-fed at 7 mo. Of the infants who had been weaned at 4 mo and 5 rna, 24.7%
and 17.6%, respectively, had received water only.
Solid foods were reportedly introduced in 31.5% of 3 mo aids, 31.5% of 4 mo aids, 66.9%
of 5 mo olds, 81.2% of 6 mo olds, and 91.5% of 7 rna olds. By 8 rna, 97.9% of infants were
eating solid foods, and all infants were eating solid foods by 9 rna of age.
Fourteen percent of infants had had some form of egg in their diet by 6 mo. Roughly the
same number had shared the family bowl, including dishes that contain small amounts of dried
fish. By 9 mo roughly 80% of infants had had some egg yolk or some form offish.
The most common solid weaning food fed, by far, was a rice-based porridge. Bread was
the next most common weaning food. Other frequently-fed foods were margarine,
mayonnaise, bananas, and cooking oil. The dishes commonly eaten in the household were the
next most common weaning food.
Formula milk was not popularly fed, particularly to younger infants. One infant had been
fed formula milk by 3 mo of age, five by 5 mo of age, and nineteen by 7 rna of age. By 9 rna,
however, nearly 20% of infants had been given formula milk.
Milk powder (made from cow's milk) can easily be bought in the villages (albeit at a high
price) and Is often added the infant's porridge or tea. Eight and fourteen infants had been fed
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powder milk by 3 and 5 rna, respectively, and 39 by 7 mo. Twenty-nine percent of infants had
been fed milk powder by age 9 mo.
4.8.4.1 Discussion
Even the most thoroughly-trained fieldworkers cannot overcome the well-known
difficulties of poor validity and bias associated with food-frequency and recall questionnaires.
A mother may report that she has given her child nothing but breast-milk when the infant is
indeed being fed small quantities of other foods, because she believes the intakes of weaning
foods are negligible in comparison to breast-milk, or because she wants to give the "correct"
answer. It is also known to be very difficult for a mother to remember specifically what her
child has eaten in the past month.
The questionnaire administered was not intended for collecting detailed or highly accurate
data, and the results should be interpreted as only a rough indication of infant weaning
practices in this population. Nevertheless, these estimates, even if imprecise, indicate that a
conslderable proportion of women were not adhering to the WHO recommendations of
exclusive breast-feeding for 6 rna (329, 330). Despite high initiation rates and a long total
duration of breast-feeding amongst Gambian women (331), only 53% of mothers were still
exclusively breast-feeding their infants at 3 mo. By 6 rna of age, only 3% of infants were
reportedly excluSively being breast-fed.
The Baby Friendly Community Initiative project, rooted in an adaptation of the United
Nations Children's Fund (UNICEF)/WHO Baby-friendly Hospital Initiative, was first launched by
the Gambian government and the Gambian National Nutrition Agency in the Lower River
Division more than 10 years ago. This community based health programme has now expanded
to 219 villages countrywide, and, amongst other activities, strongly promotes exclusive
breast-feeding up to 6 mo. It may be surprising, therefore, that so many mothers - despite
being educated on the benefits of exclusive breast-feeding and warned of the potential
dangers of early weaning -wean their infants by 3 rna of age regardless.
However, it Is well known that knowledge does not necessarily equate to changed
attitudes or practices. Traditional and cultural beliefs and customs remain strong influences for
determining a mother's decisions regarding raising her child. Social practices may, e.g., require
a mother to feed her child water and complementary foods before the infant reaches 6 rna, if
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she is to be regarded as an adequate mother by many of her peers and elderly relatives. Such
customs limit the decision making process of women (332). Additionally, demands placed on
women living in areas where subsistence farming is imperative to survival often force decisions
on breast-feeding (331). A mother who does not have the assistance of a daughter to follow
her to the rice field and act as nurse-maid while the mother cultivates the rice (whether
because she does not have a one of the appropriate age or because the daughter is attending
school), may have no choice but to leave her infant at home under the care of an elderly
relative while she goes off to work in an often far away rice field. The infant will consequently
necessarily survive off paps and other complementary foods during the day, while awaiting the
return of their mother at sunset.
Clearly, further energy into appropriate and persistent strategies are required to be
invested to break long-standing infant feeding practices and result in community and,
ultimately, nation-level change.
4.8.5 Relationship between calprotection levels and LMRs
The relationship between intestinal integrity as measured by LMRs, and intestinal
inflammation as measured by stool calprotectin concentrations was investigated graphically
and by statistical correlations.
No relationships were detected in the scatter plots drawn between calprotectin
concentrations and LMRs, or lactulose and mannitol recoveries, as seen in Figure 43.
Correlation coefficients between pooled 3 mo and 9 mo data are also shown in Figure 43, all of
which were small (r2$0.06 for all) and statistically insignificant.
When restricting the analysis to relationships at outcome, a weak but borderline significant
relationship was found between LMR and calprotectin (r2 s=O.16; p=O.'048).
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recovery (middle) and lactulose recovery (bottom), by time-point
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4.8.5.1 Discussion
Even when investigating the relationship between pooled (>300 observations) data, no
associations were detected between these two markers of enteropathy. At outcome, a weak
association was seen between lMR and calprotectin, but the overall results of this analysis
suggest that calprotectin and lMR measures are unrelated and instead are independent
indicators of intestinal state or that one or both of the measures is so variable as to obscure
any underlying physiological relationship. Stool calprotecin measurements, therefore, cannot
be used as a predictor of current gut integrity or as proxy for lMRs.
This may be due to different reasons: a) These markers can be influenced by different
factors or increased by different mechanisms (e.g. the intestinal mucosa may be damaged by
infection by various pathogens, while calprotectin levels may increase due to inflammation
which Is allergenic or not necessarily pathogen-induced); b) Calprotectin elevation occurs as a
relatively quicker response to an insult than gut damage, which is a more gradual result of
repeated insults; or c) Calprotectin largely reflects inflammation of the large intestine, whereas
lMRs reflect integrity ofthe small intestine.
4.8.6 Plasma and breast-milk fatty acids: further considerations
4.8.6.1 Breast-milkfatty acid profiles
The main lCPs in the breast-milk of mothers at baseline and endpoint are summarised in
Table 32. A summary of the other FAswas prepared, by time-point, and is presented in Table
33.
187
Chapter 4: Results and specific discussions
Table 32: LCPs in breast-milk at baseline and endpoint, relative percentages
Endpoint 3 mo 9mo
(n=86) (n=83)
Plasma FA(% total lipid) X;SD X;SD p-value
DHA 0.77; 0.39 0.80; 0.38 0.496
EPA2 0.27 (0.16,0.44) 0.26 (0.18, 0.39) 0.489
AA 0.49; 0.11 0.50; 0.11 0.520
Other FAindicators (% total lipid)
Essential:nonessential PUFAs2 0.44; 0.12 0.52; 0.63 0.155
DHA:22:5n-6 13.7; 5.85 13.5; 5.56 0.704
Total n3 FAs(ng/~I) 1.93; 0.84 1.91; 0.78 0.873
Total n6 FAs(ng/ul) 10.6; 2.45 11.2; 2.32 0.031
AA/(EPA+DHA) 0.56; 0.29 0.54; 0.24 0.489
Total n-6 ~ C20/ Total n-3 ~C20 0.77; 0.39 0.72; 0.31 0.180
1Differences between 3 mo and 9 mo FAconcentrations, tested by ANOVA
2Geometric mean (zs", zs" percentiles)
Table 33: Other breast-milk fatty acids
--- - -------------------------------
Fatty acid (% total lipid)
Saturated (C8:0 - C18:0)1
Saturated ((20:0 - (24:0)2
Monousaturated"
Oleic acic (C18:1n9c)
n-3 PUFAs
C18:3n3
C20:3n3
C22:5n3
n-6 PUFAs
C18:2n6c
C18:3n6
C20:3n6
3mo
(n=87)-----~--~----------X;SD
0.34; 0.15
54.5; 6.12
32.1; 5.10
29.2; 5.20
0.40; 0.18
0.03; 0.01
0.36; 0.18
9mo
(n=85)
X;SD p-value
0.40; 0.20 0.003*
53.9; 6.50 0.450
32.1; 6.00 0.928
29.1; 5.20 0.836
0.42; 0.20 0.459
0.03; 0.02 0.055
0.33; 0.14 0.581
0.02; 0.02 0.819
0.11; 0.04 0.010*
0.34; 0.10 <0.001 *
0.06; 0.03 0.439
0.02; 0.02
0.12; 0.04
0.38; 0.10
C22:5n6 0.06; 0.03
1 --Includes 18:0; 17:0; 16:0; 15:0; 14:0; 13:0; 12:0; 11:0; 10:0; 8:0
21ncludes 24:0; 23:0; 22:0; 21:0; 20:0
31ncludes 14:1; 15:1; 16:1; 17:1; 18:1n9c; 20:1; 22:1n9; 24:1
*p<0.05
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Breast-milk samples taken at baseline and endpoint differed significantly in relative
percentages by time-point for combined short and medium chain saturated fats, (18:3n6,
(20:3n6, and total n-6 FAs. There were no significant differences in relative percentages of
DHA and EPAmeasured at 3 mo and 9 mo.
4.8.6.2 Breast-milk l.Ci' levels in rural Gambian mothers compared to other
populations
Brenna et al. (2007) (288) studied the breast-milk DHA and AA content (%w/w of total fatty
acid) from 2472 women in more than thirty different countries around the world, including
Europe, Asia, Africa, America, Australia, and the Canadian Arctic. The summary of this study's
finding is presented in Table 34, together with summary statistics from the Gambian sample
for comparison. Because the majority of breast-milk samples in the meta-analysis were taken
from mothers with infants closer to 3 mo than 9 mo of age, baseline breast-milk values are
given below.
A graphical illustration by Brenna et al. of the same breast-milk DHA and AA levels is given
in Figure 44. An indication of where the Gambian means fall in relation is shown on the graph.
Table 34: Breast-milk DHA and AA concentrations worldwide and in rural Gambia
Data from Brenna et al. (2007) (288)
OHA (% total FA)AA (% total FA)
Wordwide Rural Worldwide Rural
Gambia Gambia
Mean; SO
Median
Range of population
0.47; 0.13
0.46
0.24-1.0
0.49; 0.11
0.48
0.32; 0.22
0.26
0.77; 0.39
0.67
0.06-1.40
means
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Figure 44: Distribution of AA (above) and DHA (below) in breast-milk,
presented as a histogram. The arrows show the average fatty acid
concentrations of the entire sample (from 2472 women), and the
Gambian sample means
A study by Yuhas et al. (2006) (287) compared FA profiles in the breast-milk of women
from nine different countries in America and Canada, Latin and South America, Asia and
Europe, and found the average of the nine population means for EPA to be 0.10±O.001% (w/w
Total FA). The Gambian population average was, in contrast, 0.36±0.29%. This EPA comparison
and comparisons between three different FA ratios (including a-linolenic to linoleic acid) is
summarised in Table 35.
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Table 35: Mean breast-milk EPAand fatty acid ratios in women in nine different countries
(Yuhas et 01., 2006), and in rural Gambia
Nine countries Rural
Gambia
% total FAs
Mean; SO Mean; SO
EPA
AA:OHA
EPA:OHA
18:3n3/18:2n6
0.10; 0.001
1.54; 0.43
0.35; 0.02
13.2; 0.55
0.36; 0.29
0.77; 0.35
0.43; 0.16
27.5; 10.3
4.8.6.2.1 Discussion
The Gambian mother's breast-milk contained a very high concentration of n-3 LCPsrelative
to data from women globally.
The highest mean breast-milk DHA levels (seen to the right side of the x-axis of the
histogram in Figure 44) were reported in women from Japan (0.53, 0.99 & 1.10), Philippines
(0.74), Canadian Arctic (1.40), and Dominican Republic (0.91). Other countries where levels
where comparable to those in The Gambia, but not as high, were Congo (0.55), Sweden (0.53),
and St. Lucia (0.53). All of these mentioned countries are bordered entirely or partly by ocean,
and have populations with a high fish intake.
It has been established that breast-milk DHA levels are strongly associated with dietary
intake of the FA, and breast-milk content increases linearly in a dose-dependent manner with
maternal DHA intake (200,333). The existent data on fish consumption in rural Gambia are not
current, and have led to conclusions that have perhaps resulted in an underestimation of the
breast-milk n-3 LCPcontent of Gambian women, more recently at least (88, 334, 335). Based
on the premise that the breast-milk DHA content is a reflection of dietary DHA (i.e. marine)
intake, the breast-milk results from the current study suggest that the Gambian women have
very high intakes of DHA, comparable with intakes of women from countries with the highest
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fish consumption in the world, such as Japan. The average DHA level of 0.77% is nearly
two-and-a-half times higher than the global average of 0.32%, and the contribution that this
level makes to infant n-3 lCP status is undoubtedly significant (as breast-milk DHA has been
shown to elevate infant DHA status (333) ).
There is a smaller literature on breast-milk EPA than DHA, but Gambian mothers'
breast-milk EPA content was more than three times higher than that of the populations
studied. The comparative ratios of AA:DHA confirm the high DHA intake in Gambian mothers,
and the higher (>2x) a-linolenic to linoleic acid ratio shows that the intake of precursors to
DHA and EPA in relation to precursors to AA, or n-3 essential FAs versus n-6 essential FAs, is
significantly higher in Gambian women than in the average woman in the populations studied.
These results are surprising, particularly when taking into account the large amount of
palm oil consumed by Gambian mothers, which is high in the n-6 linoleic acid, but devoid of
the n-3 a-linolenic FA. Additionally, the amounts of fish eaten with meals is typically very small,
and average portions far smaller than portion sizes in the developed world.
There is evidence that habitual intake of fish is also an important factor in determining
breast-milk n-3 lCP contents (336, 337), and perhaps the consistency of the fish intake
throughout life contributes greatly to the breast-milk n-3 LCPcontent. The high intakes of leafy
green vegetable in The Gambia may also be a significant contributor to the high breast-milk
DHA content, as these vegetables contain a-linolenic acid which may be converted to their
longer chain derivatives. There is also the possibility that laboratory or calculation methods
could cause artificially elevated FA results. The ratios investigated, would, however, be
expected to flag up these kinds of errors, but in the present study the ratios have consistently
pointed to high breast-milk n-3 PUFA levels.
The substantial amount of n-3 lCPs delivered to the infants in West Kiang leads one to
conclude that there are very few deficiencies existent in the infant population, and that the
lCP requirement is adequately met for the vast majority of infants. It could be the case that
infant tissues are largely saturated with these FAs at baseline, and that further
supplementation therefore adds little clinical benefit.
Nevertheless, It is not certain how efficiently the infants absorb and utilise breast-milk
lCPs. It may be that a lot of fat Is excreted in the stool, malabsorbed due to a poor villous
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surface area or some other reason (although treatment administered as oil successfully
increased infant n-3 lCP status, so it appears unlikely that breast-milk LCPswould not). To
investigate this question, the variation in plasma LCPlevels explained by breast-milk compared
to that explained by treatment will be examined shortly.
4.8.6.3 Correlations between pre- and post-treatment plasma fatty acid
concentrations, and breast-milk and plasma fatty acids
Indicative of the extent to which treatment altered FA profiles, over and above the
influence of normal diet or biological determinants, product-moment Pearson correlations
were calculated to investigate how strongly pre-treatment LCPlevels predicted endpoint ones,
and to test the relationship between breast-milk and plasma FA levels at 9 mo.
OHA and EPA concentrations were not correlated in the treatment group, while in the
control group DHA and EPA levels remained fairly stable (Table 36). AA remained as stable in
the control as the fish oil group, and was unaffected by n-3 lCP administration. Similarly, the
ratio AA:n-3LCP remained somewhat stable even in the fish oil group. The ratio DHA:C22_5n6
was significantly altered in the fish oil group but not in the control group, an indication that n-3
LCPcell usage was improved by treatment alone.
However, in contrast, the relative percentages of DHA and EPA were correlated in the
baseline and endpoint plasma of infants in the fish oil group.
Treatment was therefore strongly predictive of the absolute concentrations, but not
relative percentages, of endpoint FA profiles in individual subjects. Attention will now be
drawn to how strongly breast-milk FAspredicted plasma FA levels.
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Table 36: Correlations between pre and post-treatment plasma LCPs,by treatment group
Control Fish oil
ngfl.,iI FA Relative % FA ng/1l1FA Relative % FA
Correlation
Correlation coeff. Correlation Correlation coeff.
coeff.
(p-value) coeff. (p-value) (p-value)
(p-value)
DHA 0.44 «0.001*) 0.56 «0.001*) 0.17 (0.129) 0.39 «0.001*)
EPA 0.33 (0.002*) 0.30 (0.006*) 0.07 (0.541) 0.23 (0.041*)
AA 0.27 (0.013*) 0.30 (0.005*) 0.27 (0.013*) 0.31 (0.004*)
AA/(DHA+EPA) 0.36 «0.001*) 0.36 «0.001*) 0.33 (0.003*) 0.33 (0.003*)
DHA/C22_Sn6 0.40 «0.001*) 0.38 «0.001*) 0.20 (0.065) 0.21 (0.059)
*p<0.05
Table 37: Correlations between breast-milk and plasma LCPsat 9 mo
Control Fish oil
ng/1l1FA Relative % FA ng/1l1FA Relative % FA
Correlation Correlation
Correlation coeff. Correlation coeff.
coeff. coeff.
(p-value) (p-value)
(p-value) (p-value)
DHA -0.14 (0.203) -0.09 (0.419) 0.19 (0.081) 0.11 (0.297)
EPA -0.13 (0.235) 0.01 (0.928) 0.03 (0.777) 0.04 (0.697)
AA 0.16 (0.155) 0.01 (0.947) 0.06 (0.590) -0.06 (0.606)
AA/(DHA+EPA) 0.10 (0.357) 0.10 (0.358) 0.07 (0.496) 0.07 (0.505)
DHA/C22_Sn6 0.34 (0.001*) 0.34 (0.001 *) 0.08 (0.439) 0.08 (0.485)
- -- ---*p<O.OS
Breast-milk lCP concentrations at 9 mo did not predict any of the assessed lCP
concentrations in plasma, even in the control group. DHA:C22_5n6 was the only FA indicator
which was predicted by breast-milk levels (in the control group).
Thus, higher concentrations of particular LCPs in a mother's breast-milk did not predict
higher concentrations of the same FA in the plasma of her infant.
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Although breast-milk is very variable in its FA levels one would expect to see at least some
predictive power, certainly in the control group, given the strong relationship of n-3 LCPstatus
to diet and the great contribution of breast-milk to the infant diet.
Of course correlations are not the ideal way of testing the relationship, and are limited to
one FA at one time-point. As a follow-up therefore, the partial R2 in an analysis of variance,
including more terms, were compared in the following section.
4.8.6.4 How much variation in plasma fatty acid levels is explained by breast-milk
versus treatment?
With the aim of comparing how much variation in plasma LCP fatty acid levels was
explained by the breast-milk intake of these fats and how much by treatment, a model was
built: each 9 mo plasma LCPwas controlled for its baseline concentration and the total plasma
fat concentration. Treatment, the relevant breast-milk LCPrelative percent concentration at 9
mo and the total breast-milk lipids were then added. Various other PUFAswere tested for their
effects but these were all marginal and thus dropped from the model.
Treatment and the relevant breast-milk FAs were held constant. The partial R2 was
calculated separately for variation (in the dependent variable) due to treatment, and due to
the respective breast-milk FAs.
The bootstrap method was then used to calculate 95% confidence intervals for the partial
R2 estimates. These are presented in Table 38.
For plasma EPA, a much larger portion of variation in plasma concentrations could be
explained by treatment than by breast-milk EPA.Only minor variation was explained by either
treatment or breast-milk for DHA and AA.
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4.8.6.5 Do plasma or breast-milk fatty acids predict any a/the other outcomes?
A cross-sectional evaluation of relative percentages of PUFAs7 in plasma and breast-milk
was tested to examine the relationship with anthropometric z-scores, gut integrity, cognitive
development, and markers of inflammation.
The following FAswere tested in separate analyses:
a) Sum of n-3 FAsand sum of n-6 FAs ("DHA + c22_5n3 + EPA+ c20_3n3 + clS_3n3" and
"clS_2n6c + c20_3n6 + AA + c22_5n6")
b) EPA (log) and DHA
c) Ratio n-6 LCP:n-3 LCP("c22_5n6 + AA + c20_3n6" : "DHA + c22_5n3 + c20_3n3 + EPA")
A linear regression model was used to test the relationship between each outcome
measure at endpoint with the various FAsat 9 mo.
The statistically significant results are presented in Table 39.
7 Relativepercentageswere used rather than absolutevaiues fatty acidsbecausethey were slightly
better correlated with anthropometric measures.
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Anthropometry
Total n-3 plasma FAs were significantly positively related to MUAC z-scores (95% Cl:
0.02,0.163; p=0.018), while plasma EPA was significantly positively related to MUAC z-score
(95% Cl: 0.12,0.92; p=0.012) and marginally positively significantly related to height-for-age
z-score (95% Cl: 0.01,0.98; p=0.046). Breast-milk PUFAs were only significantly related to
height-far-age z-score, but these relationships were stronger than those plasma PUFA
relationships mentioned above: breast-milk DHA was negatively associated (95% Cl:
-2.10,-0.34; p=0.007), and EPA positively associated with height-far-age z-score (95% Cl:
0.22,1.21; p=0.005). Neither the plasma nor breast-milk n-6 LCP:n-3 LCPratios predicted any
of the anthropometric z-score outcomes.
Gut intergrity
None of the tested PUFAswere significantly related to gut integrity as measured by LMR,
and lactulose and mannitol recoveries vs. plasma and breast-milk PUFAs.
Cognitive development and calprotectin
The five main cognitive outcomes measures: the Willatts test's "total solutions", "total
intentional solutions" and "pretest average", and the "average look duration" and "inattention
rate" of the Attention Assessment, were assessed against breast-milk and plasma PUFAs (by
regression analysis and scatter plots) to examine their relationships. No relationsbips (neither
positive nor negative) or patterns were detected.
Stool calprotectln concentrations in relation to PUFA levels were similarly assessed. No
relationship between plasma or breast-milk PUFAs and calprotectin concentration was
observed.
Acute phase proteins
Although not strongly so, plasma n-6 LCP:n-3 LCPratio was a significant (positive) predictor
of plasma albumin (95% Cl: 0.24,3.00, p=0.021). The same ratio was negatively correlated to
(log) CRP (untransformed 95% Cl: 0.48,0.94; p=0.021). These were the only acute phase
protein relationships with plasma PUFAs. Breast-milk totai n-6 FAs were (weakly) positively
related to (log) AGP (untransformed 95% Cl: 1,1.04; p=0.038).
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To investigate whether these and other associations existed before the introduction of
treatment, and to increase the power of the analysis, a random effects regression model
(allowing for repeated observations on the same individual) was used to assess cross-sectional
relationships on pooled data. The relationship of 3 mo and 9 mo FAs with the corresponding
baseline and endpoint outcome measures were examined. Any significant relationships were
further investigated by testing for an interaction between the relevant FAs and time-point, and
by drawing scatter plots. The statistically significant relationships found are presented in Table
40. Scatter plots for relationships of outcome variables with plasma PUFAs are shown in Figure
45 - Figure 49 under Section 4.8.6.5.1, and those with breast-milk PUFAs in Figure 50 - Figure
53, under Section 4.8.6.5.2.
Table 39: Statistically significant regression analysis results for PUFA and outcome measure
relationships, using endpoint data
Regression eoeft. (95% Cl) P-value Partial rn=169
Plasma FAs (9 rna)
Total % n-3 FAs
MUAC z-score 0.09 (0.02, 0.163) 0.018 0.18
0.50 (0.01, 0.98) 0.046 0.15
0.52 (0.12,0.92) 0.012 0.19
1.60 (0.24, 3.00) 0.021
0.68 (0.48, 0.94) 0.021
Height-far-age z-score
MUAC z-score
Ratio n-6 LCP:n-3 LCp3
Albumin (giL)
(log) (RP (mg/L)
Breast-milk FAs (9 mol
Total % n-6 FAs
(log) AGP (mg/L) 1.02 (1, 1.04) 0.038 0.16
Height-for-age z-score 0.72 (0.22,1.21) 0.005 0.21
Height-for-age z-seore -1.21 (-2.10, -0.34) 0.007 -0.21
lReg~ession analysis adding "anthropometric z-score" or "acute phase protein" at 9 mo as dependent
variable, and "total % n-6 acids (c18_2n6c + c20_3n6 + AA + c22_5n6)" and "n-B FAs (DHA + c22_5n3 +
EPA+ c20_3n3 + c18_3n3)" at 9 mo as independent variables
2Regression analysis adding dependent variable as in "1" above, and "% (log) EPAand % DHA (9 mo)" as
independent variables
3Regression analysis adding dependent variable as in "1" above, adding "ratio n-6 LCP (c22_5n6 + AA +
c20_3n6):n-3 LCP(DHA + c22_5n3 + c20_3n3 + EPA)" at 9 mo as independent variable
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Table 40: Statistically significant PUFA& outcome measure relationships, using pooled data
Regression coeff.
Interaction'P-value
(95% Cl)
Plasma FAs (pooled 9 mo & 3 mol
Total % n-3 FAs
Weight-for-age z-score 0.06 (0.02,0.11) 0.006 0.679
Height-for-age z-score 0.06 (0.02, 0.10) 0.005 0.970
HCz-score 0.04 (0.01, 0.07) 0.009 0.562
MUAC z-score 0.08 (0.03, 0.12) 0.001 0.940
(log) CRP 1.07 (1.03, 1.11) <0.001 0.514
Total % n-6 FAs3
Albumin 0.10 (0.00, 0.21) 0.045 0.325
% EPA4
MUAC z-score 0.03 (0.02, 0.46) 0.030 0.705
Albumin -1.01 (-1.78, -0.245) 0.010 0.838
% DHA4
Albumin 0.96 (0.46, 1.46) <0.001 0.547
Ratio n-6 LCP:n-3 LCps
Height-for-age z-score -0.24 (-0.44, -0.04) 0.018 0.262
HCz-score -0.16 (-0.31, -0.01) 0.041 0.789
MUAC z-score -0.25 (-0.46, -0.04) 0.022 0.396
(log) CRP 0.75 (0.62, 0.90) 0.002 0.587
Breast-milk FA ( 9 mo & 3 mo)2
Total % n-3 FAs
Height-for-age z-score 0.11 (0.01, 0.21) 0.026 0.199
(log) CRP 1.08 (1.03, 1.12) <0.001 0.318
% EPA4
Height-for-age z-score 0.26 (0.06, 0.46) 0.012 0.477
(log) CRP 1.37 (1.12, 1.69) 0.003 0.254
Ratio n-6 LCP:n-3 LCps
Height-for-age z-score -0.40 (-0.63, -0.17) 0.001 0.431
(log) CRP 0.66 (0.52, 0.83) <0.001 0.361
1 - - --
P-value for interaction between time-point and FA
2Random-effects regression using pooled 3 mo and 9 mo data, treating "outcome measure" as
dependent variable, "relative FA level" and "time-point" (3 mo or 9 rno, a fixed effect associated
with age) as main effects, and "individual infant" as the random effect
3Adding "total n-3 FAs (DHA + c22_5n3 + EPA+ c20_3n3 + c18_3n3) and total n-6 FAs (c18_2n6c +
c20_3n6 + AA + c22_5n6)
4Adding "log EPA (%) and DHA (%)"
SAdding "ratio n-6 LCP(c22_5n6 + AA + c20_3n6) : n-3 LCP(DHA + c22_5n3 + c20_3n3 + EPA)
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4.8.6.5.1 Scatter plots of statistically significant plasma PUFA relationships with
outcomes
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Figure 45: Graphs of weight-for-age z-score (top), height-far-age z-score (middle), and He
z-score (bottom) vs. relative total plasma n-3 fatty acid, by time-point
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Figure 46: Graph of MUAC z-scores vs. relative total plasma n-3 fatty acids, by time-point
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Figure 47: Graph of HC z-score vs. relative plasma EPA (log), by time-point
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Figure 48: Graphs of height-for-age z-score (top), HCz-score (middle) and MUAC z-score
(bottom) vs. plasma n-6lCP:n-3 lCP ratio, by time-point
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Figure 49: Graphs of plasma albumin vs. EPA (top) and DHA (middle), and plasma CRP vs. n-6
LCP:n-3 LCP ratio, by time-point
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4.8.6.5.2 Scatter plots of statistically significant breast-milk PUFA relationships with
outcomes
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Figure 50: Graphs of height-for-age z-score vs. breast-milk total n-s fatty acids (top), % EPA
(middle), and % DHA (bottom), by time-point
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Figure 51: Graph of height-for-age z-score vs. breast-milk n-6 LCP:n-3 LCP ratio, by time-point
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Figure 52: Graphs of plasma AGP {top} and albumin {bottom} vs. breast-milk total n-6 fatty
acids, by time-point
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Figure 53: Graphs of plasma CRPvs. breast-milk total n-3 fatty acids (top), breast-milk EPA
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Also when including the data before treatment, plasma total n-3 FAs and EPAsignificantly
predicted MUAC z-scores in a positive direction (95% Cl: 0.03,0.12; p=0.001 and 95% Cl:
0.02,0.46; p=0.030, respectively). The negative association between plasma n-6 lCP:n-3 lCP
ratios and CRP also remained (95% Cl: 0.62,0.90; p=0.002). The only relationship which
remained with breast-milk FAswas the statistically significant correlation between breast-milk
EPA and height-far-age z-score. The relationships between plasma EPA and height-far-age
z-score, and breast-milk total n-6 FAs and plasma AGP - which were only marginal before -
were, thus, lost. The negative correlations between breast-milk DHA and height-far-age
z-score and plasma n-6 lCP:n-3 lCP with plasma albumin were also lost.
Significant relationships which were not observed at 9 mo (after treatment), but indeed
when analysing the pooled data, were found between plasma n-3 FAs and weight-far-age
z-score, height-far-age z-score, HC-z-score, and CRP (all positive). Further new relationships
were those of plasma EPA and DHA with albumin (95% Cl: -1.78,-0.245, p=O.OlO and 95%CI:
0.46, 1.46, p<0.OO1, respectively), and plasma n-6 lCP:n-3 lCP ratio with height-far-age
(negative), HC (only marginal), and MUAC (negative) z-scores. A weak positive correlation was
seen between plasma n-6 FAs and plasma albumin. Concerning breast-milk, new statistically
significant positive correlations between breast-milk n-3 FAs and height-far-age z-score (95%
CI:0.01,0.21; p=0.026) and CRP(95% Cl: 1.03,1.12; p<0.001), and breast-milk EPAand CRP(95%
Cl: 1.12,1.69; p=0.003) were observed once data were pooled. A negative association between
breast-milk n-6 LCP:n-3 LCPand height-for-age z-score and CRPwas also observed.
There were no positive Interactions between FAs and time-point on any of the significantly
correlated outcomes.
4.8.6.5.3 Discussion
No relationships were observed between plasma or breast-milk n-3 FAs and gut integrity,
cognitive development or calprotectin concentrations. Breast-milk and plasma FAs did,
however, predict anthropometric z-scores (except for skinfold thicknesses) and plasma acute
phase protein concentrations.
Apart from the association between plasma EPA and MUAC z-score, there was little
evidence that these relationships were due to treatment: associations did not appear to be
stronger after treatment, and the Interaction between treatment and time-point was never
significant.
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Associations with anthropometric z-scores were not strong, though, as demonstrated by
low regression correlation coefficients, lack of marked associations in the scatter graphs, and
low partial correlation coefficients (where calculated). The limits of 95% Cl's also often
approached "a" or "1". Given the size of these associations, even those which were strongly
significant and even if the relationship were causal, n-3 FAs would thus not have been
responsible for large differences in absolute terms.
Acute phase proteins were more strongly predicted by PUFAs in regards to certain
relationships. Apart from CRP, which displayed a consistently negative relationship with the
n-6 lCP:n-3 lCP ratio both in plasma (in the pooled sample) and breast-milk (in both samples),
no clear patterns were discernable. For example, plasma albumin was negatively correlated
with plasma EPA but positively with plasma DHA in the pooled sample, and not with plasma
EPA or DHA in the 9 mo sample, and, again, due to multiple tests (eighteen outcomes each
tested for relationships with six different FA determinants) some of these significant results
may have been due to chance.
Although the relationship between treatment and plasma FA levels at 9 mo was generally
strong, as shown below In Table 41 and discussed in Section 4.7.1 and Section 4.8.6.3,
associations between treatment and most anthropometric outcomes and acute phase proteins
were absent. This could be said to be an indication that the relationship between plasma FA
levels and these outcomes was likely confounded, and is therefore not causative. The same
factors which influenced growth and/or acute phase protein levels either positively or
negatively (e.g. poor overall nourishment, physiological stresses), may have influenced plasma
FA levels. However, It needs to be taken into account that, given the size of the effects of
plasma FAson anthropometry and acute phase proteins overall, the influence of treatment on
anthropometry would not be expected to be very big. The effect of supplementation may have
been unable to modify plasma FA levels sufficiently to have a significant effect on these
outcomes.
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Table 41: Correlation coefficients for plasma fatty acid levels at 9 mo with treatment
Plasma % r (p-value) Plasma % r2 (p-value)
DHA 0.23 «0.002)
EPA 0.50 «0.001)
n-3 fatty acids 0.38 «0.001)
n-6 LCP:n-3 LCP -DAD «0.001)
4.9 Trial monitoring
There were no concerns expressed by the trial monitors about the progress of the trial,
adherence to protocol and MRC GCP requirements, or patient safety through the duration of
the trial.
A trial monitoring report serving to inform the MRC of progress of the trial, any significant
complaints arising, and any new information that had a bearing on safety or ethical
acceptability of the trial, was prepared by the trial monitor, after a site-visit midway, and
submitted to the MRC. It can be seen in Appendix 18.
All protocol deviations were reported to and discussed with trial and safety monitors. Two
deviations occurred as follows:
Deviation 1
Initially, all infants were recruited from the database of the Peri-conceptual Micronutrient
Supplementation Trial, as stated in the trial protocol.
However, for reasons previously explained in Chapter 3, potential subjects were later
drawn from the West Kiang Demographic Surveillance System rather than the originally stated
cohort.
Deviation 2
A recording error listed a child as being born a month earlier than in reality. This infant was
subsequently recruited into the trial a month early, and baseline measurements taken at 2 mo
rather than 3 mo of age. The error was later noticed, and reported to the trial and safety
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monitors who advised the withdrawal of the infant due to not meeting the age criteria.
Treatment was stopped after 3 weeks.
4.10 Safety and ethical concerns
4.10.1 Safety of the supplement oils
There were no concerns about the safety of the supplement arising from trial safety
monitoring data. Growth, morbidity, and nurse-visit data did not differ significantly between
groups. Furthermore, analyses of outcome data showed no harmful effects of receiving fish
oil.
However, giving 2ml of oil to young infants is not without a risk of aspiration or choking.
The cases of respiratory complaints was high (roughly 3000 days' worth of reports of this
complaint in total), and there was a concern that the oil supplementation may be related to
these respiratory complaints. Therefore the incidences of respiratory reports were
Investigated in relation to the reports of "choking during supplementation."
A total of 40 reports of choking were recorded, distributed amongst 28 infants. These 40
reports were listed, and the first 26 cases - a 65% sub-sample, distributed amongst sixteen
Infants - examined for coughs or respiratory complaints reported within seven days after the
report of choking.
In five of the sixteen Infants a respiratory complaint was reported within seven days. These
are summarised in Table 42, together with a comparison of average respiratory complaint
rates in individuals In the entire population who were ever reported to choke versus those
who were not.
The rate of respiratory complaints In infants who had ever choked was not significantly
higher than in those who had not (95% Cl: -0.24,0.68, p=0.348).8'n eleven of the sixteen
Infants analysed, no respiratory complaints were reported in the seven days after the choking
incident.
• Usingnegative binomial regression
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Given these figures, it is unlikely that choking on the supplement increased the risk of
respiratory complaints.
Table 42: Respiratory complaint reports in individuals who choked versus those who did not
Sub-sample examined: 26 reports of choking distributed across 16 individuals
Cases of a respiratory complaint being reported within 7 days of a choking report
Duration of the respiratory Total cough/respiratory complaint
condition (days) ever reported (days)
Individual1 2 14
Individual2 1 13
Individual3 2 12
Individual4 1 11
IndividualS 8 62
Average cough/respiratory complaint report rates in days/individual
Individuals in study population who ever choked
(X: SO)
19.6: 15.6
Entire study population
(X: SO)
18.3: 15.3
As discussed under "Safety Considerations" in the Methods section, membranes enriched
with PUFAsare more susceptible to oxidative damage, and the inclusion of d-alpha-tocopherol
in the oils was intended to avoid this potential harm.
When blood was drawn from infants, some degree of erythrocyte haemolysis occasionally
occurred. The samples which were haemolysed (observed by a red-tinged plasma) were
recorded and compared by time-point and treatment group.
At baseline there were 5 occurrences of haemolysis, compared to 3 cases at endpoint.
At endpoint, there were 2 cases of haemolysis in the control group, and 1 case in the fish
oil group.
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These numbers are very small, and no important conclusions should be drawn from them,
but nevertheless, these figures indicate it to be unlikely that fish oil supplementation, in the
presence of added vitamin E, increased erythrocyte oxidative damage.
4.10.2 Serious Adverse Events
A total of nine SAEs occurred, all of which were reported to the TSM. Four of these were in
the treatment group, and six in the control group. These numbers and the diagnoses and
relationship with intervention product are given in Table 43.
Table 43: SAEs by treatment group
----- :-:---::--------------:----------
Fish oil group Placebo group
(n=4) (n=6)
Diagnosis Diagnosis Causal relationship
with intervention
product'
Unlikely
Not related
Unlikely
Unlikely
Unlikely
Pneumonia
Pneumonia
Pneumonia
Causal relationship
with intervention
product"
Unlikely
Unlikely
Unlikely
Pneumonia
Skull injury
Pneumonia
Nephrotic syndrome
Severe pneumonia
Bronchiolitis
SAEs resulting in death
Not related Sudden collapse &
severe respiratory
difficulty
Unlikely
-- 1 -
As judged by TSM
Two SAEs resulted in death. The first was due to nephrotic syndrome, complicated by
diarrhoea, vomiting and bacterial sepsis. The original diagnosis of glomerulonephritis was
made shortly after starting supplementation, and not long after a urinary tract infection was
diagnosed, prior to supplementation. After careful inspection of the information surrounding
the SAE, the (blinded) TSM concluded that it was most likely not related causally to the
investigational product.
In the second fatal SAE, the cause of death was not sure, but on the basis of probability
was diagnosed as sepsis, the origin of which was unclear (although the chest was the likely
source). The case, together with test reports, clinic notes, and medical history, were
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thoroughly reviewed by the T5M with assistance from the MRC Keneba medical team. No
evidence was found to suggest that the death was related to the investigational product.
Briefly, the child was brought in to the MRC Keneba clinic on zo" and so" October with
fever, couth and vomiting. On 8th November the mother took her child to the resident MRC
nurse in her village during mid-morning. The field-worker, aware of the child's critical
condition, contacted the PI. The infant was picked up and reached Keneba by noon, suffering
from severe respiratory difficulty and sudden collapse. After tests and attempts at
resuscitation the child was transferred to a hospital in the country's capital in the afternoon
but died en route. It appeared that the sepsis had consumed her lungs and suffocation
resulted.
4.10.3 Use ofa placebo control group
Infants were not receiving any routine lCP supplementation in The Gambia, and by
withholding supplement from placebo groups children were not placed in any danger.
Additionally, LCPsupplementation is not a proven therapy for infant health and development,
so benefit of receiving the intervention could not be guaranteed.
4.10.4 Evaluation of Benefits and Risks?
The sample population was a highly vulnerable group of children without recourse to
sophisticated medical Investigation and treatment. The wellbeing of these subjects was
considered the first concern of the investigating team. The trial proposal and protocol passed
through scientific and ethical reviews In both The Gambia and the UK, which judged it safe on
basis of Information provided to them. The key external trial monitoring structures and
relevant documentations, agreed In principle with the MRC Senior Scientific Officer for Clinical
Trials and TSM and in keeping with the principles of the MRC GCPGuidelines, were in place.
These measures all served to minimise any risks associated with trial participation.
The use of low dose supplementation of infant formulae in term and in preterm infants has
been the subject of two Cochrane reviews, which concluded that supplementation was safe in
the populations of babies on which It was assessed but that its benefits were unproven.
t Theauthor receivedsignificant Input from the headof clinical servicesand resident paediatrician
In Keneba,Dr StephenOwens,for this section
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Although the supplement was not a pharmaceutical, the study hypothesis stated that it
would have beneficial physiological effects on gut immune function and on growth. With such
an impact, the possibility that it might also have significant detrimental effects was in turn
considered.
These potential harmful effects were discussed in Chapter 3. In short, they included the
risk of increased bleeding time (potentially leading to catastrophic effects in the event of
Haemorrhagic Disease of the Newborn), oxidative damage, and increased erythrocyte
haemolysis. Finally, taking part in the study required the drawing of blood, introducing an
additional slight risk of bruising or infection.
However, the magnitude of the increased bleeding risk was thought to be extremely small,
particularly at 3 months of age (as discussed in Chapter 3). The addition of the antioxidant
d-alpha-tocopherol to the oils offset the risk of oxidative damage and increased erythrocyte
haemolysis, and venipuncture was conducted under hygienic standards by a qualified
phlebotomist to minimise the (already small) risk of Infection.
There was a concern that weaning diets in rural Gambian infants contain sub-optimal
levels of n-3 LCPs, and experimental arguments to suggest that supplementing such infants
would be beneficial to their gut function and growth. Expected benefits derived from the
intervention were improved Infant growth rates and gut integrity. Additionally, decreased
Intestinal and systemic inflammation, improved cognitive development, and lower rates of
morbidity were possible advantages expected. Although these benefits were not strongly
supported by the literature, if they did occur, they would potentially be highly advantageous to
the individual trial subjects. Moreover, i~ Is a generally accepted fact that Infants taking part in
trials normally enjoy better health than those who are not because of the greater clinical
attention they receive.
The rationale for beginning with treatment at 3 mo was to prime and protect the gut
before any damage set In, or at least to delay the deterioration of gut integrity in the subjects.
However, because exclusive breast-feeding for 6 mo is advised by the National Nutrition
Agency of The Gambia to mothers in the community, there were concerns that
supplementation before this time would send out conflicting messages, and the suggestion for
beginning at 6 mo Instead was put forward. By means of negotiations with the Nutrition
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Agency, however, it was agreed that the supplement - which would be viewed as a treatment
or medication rather than a weaning food, and thus still fall within WHO guidelines - would be
administered starting at 3 mo of age, but that a) the MRC fieldworkers administering it would
heavily reinforce the message of 6 mo exclusive breast-feeding to mothers, and b) the MRC
would pay for the repainting of Baby Friendly Community Initiative billboards/signs in Baby
Friendly Community villages.
In light of all of the above arguments, it was considered that the potential benefits in
generating knowledge and improving infant health and growth in the communities concerned
outweighed the minimal risks involved for the subjects.
4.10.5 Quality assurance
Most of the results of quality assurance carried out have already been discussed above. Only
the supplement oils' oxidation values and vitamin E contents measured after 8 mo of storage
will therefore be addressed here.
Oxidation values for the supplement oils provided to the PI before the oils were sent to
The Gambia were Srneq/kg. In order to comply with Norwegian Medicinal Standards and
European Pharmacopoeia Standards, the peroxide value of fish oil has to be lower than
10meq/kg.
After eight months' storage, the fish oil peroxide value was still lower than smeqjkg. The
olive oil was higher, at 10.75 and 9.ssmeqjkg (Table 44).
Table 44: Average vitamin Eand Peroxide values of stored opened and unopened
supplement oils
Averagevitamin E Average peroxide value
% recovery (meq/Kg)
Fish oil (opened) 68.5 2.45
Fish oil (unopened) 96 3.1
Olive oil (opened) 66 10.75
_Olive oil (unopene:.d::.!)~__ -=9..:..7 :...9:.5:...S _
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Fish oil was therefore still fresh at time of administration. Olive oil was on the border of
falling above the cut off established for fish oil, but fell well within the range which most
sources cite as being acceptable for extra virgin olive oil.
As oils become rancid, antioxidants such as d-alpha-tocopherol become consumed. At
least 30% of the vitamin E in the opened oils had been consumed by the time of oil testing.
Still, sufficient vitamin Ewas still left unconsumed for limiting further oxidation and for intake
by the infants. How much vitamin E would have been consumed at the end of the storage
period, or when opened bottles were nearly empty is not known; but judging from a 2%
consumption in closed bottles over a period of 8 mo, and 30% consumption in bottles which
had been stored for 8 mo and been in use for a couple of weeks, it seems likely that vitamin E
levels at the end of the storage period would still have been adequate to protect both oils and
infant tissues.
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CHAPTER 5: OVERALL DISCUSSION AND CONCLUSIONS
5.1 Discussion
Various study aspects, results and considerations have already been discussed in the
previous chapter, also in relation to previous published work. Here, therefore, the discussion
will be limited to considerations from a broader perspective.
5.1.1 Brief synopsis of key findings
To the knowledge of the author, this is the first study to investigate the effects of n-3 LCP
supplementation during infancy on gut integrity, growth, and cognitive development in infants
from a developing country. Although the effects of fish oil supplementation on DHA status in
Pakistani infants have been investigated (338), previous studies investigating the effects of n-3
LCPs during infancy on the secondary outcomes of intestinal inflammation, systemic
inflammation and morbidity in infants from developing countries have not yet been reported.
In the current study, at 9 mo follow-up, fish oil supplementation successfully increased
infant n-3 plasma FA status as reflected in significantly higher relative concentrations of
plasma EPA and DHA and significantly increased total n-3 FA plasma concentrations in the
treatment group. At 9 mo, fish oil supplementation also resulted in a O.3cm Increase in MUAC.
At 12 mo follow-up, significant increases in MUAC and subscapular, biceps and triceps skinfold
thicknesses were detected in the intervention group. No further effects on growth were
detected and the results of the trial provided insufficient evidence to support the primary
hypotheses that dietary n-3 LCP supplementation improves rural African infants' growth
performance orland protects mucosal epithelial integrity, even at a very large dose.
Dietary n-3 LCPs did not lead to enhanced cognitive development, reduced degrees of
intestinal and systemic inflammation, or reduced rates of morbidities in rurai African infants,
as measured by the chosen indicators.
Examination of associations between umbilical cord and maternal serum DHA and AA
levels with later infant cognitive development provided no evidence of a relationship between
these LCPs levels at birth and later development. Similarly, no evidence of associations
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between plasma n-3 PUFAsat 3 mo or 9 mo and problem-solving or attention behaviour at 12
mo was found.
Investigating cross-sectional associations between outcome variables and PUFA status, no
relationship between plasma or breast-milk PUFA at 3 or 9 mo and urinary lMR, lactulose or
mannitol percent recoveries, or faecal calprotectin concentrations were found. Some evidence
was found to support the existence of relationships between plasma and breast-milk n-3 FAs
and certain anthropometric z-scores, but these relationships were weak. Plasma and
breast-milk PUFAs and n-6 LCP:n-3 LCP ratios correlated more strongly with plasma acute
phase proteins, but no clear patterns were observed and the associations were likely to be
confounded.
Fish oil supplementation, at the chosen dose, proved safe, as indicated by safety
monitoring analyses, SAEreports, and outcome results.
5.1.2 Considerations and possible explanations
The reasoning behind the described trial was, briefly, that because of the low n-3 lCP
contents of weaning diets coupled with fat losses and malabsorption incurred by high rates of
chronic environmental enteropathy and diarrhoea, the n-3 lCP status of rural Gambian infants
may be low. A low n-3 LCP status, in turn, could contribute to increased intestinal
inflammation, leading to exacerbated enteropathy, and, consequently, a negative influence on
growth performance. It was hypothesised that supplementary n-3 LCPs would modulate
immune system functioning and so reduce the persistent inflammation associated with
environmental enteropathy. Simultaneously, gut damage was hypothesised to be minimised
and growth performance improved. It was further hypothesised that an improved DHA status
would enhance cognitive development and infant attention control.
However, breast-milk analyses revealed that the average mother's milk was considerably
high in EPA and DHA compared to breast-milk of women in most other populations. The
majority of Infants aged 3 to 9 mo were, therefore, ensured diets supplying adequate amounts
of n-3 FAs. Because almost all of the literature on infant fatty acid status in other countries
supplies data on infant erythrocyte or plasma phospholipid fatty acid levels (and not total
plasma fatty acid levels) and for reasons explained in Chapter 4 under Section 4.7.1.1, it is
difficult to make comparisons of the Gambian infants' FA status with other populations. One
group in Havana, Cuba, measured the plasma fatty acid status of thirty-one 2 mo old infants
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(339) and found the following relative FA concentrations (mean ± SO): EPA 0.41 ± 0.17; DHA
2.82 ± 0.84; and AA 6.35 ± 1.81. Gambian infants, at 3 mo, had the following concentrations:
EPA 1.52 ± 1.18; DHA 3.88 ± 0.93; and AA 6.78 ± 1.46. At 3 mo, then, at least compared to a
sample of Cuban infants, Gambian infants indeed had far higher plasma n-3 lCP levels. At 9
rno, Gambian infant plasma n-3 lCP means may not be as high compared to, for example
Cuban infant means, but it is likely that even at 9 mo of age, when weaning foods contribute a
large part of the infant diet, breast-milk supplied most infants with substantial amounts of
preformed lCPs even when it was consumed in smaller volumes.
It may be argued, therefore, that the intervention was targeted at infants who were
already replete with n-3 lCPs. Had the intervention been targeted at infants who were instead
older and fully weaned, or who were at least less dependent on breast-milk for their energy
needs, it might indeed have had some ofthe hypothesised effects in this population. However,
the size of the dose was large enough to still further increase in plasma n-3 lCP levels and
warrant possible associated benefits. Secondly, delaying the intervention until later would
have the disadvantage of necessarily attempting to redress a fully established enteropathy
whtch is slow to repair (16). Once injury and inflammation is initiated in the gut, the vicious
cycle of bacterial overgrowth, absorption of foreign proteins and toxins, malabsorption of
nutrients, and perpetuation or aggravation of mucosal damage, sets in. Treatment at this stage
will thus be required to reverse an extensive degree of mucosal Injury which has proven to
resist even intensive Inpatient treatment with nutritional support, antibiotics, and
antlhelminthic therapy (16). Nonetheless, the effects of supplementary n-3 lCPs given at this
later stage, may, by virtue of raising a low n-3 LPCstatus and supplementing a low n-3 LCPdiet,
prove more beneficial than when given at 3 mo, also for other endpoint measures.
Despite the dally health monitoring of infants, good primary health care provision,
effective treatment of acute Illness, and 2ml olive or fish oil daily, growth remained poor
when compared to WHO standards. Given that growth faltering cannot, to any significant
degree, be improved by energy or micronutrient supplementation (as shown in numerous
studies (13-17)), and that even a high standard of medical care provision - which has previously
been shown to have successfully reduced the prevalence of severe illness and mortality in this
population (340), is unable to significantly dilute the Impact of factors adversely affecting
growth, it may be thought that this poor growth is normal for these infants, and that it is not
pathological. It may be argued that slower, poorer increases in length and weight may be a
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beneficial adaptation allowing the use of limited resources to the best advantage of the
population and its individuals.
However, as argued by Poskitt (1999) (26), this is unlikely, given that growth is good during
the first 3 or 4 mo of life. Similarly, growth is good during the dry season at later ages.
Moreover, some children in the population do indeed grow normally, and the shape of the
population growth curve is not equivalent to any known normal infant growth pattern.
Furthermore, evidence shows that even mildly malnourished children are at increased risk of
death from infection (341) and neurodevelopmental impairment (342), and suffer a greater
propensity to conditions such as hypertention (343) and diabetes (344) in later life. For these
reasons Poskitt asserts that the average growth patterns of Keneba children is abnormal and
pathologica I.
Tanner (1989) (5), referring the work of Professor John Water low (345, 346), suggests that
in infants who are malnourished (even to a mild degree), the restrictions on exploration, play
and social interaction that this energy limitation causes may be a "more potent cause of delay
in intellectual and emotional development than any nutritional effect on the nervous system."
If this suggestion were true of the infants in West Kiang, their poor performance on the
cognitive development tests would therefore to a greater degree be explained by these
limitations on development than by a direct deficiency of nutrients, such as DHA and AA, which
are Important for central nervous system development. This might explain why some groups of
infants in developed countries, who did not suffer the same restrictions to development
caused by repeated infections and low-energy weaning foods, benefitted from LCP
supplementation (108, 192, 195, 201) while the Gambian infants did not. During the perinatal
period, n-3 FAs are required by the membranes of synapses for synaptogenesis. An infant who
is thriving should experience a greater speed of synaptogenesis, and therefore has an
increased LCPdemand, compared to an infant developing less optimally. Alternatively, or in
addition, Infants in these study groups may have featured baseline tissue LCPlevels far below
the concentration In breast-fed Gambian infants, resulting in a greater benefit from LCP
supplementation In the treatment group.
Another factor which may have diluted the observable effects of treatment was the use of
olive oil as placebo. Olive oil, composed chiefly of monounsaturated FAs, is classically used as
placebo In fish 011 studies because monounsaturated FAs are regarded as being neutral FAs
(347-349). Few other placebos offer the advantage of being quite as neutral, while
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simultaneously being comparable in energy value to fish oil and suitable for keeping
investigators blinded. Nevertheless, despite these advantages, the suitability of olive oil as
placebo cannot be guaranteed. The neutrality of the oil may be debated as it has been
suggested to indeed feature beneficial properties, including potential immunosuppressive
actions. Although these require further investigation, effects of olive oil on immune function in
rheumatoid arthritis have been suggested in human studies (350, 351). Oosthuizen et al.
(1994) (352) found fibrinogen-lowering effects due to fish oil as well as olive oil
supplementation, and a letter published in The lancet, written by a research group who had
studied the effects of fish oil in preventing the reoccurrence of blood vessel narrowing after
angioplasty (353) suggested that future oil supplementation studies should not consider olive
oil as a placebo until more research around the role of monounsaturated FAs in retarding
atherosclerosis has been conducted (354). A study investigating the effects of olive oil on
immune function (349) showed that, in middle-aged men, monounsaturated FAs alter the FA
composition of plasma phospholipids, leading the authors to reinforce the recommendation
against the use of olive oil for placebo in clinical studies. The same study found evidence to
suggest that monounsaturated FAs affect immune function by decreased expression of some
adhesion molecules.
Thus, although olive 011 is regarded as a neutral food product, the possibility that it
resulted in some beneficial effects in the infants in the control group, and therefore weakened
some potential observable effects of fish oil, albeit small, cannot be ruled out.
It was essential for vitamin E (d-alpha-tocopherol) to be gi~en in doses of 2lU/day to
Infants in both groups for reasons already discussed. Although it is unlikely, the small
possibility that vitamin Ealso had beneficial effects in both groups which could have weakened
observable effects of n-3 lCPs warrants consideration. The physiological role and importance
of vitamin E remains unclear. A recent review by Traber and Atkinson (2007) concluded that
"virtually all of the variation and scope of vitamin E's biological activity can be seen and
understood in the light of protection of PUFAs and the membrane qualities (fluidity, phase
separation, and lipid domains) that PUFAs bring about" (355). In contrast, Azzi (2007) argues
that "a-tocopherol Is not physiologically acting as an antioxidant" and that the natural function
of a-tocopherol is that of cell signalling (356). The overall results of clinical trials to date do not
support the use of vitamin E in cardiac health (357, 358), pregnancy (359), gastroinstestinal
cancers (360) or for primary and secondary prevention of various diseases (361). The
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reasonable conclusion to be made, therefore, is that it is unlikely that vitamin E improved any
of the primary outcomes in infants studied. Due to controversy and uncertainties around its
physiological roles, however, there still remains room for speculation around the possibility for
unspecified effects to have occurred, whether beneficial or harmful, although the evidence to
support this is weak.
5.1.3 Comparison of main findings with relevant findings from other
published studies
A large number of early fish oil supplementation studies in relation to infant growth have
previously been conducted, as described in Chapter 1. These studies differed from the present
one in that infants were all from developed countries, and formula-fed. In these conditions,
n-3 LCPsupplementation of infant formula did not improve the growth of term infants in all
studies considered. In preterm infants, mixed results were found but these infants are not
considered comparable with the 3 mo - 9 mo old Gambian infants studied presently. In a
study investigating breast-fed infants whose mothers were supplemented with fish oil during
lactation (130), an increased subscapular skinfold was detected in infants of supplemented
women, but only at follow-up two years after intervention was ceased. This result is similar to
that found in the present study, where no difference in HC, growth in length or weight was
found, but indeed an increased fatness, which, while not observed at endpoint, was observed
in the skinfold thicknesses 3 mo after Intervention was ceased.
Fish oil supplementation in relation to chronic environmental enteropathy has not
previously been Investigated and so no studies are available for comparison with the present
study results in relation to n-3 LCPs.Other interventions which have attempted to reduce gut
mucosal damage in infants or children from developing counries have, however, been
undertaken using some of the following treatments: oral glutamine, probiotics, vitamin A with
or without beta-carotene, and intensive inpatient treatment with nutritional support and
antibiotics (and antihelminthic therapy where required).
Similar to results from the present study, glutamine administration was unsuccessful in
Improving gut integrity in Gambian infants (259). Probiotic administration for30 days had no
effect on intestinal integrity of 3 - 5 year old Malawian children (362). In India, vitamin A was
given in two separate trials to two groups of infants: hospitalised infants (one 200,000 IU dose)
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and infants attending a community health centre (16 700 IU weekly). All treated groups had
more rapid improvement in gut integrity than the placebo groups, although no group had
urinary LMR that reached those of UK standards (363). In a randomised controlled trial
involving women infected with HIV, maternal vitamin A and beta-carotene administration (1.5
mg retinyl palmitate and 30 mg beta-carotene daily, plus 60 mg retinyl palmitate at delivery)
was associated with significantly lower lactulose excretion in a sub-group of HIV-infected
infants at one and fourteen weeks of age, but treatment did not decrease mucosal damage in
uninfected infants (364). High dose vitamin A administration as recommended by the
International vitamin A Consultative Group did not increase gut integrity in Gambian infants
when compared to the lower WHO-recommended vitamin A dose (258). Intensive in-patient
nutritional support with antibiotic medication (16) did not lead to significant improvements in
LMRs after a month of rehabilitation. Finally, fish oil may now be added to this list as a further
attempted intervention.
In Pakistan, breast-fed malnourished infants from the north of the country were found to
have very low OHA status (365). This was linked to the low breast-milk OHA concentrations of
their mothers (337). In an attempt to improve OHA status, ten malnourished infants
(weight-for-age<-2 SO compared to US National Centre for Health Statistics references) were
given SOOmgfish oil providing 112mg DHA daily for nine weeks. A 50% increase in red blood
cell OHA and total n-3 LCP was found in the treated group, while red blood cell n-6 FA
concentrations were not changed. In the present study, significant increases in plasma OHA%
were found in infants supplemented with 200mg OHA daily compared to the control subjects.
Although the dose was nearly double that given to the Pakistani infants, plasma OHA levels
Increased by only 11%. in supplemented Gambian infants. It is not easy to make valid direct
comparisons between plasma OHA and red blood cell OHA levels, yet these results are not
surprising considering the low baseline OHA status of Pakistani infants versus that of Gambian
infants. The Impact of a lower dose in deficient infants can reasonably thought to be greater
than that of a higher dose in infants with a higher n-3 LCPstatus consuming breast-milk rich in
OHA.
n-3 LCPs In relation to cognitive development in infants of developed countries have,
similarly, shown mostly null effects, although a randomised controlled trial in 44 British term
infants randomlsed to receive formula with or without LCPsupplementation showed improved
performance on the Willatts Test at 10 mo age (195). British infants were exposed to different
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conditions than Gambian infants, however: British infants fed no preformed lCPs were
compared with infants supplemented with lCPs. In the Gambian sample, not only were infants
tested using a measure developed on infants from the developed world, but all infants in the
sample were receiving some degree of preformed LCPsthrough the breast-milk. It is therefore
not surprising that results from these two studies differed. No other fish oil trials in relation to
cognitive development in infants in developing countries have been identified by the author
for comparison purposes. However, observational studies assessing the relationship between
prenatal DHA exposure and later cognitive development have been identified but these were
already discussed in Section 4.8.1.
5.1.4 Strengths and limitations of the present study
The present trial was properly randomised and sufficiently powered, treatment allocation
was well concealed, and outcome assessments performed blinded to treatment allocations.
Randomlsed controlled trials, by virtue of their randomisation procedure, provide a direct test
of the causal hypothesis that a certain exposure affects the outcome. Random allocations
assure that the characteristics of participants are likely to be Similar across groups at baseline,
and so reduce the risk of serious Imbalances in factors known or not, which could bias the
results.
Random allocation, however, does not protect controlled ~rials against multiple types of
bias which may occur at various stages of its setup, conduct and analysis. Poor compliance,
loss to follow-up and exclusions may, for example, bias the results (although randomisation
will neutralise at least the last of these). Such biases reduce the validity of inferences which
may be made from studies. In the following section the overall strengths and limitations of the
present trial will be discussed in the context of its validity, with reference to four different
classes of validity.
5.1.4.1 Validity of the trial
Internal and external validity, as described by Campbell and Stanley (1966) (366) and
summarised in Box 6, are important elements contributing to the overall quality of controlled
clinical trials (367). Conclusion and construct validity were also later described by Cook and
Campbell (1979) (368) and will be discussed below.
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Box 6: Components of internal and external validity of controlled trials
Reproduced from Juni et al. (2001) (367)
Internal validity - extent to which systematic error is minimised in
clinical trials:
1. Selection bias: biased allocation to comparison groups
2. Performance bias: unequal provision of care apart from
treatment under evaluation
3. Detection bias: biased assessment of outcome
4. Attrition bias: biased occurrence and handling of deviations
from protocol and loss to follow-up
External validity - extent to which results of trials provide a correct
basis for generalisation to other circumstances
1. Patients: age, sex, severity of disease and risk factors,
comorbidity
2. Treatment regimens: dosage, timing and route of
administration, type of treatment within a class of treatments,
concomita nt treatments
3. Settings: level of care and experience and specialisation of care
provider
4. Modalities of outcomes: type or definition of outcomes and
duration offollow-up
Internal validity
Internal validity refers to the degree of confidence with which one can conclude whether
there is any causal relationship between the dependent and independent variables (368). The
present trial was little-affected by threats to its internal validity for the following reasons:
1. Subjects were allocated to comparison groups in a non-biased way (computerised
block randomisation concealed from investigators recruiting subjects), facilitating the
forming of groups that were comparable for potential confounding factors.
2. The PI, fieldworkers, village assistants and other investigators on the ground were
blinded to treatment allocation, resulting in an identical division of medical care and
other provisions between groups.
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3. Outcomes were assessed in a non-biased way, approached identically across groups.
4. Similar compliance rates between groups enhanced comparability.
5. Finally, losses to-follow up were balanced between groups, limiting attrition bias.
These factors strengthened the internal validity so that systematic errors were minimised,
and, apart from random errors and chance, any detected group differences could be explained
by treatment alone.
External validity
In contrast, the external validity (the extent to which a research finding can be generalised
across different circumstances (368) ) suffered more threats. The extent to which present
results may be extrapolated to apply to other age groups, populations, dosages etc. is not
clear. The trial assessed and generated evidence for the effects of a daily dose of SOOmgn-3
LCPs in a very specific group of infants living in one division of a small African country. The
following questions about the relevance of this study in other settings might be raised:
1. Were the dose altered in its magnitude, DHA:EPA ratio, duration, regularity or mode of
administration (e.g. administered via breast-milk), would results have differed,
possibly profoundly?
2. Were flsh oil to be introduced to children aged 18 mo rather than 3 mo, how would
results have differed?
3. How applicable are the results of this trial to infants living in other rural areas of Africa,
or indeed the world, where fish and breast-milk intakes, desaturase enzyme activity or
other n-3 LCPstatus influences differ?
4. Would infants with greater or lesser degrees of growth faltering or gut damage, or
who do not receive the same care as infants taking part in a study, respond differently
to fish oil supplementation?
The generalisability of the results were, thus, limited. Unless the trial is replicated in other
settings, or altered to match these determined circumstances of different dosages or
durations, the answers to these questions cannot be given.
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Statistical conclusion validity
Statistical conclusion validity is the extent to which conclusions about the existence and
strength of co-variation between presumed dependent and independent variables can
correctly be drawn from the data. Low statistical power, the use of inappropriate statistical
tests and low reliability of independent and dependent variables are some of its threats. These
and some further threats are summarised in Box 7 and shall be discussed in relation to the
present study below.
Statistical power
Insufficient statistical power due to an inadequate sample size may lead to an inability to
detect true differences, leading to Type II errors. The present study was sufficiently powered
to detect, at 90% power and 5% significance levels, differences, determined before the start of
the trial, to be functionally significant. A sample size of 150 would allow the detection of
differences of 18 and 13% for change in weight and length, respectively, a 0.60 SDdifference in
LMRs, and a difference of 2.1 and 6.1 points in the Willatts and Attention tests, respectively,
between groups.
Box 7: Threats to statistical conclusion and construct validity
Summarised from Cook & Campbell (1979) (368)
Threats to statistical conclusion validity
1. Inadequate study sample size and power
2. Use of inappropriate statistical tests
3. Multiple statistical testing
4. Poor measurement reliability
5. Poor reliability of administration of treatments
6. Heterogeneous sample
Threats to construct validity
1. Inadequate pre-operational explanation of concept
2. Mono-operational and method biases
3. Hypothesis guessing and evaluation apprehension
4. Experimenter expectancies
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The use of appropriate statistical tests
Subjects were randomised at individual level into two treatment groups. The methods
used for statistical analysis are described in Chapter 3. Briefly, using intention-ta-treat analysis,
effect of treatment on individual outcomes was examined using, chiefly, multiple linear or
log-linear regression analysis. The outcome measure was added as dependent variable, and
relevant covariates and treatment as the independent variables. All covariates were only
added if identified as potential variance inflators or/and effect modifiers. Cl limits were
provided for all effect size estimates. The validity of the following regression assumptions were
considered:
a) Sample representativeness: the sample comprised the majority of infants living in the
population who met the inclusion criteria, and was thus representative of the
population under examination.
b) Variables normally distributed: all variable distributions were examined. Apart from
the Willatts Test results, all data were normally distributed or log-transformed, where
appropriate, when entered into the regression model. The distribution of the Willatts
Test results, and justification for adding the data as a mixed distribution to the model
has already been discussed (Section 4.7.2).
c) Linear relationship between dependent and independent variables: all data were
plotted before being analysed to examine, amongst others, the relationship between
dependent and independent variables. STATA's "qnorm" command was used to draw
scatterplots of the standardised residuals, and plots of standardised residuals as a
function of standardised predicted values were used to test that relationships were
linear (vs. curvilinear).
d) No error in the independent variables: the independent variable of "treatment" and
covarlates of sex, season of birth, and age of first supplementation were considered
error-free.
Baseline values added as covariates were affected by measurement error and were
thus not added to the models "error free". The error in the variable "growth" was,
however, shown In the previous chapter to be small. FA levels, acute phase proteins,
and stool calprotectin concentration measurement errors were difficult to estimate
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because no repeat assessments were made. However, the laboratory methods used
for their measurement were considered to be reliable, and the measurement errors
small relative to the overall sample variation in these outcomes. The size of the errors
introduced with the measurement of LMRs was discussed in Chapter 3. These errors
increased the potential for both Type II (for lMR) and Type I (for other variables in the
equation) errors. Where the concentrations of lactulose, and, to a lesser degree,
mannitol, were added to regression models as independent variables, the correlation
between the independent and dependent variables was reduced, and the variance
introduced by error in the variable concerned possibly apportioned incorrectly.
However, when baseline variables were added to regression models, little interest was
placed in their effects, as they were only added to reduce the variance. Thus,
measurement error in baseline values did little to bias the results.
e) Homoscedasticity: for relevant independent variables, the variance across all
observations was assessed by plotting the standardised residuals against the
regression standardised predicted value. No clear heteroscedasticity was observed.
Multiple testing
Because multiple testing of various outcomes causes an increased likelihood of falsely
concluding that a statistical relationship exists when it does not, and no allowance was made
for multiple testing, inferences about secondary outcome significant results had to be made
with caution. Clear statements about these limitations were made when discussing results
which were not primary outcome measures. There were, however, only a small number of
significant results, not averaging more than what would be expected from the number of tests
performed.
Reliability of measures and treatment administration
Unreliable measurements may inflate the standard errors and increase the variability of the
estimates, increasing the potential for Type II errors. It increases unexplained variation within
groups and reduces the power of the analysis. Error is generally inherent to measurement,
resulting in often unavoidable imperfections in the reliability of estimates, as demonstrated in
the present study where a degree of error did indeed enter into the variables examined. The
reliability of plasma and breast-milk FA estimates, e.g., suffered constraints caused by
numerous factors influencing measured FA levels, and high degrees of biological variability,
particularly in breast-milk. Lipid levels vary due to differences in their absorption and
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metabolism, and discrepancies in sample handling, storage, and laboratory methods (93).
Efforts were, however, taken to minimise these errors, as described in the Methods Section.
These included the collection of and adjustment for baseline information, the use of
standardised measurement methods and refined instruments or procedures, and the use of a
limited number of experienced and/or well-trained observers. Further efforts included the use
of triplicate endpoint measures for all primary outcomes. Where possible, inter- and
intra-observer reliabilities were assessed and quantified.
To minimise errors introduced by intervention implementation, treatment administration
across all infants was stringently managed by ensuring doses were given only by fieldworkers,
daily, using standardised, clearly defined procedures. Compliance was strictly monitored, and
when adjusting for compliance in outcome analyses, the findings were not changed.
Sample heterogeneity
Sample heterogeneity also leads to increased unwanted variability. Homogeneity was
improved by recruiting subjects within a narrow band of ages (3 mo ±7 days), all living in rural
Gambia in communities sharing similar socioeconomic statuses, diets, breast-feeding rates and
weaning practices. Sample heterogeneity was further minimised by ensuring adherence to
clearly defined inclusion and exclusion criteria and by testing outcomes at similar ages.
Variability was distributed evenly across treatment groups by implementing adequate
randomisation procedures.
Construct validity
Construct validity of putative causes and effects addresses the conceptual validity of the
research findings and so the degree to which interpretations and inferences drawn from the
study findings can legitimately be made. It has been described by Barret (1984) (369) as the
degree to which the conceptualisations of dependent and independent variables match the
operationalisatlon of the measurements ("and therefore the extent to which the theoretical
inferences we draw from the findings are empirically justified"). Some of its main threats,
summarised In Box 7, will be discussed below.
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Inadequate pre-operational explanation of concept
Proper analysis of the theoretical concept of the study and adequate conceptualisation of
the dependent and independent variables are required for adequate pre-operational
explanation of how the independent variable influences the dependent one.
The theoretical basis of the present study is described in Chapter 1. It was reviewed and
approved by three panels on the basis of its scientific credibility (candidate's advisory
committee and upgrading panel; MRC Scientific Coordination Committee), and two
committees further endorsed the ethical justification for conducting the trial (London School
of Hygiene and Tropical Medicine and Gambian Government ethics committees).
Many reasons exist why fish oil may be beneficial to the health and development of
infants, and the physiological mechanisms of dietary LCPs have been well-described. The
independent and dependent variables were relatively simple constructs, limiting the
complexity required to conceptualise the influences oftreatment on outcome variables.
Mono-operational and mono-method biases
When only one aspect of a dependent variable is measured, mono-operational biases can
result. When only one form of assessment is considered to study the dependent variable while
investigating treatment causal effects, mono-method biases can result (369).
Various dimensions of growth were measured, using validated techniques. Overall gut
integrity was measured as a function of villous atrophy and intestinal leakiness. The dual-sugar
permeability test assesses both gut integrity and absorptive capacity, and has been used in
several studies characterising the aetiology of growth failure in The Gambia (30) and
elsewhere (37, 38). Three different plasma acute phase proteins were measured for the
secondary outcome assessing systemic inflammatory and acute phase markers. For
morbidities, complaints of overall unwellness were assessed, and four common complaints as
further components of this outcome. These variables, whether by their specific nature or by
being assessed by multiple measures, therefore likely suffered only trivial degrees of
mono-operational or mono-method biases.
Plasma FAs were measured to indicate infant FA status, and to assess corresponding
changes due to treatment. Plasma levels of individual FAs reflect short term intakes over the
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last few days (93) and thus are not an ideal indicator of overall FA status. (Adipose tissue is the
preferred medium for the measurement of FAsas a reflection of long-term dietary intakes, but
because of its invasive nature, its use is limited in studies involving infants). As the distribution
of FAs differ among different biological compartments (280), the measurement of plasma FAs
as the only indicator of FA status could lead to mono-method and operational biases if the
outcome assessed was "(overall) fatty acid status". However, by confining the outcome
definition to "plasma FAstatus" this kind of bias was reduced.
Cognitive development was assessed by two aspects of development: attention and
problem-solving behaviour, representing a limited scope of cognitive functions and abilities.
The narrow range of cognitive aspects measured were chosen for reasons already described,
but the limitations of this decision were that construct validity of the study may have suffered
because e.g. differences may indeed have occurred in other, unmeasured domains of cognitive
functions, or in the functions tested if tests of a different nature were used. The same holds
true of calprotectin as a measure of intestinal inflammation. It is only one aspect of a complex
outcome, measured using one method only, and thus the extent to which the inferences about
fish oil supplementation in relation to intestinal inflammation (as opposed to "stool
calprotectin levels") may be drawn from the findings in this study are restricted.
Hypothesis guessing and evaluation apprehension
This threat is introduced when subjects guess the hypothesis being tested, and adjust their
behaviour accordingly. The infants in this study were too young to guess the hypothesis and so
influence outcomes assessed. Although evaluation apprehension may have affected morbidity
assessments, it is unlikely that the effect was different between the two treatment groups.
Experimenter expectancies
Because Investigators may expect a particular group of subjects to perform more
favourably In outcome assessments, their observations may become biased. However, these
expectancies were not able to influence the results of the present study as all investigators
were blind to the treatment status of the infants.
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5.1.4.2 Other strengths and limitations
Apart from the topics covered by the section above, other trial strengths and limitations
include the following:
The cognitive tests used on these Gambian infants were developed on infants living in the
UK and USA, where brain development and maturity possibly follow different trajectories to
that in Gambian infants, and so this outcome may not be measured as sensitively by these
tests in a rural African population. Inferences and comparisons with other studies are thereby
limited.
The placebo used as control, although suitable for blinding purposes, may have contained
compounds that benefited infants in unknown ways. The antioxidants supplied by both oils
(0.5% rosemary oil and 11Uvitamin E/ml) may, similarly, have provided unidentified benefits
(or harm) to both groups of infants, which could have diluted treatment effects.
As briefly discussed above, plasma FAs reflect short term FA intakes and are thus not an
ideal Indicator of overall FA status. Animal studies provide evidence that FA uptake kinetics
differ across tissues, and that plasma does not reflect whole-body equilibrium (370). Although
plasma n-3 FA levels were increased by supplementation, therefore, the true n-3 LCPstatus of
infants could not precisely be known. The assessments of the effect of treatment on true
overall FA status, and subsequent cross-sectional associations with outcome variables, could
thus have suffered a compromised validity, i.e. they may not have been measuring what they
were Intended to measure.
The age-group assessed was probably inappropriate, given that breast-milk was high in n-3
LCPsand intakes at this age were still important. This assumed weakness could have been
avoided had the initial pilot study breast-milk data been available at a sooner point. Analyses
would have indicated that Gambian mothers' breast-milk was rich in LCPsand this would likely
have led to a decision to increase age of recruitment into the study, and so the age of
treatment initiation, to when breast-milk intakes were trivial. Because of time constraints
placed on the PI for a timely completion of her PhD, it was imperative to continue with ethical
approval seeking and trial set-up procedures even though this data were outstanding.
However, the consequences of having proceeded regardless demonstrates the potential
dangers of pursuing a trial without first having access to important relevant information, and
the author has learned a valuable lesson through it.
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5.1.5 Implications of the study
Despite supplementing young infants with a very large dose of fish oil, remarkably little
effect was observed on the tested outcomes. The 95% Cl calculated for most endpoints were,
overall, fairly narrow, providing reasonable certainty that the differences observed were
minimal. Previously there have been theoretical reasons for supposing that n-3 lCP
supplementation might have observable impacts, but data have now been produced to
disprove this.
Because so many interventions have failed to improve the growth and gut integrity of
Gambian infants, it was hoped that n-3 lCP supplementation would indeed provide some
beneficial impact. However, although n-3 lCP-rich fish oil was not successful at having the
hypothesised effects at the end of the follow-up period, the study will contribute to the
scientific body of literature by being the first trial addressing this specific subject, and
providing definitive answers on it. Furthermore, the study will contribute to sclentlflc
knowledge by raising further questions; these questions, in turn, may lead to subsequent
investigations which will build on the topic of fish oil in relation to infant health and
development, and the subject of growth faltering and environmental enteropathy.
Certain analytic and measurement techniques (e.g. stool calprotectin assay, knee-heel
length measures, problem-solving and attention behaviour assessment) have been tested or
refined by this study, and data to support their validity or question it generated. For instance,
triplicate measurements at baseline and endpoint produced good data on the reproducibility
of the dual-sugar-permeablllty test, indicating its susceptibility to errors and thus its clear
limitations to research studies when applying the methods described. Finally, this study has
yielded data on African Infants that were not previously available.
5.1.5.1 Research implications and recommendations
Consideration of single nutrients in isolation does not take account of the influence of
other nutrients in the diet, or combinations of nutrients. Jackson (2001) writes that deficiency
In one nutrient may act as a marker of other dietary deficiencies, and that focusing on single
nutrients limits the understanding of nutrient-nutrient interactions. Such an interaction may,
for example, allow the effect of a limitation of one nutrient to be buffered by the ready
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availability of another (371). The significance of nutrient-nutrient interactions in investigations
of n-3 LCPsin relation to infant health and development, which may be highly intricate, is not
known in any detail. This minimises the degree of inference that can be made from a trial
supplementing with n-3 LCPsin isolation, without considering levels of other nutrients at the
same time. An infant may have high plasma n-3 LCPconcentrations, for example, but because
of deficiencies existing in other nutrients or extra nutritional constituents (called "bioactive
compounds" (372) ) which may be necessary for proper usage of these fats or to act as
co-factors In reactions in which LCPs are involved - facilitating their conversions or
incorporations Into cellular components - the benefits of supplementary LCPs may be
restricted. Further knowledge of nutrient-nutrient interactions in this area may, in the future,
facilitate trials which investigate n-3 LCPsand infant health in a broader context, and it is thus
recommended that it be studied in greater depth.
The present study has suggested that fish oil administration may have a delayed effect on
growth, as demonstrated by Increases in skinfold thicknesses and MUAC seen at 12 mo but not
at 9 mo of age. The n-3 LCP-supplemented infants had significantly more dilute urine than the
olive oil-supplemented infants, as indicated by urinary mannitol concentrations. The
implications of these finding are not known but could potentially be important, leading to
investigations which further elucidate the still unknown impacts of fish 011.
Compared with populations already investigated, the breast-milk n-3 LCP levels of
Gambian women were found to be of the highest in the world. The reasons for this are not
certain. The Gambian diet Is not considered to supply large quantities of n-3 LCPs,although
precursor n-3 FAs are regularly consumed via green leafy vegetables. Conversion efficiency
may be particularly high In these women, possibly due to polymorph isms of the FADSl and
FADS2 gene clusters mentioned above. An'swers to these speculations remain to be given.
Cognitive maturity of the studied infants, as measured by the Willatts Test was found to
lag far behind other population groups. The accuracy of this observation will require
confirmation, but, if found to be true, reasons for this delay might be investigated and
consequently lead to effective Interventions for promoting optimum infant cognitive
development In rural Gambian communities. The foundation for such future studies in rural
Africa has now been laid by ground-work carried out during the pilot and main studies. It is
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recommended that the predictive power of these tests for later cognitive performance in
African infants be investigated.
The impact of early n-s lCP supplementation may change over time, suggesting a
physiological effect at the gene level. Not only might growth effects be delayed, but also
effects on other outcomes such as cognitive development. Helland et al. (2001), for example,
supplemented pregnant women with fish oil until 3 mo after delivery. At 6 mo of age no
cognitive benefit was detected in infants of the supplemented group (172). However, at 4
years of age, children born to fish 011 supplemented mothers showed significantly higher
intelligence quotient scores than children born to mothers given placebo (173). In contrast,
Agostoni and colleagues, using the Brunet-lezine developmental quotient, reported a positive
effect of supplementation at 4 mo (192) but not at follow up at 1 and 2 years (191). It is
therefore recommended that these Gambian children be followed longitudinally to examine
whether benefits which were not seen in the first year of life may manifest at a later age. Such
a follow-up would also provide insights into the long-term effects of n-3 lCPs on skinfold
thickness and MUAC measures (i.e., whether they are maintained, fade away, or become more
pronounced).
A better understanding of the cause and pathogenesis of environmental enteropathy is
recommended for assisting in the development of effective interventions. Etiological
assumptions should be confirmed or refuted, and the mucosal immune response studied in
further depth. The Identification of specific gut pathogens leading to gut damage and
consequent Immunoprophylactic approaches targeting these and established pathogens are
recommended. The increased power of analytical methods for studying the human
mlcrobiome may facilitate such exploration. The importance of attempts to address the
worldwide problems of poor hygiene and sanitation - which lead to enteric infections in the
first instance - should not be undermined, and their priority should be considered high.
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5.2 Conclusions
A significant increase in relative concentrations of plasma n-3 lCPs were observed when
providing a daily supplement of fish oil providing 500mg combined DHA+EPA to breast-fed
rural African infants. No clear associated improvements in gut integrity and growth at 9 mo of
age, and cognitive development at 12 mo of age, were observed when compared to endpoint
measures in the olive oil-placebo control group. Although daily fish oil supplementation proved
safe, no benefits were demonstrated in further outcome measurements of intestinal
inflammation, acute phase plasma levels, and morbidity patterns, and the results of the trial
do not support the use of supplementary n-3 lCPs in young, breast-fed, rural Gambian infants
for the improvement of health and development. n-3 lCPs remain critical to human health and
development, but breast-fed infants in rural Gambia are ensured an adequate supply of
pre-formed lCPs by mother's milk which in the present sample proved considerably rich in
these FAs.
Growth faltering and environmental enteropathy is the result of a complex set of
mechanisms Involving varied physiologic and environmental interactions, and much
investigation is stili needed before a full understanding can be reached. Although
environmental enteropthy appears to be asymptomatic, its impact on growth remains big, and
its full impact on the child cannot be known until an effective intervention to ameliorate or
prevent the condition is found. The author believes that the problem should thus continue to
be explored for the benefit of future generations in The Gambia and elsewhere.
238
Chapter 5: Overall discussion and conclusion
REFERENCES
1. Department of State US. Background note: The Gambia. Bureau of Public Affairs, 2008.
2. Black RE, Alien LH, Bhutta ZA, et al. Maternal and child undernutrition: global and
regional exposures and health consequences. Lancet 2008;371:243-60.
3. Black RE,Morris SS,Bryce J. Where and why are 10 million children dying every year?
Lancet 2003;361:2226-34.
4. Caulfield LE,de Onis M, Blossner M, Black RE.Undernutrition as an underlying cause of
child deaths associated with diarrhea, pneumonia, malaria, and measles. Am J Clin
Nutr 2004;80:193-8.
5. Tanner JM. Foetus into man. 2nd. ed. Herts: Castlemeads Publications, 1989.
6. FAO. The State of Food Insecurity in the World 2006. Rome: FAO, 2006:1-42.
7. McGregor lA. Growth and Mortality in Children in an African Village. British Medical
Journal 1961;2:1661-1666.
8. Lunn PG. The impact of Infection and nutrition on gut function and growth in
childhood. Proc Nutr Soc 2000;59:147-54.
9. Campbell 01, Elia M, Lunn PG. Growth faltering in rural Gambian infants is associated
with Impaired small intestinal barrier function, leading to endotoxemia and systemic
inflammation. J Nutr 2003;133:1332-8.
10. Hamill PV, Drlzd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth:
National Center for Health Statistics percentiles. Am JClin Nutr 1979;32:607-29.
11. Freeman JV, Cole TJ, Chinn 5, Jones PR,White EM, Preece MA. Cross sectional stature
and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17-24.
12. Collinson A, Moore 5, O'Connell M, Charalambos C, Prentice A. Developmental changes
In leptin as a measure of energy status in human infants In a natural ecologic setting.
Am J elin Nutr 2005;81:488-94.
13. Beaton GH, Ghassemi H. Supplementary feeding programs for young children in
developing countries. Am Jelin Nutr 1982;35:863-916.
14. Hoare 5, Poppitt SO, Prentice AM, Weaver LT. Dietary supplementation and rapid
catch-up growth after acute diarrhoea in childhood. Br J Nutr 1996;76:479-90.
239
Chapter 5: Overall discussion and conclusion
15. Sullivan PB, Mascie-Taylor CG, Lunn PG, Northrop-Clewes CA, Neale G. The treatment
of persistent diarrhoea and malnutrition: long-term effects of in-patient rehabilitation.
Acta Paediatr Scand 1991;80:1025-30.
16. Sullivan PB, Lunn PG, Northrop-Clewes C, Crowe PT, Marsh MN, Neale G. Persistent
diarrhea and malnutrition--the impact of treatment on small bowel structure and
permeability. J Pediatr Gastroenterol Nutr 1992;14:208-15.
17. Schroeder DG, Brown KH. Nutritional status as a predictor of child survival:
summarizing the association and quantifying its global impact. Bull World Health
Organ 1994;72:569-79.
18. Prentice A. Nutrient requirements for growth, pregnancy and lactation: the Keneba
experience. South African Journal of Clinical Nutrition 1993;6:33-38.
19. Lunn PG. Growth retardation and stunting of children in developing countries. Br J
Nutr 2002;88:109-10.
20. Scrimshaw NS, Taylor CE,Gordon JE. Interactions of nutrition and infection. Am J Med
Sci 1959;237:367-403.
21. Mata L. Diarrheal disease as a cause of malnutrition. Am J Trop Med Hyg
1992;47:16-27.
22. Rowland MG, Cole TJ, Whitehead RG.A quantitative study into the role of infection in
determining nutritional status in Gambian village children. Br J Nutr 1977;37:441-50.
23. Rowland MG, Rowland SG,Cole TJ. Impact of infection on the growth of children from
o to 2 years In an urban West African community. Am JClin Nutr 1988;47:134-8.
24. Bhan MJ, Bahl R., Bhandari N. Infection: how important are its effects on child
nutrition and growth? In: Atorell R. HF, ed. Nutrition and Growth. Philadelphia: JB
Lippincott Company, 2001.
25. Brlend A, Hasan KZ, Azlz KM, Hoque BA. Are diarrhoea control programmes likely to
reduce childhood malnutrition? Observations from rural Bangladesh. Lancet
1989;2:319-22.
26. Poskltt EM, Cole TJ,Whitehead RG. Lessdiarrhoea but no change in growth: 15 years'
data from three Gambian villages. Arch Dis Child 1999;80:115-9; discussion 119-20.
27. Stephensen CB.Burden of infection on growth failure. J Nutr 1999;129:534S-538S.
240
Chapter 5: Overall discussion and conclusion
28. Keusch GT. The history of nutrition: malnutrition, infection and immunity. J Nutr
2003;133:3365-3405.
29. Brown KH, lanata CF, Vuen Ml, Peerson JM, Butron B, lonnerdal B. Potential
magnitude of the misclassification of a population's trace element status due to
infection: example from a survey of young Peruvian children. Am J Clin Nutr
1993;58:549-54.
30. lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability, mucosal injury,
and growth faltering in Gambian infants. lancet 1991;338:907-10.
31. Behrens RH, Lunn PG,Northrop CA, Hanlon PW, Neale G. Factors affecting the integrity
of the intestinal mucosa of Gambian children. Am JClin Nutr 1987;45:1433-41.
32. Sprinz H, Sribhibhadh R, Gangarosa EJ, Benyajati C, Kundel 0, Halstead 5. Biopsy of
small bowel of Thai people. With special reference to recovery from Asiatic cholera
and to an intestinal malabsorption syndrome. Am JClin Pathoi 1962;38:43-51.
33. Mathan VI. Tropical sprue. Springer Semin ImmunopathoI1990;12:231-7.
34. Thomas G, Clain OJ,Wicks AC. Tropical enteropathy in Rhodesia. Gut 1976;17:888-94.
35. Brusner 0, Araya, M., Espinoza, J., Figuaeroa, G., Pacheco, J.I., Lois I. Chronic
environmental enteropathy in a temperate climate. Hum Nutr Clin Nutr
1987;41:251-61.
36. Veitch AM, Kelly P, Zulu IS, Segal I, Farthing MJ. Tropical enteropathy: a
T-cell-medlated crypt hyperplastic enteropathy. Eur J Gastroenterol Hepatol
2001;13:1175-81.
37. Goto R, Panter-Brick C, Northrop-Clewes CA, Manahdhar R, Tuladhar NR. Poor
intestinal permeability in mildly stunted Nepali children: "associations with weaning
practices and Giardia lamblia infection. Br J Nutr 2002;88:141-9.
38. Goto K, Chew F, Torun B, Peerson JM, Brown KH. Epidemiology of altered intestinal
permeability to lactulose and mannitol in Guatemalan infants. J Pediatr Gastroenterol
Nutr 1999;28:282-90.
39. Lunn PG, Northrop-Clewes CA, Downes RM. Recent developments in the nutritional
management of diarrhoea. 2. Chronic diarrhoea and malnutrition in The Gambia:
studies on intestinal permeability. Trans RSocTrap Med Hyg 1991;85:8-11.
241
Chapter 5: Overall discussion and conclusion
40. Juby lD, Rothwell J, Axon AT. lactulose/mannitol test: an ideal screen for celiac
disease. Gastroenterology 1989;96:79-85.
41. Schenk EA, Klipstein FA. Tropical jejunitis (tropical enteropathy). A protocol for the
evaluation of small bowel biopsies. Am J Clin Nutr 1972;25:1108-17.
42. Kelly P, Menzies I, Crane R, et al. Responses of small intestinal architecture and
function over time to environmental factors in a tropical population. Am J Trop Med
Hyg 2004;70:412-9.
43. labenthal E. Prolonged small intestinal mucosal injury as a primary cause of intractable
diarrhoea of infancy. In: labenthal E, ed. Chronic diarrhea in children. New York: Raven
Press, 1986:5-29.
44. Menzies IS, Zuckerman MJ, Nukajam WS, et al. Geography of intestinal permeability
and absorption. Gut 1999;44:483-9.
45. Salazar-lindo E, Allen 5, Brewster DR, et al. Intestinal infections and environmental
enteropathy: Working Group report of the second World Congress of Pediatric
Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004;39
Suppl 2:5662-9.
46. Northrop-Clewes CA, Lunn PG, Downes RM. Lactose maldigestion in breast-feeding
Gambian Infants. J Pedlatr Gastroenterol Nutr 1997;24:257-63.
47. Baker 5J. Subclinical Intestinal malabsorption in developing countries. Bull World
Health Organ 1976;54:485-94.
48. Russell RK, Wilson DC, Satsangl J. Unravelling the complex genetics of inflammatory
bowel disease. Arch Dis Child 2004;89:598-603.
49. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunoblology.
lancet 2007;369:1627-40.
50. Flocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology
1998;115:182-205.
51. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and
development. Am JClin Nutr 1991;54:438-63.
52. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic,
docosapentaenolc and docosahexaenoic acids in young women. Br J Nutr
2002;88:411-20.
242
Chapter 5: Overall discussion and conclusion
53. Burdge GC, Calder PC. Conversion of alpha-linolenic acid to longer-chain
polyunsaturated fatty acids in human adults. Reprod Nutr Oev 2005;45:581-97.
54. Sanders TA, Reddy S. The influence of a vegetarian diet on the fatty acid composition
of human milk and the essential fatty acid status of the infant. J Pediatr
1992;120:S71-7.
55. Birch EE,Hoffman DR, Uauy R, Birch DG, Prestidge C. Visual acuity and the essentiality
of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res
1998;44:201-9.
56. Putnam JC,Carlson SE,DeVoe PW, Barness LA. The effect of variations in dietary fatty
acids on the fatty acid composition of erythrocyte phosphatidylcholine and
phosphatidylethanolamine in human infants. Am J Clin Nutr 1982;36:106-14.
57. Uauy R, Hoffman DR, Birch EE, Birch DG, Jameson OM, Tyson J. Safety and efficacy of
omega-3 fatty acids in the nutrition of very low birth weight infants: soy oil and marine
oil supplementation of formula. J Pediatr 1994;124:612-20.
58. Leonard AE, Bobik EG, Dorado J, et al. Cloning of a human cDNA encoding a novel
enzyme involved in the elongation of long-chain polyunsaturated fatty acids. Biochem
J 2000;350 Pt 3:765-70.
59. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat
from the diet. The Journal of Biological Chemistry 1929;82:345-367.
60. Burr GO, Burr MM. The nature and role of the fatty acids essential in nutrition. The
Journal of Biological Chemistry 1930;86:587-621.
61. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in
Greenland Eskimos. Am J Clln Nutr 1975;28:958-66.
62. Bang HO, Oyerberg J, Hjoorne N. The composition of food consumed by Greenland
Eskimos. Acta Med Scand 1976;200:69-73.
63. Bang HO, Oyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos.
Acta Med Scand 1972;192:85-94.
64. Oyerberg J, Bang HO, Stoffersen E, Moncada 5, Vane JR. Eicosapentaenoic acid and
prevention ofthrombosls and atherosclerosis? Lancet 1978;2:117-9.
65. Oyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in
Eskimos. Lancet 1979;2:433-5.
243
Chapter 5: Overall discussion and conclusion
66. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of
cell-cell interactions. Semln HematoI1994;31:261-9.
67. Yaqoob P. Fatty acids and the immune system: from basic science to clinical
applications. Proc Nutr Soc 2004;63:89-104.
68. Higgs GA, Moncada 5, Vane JR. Eicosanoids in inflammation. Ann Clin Res
1984;16:287-99.
69. Khanapure SP, Garvey OS, Janero DR, Letts LG. Eicosanoids in inflammation:
biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem
2007;7:311-40.
70. Muskiet FA, Fokkema MR, Schaafsma A, Boersma ER, Crawford MA. Is
doccsahexaenolc acid (DHA) essential? Lessons from DHA status regulation, our
ancient diet, epidemiology and randomized controlled trials. J Nutr 2004;134:183-6.
71. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc
2002;61:345-58.
72. Decsi T, Koletzko B. Polyunsaturated fatty acids in infant nutrition. Acta Paediatr Suppl
1994;83:31-7.
73. Broughton KS, Whelan J, Hardardottir I, Kinsella JE. Effect of increasing the dietary
(n-3) to (n-6) polyunsaturated fatty acid ratio on murine liver and peritoneal cell fatty
acids and eicosanoid formation. J Nutr 1991;121:155-64.
74. 51mopoulos AP, Leaf A, Salem N, Jr. Workshop statement on the essentiality of and
recommended dietary Intakes for Omega-6 and Omega-3 fatty acids. Prostaglandins
Leukot Essent Fatty Acids 2000;63:119-21.
75. 51mopoulos AP. Importance of the ratio of omega-6/omega-3 essential fatty acids:
evolutionary aspects. World Rev Nutr Diet 2003;92:1-22.
76. Hlbbeln JR, Nlemlnen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and
n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr
2006;83:14835-14935.
77. Goyens PL, Spilker ME, Zock Pl, Katan MB, Mensink RP. Conversion of alpha-linolenic
acid In humans Is Influenced by the absolute amounts of alpha-linolenic acid and
linoleic acid In the diet and not by their ratio. Am JClin Nutr 2006;84:44-53.
244
Chapter 5: Overall discussion and conclusion
78. FAO/WHO. Fats and oils in human nutrition: report of a joint expert consultation. FAO
Food and Nutrition Papers. Rome: Food and Agricultural Organisation, FAO 1994.
79. Uauy RD, Birch DG, Birch EE, Tyson JE, Hoffman DR. Effect of dietary omega-3 fatty
acids on retinal function of very-Iow-birth-weight neonates. Pediatr Res
1990;28:485-92.
80. Carlson SE,Werkman SH, Rhodes PG, Tolley EA. Visual-acuity development in healthy
preterm infants: effect of marine-oil supplementation. Am JClin Nutr 1993;58:35-42.
81. Makrides M, Neumann M, Simmer K, Pater J, Gibson R.Are long-chain polyunsaturated
fatty acids essential nutrients in infancy? Lancet 1995;345:1463-8.
82. Uauy R, Mena P,Wegher B, Nieto 5, Salem N, Jr. Long chain polyunsaturated fatty acid
formation in neonates: effect of gestational age and intrauterine growth. Pediatr Res
2000;47:127-35.
83. Muskiet FA, van Goor SA, Kuipers RS,et al. Long-chain polyunsaturated fatty acids in
maternal and infant nutrition. Prostaglandins Leukot Essent Fatty Acids
2006;75:135-44.
84. Larque E, Demmelmair H, Koletzko B. Perinatal supply and metabolism of long-chain
polyunsaturated fatty acids: importance for the early development of the nervous
system. Ann N V Aead Sci 2002;967:299-310.
85. Mata U, Urrutia JJ, Lechtig A. Infection and nutrition of children of a low
socioeconomic rural community. Am J Clin Nutr 1971;24:249-59.
86. Xiang M, Lei 5, Li T, Zetterstrom R. Composition of long chain polyunsaturated fatty
acids In human milk and growth of young infants in rural areas of northern China. Acta
Paedlatr 1999;88:126-31.
87. Ghafoorunlssa. Fats In Indian diets and their nutritional and health implications. Lipids
1996;31Suppl:S287-91.
88. Prentice AM, Paul, A.A. Fat and energy needs of children in developing countries. Am J
Clln Nutr 2OOO;72:1253S-1265S.
89. Holman RT, Johnson SB,Ogburn Pl, Deficiency of essential fatty acids and membrane
fluidity during pregnancy and lactation. Proc Natl Acad Sci USA 1991;88:4835-9.
90. AI MD, van Houwellngen AC, Hornstra G. Relation between birth order and the
maternal and neonatal docosahexaenoic acid status. Eur JClin Nutr 1997;51:548-53.
245
Chapter 5: Overall discussion and conclusion
91. van den Ham EC,van Houwelingen AC, Hornstra G. Evaluation of the relation between
n-3 and n-6 fatty acid status and parity in nonpregnant women from the Netherlands.
Am J Clin Nutr 2001;73:622-7.
92. Fagundes-Neto U, Viaro T, Wehba J, Patricio FR, Machado Nl. Tropical enteropathy
(environmental enteropathy) in early childhood: a syndrome caused by contaminated
environment. J Trop Pediatr 1984;30:204-9.
93. Arab L, Akbar J. Biomarkers and the measurement of fatty acids. Public Health Nutr
2002;5:865-71.
94. Kohlmeier l. What you should know about your marker. In: Kok FJ,van't Veer, P., ed.
Biomarkers of Dietary Exposure. London: Smith-Gordon, 1991.
95. Simopoulos AP, Kifer, R.R., Martin, R.E., ed. Health effects of polyunsaturated fatty
acids In seafoods. Orlando: Academic Press, 1986.
96. Walker Bl. Maternal diet and brain fatty acids in young rats. Lipids 1967;2:497-500.
97. Connor WE, Neuringer M, Reisbick S. Essentiality of omega 3 fatty acids: evidence from
the primate model and implications for human nutrition. World Rev Nutr Diet
1991;66:118-32.
98. Crawford MA, Sinclair, A.J., Msuya, P.M., et al. Structural lipids and their polyenoic
constituents in human milk. In: Galli C, Jacini, G., and Pecile, A., ed. Dietary Lipids and
postnatal development. New York: Raven Press, 1973.
99. Sanders TA, Naismith OJ. Long-chain polyunsaturated fatty acids in the erythrocyte
lipids of breast-fed and bottle-fed infants [proceedings]. Proc Nutr Soc
1976;35:63A-65A.
100. Simmer K, Patole SK,Rao SC.Longchain polyunsaturated fatty acid supplementation in
Infants born at term. Cochrane Database Syst Rev 2008:C0000376.
101. Makrides M, Gibson RA, Udell T, Ried K. Supplementation of infant formula with
long-chain polyunsaturated fatty acids does not influence the growth of term infants.
Am J Clin Nutr 2005;81:1094-101.
102. Makrides M, Neumann MA, Simmer K, Gibson RA. A critical appraisal of the role of
dietary long-chain polyunsaturated fatty acids on neural indices of term infants: a
randomized, controlled trial. Pediatrics 2000;105:32-8.
246
Chapter 5: Overall discussion and conclusion
103. Makrides M, Neumann MA, Simmer K, Gibson RA. Dietary long-chain polyunsaturated
fatty acids do not influence growth of term infants: A randomized clinical trial.
Pediatrics 1999;104:468-75.
104. Auestad N, Halter R, Hall RT, et al. Growth and development in term infants fed
long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel,
prospective, multivariate study. Pediatrics 2001;108:372-81.
105. Auestad N, Montalto MB, Hall RT, et al. Visual acuity, erythrocyte fatty acid
composition, and growth in term infants fed formulas with long chain polyunsaturated
fatty acids for one year. RossPediatric Lipid Study. Pediatr Res 1997;41:1-10.
106. Auestad N, Scott OT,Janowsky JS,et al. Visual, cognitive, and language assessments at
39 months: a follow-up study of children fed formulas containing long-chain
polyunsaturated fatty acids to 1 year of age. Pediatrics 2003;112:el77-83.
107. Morris G, Moorcraft J, Mountjoy A, Wells JC. A novel infant formula milk with added
long-chain polyunsaturated fatty acids from single-cell sources: a study of growth,
satisfaction and health. Eur J Clin Nutr 2000;54:883-6.
108. Birch EE,Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of
early dietary supply of long-chain polyunsaturated fatty acids and mental development
in term infants. Dev Med Child NeuroI2000;42:174-81.
109. Birch EE, Castaneda VS, Wheaton OH, Birch OG, Uauy RD, Hoffman DR. Visual
maturation of term infants fed long-chain polyunsaturated fatty acid-supplemented or
control formula for 12 mo. Am J CUnNutr 2005;81:871-9.
110. Ben XM, Zhou XV, Zhao WH, et al. Growth and development of term infants fed with
milk with long-chain polyunsaturated fatty acid supplementation. Chin Med J (Engl)
2004;117:1268-70.
111. Agostonl C, Riva E, Bellu R, Trojan S, luotti 0, Giovannini M. Effects of diet on the Upid
and fatty acid status of full-term infants at 4 months. J Am Call Nutr 1994;13:658-64.
112. Asostoni C, Riva E, Scaglioni S, Marangoni F, Radaelli G, Giovannini M. Dietary fats and
cholesterol in Italian infants and children. Am JClin Nutr 2000;72:1384S-1391S.
113. lucas A, Stafford M, Morley R, et al. Efficacy and safety of long-chain polyunsaturated
fatty acid supplementation of infant-formula milk: a randomised trial. lancet
1999;354:1948-54.
247
Chapter 5: Overall discussion and conclusion
114. lucas A, Morley R, Stephenson T, Elias-Jones A. long-chain polyunsaturated fatty acids
and infant formula. lancet 2002;360:1178.
115. Bouwstra H, Dijck-Brouwer DA, Boehm G, Boersma ER, Muskiet FA, Hadders-Algra M.
long-chain polyunsaturated fatty acids and neurological developmental outcome at 18
months in healthy term infants. Acta Paediatr 2005;94:26-32.
116. Simmer K, Schulzke SM, Patole S. longchain polyunsaturated fatty acid
supplementation in preterm infants. Cochrane Database Syst Rev 2008:CD000375.
117. Hansen J, Schade, D., Harris, C. Docosahexanoic acid plus arachidonic acid enhance
preterm infant growth. Prostaglandins leukot Essent Fatty Acids 1997;57 196A.
118. Innis SM, Adamkin OH, Hall RT, et al. Docosahexaenoic acid and arachidonic acid
enhance growth with no adverse effects in preterm infants fed formuia. J Pediatr
2002;140:547-54.
119. Fewtrell MS, Abbott RA, Kennedy K, et al. Randomized, double-blind trial of long-chain
polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm
infants. J Pediatr 2004;144:471-9.
120. Clandinin MT, Van Aerde JE, Parrott A, Field CJ, Euler AR, lien El. Assessment of the
efficacious dose of arachidonic and docosahexaenoic acids in preterm infant formulas:
fatty acid composition of erythrocyte membrane lipids. Pediatr Res 1997;42:819-25.
121. Carlson SE,Werkman SH,Tolley EA. Effect of long-chain n-3 fatty acid supplementation
on visual acuity and growth of preterm infants with and without bronchopulmonary
dysplasia. Am J Clin Nutr 1996;63:687-97.
122. Carlson SE,Werkman SH. A randomized trial of visual attention of preterm infants fed
docosahexaenoic acid until two months. lipids 1996;31:85-90.
123. Fewtrell MS, Morley R, Abbott RA, et al. Double-blind, randomized trial of long-chain
polyunsaturated fatty acid supplementation in formula fed to preterm infants.
Pediatrics 2002;110:73-82.
124. Faldella G, Govoni M, Alessandroni R, et al. Visual evoked potentials and dietary long
chain polyunsaturated fatty acids in preterm infants. Arch Dis Child Fetal Neonatal Ed
1996;75:F108-12.
248
Chapter 5: Overall discussion and conclusion
125. Vanderhoof J, Gross S, Hegyi T, et al. Evaluation of a long-chain polyunsaturated fatty
acid supplemented formula on growth, tolerance, and plasma lipids in preterm infants
up to 48 weeks postconceptional age. J Pediatr Gastroenterol Nutr 1999;29:318-26.
126. Clandinin MT, Van Aerde JE, Merkel KL, et al. Growth and development of preterm
infants fed infant formulas containing docosahexaenoic acid and arachidonic acid. J
Pediatr 2005;146:461-8.
127. O'Connor DL, Hall R,Adamkin D, et al. Growth and development in preterm infants fed
long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial.
Pediatrics 2001;108:359-71.
128. Groh-Wargo S, Jacobs J, Auestad N, O'Connor DL, Moore JJ, Lerner E. Body
composition in preterm infants who are fed long-chain polyunsaturated fatty acids: a
prospective, randomized, controlled trial. Pediatr Res 2005;57:712-8.
129. Decsi T, Koletzko B. Growth, fatty acid composition of plasma lipid classes, and plasma
retinol and alpha-tocopherol concentrations in full-term infants fed formula enriched
with omega-6 and omega-3 long-chain polyunsaturated fatty acids. Acta Paediatr
1995;84:725-32.
130. Lapillonne A, Brossard N, Claris 0, Reygrobellet B, Salle Bl. Erythrocyte fatty acid
composition in term infants fed human milk or a formula enriched with a low
elcosapentanoic acid fish oil for 4 months. Eur J Pediatr 2000;159:49-53.
131. Willatts P, Forsyth JS, DiModugno MK, Varma S, Colvin M. Influence of long-chain
polyunsaturated fatty acids on infant cognitive function. lipids 1998;33:973-80.
132. 5erhan CN, CUshCB, Brannon J, Colgan SP,Chiang N, Gronert K. Novel functional sets
of lipid-derived mediators with antIInflammatory actions generated from omega-3
fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular
processing. J ExpMed 2000;192:1197-204.
133. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of
omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter
prolnflammation signals. J ExpMed 2002;196:1025-37.
134. Hong 5, Gronert K, Devchand PR, Mousslgnac RL, Serhan CN. Novel docosatrienes and
175-resolvins generated from docosahexaenoic acid in murine brain, human blood,
and llial cells. Autacolds In anti-inflammation. J Bioi Chem 2003;278:14677-87.
249
Chapter 5: Overall discussion and conclusion
135. Marcheselli VL, Hong 5, Lukiw WJ, et al. Novel docosanoids inhibit brain
ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene
expression. J Bioi Chern 2003;278:43807-17.
136. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin 01: a
docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial
cells from oxidative stress. Proc Natl Acad Sci USA 2004;101:8491-6.
137. Endres 5, von Schacky C. n-3 polyunsaturated fatty acids and human cytokine
synthesis. Curr Opin LipidoI1996;7:48-52.
138. Endres 5, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3
polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor
by mononuclear cells. N Engl J Med 1989;320:265-71.
139. Lapillonne A, Clarke SO, Heird WC. Polyunsaturated fatty acids and gene expression.
Curr Opin Clin Nutr Metab Care 2004;7:151-6.
140. van den Berg R, Haenen GR, van den Berg H, Bast A. Transcription factor NF-kappaB as
a potential biomarker for oxidative stress. Br J Nutr 2001;86 SuppI1:5121-7.
141. Teitelbaum JE, Allan Walker W. Review: the role of omega 3 fatty acids in intestinal
inflammation. J Nutr Biochem 2001;12:21-32.
142. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis.
Semin Arthritis Rheum 1997;27:85-97.
143. Kremer JM. n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr
2000;71:3495-515.
144. Calder PC, Zurier RB. Polyunsaturated fatty acids and rheumatoid arthritis. Curr Opin
Clin Nutr Metab Care 2001;4:115-21.
145. Cleland LG, James MJ. Fish oil and rheumatoid arthritis: antiinflammatory and
collateral health benefits. J RheumatoI2000;27:2305-7.
146. Cawood AL, Carroll MP, Wootton SA, Calder PC. Is there a case for n-3 fatty acid
supplementation in cystic fibrosis? Curr Opln Clin Nutr Metab Care 2005;8:153-9.
147. Ziboh VA. The role of n-3 fatty acids in psoriasis. In: Kremer JM, ed. Medicinal Fatty
Acids in Inflammation. Basel: Birkhauser Verlag, 1998:45-53.
148. Calder PC. n-3 fatty acids, inflammation, and immunity--relevance to postsurgical and
critically III patients. Lipids 2004;39:1147-61.
250
Chapter 5: Overall discussion and conclusion
149. Belluzzi A. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr
Soc 2002;61:391-5.
150. Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty
acids and inflammatory bowel disease. Am JClin Nutr 2000;71:3395-425.
151. Calder PC.Polyunsaturated fatty acids and inflammation. Prostaglandins leukot Essent
Fatty Acids 2006;75:197-202.
152. Maclean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3
fatty acids in inflammatory bowel disease. Am JClin Nutr 2005;82:611-9.
153. Turner 0, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for
maintenance of remission in Crohn's disease. Cochrane Database Syst Rev
2oo9:CD006320.
154. De ley M, de Vos R, Hommes OW, Stokkers P. Fish oil for induction of remission in
ulcerative colitis. Cochrane Database Syst Rev 2007:CD005986.
155. Turner 0, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of
remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD006443.
156. Almallah VZ, Richardson S, O'Hanrahan T, et al. Distal procto-colitis, natural
cytotoxicity, and essential fatty acids. Am J GastroenteroI1998;93:804-9.
157. Asian A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative
colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol
1992;87:432-7.
158. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an
enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med
1996;334:1557-60.
159. Dichi I, Frenhane P, Dichi JB, et al. Comparison of omega-3 fatty acids and sulfasalazine
in ulcerative colitis. Nutrition 2000;16:87-90.
160. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the
maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.
Jama 2008;299:1690-7.
161. Greenfield SM, Green AT, Teare JP, et al. A randomized controlled study of evening
primrose oil and fish 011 in ulcerative colitis. Aliment Pharrnacol Ther 1993;7:159-66.
251
Chapter 5: Overall discussion and conclusion
162. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with
fish oil supplementation: a prospective 12 month randomised controlled trial. Gut
1992;33:922-8.
163. loeschke K, Ueberschaer B, Pietsch A, et al. n-3 fatty acids only delay early relapse of
ulcerative colitis in remission. Dig Dis Sci 1996;41:2087-94.
164. lorenz R, Weber PC,Szimnau P, Heldwein W, Strasser T, loeschke K. Supplementation
with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized,
placebo-controlled, double-blind cross-over trial. J Intern Med SuppI1989;731:225-32.
165. lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate
diet for maintenance of remission in Crohn's disease. A randomized controlled
multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scand
JGastroenteroI1996;31:778-85.
166. Mantzarls GJ, Archavlis, E., Zografos, C., Petraki, K., Spiliades, C., Triantafyllou, G. A
prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis.
Hellenic Journal of Gastroenterology 1996;9:138-41.
167. Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-blind, randomized,
placebo-controlled trial of essential fatty acid supplementation in the maintenance of
remission of ulcerative colitis. Aliment Pharmacol Ther 2002;16:1131-5.
168. Romano C, Cucchiara 5, Barabino A, Annese V, Sferlazzas C. Usefulness of omega-s
fatty acid supplementation in addition to mesalazine in maintaining remission in
pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.
World J GastroenteroI2005;11:7118-21.
169. Stenson WF, Cort 0, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative
colitis. Ann Intern Med 1992;116:609-14.
170. Malcolm CA, McCulloch Ol, Montgomery C, Shepherd A, Weaver l T. Maternal
docosahexaenoic acid supplementation during pregnancy and visual evoked potential
development in term infants: a double blind, prospective, randomised trial. Arch Dis
Child Fetal Neonatal Ed 2003;88:F383-90.
171. Lauritzen l, Jorgensen MH, Mikkelsen TB, et al. Maternal fish oil supplementation in
lactation: effect on visual acuity and n-3 fatty acid content of infant erythrocytes.
lipids 2004;39:195-206.
252
Chapter 5: Overall discussion and conclusion
172. Helland IB, Saugstad OD, Smith L, et al. Similar effects on infants of n-3 and n-6 fatty
acids supplementation to pregnant and lactating women. Pediatrics 2001;108:E82.
173. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation
with very-long-chain n-3 fatty acids during pregnancy and lactation augments
children's IQ at 4 years of age. Pediatrics 2003;111:e39-44.
174. Innis SM, Gilley J, Werker J. Are human milk long-chain polyunsaturated fatty acids
related to visual and neural development in breast-fed term infants? J Pediatr
2001;139:532-8.
175. Bazan NG. The supply of omega-3 polyunsaturated fatty acids to photoreceptors and
synapses. In: Galli C, Simopoulos, A.P., ed. Dietary w3 and w6 fatty acids: biological
effects and nutritional essentiality. New York: Plenum Press, 1989:227-40.
176. Martinez M. Dietary polyunsaturated fatty acids in relation to neural development in
humans. In: Galli C, Simopoulos, A.P., ed. Dietary w3 and w6 fatty acids: biological
effects and nutritional essentiality. New York: Plenum Press, 1989:123-33.
177. Reynolds A. Breastfeeding and brain development. Pediatr Clin North Am
2001;48:159-71.
178. Lucas A, Morley R, Isaacs E. Nutrition and mental development. Nutr Rev
2001;59:S24-32; discussion S32-3.
179. Anderson JW, Johnstone BM, Remley DT. Breast-feeding and cognitive development: a
meta-analysis. Am J Clln Nutr 1999;70:525-35.
180. Jain A, Concato J, Leventhal JM. How good is the evidence linking breastfeeding and
intelligence? Pediatrics 2002;109:1044-53.
181. Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE. Essential fatty acids in visual and
brain development. lipids 2001;36:885-95.
182. Willatts P. Development of means-end behavior in young infants: pulling a support to
retrieve a distant object. Dev PsychoI1999;35:651-67.
183. Wlilatts P. Development of problem solving in Infancy. In: Slater A, Bremner, J.G., ed.
Infant Development. London: Erlbaum, 1989:143-182.
184. Birch EE, Birch DG, Hoffman DR, Uauy R. Dietary essential fatty acid supply and visual
acuity development. Invest Ophthalmol Vis Sci 1992;33:3242-53.
253
Chapter 5: Overall discussion and conclusion
185. Birch DG, Birch EE, Hoffman DR, Uauy RD. Retinal development in
very-Iow-birth-weight infants fed diets differing in omega-3 fatty acids. Invest
Ophthalmol Vis Sci 1992;33:2365-76.
186. Carlson SE,Werkman SH, Peeples JM, Wilson WM, 3rd. Growth and development of
premature infants in relation to omega 3 and omega 6 fatty acid status. World Rev
Nutr Diet 1994;75:63-9.
187. Werkman SH, Carlson SE.A randomized trial of visual attention of preterm infants fed
docosahexaenoic acid until nine months. Lipids 1996;31:91-7.
188. Carlson SE, Ford AJ, Werkman SH, Peeples JM, Koo WW. Visual acuity and fatty acid
status of term infants fed human milk and formulas with and without
docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res
1996;39:882-8.
189. Horby Jorgensen M, Holmer G, Lund P, Hernell 0, Michaelsen KF. Effect of formula
supplemented with docosahexaenoic acid and gamma-linolenic acid on fatty acid
status and visual acuity In term infants. J Pediatr Gastroenterol Nutr 1998;26:412-21.
190. Scott DT, Janowsky JS, Carroll RE, Taylor JA, Auestad N, Montalto MB. Formula
supplementation with long-chain polyunsaturated fatty acids: are there developmental
benefits? Pediatrics 1998;102:E59.
191. Agostonl C, Trojan S, Bellu R, Rlva E, Giovannini M. Neurodevelopmental quotient of
healthy term infants at 4 months and feeding practice: the role of long-chain
polyunsaturated fatty acids. Pediatr Res 1995;38:262-6.
192. Agostonl C, Trojan S, Bellu R, Riva E, Bruzzese MG, Giovannini M. Developmental
quotient at 24 months and fatty acid composition of diet in early infancy: a follow up
study. Arch Dis Child 1997;76:421-4.
193. Gibson RA, Neumann MA, Makrides M. Effect of increasing breast milk
docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural
indices of exclusively breast fed infants. Eur J Clin Nutr 1997;51:578-84.
194. Forsyth JS, Willatts P, DiModogno MK, Varma S, Colvin M. Do long-chain
polyunsaturated fatty acids influence infant cognitive behaviour? Biochem Soc Trans
1998;26:252-7.
254
Chapter 5: Overall discussion and conclusion
195. Willatts P, Forsyth JS, DiModugno MK, Varma 5, Colvin M. Effect of long-chain
polyunsaturated fatty acids in infant formula on problem solving at 10 months of age.
lancet 1998;352:688-91.
196. Slater A. Individual differences in infancy and later IQ. J Child Psychol Psychiatry
1995;36:69-112.
197. Gibson RA. Long-chain polyunsaturated fatty acids and infant development. Lancet
1999;354:1919-20.
198. Simmer K. longchain polyunsaturated fatty acid supplementation in infants born at
term. Cochrane Database Svst Rev 2001:CD000376.
199. Janowsky JS, Scott, D.T., Wheeler, R.E., Auestad, N. Fatty acids affect early language
development. Pediatr Res 1995;41:310(abstr.).
200. Makrldes M, Neumann MA, Gibson RA. Effect of maternal docosahexaenoic acid (DHA)
supplementation on breast milk composition. Eur J Clin Nutr 1996;50:352-7.
201. Clausen V, Damli, A., Schenck, U.V., Koletzko, B. Infuence of longchain polyunsaturated
fatty acids (LCPUFA)on early visual acuity and mental development of term infants.
Barcelona, 1996.
202. Salem N, Jr., Moriguchi T, Greiner RS,et al. Alterations in brain function after loss of
docosahexaenoate due to dietary restriction of n-3 fatty acids. J Mol Neurosci
2001;16:299-307; discussion 317-21.
203. Clements KM, Girard TA, Xing HC, Wainwright PE. Spontaneously hypertensive and
Wistar Kyoto rats differ in delayed matching-to-place performance and response to
dietary 10nB-chaln polyunsaturated fatty acids. Dev PsychobioI2003;43:57-69.
204. Gamoh 5, Hashimoto M, Hossain 5, Masumura S. Chronic administration of
docosahexaenolc acid improves the performance of radial arm maze task in aged rats.
Clin Exp Pharmacol PhysloI2oo1;28:266-70.
205. Gamoh 5, Hashimoto M, SUBloka K, et al. Chronic administration of docosahexaenoic
acid improves reference memory-related learning ability in young rats. Neuroscience
1999;93:237-41.
206. Morlguchi T, Greiner RS, Salem N, Jr. Behavioral deficits associated with dietary
Induction of decreased brain docosahexaenolc acid concentration. J Neurochem
2000;75:2563-73.
255
Chapter 5: Overall discussion and conclusion
207. Moriguchi T, Salem N, Jr. Recovery of brain docosahexaenoate leads to recovery of
spatial task performance. J Neurochem 2003;87:297-309.
208. Colombo J, Kannass KN, Shaddy DJ, et al. Maternal DHA and the development of
attention in infancy and toddlerhood. Child Dev 2004;75:1254-67.
209. Reisbick S, Neuringer M, Gohl E, Wald R, Anderson GJ. Visual attention in infant
monkeys: effects of dietary fatty acids and age. Dev PsychoI1997;33:387-95.
210. Kupfermann I. Neurophysiology of learning. Annu Rev PsychoI1975;26:367-91.
211. Wiggins RC. Myelin development and nutritional insufficiency. Brain Res
1982;257:151-75.
212. Willatts P. Beyond the "couch potato" infant: how infants use their knowledge to
regulate action, solve problems, and achieve goals. In: Bremmer JG, Slater, A.,
Butterworth, G., ed. Infant development: recent advances. Hove, UK: Psychology
Press, 1997:109 -35.
213. Brown Jl, Pollitt E. Malnutrition, poverty and intellectual development. Sci Am
1996;274:38-43.
214. Whaley SE, Sigman M, Espinosa MP, Neumann CG. Infant predictors of cognitive
development in an undernourished Kenyan population. J Dev Behav Pediatr
1998;19:169-77.
215. Mendez MA, Adair lS. Severity and timing of stunting in the first two years of life affect
performance on cognitive tests in late childhood. J Nutr 1999;129:1555-62.
216. Powell CA, Walker SP, Himes JH, Fletcher PO, Grantham-McGregor SM. Relationships
between physical growth, mental development and nutritional supplementation in
stunted children: the Jamaican study. Acta Paediatr 1995;84:22-9.
217. MacDonald TT, Spencer J. Evidence that activated mucosal T cells playa role in the
pathogenesis of enteropathy In human small intestine. J Exp Med 1988;167:1341-9.
218. lundberg JO, Hellstrom PM, Fagerhol MK, Weitzberg E, Roseth AG. Technology insight:
calprotectln, lactoferrin and nitric oxide as novel markers of inflammatory bowel
disease. Nat Clln Pract Gastroenterol HepatoI2005;2:96-102.
219. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the
assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther
2002;16:675-81.
256
Chapter 5: Overall discussion and conclusion
220. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of
indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in
patients with inflammatory bowel disease. Scand JGastroenteroI1999;34:50-4.
221. Travis S, Menzies r. Intestinal permeability: functional assessment and significance. Clin
Sci (lond) 1992;82:471-88.
222. Buller H, Chin 5, Kirschner B, et al. Inflammatory bowel disease in children and
adolescents: Working Group Report of the First World Congress of Pediatric
Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2002;35
SuppI2:S151-8.
223. Hudert CA,Weylandt KH, lu V, et al. Transgenic mice rich in endogenous omega-3 fatty
acids are protected from colitis. Proc Natl Acad Sci USA 2006;103:11276-81.
224. Nieto N, Fernandez MI, Torres MI, Rios A, Suarez MD, Gil A. Dietary monounsaturated
n-3 and n-6 long-chain polyunsaturated fatty acids affect cellular antioxidant defense
system in rats with experimental ulcerative colitis induced by trinitrobenzene sulfonic
acid. Dig Dis Sci 1998;43:2676-87.
225. Gunther M. Diet and milk secretion in women. Proc Nutr Soc 1968;27:77-82.
226. Hall B. Uniformity of human milk. Am J Clin Nutr 1979;32:304-12.
227. Neville MC, Keller RP, Seacat J, Casey CE, Allen JC, Archer P. Studies on human
lactation. r. Within-feed and between-breast variation in selected components of
human milk. Am J Clin Nutr 1984;40:635-46.
228. Koletzko B, Mrotzek, M., Bremer, H.J. Fat Content and cis- and trans-Isomeric Fatty
Acids In Human Fore- and Hindmilk. Hum. lactation Maternal Environ. Factors
1986;2 :589-594.
229. Daly SE, Di Rosso A, Owens RA, Hartmann PE. Degree of breast emptying explains
changes in the fat content, but not fatty acid composition, of human milk. Exp Physiol
1993;78:741-55.
230. Emery WB, 3rd, Canolty Nl, Aitchison JM, Dunkley Wl. Influence of sampling on fatty
acid composition of human milk. Am JClin Nutr 1978;31:1127-30.
231. WHO multicentre growth reference study group. WHO child growth standards:
length/height-for-age, weight-for-age, weight-for-Iength, weight-far-height and body
257
Chapter 5: Overall discussion and conclusion
mass index for-age: methods and development. Geneva: World Health Organization,
2006.
232. WHO multicentre growth reference study group. WHO child growth standards. Acta
Paediatrica Supplement 2006;95:1-104.
233. Behrens RH, Docherty H, Elia M, Neale G. A simple enzymatic method for the assay of
urinary lactulose. Clin Chim Acta 1984;137:361-7.
234. Lunn PG, Northrop CA, Northrop AJ. Automated enzymatic assays for the
determination of intestinal permeability probes in urine. 2. Mannitol. Clin Chim Acta
1989;183:163-70.
235. Lunn PG, Northrop-Clewes CA. Intestinal permeability: update on the enzymatic assay
of mannitol. Clin Chim Acta 1992;205:151-2.
236. Northrop CA, lunn PG, Behrens RH. Automated enzymatic assays for the
determination of intestinal permeability probes in urine. 1. Lactulose and lactose. Clin
Chim Acta 1990;187:79-87.
237. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification
of total lip ides from animal tissues. J Bioi Chem 1957;226:497-509.
238. Colombo J. Recent advances in infant cognition: implications for long-chain
polyunsaturated fatty acid supplementation studies. lipids 2001;36:919-26.
239. Gardner JM, Walker SP, Powell CA, Grantham-McGregor S. A randomized controlled
trial of a home-visiting intervention on cognition and behavior in term low birth weight
infants. J Pedlatr 2003;143:634-9.
240. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest
2003;111:1805-12.
241. Fournier T, MedJoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta
2000;1482:157-71.
242. Carter P. Ultramicroestimation of human serum albumin: binding cationic dye
5,5'dibromo-o cresolsulfonphthalein. Mlcrochem. J. 1970;15:531-539.
243. Louderback A, Measley, E.H., Taylor, N.A. A new dye-binder technic using bromocresol
purple for determination of albumin in serum. Clinical Chemistry 1968;14:793-794.
258
Chapter 5: Overall discussion and conclusion
244. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil
dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol
1992;27:793-8.
245. limburg PJ,Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal
inflammation among patients with chronic diarrhea referred for colonoscopy. Am J
GastroenteroI2000;95:2831-7.
246. Johne B, Kronborg 0, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for
colorectal neoplasia. Clinical results and comparison with previous method. Scand J
GastroenteroI2001;36:291-6.
247. Andert SE, Muller MM. Neopterin: biochemistry and clinical usefulness. J Int Fed Clin
Chem 1995;7:70-6.
248. Jacobson Jl, Jacobson SW, Muckle G, Kaplan-Estrin M, Ayotte P, Dewailly E. Beneficial
effects of a polyunsaturated fatty acid on infant development: evidence from the inuit
of arctic Quebec. J Pediatr 2008;152:356-64.
249. Carlson SE. Docosahexaenoic acid supplementation in pregnancy and lactation. Am J
Clin Nutr 2009;89:6785-845.
250. Koo WW. Efficacy and safety of docosahexaenoic acid and arachidonic acid addition to
Infant formulas: can one buy better vision and intelligence? J Am Coli Nutr
2003;22:101-7.
251. Trumbo P, Schlicker 5, Yates AA, Poos M. Dietary reference intakes for energy,
carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet
Assoc 2002;102:1621-30.
252. Knapp HR. Dietary fatty acids In human thrombosis and hemostasis. Am J Clin Nutr
1997;65:16875-16985.
253. Wheeler OH. Peroxide formation as a measure of autoxidative deterioration. Journal of
the American Oil Chemists' Society 1932;9:89-97.
254. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. lancet
1990;335:149-53.
255. Pocock SJ, Assmann SE, Enos lE, Kasten lE. Subgroup analysis, covariate adjustment
and baseline comparisons in clinical trial reporting: current practice and problems. Stat
Med 2002;21:2917-30.
259
Chapter 5: Overall discussion and conclusion
256. Schulz KF, Chalmers I, Grimes OA, Altman OG. Assessing the quality of randomization
from reports of controlled trials published in obstetrics and gynecology journals. Jama
1994;272:125-8.
257. Senn S.Testing for baseline balance in clinical trials. Stat Med 1994;13:1715-26.
258. Oarboe MK, Thurnham 01, Morgan G, et al. Effectiveness of an early supplementation
scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers
and infants: a randomised controlled trial. Lancet 2007;369:2088-96.
259. Williams EA, Elia M, Lunn PG. A double-blind, placebo-controlled,
glutamine-supplementation trial in growth-faltering Gambian infants. Am J Clin Nutr
2007;86:421-7.
260. Weaver LT. The impact of milk and weaning diet on gastrointestinal permeability in
English and Gambian infants. Trans RSocTrop Med Hyg 1988;82:784-9.
261. Ford RP, Menzies IS, Phillips AD, Walker-Smith JA, Turner MW. Intestinal sugar
permeability: relationship to diarrhoeal disease and small bowel morphology. J Pediatr
Gastroenterol Nutr 1985;4:568-74.
262. Pearson AD, Eastham EJ, Laker MF, Craft AW, Nelson R. Intestinal permeability in
children with Crohn's disease and coeliac disease. Br Med J (Clin Res Ed)
1982;285:20-1.
263. . Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations
in children. J Pediatr Gastroenterol Nutr 2002;34:323-4; author reply 324-5.
264. Simondon KB, Simondon, F., Gartner, A., Berger, J. Growth in knee-heel length and
recumbent length during the weaning period (4-7 mol in less developed countries.
Human Bioi. Budapest 1994;25:311-319.
265. Bland JM, Altman DG. Measurement error. BMJ 1996;313:744.
266. Bland JM, Altman DG. Measurement error proportional to the mean. BMJ
1996;313: 106.
267. Bland JM, Altman DG. Measurement error and correlation coefficients. BMJ
1996;313:41-2.
268. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO
Expert Committee. World Health Organ Tech Rep Ser 1995;854:1-452.
260
Chapter 5: Overall discussion and conclusion
269. Gibson RS. Principles of nutritional assessment. New York: Oxford University Press,
1990.
270. Ulijaszek SJ, Kerr DA. Anthropometric measurement error and the assessment of
nutritional status. Br J Nutr 1999;82:165-77.
271. Mueller WH, Martorell, R. Reliability and accuracy of measurement. In: T.G. Lohman
AFR, R. Martorell, ed. Anthropometric Standardisation Reference Manual. Champaign,
IL: Human Kinetics Books, 1988:83-86.
272. Prentice AM, Cole TJ. Seasonal changes in growth and energy status in the Third
World. Proc Nutr Soc 1994;53:509-19.
273. Cole TJ. Seasonal effects on physical growth and development. In: Ulijaszek SJ,
Strickland, 5.5., ed. Seasonality in Human Ecology. Cambridge: Cambridge University
Press, 1993:89-106.
274. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ
1996;312:1079.
275. Bland JM, Altman DG. Transforming data. BMJ 1996;312:770.
276. van Elburg RM, Uil JJ, Kokke FT, et al. Repeatability of the sugar-absorption test, using
lactulose and mannitol, for measuring intestinal permeability for sugars. J Pediatr
Gastroenterol Nutr 1995;20:184-8.
277. Fleming SC,Duncan A, Russell RI, Laker MF. Measurement of sugar probes in serum: an
alternative to urine measurement in intestinal permeability testing. Clin Chem
1996;42:445-8.
278. Mlkl K, Butler R, Moore D, Davidson G. Rapid and simultaneous quantification of
rhamnose, mannitol, and lactulose in urine by HPlC for estimating intestinal
permeability In pediatric practice. Clln Chem 1996;42:71-5.
279. Fekete K, Marosvolgyl T, Jakoblk V, Decsi T. Methods of assessment of n-3 long-chain
polyunsaturated fatty acid status in humans: a systematic review. Am J Clin Nutr
2009;89:20705-20845.
280. Baylin A, Kim MK, Donovan-Palmer A, et al. Fasting whole blood as a biomarker of
essential fatty acid intake in epidemiologic studies: comparison with adipose tissue
and plasma. Am J EpldemioI2005;162:373-81.
261
Chapter 5: Overall discussion and conclusion
281. Calder PC, Deckelbaum RJ.Omega-3 fatty acids: time to get the messages right! Curr
Opin Clin Nutr Metab Care 2008;11:91-3.
282. Malia A, Malia, A.M., Rahim, A., Sarker, S.A., Khatoon, M., Rahaman, M.M. Intake and
absorption of nutrients in children with cholera and rotavirus infection during acute
diarrhea and after recovery. Nutr Res 1982;2:232-42.
283. Briscoe J. The quantitative effect of infection on the use of food by young children in
poor countries. Am J Clin Nutr 1979;32:648-76.
284. Rosenberg IH, Solomons NW, Schneider RE. Malabsorption associated with diarrhea
and intestinal Infections. Am J Clin Nutr 1977;30:1248-53.
285. Baker SJ, Mathan VI. Tropical enteropathy and tropical sprue. Am J Clin Nutr
1972;25:1047-55.
286. Crompton OW, Nesheim MC. Nutritional impact of intestinal helminthiasis during the
human life cycle. Annu Rev Nutr 2002;22:35-59.
287. Yuhas R, Pramuk K, lien EL. Human milk fatty acid composition from nine countries
varies most In DHA.lipids 2006;41:851-8.
288. Brenna JT, Varamini B, Jensen RG, Diersen-Schade DA, Boettcher JA, Arterburn LM.
Docosahexaenoic and arachidonic acid concentrations in human breast milk
worldwide. Am JClin Nutr 2007;85:1457-64.
289. Martinelli N, Glrelll D, Malerba G, et al. FADS genotypes and desaturase activity
estimated by the ratio of arachidonic acid to linoleic acid are associated with
Inflammation and coronary artery disease. Am J Clin Nutr 2008;88:941-9.
290. Marquardt A, Stohr H, White K, Weber BH. cDNA cloning, genomic structure, and
chromosomal localization of three members of the human fatty acid desaturase
family. Genomlcs 2000;66:175-83.
291. Schaeffer L, Gohlke H, Muller M, et al. Common genetic variants of the FADS1FADS2
gene cluster and their reconstructed haplotypes are associated with the fatty acid
composition in phospholipids. Hum Mol Genet 2006;15:1745-56.
292. Koletzko B. Prenatal supply of docosahexaenoic acid (DHA): should we be worried? J
Perinat Med 2008;36:265-7; author reply 268-9.
293. Dougherty RM, Galli C, Ferro-Luzzi A, Iacono JM. lipid and phospholipid fatty acid
composition of plasma, red blood cells, and platelets and how they are affected by
262
Chapter 5: Overall discussion and conclusion
dietary lipids: a study of normal subjects from Italy, Finland, and the USA. Am J Clin
Nutr 1987;45:443-55.
294. Judd JT, Marshall, M.W., Dupont, J. Relationship of dietary fat to plasma fatty acids,
blood pressure and urinary eicosanoids in adult men. J. Am. Coil. Nutr.
1989;8:386-399.
295. Ma J, Folsom AR, Shahar E, Eckfeldt JH. Plasma fatty acid composition as an indicator
of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in
Communities (ARIC)Study Investigators. Am JClin Nutr 1995;62:564-71.
296. Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hanninen 0, Uusitupa Mt. Incorporation
of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets
during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil
among healthy young men. Lipids 1997;32:697-705.
297. Uauy R, Rojas C, Llanos A, Mena P. Dietary essential fatty acids in early postnatal life:
long-term outcomes. Nestle Nutr Workshop Ser Pediatr Program 2005;55:101-33;
discussion 134-6.
298. Conquer JA, Holub 8J. Supplementation with an algae source of docosahexaenoic acid
Increases (n-3) fatty acid status and alters selected risk factors for heart disease in
vegetarian subjects. J Nutr 1996;126:3032-9.
299. Hadders-Algra M. Prenatal long-chain polyunsaturated fatty acid status: the
importance of a balanced intake of docosahexaenoic acid and arachidonic acid. J
Perinat Med 2008;36:101-9.
300. Bornstein M. Habituation of Attention as a Measure of Visual Information Processing
in Human Infants: Summary, Systematisation, and Synthesis. In: Gottleib G, Krasnegor,
N.A, ed. Measurement of Audition and Vision in the First Year of Postnatal Life: A
Methodological Overview. Norwood: Ablex, 1985:253-300.
301. Bayley N. The Bayley Scales of infant development. 2nd ed. San Antonio: The
Psychological Corporation, 1993.
302. Bornstein MH, Sigman MD. Continuity in mental development from infancy. Child Dev
1986;57:251-74.
303. Ruff HA, Rothbart, M.K. Attention in Infancy: Themes and variations. New York: Oxford
University Press, 1996.
263
Chapter 5: Overall discussion and conclusion
304. Colom R, Lynn, R. Testing the developmental theory of sex differences in intelligence
on 12-18 year olds. Personality and individual differences 2003;36:75-82.
305. Clarke-Stewart KA. Interactions between mothers and their young children:
characteristics and consequences. Monogr Soc ResChild Dev 1973;38:1-109.
306. Snow ME, Jacklin, C.N., Maccoby, E.E. Sex-of-child differences in father-child
interaction at one year of age. Child Development 1983;54:227-232.
307. Lauritzen L, Jorgensen MH, Olsen SF, Straarup EM, Michaelsen KF. Maternal fish oil
supplementation in lactation: effect on developmental outcome in breast-fed infants.
Reprod Nutr Dev 2005;45:535-47.
308. Judge MP, Harel 0, Lammi-Keefe O. Maternal consumption of a docosahexaenoic
acid-containing functional food during pregnancy: benefit for infant performance on
problem-solving but not on recognition memory tasks at age 9 mo. Am J Clln Nutr
2007;85:1572-7.
309. Tofail F, Vahter M, Hamadani JO, et al. Effect of arsenic exposure during pregnancy on
infant development at 7 months in rural Matlab, Bangladesh. Environ Health Perspect
2009;117:288-93.
310. Tofall F, Persson LA, El Arlfeen 5, et al. Effects of prenatal food and micronutrient
supplementation on infant development: a randomized trial from the Maternal and
Infant Nutrition Interventions, Matlab (MINIMat) study. Am J Clin Nutr
2008;87:704-11.
311. Ross DA, Vaughan JP. Health interview surveys in developing countries: a
methodological review. Stud Fam Plann 1986;17:78-94.
312. Kroeger A. Health Interview surveys in developing countries: a review of the methods
and results. Int J EpldemioI1983;12:465-81.
313. Manesh AO, Sheldon TA, Pickett KE, Carr-Hill R. Accuracy of child morbidity data in
demographic and health surveys. Int J EpidemioI2008;37:194-200.
314. Otto SJ, Houwelingen AC, Antal M, et al. Maternal and neonatal essential fatty acid
status In phospholipids: an international comparative study. Eur J Clin Nutr
1997;51:232-42.
315. Outta-Roy AK. Transport mechanisms for long-chain polyunsaturated fatty acids in the
human placenta. Am JClin Nutr 2000;71:3155-225.
264
Chapter 5: Overall discussion and conclusion
316. Cheruku SR, Montgomery-Downs HE, Farkas SL, Thoman EB, Lammi-Keefe CJ. Higher
maternal plasma docosahexaenoic acid during pregnancy is associated with more
mature neonatal sleep-state patterning. Am J Clin Nutr 2002;76:608-13.
317. Voigt RG, Jensen CL, Fraley JK, Rozelle JC, Brown FR, 3rd, Heird WC. Relationship
between omega3 long-chain polyunsaturated fatty acid status during early infancy and
neurodevelopmental status at 1 year of age. J Hum Nutr Diet 2002;15:111-20.
318. Ghys A, Bakker E, Hornstra G, van den Hout M. Red blood cell and plasma phospholipid
arachidonic and docosahexaenoic acid levels at birth and cognitive development at 4
years of age. Early Hum Dev 2002;69:83-90.
319. Bakker EC, Ghys AJ, Kester AD, et al. Long-chain polyunsaturated fatty acids at birth
and cognitive function at 7 y of age. Eur J Clin Nutr 2003;57:89-95.
320. Lapillonne A, Carlson SE. Polyunsaturated fatty acids and infant growth. lipids
2001;36:901-11.
321. Lauritzen L, Hoppe C, Straarup EM, Michaelsen KF. Maternal fish oil supplementation
In lactation and growth during the first 2.5 years of life. Pediatr Res 2005;58:235-42.
322. Whitaker RC, Pepe MS, Wright JA, Seidel KO, Dietz WHo Early adiposity rebound and
the risk of adult cbesltv. Pediatrics 1998;101:E5.
323. Rolland-Cachera MF, Deheeger M, Bellisle F, Sempe M, Guilloud-Bataille M, Patois E.
Adiposity rebound in children: a simple indicator for predicting obesity. Am J Clin Nutr
1984;39:129-35.
324. Fok TF, Hon KL, NS PC, et al. Normative data for triceps and subscapular skinfold
thicknesses of Chinese infants. Acta Paedlatr 2006;95:1614-9.
325. Malina RM. Patterns of development in sklnfolds of Negro and white Philadelphia
children. Hum 81011966;38:89-103.
326. Rauh JL, Schumsky DA. An evaluation of triceps skinfold measures from urban school
children. Hum 81011968;40:263-74.
327. Robson JR, Bazln M, Soderstrom R. Ethnic differences in skin-fold thickness. Am J Clin
Nutr 1971;24:864-8.
328. Yajnik CS, Fall CH, Coyaji KJ, et al. Neonatal anthropometry: the thin-fat Indian baby.
The Pune Maternal Nutrition Study. Int JObes Relat Metab Disord 2003;27:173-80.
329. WHO. The optimal duration of exclusive breastfeedlng. Geneva, 2001.
265
Chapter 5: Overall discussion and conclusion
330. Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. Cochrane
Database Syst Rev 2002:C0003517.
331. Semega-Janneh IJ, Bohler E, Holm H, Matheson I, Holmboe-Ottesen G. Promoting
breastfeeding in rural Gambia: combining traditional and modern knowledge. Health
Policy Plan 2001;16:199-205.
332. Rosenberg IH. Resume of the discussion on "Direct nutrition interventions". Am J Clin
Nutr 1978;31:2083-2088.
333. Jensen CL, Maude M, Anderson RE, Heird Wc. Effect of docosahexaenoic acid
supplementation of lactating women on the fatty acid composition of breast milk lipids
and maternal and Infant plasma phospholipids. Am JClin Nutr 2000;71:2925-95.
334. Prentice A. Regional variations in the composition of human milk. In: Jensen RG, ed.
Handbook of Milk Composition. New York: Academic Press, 1995:115-221.
335. Hudson GJ. Food intake in a west African village. Estimation of food intake from a
shared bowl. Br J Nutr 1995;73:551-69.
336. Specker Bl, Wey HE, Miller D. Differences in fatty acid composition of human milk in
vegetarian and nonvegetarian women: long-term effect of diet. J Pediatr Gastroenterol
Nutr 1987;6:764-8.
337. Smlt EN, Oelen EA, Seerat E, Muskiet FA, Boersma ER. Breast milk docosahexaenoic
acid (DHA) correlates with DHA status of malnourished infants. Arch Dis Child
2000;82 :493-4.
338. Smlt EN, Oelen EA, Seerat E, Boersma ER, Muskiet FA. Fish oil supplementation
Improves docosahexaenolc acid status of malnourished Infants. Arch Dis Child
2000;82:366-9.
339. Krasevec JM, Jones PJ, Cabrera-Hernandez A, Mayer OL, Connor WE. Maternal and
Infant essential fatty acid status in Havana, Cuba. Am JClin Nutr 2002;76:834-44.
340. lamb WH, Foord FA, lamb CM, Whitehead RG. Changes in maternal and child
mortality rates in three Isolated Gambian villages over ten years. lancet 1984;2:912-4.
341. Pelletier DL, Fronglllo EA, Jr., Schroeder OG, Habicht JP. The effects of malnutrition on
child mortality in developing countries. Bull World Health Organ 1995;73:443-8.
266
Chapter 5: Overall discussion and conclusion
342. Grantham-McGregor SM, Powell C, Stewart M, Schofield WN. Longitudinal study of
growth and development of young Jamaican children recovering from severe
protein-energy malnutrition. Dev Med Child NeuroI1982;24:321-31.
343. Barker DJP,Winter, P.O., Osmond, C., Margetts ,B.M., Simmonds, S.J.Weight in infancy
and death from ischaemic heart disease. In: Barker DJP,ed. Fetal and infant origins of
adult disease. London: BMJ Publishing Group, 1992:141-149.
344. Barker DJP. Mothers, babies and disease in later life. 2nd. ed. London: BMJ Publihing
Group, 1994.
345. Waterlow JC,Payne PR.The protein gap. Nature 1975;258:113-7.
346. Waterlow JC. Linear growth retardation in less developed countries. New York: Raven
Press Ltd., 1988.
347. Vlrella G, Fourspring K, Hyman B, et al. Immunosuppressive effects of fish oil in normal
human volunteers: correlation with the in vitro effects of eicosapentanoic acid on
human lymphocytes. Clin ImmunollmmunopathoI1991;61:161-76.
348. Cleland lG, French JK, Betts WH, Murphy GA, Elliott MJ. Clinical and biochemical
effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol
1988;15:1471-5.
349. Yaqoob P, Knapper JA, Webb OH, Williams CM, Newsholme EA, Calder Pc. Effect of
olive oil on immune function in middle-aged men. Am JClin Nutr 1998;67:129-35.
350. Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation
in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum
1990;33:810-20.
351. Linos A, Kaklamanis E, Kontomerkos A, et al. The effect of olive oil and fish
consumption on rheumatoid arthritis--a case control study. Scand J Rheumatol
1991;20:419-26.
352. Oosthuizen W, Vorster HH, Jerling JC, et al. Both fish oil and olive oil lowered plasma
fibrinogen In women with high baseline fibrinogen levels. Thromb Haemost
1994;72:557-62.
353. Dehmer GJ, Popma JJ,van den Berg EK,et al. Reduction in the rate of early restenosis
after coronary angioplasty by a diet supplemented with n-s fatty acids. N Engl J Med
1988;319:733-40.
267
Chapter 5: Overall discussion and conclusion
354. Milner MR. Fish oil for preventing coronary restenosis. 1989;2:693.
355. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Bioi Med
2oo7j43:4-15.
356. Azzi A. Molecular mechanism of alpha-tocopherol action. Free Radic Bioi Med
2007;43:16-21.
357. Ueda 5, Yasunari K. What we learnt from randomized clinical trials and cohort studies
of antioxidant vitamin? Focus on vitamin E and cardiovascular disease. Curr Pharm
BiotechnoI2006j7:69-72.
358. Sesso HO, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of
cardiovascular disease in men: the Physicians' Health Study I( randomized controlled
trial. Jama 2008j3OO:2123-33.
359. Rumbold A, Crowther CA. Vitamin E supplementation in pregnancy. Cochrane
Database Syst Rev 2005:COO04069.
360. Bjelakovic G, Nikolova 0, Simonetti RG, Gluud C. Antioxidant supplements for
prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet
2004;364: 1219-28.
361. Bjelakovic G, Nikolova 0, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized
trials of antioxidant supplements for primary and secondary prevention: systematic
review and meta-analysis. Jama 2007;297:842-57.
362. Galpin L, Manary MJ, Fleming K, Du CN, Ashorn P, Shulman RJ. Effect of Lactobacillus
GG on intestinal integrity in Malawian children at risk of tropical enteropathy. Am J
Clln Nutr 2005;82:1040-5.
363. Thurnham 01, Northrop-Clewes CA, McCullough FS,Das BS,Lunn PG. Innate immunity,
gut integrity, and vitamin A in Gambian and Indian infants. J Infect Dis 2000j182 Suppl
1:523-8.
364. Filteau SM, Rollins NC, Coutsoudis A, Sullivan KR, Willumsen JF, Tomkins AM. The
effect of antenatal vitamin A and beta-carotene supplementation on gut integrity of
Infants of HIV-infected South African women. J Pediatr Gastroenterol Nutr
2001;32 :464-70.
268
Chapter 5: Overall discussion and conclusion
365. Smit EN, Dijkstra JM, Schnater TA, Seerat E, Muskiet FA, Boersma ER. Effects of
malnutrition on the erythrocyte fatty acid composition and plasma vitamin E levels of
Pakistani children. Acta Paediatr 1997;86:690-5.
366. Campbell DT, Stanley, J.C. Experimental and quasi-experimental designs for research.
Boston: Houghton Mifflin Company, 1966.
367. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of
controlled clinical trials. BMJ 2001;323:42-6.
368. Cook T, Campbell, D. Quasi-experimentation. Design and analysis for field settings.
Boston: Houghlin Mifflin Company, 1979.
369. Barrett D. Methodological requirements for conceptually valid research studies on the
behavioural effects of malnutrition. In: Galler J, ed. Nutrition and behaviour. New York:
Plenum Press, 1984.
370. Greiner RC,Winter J, Nathanielsz PW, Brenna rr. Brain docosahexaenoate accretion in
fetal baboons: bioequivalence of dietary alpha-linolenic and docosahexaenoic acids.
Pedlatr Res 1997;42:826-34.
371. Jackson AA, Robinson SM. Dietary guidelines for pregnancy: a review of current
evidence. Public Health Nutr 2001;4:625-30.
372. Kris-Etherton PM, Hecker KO, Bonanome A, et al. Bioactive compounds in foods: their
role in the prevention of cardiovascular disease and cancer. Am J Med 2002;113 Suppl
9B:71S-88S.
269
Chapter 5: Overall discussion and conclusion
APPENDICES
270
Appendix 1.
Chapter S·Overall discussion and conclusion
Treatment code pictures
Here in black and white but ordinarily in colour, representing treatment group allocations.
The labels below also appeared on the supplement bottles.
Infant Omega 3
Supplementation Study
Infant Omega 3
Supplementation Study
HutTree
Infant Omega 3
Supplementation Study
Infant Omega 3
Supplementation Study
Fish Football
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Example of the treatment cards given out to the
The image (ordinarily in colour) was folded onto the back of the card so that the PI was
shown only the front of the card displaying demographic details, when needed.
lntant Ome~l(}3 SllQQlementalion Studv2007.
Study ID Number I
Nome ILaml" Niai I
Sex 1M I
008 115/0312005 I
Village 1002 I
Compound 1002 I
Mother's Nome I I
Father's Nome
_. - . I
272
Infant Omega 3 Supplementation
Study 2007.
c
.2
\11
.2
u
0
U
-0
C
ro
.~
VI
\11
:::l
u
.!::':!
-0
==ro
I...
(I)
>
0
Lt')
'- "0
(I)
._
..... ::a.
co 0",... ._
0 -
M•:":lec
C!J-...-0
Cl)-:":l
"'"::....
(1:1
Z
t.J:e
"'"0
Z-:":l._
t.J
"'"QJEa
0
(,J
C!J..c:....
c:
0
Cl)
"'":":lC!J
0.
0.
:":l
..c:
t.J._
..c:
~.-
QJ
..c
C'd
..:l
M
.::S
"0c
C!J
Q..
e,
-<
Chapter 5: Overall discussion and conclusion
Appendix 4. Information sheet & consent forms: cognitive
development tests
SUBJECT INFORMATION SHEET
Developmental outcomes testing
(to be read to mothers in their own language)
You/your child are being invited to take part in a research study. Before you decide it is important
for you to understand why the research is being done and what it will involve. Please take time to
listen to this carefully and discuss it with others if you wish. Ask us if there is anything that is not
clear or if you would like more information. Take time to decide whether or not you wish to take
part.
What Is the purpose of the study?
Some special kinds of oils contain benefits for the development of a child's brain. In order to test
whether the oil your child was supplemented with for 6 months has had an effect on the
development of his/her brain, we would like to observe them to measure their attention and
problem-solving behaviour. You/your infant have been chosen to participate in this study as a
follow-up from the omega-3 study you were involved in before.
The study Involves the following If you take part:
We will provide transport and ask you to bring your infant to MRC Keneba on one occasion for a
morning.
One of the Keneba nurses will examine your child to ensure he/she is healthy. It your child is
found to be ill, they will not be tested although we may ask you to bring him/her in once they have
recovered. If your child is ill when they visit Keneba they will be treated.
You will be seated at a table with your child while he/she plays with a toy and his attention to the
toy is observed as he plays.
Three simple tests will be given to your child in which the toy is removed and he/she has to try and
get it back.
Your child will be filmed as he/she plays, so that we can watch the test again on another day. This
film will only be viewed by the project co-ordinators and will assist us in evaluating the children's
behaviour.
All information which is collected about your child during the course of the research will be kept
strictly confidential. You/your child will be identified by an ID number.
It is up to you to decide whether or not to take part. If you do decide to take part you will be asked
to sign a consent form. If you decide to take part you are still free to withdraw at any time and
without giving a reason. Your decision will not affect the medical care we provide you in any way.
Thank you very much.
Prlnclpallnv .. tlgator: Liandre van der Merwe : MRC Keneba : tel 9878099
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CONSENT FORM
Developmental outcomes testing
The infonnation sheet has been read to me and I understand it. I understand what participation in
the study means for me and the infant in my care. I understand that the infonnation that is
collected in the course of this study will remain confidential.
Iunderstand that if Ior the infant in my care gets sick during the study period. we can go to the
clinic where study staff are providing care. and be examined and treated for free.
Iunderstand that we are free to take part in the study or refuse. and that we can withdraw from the
study at any time. and without giving any reason. Deciding not to take part or to withdraw from the
study will not affect the care that we are nonnally entitled to.
Ihave had a chance to ask questions and have them answered.
Signature or thumb print of volunteer: _
This fonn has been read by II have read the above to
(write name of volunteer)
in a language that he/she understands. The volunteer has understood what Ihave explained and
he/she has freely agreed to take part in the study.
Name of infant:
Signature of PI:
Name of field worker:
Date: 1-'_1 I 1_1_1 1_1_1_1_1
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Appendix 5. Mother's education questionnaire
Omega-3 Study
Mother name:
Baby name:
Village:
Study number:
What is the highest level of education you attained?
(Tick as appropriate)
English
Any
Grade Arabic comments
0
1
2
3
4
5,
7
8
9
10
11
12
Ust any other education (type and duration):
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Appendix 6. Detailed scoring instructions for the Willatts test
(Compiled by Dr Peter Willatts)
CLOTH (SUPPORT) STEP
CLOTH BEHAVIOUR - continue scoring until cover/base is contacted or trial
ends.
Score D
• No contact with cloth.
• Coverlbase not within reach.
• Infant plays with or examines the cloth.
Score 1
Infant pulls the cloth without any play or examination. and brings the
cover/base within reach. but:
• Infant begins an activity which might be play or examining. but does not
carry it through to completion.
• Infant lets go of the cloth for more than 1 sec before the cover/base
comes within reach.
Score 2
• Infant pulls the cloth without any play or examination. and brings the
coverlbase within reach. Short breaks in contact of less than 1 sec are
allowed. provided the infant immediately regains contact. Pauses of
any duration between movements of the cloth are permitted.
FIXATION - continue scoring until cover/base is contacted or trial ends.
Score D
• Infant looks away from the coverlbase for more than 2 sec.
kore1
• Infant briefly looks away from the cover/base. but looks back within 2
sec.
Score 2
• Infant fixates the coverlbase continuously.
COVERIBASE BEHAVIOUR - continue scoring until cover/base is picked up or
trial end•.
ScoreD
• Infant faila to contact the cover/base. or only touches the cover/base
and make. no attempt at grasping.
• The cloth is pulled too far and the cover and toy are dragged off the
edge of table.
Score1
• Infant attempts to grasp the cover/base, but does not pick it up.
Score 2
• Infant grasps the cover/base and picks it up.
277
Chapter 5: Overall discussion and conclusion
CQVER(SEARCH)STEP
COVER/BASE BEHAVIOUR - continue scoring until toy is contacted or trial
ends.
Score 0
• No contact with cover/base.
• Infant touches the cover/base. but fails to reveal the toy.
• Infant plays with or examines the cover/base.
Score 1
Infant removes the cover or tips the base to reveal the toy without any
play or examining. but:
• Infant begins an activity which might be play or examining. but does not
carry it through to completion.
• Infant knocks the cover away.
• Infant grasps the cover/base. but lets go for more than 1 sec before the
toy is revealed.
Score 2
• Infant removes the cover or tips the base to reveal the toy without any
play or examining. Short breaks in contact of less than 1 sec are
allowed provided the infant immediately regains contact.
FIXATION - continue scoring until the toy is contacted or trial ends.
Score 0
• Infant never looks at the toy (either because it is not uncovered. or it is
uncovered and ignored).
• From the moment the toy is uncovered or tipped out. the infant looks
away from it for more than 2 sec.
Score 1
• From the moment the toy is uncovered or tipped out. the infant briefly
looks away from it. but looks back within 2 sec.
Score 2
• From the moment the toy is uncovered or tipped out. the infant
maintains continuous fixation on it until it is contacted or the trial ends.
TOY BEHAVIOUR· continue scoring until toy is picked up or trial ends.
ScoreO
• Infant fails to contact the toy. or only touches it and makes no attempt at
grasping.
Score 1
• Infant attempts to grasp the toy. but does not pick it up.
Score 2
• Infant grasps the tc.y ar'd picks it up.
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4
ONE-STEP PROBLEMS (PRETESTS)
BARRIER
BARRIER BEHAVIOUR - continue scoring until toy is contacted or trial ends.
SeoreO
• No contact with barrier.
• Barrier not moved sufficiently to permit access to toy.
• Infant plays with or examines the barrier.
Score1
Infant moves the barrier sufficiently to permit access to toy. and
does not engage in any play or examination. but:
• Infant begins an activity which might be play or examining. but does not
carry it through to completion.
• Infant lets go of the barrier for more than 1 sec before moving it away.
Score 2
• Infant moves the barrier sufficiently to permit access to toy. and does
not engage in any play or examination. Short breaks in contact of less
than 1 sec are allowed. provided the infant immediately regains contact.
FIXATION - begin scoring when the barrier is first contacted (or when barrier
com .. within reach if no contact) and continue until toy is contacted or trial ends.
Scorea
• Infant looks away from the toy for more than 2 sec.
Score1
• Infant briefly looks away from the toy. but looks back within 2 sec.
Score2
• Infant fixates the toy continuously.
TOY BEHAVIOUR - continue scoring until toy is picked up or trial ends.
ScoreO .
• Infant 'ails to contact the toy, or only touches the toy and makes no
attempt at grasping.
Score1
• Infant attempts to grasp the toy. but does not pick it up.
Score2
• Infant grasps the toy and picks it up.
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NOTES
1. Coverlbase behaviour may receive different scores on each of the cloth and
cover steps. For example. on the cloth step the infant may pick up the cover
and play with it. A score of 2 would be given for cover/base behaviour (infant
retrieved the cover/base at the conclusion of the cloth step), but a score of 0
would be given for coverlbase behaviour on the cover step (infant played with
the cover/base at the start of the cover step).
2. Play or examining behaviour includes:
• taking the object to the mouth
• striking the object
• scratching the surface of the object
• shaking or waving the object
• manipulating, crumpling, or fingering the object.
3. Also record:
(a) whether the coyer was brought within reach (./ x).
(b) whether the cloth was pulled too far so that the cover and toy were dragged
off the table (,( x),
(c) whether the cloth base was tipped to reveal the toy (.t x).
4. If the infant pulls the cloth too far and the cover and toy fall off the table, give
o scores for I!Ibehaviours on the cover step, and a 0 score for cover/base
behaviour on the cloth step.
5. The coding scheme for the cover step allows for two methods of retrieving
the hidden toy. Infants may reveal the toy by either removing the cover. or
graSping the base of the cloth and tipping it so that the toy falls out. Either
method is acceptable. Tipping is relatively infrequent and occurs on about 10%
of trials.
6, The trial starts when the infant first makes any contact with the barrier. If the
infant flils to contad the barrier, the start of the trial is the moment when the
barrier first comes within reach. Trials last for a maximum of 30 sec. If the trial
continues beyond 30 sec, scoring ends when the maximum time has elapsed.
7. Toy retrieval is defined as either an attempt at grasping or success at
ptcking up the toy (i.e., toy behaviour score of 1 or 2).
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MEASURES
We use two measures of means-end behaviour: total intention score and number
of intentional solutions.
Total intention score on each step of the problem is defined as the sum of the 3
intention scores relevant to the step. averaged across trials (range 0 - 6).
Intention scores are calculated for each step of the problem. and the total
intention score for the entire problem is defined as the sum of the average
intention scores on the barrier. cloth and cover steps (range 0 - 18).
Intentional solutions on each step are defined as the number of trials on which
there is evidence of intention (scores of 1 or 2) on all 3 behaviours relevant to the
step. Intentional solutions on the entire problem are defined as the number of
trials on which an intentional solution occurred on each of the barrier. cloth and
cover steps. This method of combining intention scores into a single measure
offers a better way of capturing qualitative differences in behaviour than can be
achieved by summing intention scores (total intention score). Total intention
score might reflect the greater contribution of one behaviour over another. and
would not necessarily be related to overall level of behaviour because the same
total score could occur at different levels. An infant might retrieve the toy on
every trial. but the number of intentional solutions indicates how often this was
accomplished by intentional means-end behaviour. rather than by transitional
behaviour.
CODER RELIABILITY
We normally have one observer score all the trials (this is usually the tester). and
as a check on the reliability of scoring. a second trained observer scores a
random sample of one third of all sets of trials. The second observer is blind to
the aims of the study. We use a chance-adjusted statistic (Kappa) to estimate
reliability on the percentage of agreement on intention scores for each of the 9
behaviours and identification of intentional solutions.
ONE-8TEP PRETESTS
Infants' performance on the one-step pretests may be also be obtained using the
scoring procedures given on pages 4 - 6.
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Scoring sheet for the two-step problem
Cloth (Support) Step
Trial
1 : 2 I 3 4 , 5
Cloth I i
Fixation
Cover/base I
Within reach?
,
I
Pull off table?
i ! II ,
Cover (Search) Step
Trial
1 2 3 4 5
Coverlbase
Fixation
Toy I
Tip?
0: no intention; 1: possible intention; 2: clear intention
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Appendix 7, Attention Assessment Scoring Sheet Example
Baby Name Age in Mother's Date ofNumber
days DOB ID Test
30107/2008
Trial Total Look Total
Mean Looks Inattention Max FirstLook
Duration Time Looks Time Away Rate Look Look
300.0 252.88 16 15.81 15 3.56 67.40 28.68
Trial Frame
Trial start 51403
Trial end 58903
Max end 58903
Looks START END
1 51403 52120
2 52157 52328
3 52367 52410
4 52503 52535
5 52767 53366
6 53398 53738
7 53913 55598
8 55633 56146
9 56191 56~37
10 56313 56566
11 56631 57142
12 57284 57479
13 57510 57584
14 57673 57835.- ...._
15 57877 58069
. --
- 16 58114 5890317
18
19-- 20
Look Away
28.68 1.48
6.84 1.56
1.72 3.72
1.28 9.28
23.96 1.28
13.60 7.00
67.40 1.40
20.52 1.80
1.84 3.04
10.12 2.60
20.44 5.68
7.80 1.24
2.96 3.56
6.48 1.68
7.68 1.80
31.56 0.00
0.00 0.00
0.00 0.00
0.00 0.00
0.00 0.00
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Appendix 10. Weaning foods questionnaire
IN3SS Introduction of weaning foods questionnaire
Infant name:
Study number:
Today'. Date:
Cbild's age
3mo I
4mo L
5mo I
6mo r
7mor
8mo L
9mo I
Have you given your child any food/drink other than breast-milk (e.g. water or mono?).
YEsmo _
If Yes, what?
Water
Juice
Tea
Cow's milk (includes powder milk)
Formula milk r
Mono/porridge
Bread r
Mango L
Other fruit r:
Egg yolk l.J
Rkedllba:
r, :
Kino
Tulo
Tulsa),
Durango
Jambo
Nyankatang
Fuuto
Anything else?
L
r
LJ
n
LJ
L
L
lnterviewernamc: _
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Appendix 11. Ethical Approval obtained
LONDON SCHOOL OF HYGIENE
& TROPICAL MEDICINE
ETHICS COMMIITEE
APPROVAL FORM
Applic tlon numbor: 5072
me or Pnnctp I Investigator Llandre van dor Morwo
o P rltTlCnl Epldomlology and Population Health
H ad of D p rtm nt Pat Doyle
Tillo: n-3Iong-chaln polyunsaturated fatty acids (LC.PUFAs) in relation to
gut Intognty and growth falluro on rural African children.
Applov'llo th a tudy IS grant d by the commrt e.
Ch.i, . .f.:.1-:'i J~ ..
Profo sor Tom M ado
Approv I is dep~nd nt on local thleal approval havIng boon r coivod.
Any lubl quon! ch ngo to lh con nt form mUlt be re-aubrmttcd to tho
Commitl o.
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n.-...alllU.I•••• /1IRC ~ .....
eIo MAC~ F.,.,.
P. O. eo. 273. II8njufn..~_AInce
ETHICS COJDflTTBB Fp' -220 -~ ..... or 4411051J
Tel '22O-44t407U eIl_
J J'" Fchruary 2007
M. Liandre \ .....«r ~"C
PhDSludcnI
tSIITM .t Kmcb.
... sce I'"~.., .... dui .. ,_.,. ...... nted r••.,. .clcb I. rdatioe 10pt ..teptty •• d
.,..... ,. ...... la ,.nl Afrinut cIriId,..
1'hank you lOr your Ic:ncr dated 9 Ft:bnIary 2007 in rerly 10our queries of 2 t· November
2006 Oft Ihe 8b.wc proposal. I al50 acknowledllc fCl:cil'l of Ihe ICCompan)'i1lj m1IIil sent by
the Actilll Dir«1Or of NINA. 'note, "lib appro\'al, your consuitalionl \\;th NaNA and lheir
1IfIP'O''lII Md suppon of Ihe prupoted study. , allO noIC thai you no lonaer plan to do RX1al
catbcr~
,_ thetcfon: hippy 10 ~ our o;ommincc's full apflnwaJ for Ibis study 10 proceed. You
will be rtquircd 10 submit. summary report 0" the "ond~ and main lindin", al lhe end of
!he calendar year.
Wilh bell "iw.
Yours Iinn,"ly
Mr. MakOlIll Cllrte
C'1Sa1rmIn, (iamhil {io,emmcntlMRC Joint Ethics Committee
n.. ...... De..... , •• ,.IIC~ .................~:
...~o..w,o.-.........'''''.s..-,.
'" "'-dI Alt rs..-,.
,...",_c-..v_ !kW*l/l< -.. ......-~..,.,....,..~ ,._..,.,r_c ......r...,....,III1_If_Drs"fl-H-"Drll_;.n..,Lw lAot .. _.Ur AI4J"j"s.w...,
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The GIna.Gow ...... '" I MAC UborIlClfies Joint
ETHICS COMMITTEE
c/o MRC I.abcntories I
P. o. Box 273, I
The GambIa, West
Fax: +220 - 4494498 or 445
Tef: +220-4494 073-9 tp
Dr l.&aDdre \'111 der Merwe
ClO Dr. Stephen Owms
MR.C Nutrition PrograJDDt
K.meba
RI L200'7.1%: ,. Ftbnwy 2007. ~ sce 1061 .31oq e.... polya ... tanC.d la..y adds iD
rfla •• to ... ,.........,. ad ....wtJa Iahn 1a ...... 1AlIi" •• daildr..: P..-misdoD to __ ad
proIOtOI
TbaDb you for submitting tilt above itttcr
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sWldantisatIOD of SUPP~. 1brthcr aothropomttric measurtmmts, simplification of urin~
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Mr. Malcolm Ctam
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ETHICS COMMITTEE
clo MRC Labor_ones FIjanI
POBox 213, Barlu
The Gambia, West AtrIca
FBIC +220-~96or4496513
Tel: +220 - «94 073-9 ext 409
16* January 2008
M$ Uandr~ van doer MeJWt
c/o Nutrition Pro~ammr
MRC. faJar3
Dear Ms \'30 doer Merwe,
Itt: U007.100. %0"~o,·tIIl"'r 2007. P.l1Dis~onto add a d.nlopm.ntal
08ttO.. to S(:C 10451: n-3 10111til. polyunsatunt.cl fatty adds in ~lariOD
toP' la•....,· a.d P'OWtll faUar. in nral AfritaD tbUdr.n.
Thank you for submIrtiag tbt above project whicb was considered and approved
at tht reeeer GG!MR.C Etlucs Comnutt~ meet~ ~ld 00 January 11. :!OO8
Belt wishH
Yours _crt!),
Mr. Malcolm Clarke
Chairman. Gambia Go\'eI'1lIDe1ltiMRC JOint Et1ucs Commirree
Pr-q/cStlr T_ C-.,
1+qfcstw Hil_ rn.,.,.
Drs.-HtM.
Dr It.ri_ ;"0_
Dr. r-;" SitlfW
Mr.
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LONDON SCHOOL OF HYGIENE
TROPICAL MEDICINE
ETHICS COMMITTEE
APPROVAL FORM
Apphcancn number: 5072
N me of Pnnopal Investigator Llandre van der Merwe
Department Epidemiology and Pcputatien Health
He d of Department Professor Laura Rodrigues
Tltf n-a Long-chain polyunsaturated fatty acids (LC-PUFAs) in relation to
gut Integrity and growth tauure of rural African lntants.
Tile Committee nas approved amendments to this study.
--
Ch31r
Prof $$O( Tom Mead
01 15Apnl 2008
ApprOV.l1 s depend nt on leea' ethic'll appreva h..ving been received.
Any SUDS quent ch\lng.s to th appucanen must be re-submitted to the
Commltt •.
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Appendix 12. Subject information sheet
n-3 Polyunsaturated fatty acids in relation to infant gut integrity & growth in rural Africa.
(to be read to mothers in their own language)
You/your child are being invited to take part in a research study. Before deciding it is
important for you to understand why the research is being done and what it will involve.
Please take time to listen to this carefully and discuss it with others if you wish. Ask us if there
is anything that is not clear or if you would like more information. Take time to decide whether
or not you wish to take part.
Wh.t Is the purpose of the study?
Certain types of fat, that occur especially in fish, are very important to children's diets. We
are running a project to Investigate whether feeding babies additional amounts of these
special fats may strengthen their Intestines and hence help them grow better.
Your infant has been chosen randomly to participate in this study which involves 150
Infants. Half the babies will receive normal 011and half will receive the type of oil we wish to
test to see If It Is better. We will not know which 011your baby has until after the trial has been
completed. 80th types are believed to be safe and healthy.
The followinl will be required of you and your baby if you decide to take part:
1. We will provide transport and ask you to bring your infant to MRC Keneba six times: 3
times at the belinnlnl, and 3 times at the end of six months. Here your infant will be
given a small amount of sUII' water to drink. We will then collect urine and stool
samples for 5 hours. At the same time we will measure your child's growth. We will
also collect a small amount of your breast-milk in order to investigate its fat content.
On the first and last occasion we will collect 2-3ml (half a teaspoon) of blood from your
baby to Investigate how much of these special fats he/she has.
2. You will also be required to bring your child to the fieldworker in your village everyday
for 6 months. The fieldworker will give a small amount of oil for your baby to take
everyday, and ask you to answer 8 short questions about your child's health. If your
child Is III we will provide treatment or transport to Keneba.
3. lastly, the fleldworker In your village will measure your child's growth on 2 occasions
(at 5 mo and 7 mo of age).
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All information which is collected about you or your child during the course of the research
will be kept strictly confidential. He/she will be identified by an ID number. If you have any
questions, please ask.
It is up to you to decide whether or not to take part. If you do decide to take part you will
be asked to sign a consent form. If you decide to take part you are still free to withdraw at any
time and without giving a reason. Your decision will not affect the medical care we provide you
in any way. We hope that you will agree to participate.
Thank you very much.
Keneba;te19878099
Principal Investigator: tlandre van der Merwe ; MRC
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Appendix 13. Consent form
Infant Omega-3 Supplementation Study
Principal investigator:
tlandre van der Merwe; MRC Keneba
Mother's WK ID Number: LLI_I_LLLI_LLLI
Child's DOB: I_LI_I_LI_I
Child's Name: .
Mother's Name: .
Father's Name: .
Village Name:
I have read the information sheet concerning this study and I understand what will be
required of me and my child If I take part in the study. You have answered all my questions and
doubts. I understand that I can withdraw from the study any time I wish without giving a
reason and this will not affect my normal health care I receive from your clinic.
I agree to take part in this study.
Mother's signature / thumb print: .. Date: ..
Father's signature /thumb print: . Date: .
Investigator's Signature: .
Name of fieldworker: .
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Appendix 14. Letter submitted to ISRCTNadministrator
The changes to be made, if possible and acceptable, are as follows:
Study hypothesis:
The primary/secondary hypotheses do not correspond to primary/secondary outcomes. We
would like to leave our primary outcomes as is, but would like to line the hypotheses up with
them, sa that the hypotheses and outcomes are matched, and "Study hypothesis" reads as
follows:
Primary hypotheses:
1. Dietary n-3 long-chain polyunsaturated fatty acid (LCP)supplementation will improve
rural African infants' growth performances.
2. Dietary n-3 LCPsupplementation will protect infant mucosal epithelial integrity.
Secondary hypotheses:
1. Dietary n-3 LCPsupplementation improves Infant plasma n-3 fatty acid status.
2. Dietary n-3 LCPsupplementation will enhance the cognitive development of rural
African infants.
3. Dietary n-3 LCPsupplementation will reduce the degree of intestinal inflammation of
rural African infants.
4. Dietary n-3 LCPsupplementation will reduce infant systemic inflammation.
5. Dietary n-3 LCPsupplementation reduces incidence and severity of morbidities in rural
African infants.
Exclusion criteria:
The following addition was made:
1. Infants from multiple births.
Interventions:
The intervention Is listed as 500mg EPHand 500mg DHA. This should be 500mg combined
EPH+ DHA, or 300mg EPHand 200mg DHA. Perhaps best if read as "300mg EPHand 200mg
DHA".
Outcomes:
No change to 'primary outcomes'. We have added 'cognitive development' as a secondary
outcome. We have removed the level 'tertiary outcomes' so that all non-primary outcomes fall
under 'secondary outcomes'. Note that '[aeca! neopterin' was not measured (due to assay
problems) and is no longer listed under 'intestinal inflammation'.
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Secondary outcome measures should now, therefore (corresponding to secondary
hypotheses), read:
1. Plasma fatty acid status (Gas Chromatography [GC])
2. Infant cognitive development (infant planning test and attention assessment).
3. Systemic inflammatory markers (a-Acid GlycoProtein [AGP], C-Reactive Protein [CRP]
and plasma albumin).
4. Intestinal inflammation (faecal calprotectin).
5. Infant morbidities (daily morbidity assessments, clinic/nurse visits).
Measures 1, 3 and 4 will be measured at 3 and 9 months of age (i.e. at baseline and
6-month follow-up).
Measure 2 will be measured at 12 months of age.
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Appendix 15. Field Supervisor Quality Control Sheet
Date: .......•..•.•...•...•......• Fleldworker reviewed: ............•......•.................
Village: .....................••••.•••
1. Supplementation
Accuracy of dosage:
Technique for supplementing child:
Mother breast-feeds child Imm afterward:
Infant acceptance:
Random checks - child supplemented daily:
good/needs attention
good/needs attention
good/needs attention
good/needs attention
good/needs attention
2. Supplement handling
Labels visible or re-marked:
Condition In field:
Condition In fridge:
3. Fridge
good/needs attention
good/needs attention
good/needs attention
Temperature record sheet:
Contents:
Cleanliness:
Freezer compartment:
Handling:
4. Motorbike
good/needs attention
good/needs attention
good/needs attention
good/needs attention
good/needs attention
Condition of:
Riding technique:
Cere of:
good/needs attention
good/needs attention
good/needs attention
5. Anthropometry
Overall technique:
Repeat anthropometry forms attached:
good/needs attention
yes/no
6. Anthropometry Equipment
calibration:
Condltlon/deanllnea:
Care In field:
good/needs attention
good/needs attention
good/needs attention
7. Morbidity questionnaires:
. Repeats attached
good/needs attention
yes/no
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8. Recruitment information and consenting procedure good/needs attention
Comment: .
9. Fieldworker-subject/community relationship
Comment: .
good/needs attention
10. Treatment group accuracy - treatment card/supplement:
Comment: .
good/needs attention
11. Bread and Tea supplying: distribution/subject satisfaction/supplies handling:
good/needs attention
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Appendix 16. Example safety monitoring report
The body of the statistical output has been omitted for the sake of brevity.
Pufa supplemention study - Safety Monitoring summary. April2008
"Again there seem to be few safety concerns.
Below is a summary of the numbers of individuals experiencing the main types of adverse
event seen - none (not even conjunctivitis) differ significantly between the groups. Most are
similar to before but the incidence of diarrhoea seems to have increased a fair bit.
A B
Unclassified cough 5 6
Impetigo 9 4
Unspecified conjunctivitis 3 9
Diarrhoea (unknown cause) 28 27
Cold/coryza 29 38
Pneumonia/pleurisy 27 35
possibly due to intervention 22 20
Anthropometry output
----------------------------------------------------------------------------------------
log: C: \Documents and Settings\fulfordt .MRC-HNR\Desktop\Liandre - Pufa study\Liandre
safety monitoring\Apr 200S\safety anthrops, Apr 200S.log
log type: text
opened on: 29 Apr 200S, 21:13:43
end of do-file
. exit, clear
Morbidity output
----------------------------------------------------------------------------------------
log: C: \Documents and Set tings \fu1fordt .MRC- HNR\Des ktop \Liandre - Pufa study\Liandre
safety monitoring\Apr 2008\safety mobidity, Apr 2008.10g
log type: text
opened on: 29 Apr 2008, 10:38:33
. insheet using Wsafety morbidity. txt"
(10 vars, 173 obs)
. exit
end of do-file
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Appendix 17. Serious adverse event forms
SERIOUS ADVERSE EVENT - INITIAL REPORTING FORM
IN3SS - sec 1061
Please send this information immediately by fax.
In addition please complete the adverse events section in the case report form.
Date of receipt:
Country:
From
Investigator:
Address:
Telephone-No:
Fax No.
Email address:
Fax to:
For the purposes of this form, a serious adverse event is defined as any untoward medical occurrence that at any dose
results in death, is life-threatening, requires inpatient hospitalization or prolongation or existing hospitalization, results
in persistent or significant disability or incapacity. Important medical events that may not result in death, be life-
threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriated
medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of
the outcomes Iisted above.
INSTRUCTIONS:
Infant omega-3 supplementation study
PRINCIPAL IN VESTlGA TOR: MRC Keneba Phone: +2209878099
liandre van der Merwe E-mail: Liandre.vanderMerwe@LSHTM.ac.uk.
SUBJECT'S INITIALS AND STUDY
NUMBER:
DATE & TIME OF SAE ONSET: _J_J
LOCATION AT ONSET OF SAE:
BRIEF DESCRIPTION OF SUBJECT: SEX: M/F DOB DRAGE:
Diagnosis:
HAS THE BLINDING CODE BEEN No C8J Yes0 Results:
BROKEN FOR THE SUBJECT?
First dose of study medication:
Last dose given:
.....................................(date)
Dose administered: ....................................(date)
No. of doses given so far: 500 (mg)
Batch number:
-II
-
Expiry Date:
Lot# 1806-- --
04/09
NAME OF REPORTER
BRIEF DESCRIPTION OF THE NATURE OF THE SERIOUS ADVERSE EVENT:
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MEDICAL MANAGEMENT:
CATEGORY (outcome) OF THE SERIOUS PRELIMINARY EVALUATION OF CAUSAL
ADVERSE EVENT: RELATIONSHIP WITH INVESTIGAT/ONAL PRODUCT
[ ] death [ ]1 = unrelated (clearly not related to the
[ ] disability/incapacity research)
[ ]Iife-threatening [ ] 2 = unlikely (doubtfully related to the
[ ] hospitalisation-initial or prolonged research)
[ 1 required intervention to [ ] 3 = possible (may be related to the
prevent permanent impairment research)
[ ] Medically important event [ ]4 = probable (likely related to the research)
[ ] Other [ ]5 = definite (clearly related to the research)
ANY CONCOMITANT [ ] YES
MEDICA T/ON/TREATMENT? [ ] NO
Description:
What steps do you plan to take as a [ ] no action required
result of the adverse event reported above? [ ] terminate or suspend protocol
[ ] other, describe:
OUTCOME: [ ]1 = Recovered
[ ] 2 = Not yet recovered
[ ] 3 = Alive with sequelae
[ ]4 = Death
[ ]5 = Unknown
SUBMITTED TO: [ 1 Safety monitor
[ ] Trial monitor
[ ] SCC/ethics committee
SIGNATURE: I DATE:
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SERIOUS ADVERSE EVENT - FOLLOW-UP FORM
IN3SS - sec 1061
Please send this information immediately by fax.
In addition please complete the adverse events section in the case report form.
Fax to:
Date of receipt:
From Country:
Investigator:
Address:
Telephone-No:
Fax No.
Email address:
Infant omega-s supptementation study
PRINCIPAL INVESTIGATOR: MRC Kencba Phone: +220 9878099
Liandr« 1'0// del' Heme E-mail: Liandre.vanderMerwefel.Sf l'I'Mac.uk,
SUBJECT'S INITIALS AND STUDY
NUMBER:
DA TE & TIME OF SAE ONSET: / /
LOCATIONAT ONSET OFSAE:
BRJEF DESCRIPTION OF SUBJECT(S) SEX: M/F DOBORAGE:
Diagnosis:
Additional information on SAE and on actions taken (including' allY newmedication given as part a/treatment/or SAE:
I Ideath
I Idisabi Iity/incapacity
I l lifc-thrcatcning
I Ihospital ization-initial or prolonged
I I required intervcnt ion to prevent permanent impairment
I IMedically important event
I IOther
CATEGORY (outcome) OF TIlE SERIOUS EVALUATION OF CAUSAL RELATIONSHIP WITH
ADVERSE EVENT: INVESTIGATIONAL PRODUCT
I Ideath r )1 = unrelated (clearly not related to the research)
I Idisability/incapacity [ )2 = unlikely (doubtfully related to the research)
r jlifc-threatening [ )3 = possible (may be related to the research)
[I hospitalization-initial or prolonged r )4 = probable (likely related to the research)
I Irequired intervention to prevent permanent [ )5 = definite (clearly related to the research)
impairment [ ) 6 = not assessable
I IMedically important event
[ ) Other
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OUTCOME: [ ] I - Reco vered
I
[ ]2 = Not yet recovered
[ ]3 = Alive with sequelae
[ ]4= Death
[ ] 5 = Unknown
NAME AND SIGNITURE OF OF REPORTER DATE.'
INVESTIGATOR'S SIGNATURE: DATE:
Please attach any relevant reports.
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Appendix 18. Trial monitoring report
Monitoring report on "long chain n-3 polyunsaturated fatty acids in relation to gut integrity
and growth failure in rural African infants", MRC Keneba
Name of trial: long chain n-3 polyunsaturated fatty acids in relation to gut integrity and
growth failure in rural African infants
ID numbers: Protocol number SCC1061; ISRCTN66645725
Date of monltorlnl visit: 4-7/12/07
Sample size soulht: 150
Date recruitment started: May 2007
Proposed date for recruitment end: By end of 2007
Actual recruitment rate vs. tarlet: The actual recruitment rate matches the target
Acceptance rate: 83%
Forecast of recruItment for the remainder of the trial: 148 infants have been recruited;
recruitment Is anticipated to be completed within a few weeks of the monitoring visit (Le. by the
end of 2007).
Losses to follow-up: 4
Number for which follow-up has been completed successfully: 26 infants have had their 9
month follow-up
Completeness of dlta collected: Anthropometric data is complete for those infants who have
been studied at 3 months (n = 148) and 9 months (n = 26) of age. No laboratory data has been
generated yet, but this will be Initiated once all samples are collected. No developmental
outcomes have been assessed yet; these will be assessed at 12 months of age
Any Iv.llable results: None yet
Any o.... nllatlonal problems: None that I could see. I was impressed at the degree of
organisation of the processes and researchers Involved.
Specific Issues: There was a problem with the initial shipment of fish oil capsules which did not
arrive. The setting of the study (recruiting Is spread across a number of villages) and Its nature (i.e.
supplementation in infants) mean that It Is logistically difficult to conduct. However the available
Infrastructure coupled with the motivation, organisation and level of training of personnel involved
appear to have overcome the difficulties Imposed and the trial Is progressing very satisfactorily. In
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trial experiments there have been difficulties with measurement of intestinal (faecal) inflammatory
markers; however the personnel involved are working towards resolving these difficulties. I am
fully satisfied with the conduct of the trial, with procedures involved in recruiting and tracking
subjects, with the field supplementation procedure, and with primary data recording and its
transfer to electronic form.
P.e. Calder
University of Southampton
10/12/07
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